
CURRICULUM VITAE

JOSEP M. LLOVET i BAYER, MD, PhD

Barcelona- New York, February 2026

INDEX

EXECUTIVE SUMMARY- CURRICULUM VITAE.....	3
1. PERSONAL INFORMATION.....	7
2. EDUCATION, ACADEMIC DEGREES AND TEACHING	8
MEDICAL SCHOOL AND POSTGRADUATE STUDIES	8
DOCTORAL THESIS (PHD)	8
LICENSURE, CERTIFICATION AND ACCREDITATIONS	8
TRAINING RECORD AND TEACHING ACTIVITIES.....	9
MENTORSHIP	13
3. ACADEMIC AND HOSPITAL APPOINTMENTS	17
4. MAIN ACHIEVEMENTS	18
5. PUBLICATIONS.....	21
PERSONAL CITATION INDEX.....	21
TOP MOST CITED ARTICLES	24
PUBLICATIONS IN INTERNATIONAL JOURNALS	26
ORIGINALS	26
REVIEWS	42
OTHER PUBLICATIONS	51
BOOK CHAPTERS	53
6. PROFESSIONAL ASSOCIATIONS AND EDITORIAL ACTIVITY	57
7.INTERNATIONAL RESEARCH CONSORTIUMS	66
8.PATENTS.....	68
9. PROJECTS AND GRANT SUPPORT	69
PUBLIC GRANTS – PI: PROF JOSEP M LLOVET	69
PRIVATE GRANTS – PI:PROF JOSEP M LLOVET	70
OTHER PUBLIC & PRIVATE FUNDING AS CO-INVESTIGATORS	74
10.HONORS AND AWARDS	77
11.VISITING PROFESSORSHIP, INVITED LECTURES,PRESENTATIONS	81
TOP VISITING PROFESSORSHIP	81
TOP ORAL COMMUNICATIONS IN SCIENTIFIC MEETINGS (PLENARY SESSION)	82
VISITING PROFESSORSHIP AND INVITED LECTURES (RECENT 2008-2025).....	84
VISITING PROFESSORSHIP AND INVITED LECTURES (1995-2007)	110
PRESENTATIONS IN INTERNATIONAL SCIENTIFIC MEETINGS (SEE TOP ORAL IN SECTION 11 TH).....	119
12. ADDENDUM.....	153
MEDIA IMPACT	153

EXECUTIVE SUMMARY- CURRICULUM VITAE

Personal information

- Family name, First name: **LLOVET, JOSEP M.**
- Researcher unique identifier: ORCID: 000-0003-0547-2667
- Citizenship: Spanish; Born in Barcelona (BCN), December 2nd, 1962.
- URL for websites:
 1. <https://www.icrea.cat/Web/ScientificStaff/josep-m-llovet-bayer-387>
 2. <https://www.clinicbarcelona.org/en/idibaps/areas-and-programs/liver-digestive-system-and-metabolism/translational-research-in-hepatic-oncology>
 3. <http://labs.icahn.mssm.edu/llovetlab/>

Current academic positions

- **Full Professor of Research-ICREA. Director, Program of Translational Research in Cancer. Coordinator- Area #5 -Cancer-IDIBAPS;** Group Leader- Translational research in Hepatic Oncology. Liver Unit. IDIBAPS-Hospital Clínic. 2006-
- **Full Professor of Medicine-Hepatic Oncology,** 2020- & **Director, Master in Translational Medicine,** Faculty of Medicine, University of Barcelona. 2013-
- **Full Professor of Medicine** (Academic Track, part time). 2009-
- **Director Liver Cancer Program,** The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, 2005-
- **Editor-in-Chief,** *Journal of Hepatology Reports* (Official Journal of EASL; IF: 9.5), 2023-

Previous positions & Fellowships

- Board certified in Gastroenterology (1989-1992), and fellow in Hepatology (1993-1994). Hospital Germans Trias i Pujol. BCN.
- Faculty at the Liver Unit-Hospital Clínic (1995-1997)
- Faculty of Gastroenterology, Area 8, BCN (1993-2003).
- Senior Investigator- BCLC group. IDIBAPS, Min. Ciencia Tecnología. BCN (1998-03).
- Senior Scientist (2003-04) and Associate Professor of Medicine (2005-09), Division of Liver Diseases. Mt Sinai School of Medicine. New York. USA

Managerial positions- Institutional responsibilities

- IDIBAPS-Hospital Clínic: a) IDIBAPS Executive Committee, member (2013-2025); b) IDIBAPS Director's Consulting Committee, member (2013-2025); c) Director, Program of Translational Research in Cancer, 2023-; d) Coordinator- Area #5 -Cancer, IDIBAPS, 2024-; f) Chair, Talent Committee, 2016-; g) Senior Group Leader- Translational research in Hepatic Oncology. 2006-
- University of Barcelona: a) Master's Steering Committee, Faculty of Medicine; b) Master's Steering Committee- Department of Medicine, Faculty of Medicine; c) Comissió Acadèmica de Graus, member
- Mount Sinai, NYC: a) Strategic Planning Initiative, member (2004-); b) Search Committees, member Director of Department of Medicine Biostatistics Core (2005-); Senior Leadership Executive Committee, Tisch Cancer Institute (2008-2017); Developmental Funds Committee, Tisch Cancer Institute (2009); Chair: Liver Cancer Disease Focus Group (2013-2024).

Education, teaching and mentoring

- Medical Doctor (MD) at University of Barcelona, 1980-1986. Final qualification: *Excellent*.
- Doctoral Thesis (PhD) in Medicine and Surgery, Autonomous University of Barcelona, 1995. *Magna cum laude by unanimous decision, and extraordinary doctoral thesis award*, 1998.
- Full Professor Accreditation, Generalitat Catalunya-2008; ANECA, Ministry of Education, Spain-2011.
- Teaching at University of Barcelona: a) Director, Master's in Translational Medicine (60 credits), 2013-2026 (25-40 students); b) Coordinator, subject of Translational Medicine (Medicine Degree); c) Coordinator, subject of Translational Research in Oncology (Biomedicine Degree).
- Teaching at Icahn School of Medicine, Mount Sinai: Coordinator, Translational Research in Oncology (10 credits), within the Master's of Science in Clinical Research. (2016-2018)
- Educational Committee, European Association for the Study of Liver (EASL) 2022-2024

- **Mentorship:** a) Mentorship of **64 MD and PhD students, fellows, residents and 6 young faculty** in my two Labs; b) PhD Thesis Director: 21 (6 ongoing); c) Master's Thesis Director: 25 (2 ongoing).

Achievements of mentored students, post-docs and fellows: 30 obtained faculty positions in academic institutions: [Mount Sinai (A. Villanueva, D. Sia, and R. Savic), UTS-Texas (Y. Hoshida), Chief Medical Examiner- NYC (E. Wurmbach), Brookdale Hospital (A Harrington), Hosp. Clínic (M. Burrel, M. Real, V. Hernández-Gea, M. Montironi), Hosp. Vall D'Hebron (B. Minguez, F. Castet), Hosp Charité Berlin (P. Haber), Univ. of Bern (A. Lachenmayer), Portland Univ. (P. Newel), MSKCC (O. Miltiadous, Y. Chen), Univ. Modena (M. Gambato), Hosp. Cruces (J. Bustamante), Hosp. Germans Trias (M. Sala), Hosp del Mar -Barcelona (M. Puigvehí), Hosp Arnau Vilanova-Lleida (R. Montal), Brandon-Florida (V. Lourdusamy)] and 10 in biotechnology industries [D. Chiang, V. Tovar, S. Toffanin, K. Revill, C. Alsinet, H. Cornella, S. Torrecilla, I. Martinez-Quetlas, A. Moeini, C. Andreu]. In addition, 4 hold a senior position as staff scientist or post-doc [L. Torrens - IARC-Lyon; Y. Jiao - MIT Boston; M. Torres - HGTP]

Lifetime highlights

During my 30-year career as a physician-scientist, I have led a **paradigm change in the understanding of the molecular and immune classification of hepatocellular carcinoma (HCC) and new therapeutic interventions accepted by guidelines**. As the third leading cause of cancer-related deaths, HCC is the most common liver cancer and a major public health problem with more than 1M annual cases worldwide.

- **World's most cited investigator** in the area of liver cancer: Scopus: ~133,751 citations (Scopus) >170,976 (Google scholar), **h-index: 145** and top 1% Clarivate analytics every year since 2014-2024. Top 0.5% Stanford investigator (# 672 globally among all disciplines, #3 in Spain)
- **Leading author / Principal investigator** of RCT, leading to **practice-changing standard of care therapies**.
 - A) Systemic treatment (**sorafenib**) for hepatocellular carcinoma (HCC) (NEJM 2008), and first approved drug ever for patients with advanced tumors, 2008.
 - B) First author of the clinical trial and meta-analysis establishing **chemoembolization** (TACE) as the standard of care for intermediate HCC (Lancet 2003).
 - C) LEAP012 - Combination of **lenvatinib plus pembrolizumab plus TACE**, in intermediate HCC, 2024 (Lancet 2025).
- Leading author/Principal investigator of the proposals of **molecular and immune classification** of HCC (2008, 2017, NRCO 2022 and 2024).
- Establishment of an imaging criteria for assessment of response to therapies (**modified RECIST**) accepted by guidelines.
- **Founder, Secretary and President of the International Liver Cancer Association** (ILCA), the only international scientific society devoted to liver cancer (2006-2013).
- **Founder and Director of the Mount Sinai Liver Cancer Program** (2005-2023), the first liver cancer program recognized by NCI in the USA.
- Principal investigator of research funding with **104 awards as PI**, including coordinator of 2 European Union FP7 and Horizon Europe grants (HEPTROMIC and THRIVE) and 2 NIH-RO1 and the AECC-Reto 70% award, with an total of ~56M€ as PI

Academic trajectory

Training track: My career started with a medical doctor (MD) degree from the Faculty of Medicine-Hospital Clínic-University of Barcelona (grade: excellent, 1986) and continued with a PhD from the Autonomous University of Barcelona (1995, Extraordinary Prize). After completing my residency in Digestive Diseases at the Germans Trias i Pujol Hospital (1992),

Physician - scientist track: I worked as a physician and researcher in the Liver Unit-Barcelona Clínic Liver Cancer Group (BCLC) at the Hospital Clínic (1995-2003) and as a digestive disease specialist (1993-2003). In 2003-06, I began a sabbatical stay at Mount Sinai Hospital in New York, where I was appointed as full-time professor (2005) and later a part-time Full-Professor (2009-present). I **founded the Mt Sinai Liver Cancer Program** (2005), which has been recognized by the National Cancer Institute [NIH] as the first and only liver cancer program in the US (2015) to date. I returned to Barcelona as an ICREA Professor at IDIBAPS in 2006, where I lead the Group of Translational Research in Liver Cancer (15 members). In IDIBAPS, I became a member of the **Executive Committee (2012-present)**, **co-coordinated the multidisciplinary program in Translational Research in Cancer (2023)**, as well as the **Area of Cancer (2024)**.

Regarding **international recognition**, I co-founded the International Liver Cancer Association (ILCA) in 2006 and served as Secretary and President from 2007 to 2013. ILCA is the first

international scientific association specific to liver cancer. Subsequently, I was elected President of the Special Interest Group in Liver Tumors of the American Association for the Study of Liver Diseases (AASLD; 2019-2020). I have served as coordinator and/or panelist on 11 Clinical Practice guidelines for European (EASL, ESMO), North American (AASLD), and international (ILCA) scientific societies. I created the International Genomic HCC Consortium, involving ~30 leading research centers in HCC research worldwide. Regarding **editorial work**, I have served as Associate or Senior Editor (*Journal of Hepatology*, *Gastroenterology*, *Clinical Cancer Research*), and I am currently member of the Advisory Board of *Nature Reviews Clinical Oncology* and Editor-in-Chief of the *Journal of Hepatology Reports* (2023), an official journal of the EASL. I have been awarded with the AACR-Landon International Award (2009), the Hans Popper Award for Best Hepatologist (2012), the Josep Trueta Award (2013), Fellow-AASLD (2015), and a consecutive recognition by Clarivate Analytics as one of the World's Most Influential Minds - Top 1% Most Cited Investigator (2014-2023). **Teaching trajectory:** I coordinate the Master's in Translational Medicine at the University of Barcelona (~40 yearly students, since 2013) and obtained the Professorship in Medicine-Hepatic Oncology at the same University (2020). I have been a mentor and/or thesis advisor for 75 doctoral students or faculty members in Barcelona and New York, ~35 of whom hold academic positions.

Main paradigm-changing contributions in Liver Cancer

The main scientific contributions that have represented major paradigm shifts and breakthroughs in the pathogenesis and treatment of HCC and cholangiocarcinoma (CCA) are:

1. Clinical Research and Treatment of Hepatocellular Carcinoma

a) **Establishment of the standard of care sorafenib and other systemic therapies for HCC.** Around 50-60% of HCC patients are exposed to systemic therapies during their natural history. I have been involved in the approval of three treatments: **sorafenib**, **ramucirumab**, and **regorafenib**. In total, as international principal investigator I have led several phase III trials (SHARP, STORM SPACE; BRISK, LEAP-002), among which the SHARP trial stands out, as it established **sorafenib** as the standard treatment for advanced HCC (Llovet, *NEJM* 2008). This trial revolutionized the management of HCC, and sorafenib was adopted by clinical guidelines globally and was approved by regulatory agencies, benefiting ~100,000 patients annually worldwide. The article in *NEJM* is the most cited in the field of liver cancer (total >10,000 citations). In addition, I co-authored two positive Phase III studies that established the anti-VEGF monoclonal antibody **ramucirumab** and **regorafenib** as 2nd-line therapies accepted by guidelines and regulatory agencies.

b) **Establishment of standard of care for intermediate HCC.**

b1: Chemoembolization (TACE). Approximately 30-40% of patients with HCC are diagnosed at the intermediate stage, for which the accepted standard treatment according to American and European guidelines is chemoembolization (TACE). This treatment was adopted as a result of a randomized clinical trial (Llovet JM, *Lancet* 2002) and a confirmatory meta-analysis (Llovet, *Hepatology* 2003), for which I was the first author. TACE has remained the standard treatment for intermediate-stage HCC in clinical guidelines for the last 20 years and has had a greater global impact than sorafenib.

b2: Lenvatinib+pembolizumab+TACE. The LEAP012 RCT was presented at the Presidential session at ESMO in 2024 (Llovet JM, *Ann Oncol* 2024), demonstrating that Lenvatinib + pembolizumab + TACE is superior than TACE in PFS (*Lancet*, 2025).

c) **Criteria for assessment of therapeutic response: modified RECIST.** In 2010 we published the modification of RECIST (mRECIST) to assess therapeutic response in HCC (Lencioni & Llovet, *Semin Liv Dis* 2010), an article that has received > 2,800 citations. Currently, it is the main method of therapeutic response assessment in the initial and intermediate stages of HCC treated with locoregional therapies by both European and American guidelines. An updated version of mRECIST was reported in 2020 (Llovet & Lencioni, *J Hepatol* 2020).

d) **Clinical Classification of HCC: BCLC (Barcelona-Clinic Liver Cancer).** This classification was first proposed in 1999 (Llovet, *Semin Liv Dis* 1999; >2500 citations) and has been updated multiple times. It incorporates the concept of integrating the best evidence in the assignment of treatment for each prognostic stage of the disease. Currently, it is the most widely used staging system internationally and it has been adopted by European and American guidelines.

2. Translational Research

a) **Establishment of a molecular classification of hepatocellular carcinoma**, describing two proliferative classes with worse prognosis (one characterized by progenitor cell markers and the other by TGF-beta activation), and a third characterized by better prognosis with beta-catenin activation. The classification is based on multiple publications [Wurmbach, *Hepatology* 2007; Hoshida, *New Engl J Med*, 2008, Chiang, *Cancer Res*, 2008; Villanueva, *Gastroenterology* 2011]

and high-impact reviews [Llovet, *Nat Rev Dis Primers* 2021 and Llovet, *Nat Rev Clin Oncol* 2018].

b) Establishment of an immune classification of hepatocellular carcinoma associated with immunotherapy response markers. This classification includes an inflamed class and a non-inflamed class, with an immune desert subclass, primarily refractory to immunotherapy (Sia, *Gastroenterology* 2017; Montironi, *Gut* 2023). The inflamed class is associated with predictors of immunotherapy response (Harber P, *Gastroenterology* 2023). The classification has been reported in Llovet, *Nat Rev Dis Primers* 2021 and *Nat Rev Clin Oncol* 2022 and 2024.

c) Identification of therapeutic targets for liver cancer. The most notable targets for HCC are potentially actionable mutations (Shultze, *Nat Gen*, 2015), such as oncogenes involved in AKT/mTOR activation (Villanueva *Gastroenterology*, 2008), and beta-catenin (Rialdi, *Nature Cancer* 2023); and for CCA, IDH mutations (Saha, *Nature*, 2014), and FGFR2 fusion protein (Sia, *Nature Communications* 2015). Recently, regulatory agencies (FDA, EMA) have approved drugs targeting IDH and FGFR2 for advanced cholangiocarcinoma treatment.

d) Pathogenesis of HCC associated with non-alcoholic steatohepatitis (NASH) and its impact on immunosurveillance. Immune alterations associated with NASH in experimental models (Pfitzer, *Nature* 2021) may influence the response to immunotherapy in patients with NASH-associated HCC (Harber, *Gastroenterology* 2023, Llovet *Nat Rev Gastro Hepatol* 2023).

Publications and scientific communications.

In the field of liver cancer, I have 397 publications in peer-reviewed journals, of which ~2/3 are as senior author and ~40 are listed as *highly cited articles* by Clarivate Analytics. I have a total number of citations of 136,899 (Scopus, January 2026); 173,156 (Google Scholar); 156,527 (Research.com) and IF 8590,716, as well as 54 book chapters. These publications have been published in *NEJM*, *Nature*, *Lancet*, *Lancet Oncology*, *Cancer Cell*, *Nature Biotech*, *Nature Genetics*, *Nature Com*, *Nature Rev Clin Oncol*, *J Clin Oncol* and *Gastroenterology*. As a result of this effort, my current indexes stand at: H index: 147 (H index Google Scholar: 159); i100: **172**; i1000:**31** and D Index: **144** (Research.com). I have authored 5 out of the 10 most quoted publications ever in HCC, have been recognized by Clarivate Analytics as a top 1% cited investigator, from 2014 through to 2024, and have been ranked #1,025 scientist in the world (Research.com). Finally, I have delivered ~700 lectures worldwide and presented over 700 communications at scientific meetings.

Competitive Funding

Throughout my scientific career, I have received funding for 130 projects, including 104 as Principal Investigator, with a total value of ~**€61 million (€ 56M as PI)**. Of the three projects that were funded by the European Union, I served as Coordinator in two [FP7-2010-Health; HEPTROMIC; Horizon-Miss-2023-Cancer-01; THRIVE]. I have also received competitive funding from the National Institute of Health (NIH/NCI) as the PI for two R01 projects (1R01DK07698; 1R01CA273932-01A1) and competitive private funding from the Spanish Association Against Cancer (AECC), including a recent top Reto 70% award, alongside other grants (i.e HUNTER-Accelerator Award).

Awards

- 1) Extraordinary award of Doctoral Thesis, 1998
- 2) AACR-Landon International Award, USA 2009;
- 3) International Hans Popper Award, Falk Foundation, Mainz, Germany; 2012;
- 4) Josep Trueta award, Barcelona; 2013;
- 5) Fellow, American Association for the Study of Liver Diseases, USA; 2015;
- 6) Leon Schiff State-of-The-Art lecture AASLD, 2019;
- 7) ICREA scientific evaluation: Outstanding in 2008, 2015 and 2020.
- 8) Top 1% cited investigator Clarivate Analytics each year from 2014 to 2024
- 9) Stanford University world's top scientist ranking :Top 0.013%; #4 in Spain.
- 10) HCC-Life award, 1st awardee for lifetime achievements in liver cancer research, 2024

Major Collaborations

- THRIVE (EU-Mission cancer) & FP7- HEPTROMIC: Profs M. Esteller (IDIBELL), J. Zucman-Rossi (INSERM), V. Mazzaferro., M Heikenwarder (Germany), G Zeler (Netherlands)
- HUNTER-Accelerator: Profs H. Reeves (Newcastle), T. Meyer (Royal Free), Mala Maini (UCL).
- H2020 HEP-CAR: Prof. Thiemme (U. Freiburg), P. Schirmacher (U. Heidelberg),
- AACR-Landon International Award: T. Golub and M. Meyerson (Dana-Farber, Harvard).
- ISMMS: S. Friedman, M. Schwartz, A. Villanueva, S. Thung, A. Lujambio, Uzilov, B. Losic.
- Other collaborators: M. Colombo (Milan), P. Galle (Mainz), J. Marrero (UTS Texas), L. Roberts (Mayo Clinic), S. Roayaie (White Plains) and N. Bardeesy (Harvard Univ.).

1. PERSONAL INFORMATION



- Name: Josep M. Llovet i Bayer
- Place and date of birth: Barcelona. December 2nd, 1962.
- Professional address:

Barcelona:

Josep M Llovet, MD, PhD, FAASLD
 Professor of Medicine, University of Barcelona,
 Professor of Research, ICREA
 Head, Translational research in Liver Cancer Group, Liver Unit,
 IDIBAPS, Hospital Clínic Barcelona.
 Email: jmllovet@clinic.cat
 Assistant: Ariadna Farré (afarrec@recerca.clinic.cat)
 Phone: +34-93.2279156
 Lab: +34-93.2279155

New York:

Josep M Llovet, MD, PhD, FAASLD
 Professor of Medicine
 Director, Mount Sinai Liver Cancer Program
 Division of Liver Diseases. Tisch Cancer Institute
 Icahn School of Medicine at Mount Sinai
 Madison Ave 1425. 11F-70. Box: 1123
 New York, NY10029. USA
 Phone: +1-212-6599503
 E-mail: Josep.Llovet@mountsinai.org
 Assistant: Assistant: Julie Mercado (julia.mercado@mssm.edu) : +1-212-659-9514

- Nationality: Spanish, ID number: 46.117.852-T.
- Address in Barcelona: Escoles Pies 18, Àtic 2a.
 Barcelona 08017, Catalonia, Spain
 Phone: +34-93-2113138
 Cell: +34-629489533
 Cell (USA): +1 9174883207
- Licensed physician (1986). Barcelona, Spain. Number: 24.172.
- United States VISA: Type: O1 (Outstanding ability in the sciences).
 Period: From April 2006 to June 2027
- Marital status: Married. Spouse: Esther Bigas.
 Two children: Aina, Barcelona 1998; Marc, NY 2004

2. EDUCATION, ACADEMIC DEGREES AND TEACHING

MEDICAL SCHOOL AND POSTGRADUATE STUDIES

- 1980-1986. **Medical Doctor (MD)** at University of Barcelona, Hospital Clínic, Date of Issuance: July 22th. Licensure: Licensed physician. Barcelona, Spain. # 24.172.
- 1986. Graduation degree: Excellent. University of Barcelona, Date of Issuance: Nov 6th, 1986
- 1985-86. Intern, Internal Medicine Department, Hospital Clínic.
- 1988-1990. Doctorate Courses in Medicine at the Autonomous University of Barcelona: 32 credits. Research study: "Study of the prognostic factors of hospital mortality in an episode of SBP in patients with liver cirrhosis".

DOCTORAL THESIS (PHD)

- 1995. Title: "Spontaneous bacterial peritonitis in cirrhosis. Pathogenesis and prognosis". First thesis read based on published papers (Medicine Department, Autonomous University of Barcelona). Directors: Dr. Ramon Planas, i Dr. Miquel A. Gassull. Excellent "Cum Laude" by unanimous decision.
Lecture: April, 7th 1995. Date of Issuance: June 21th, 1995.
- 1998. Extraordinary Doctoral Thesis Award.

LICENSURE, CERTIFICATION AND ACCREDITATIONS

- Medical Doctor at University of Barcelona, Hospital Clínic. Date of Issuance: July 22th, 1986. Licensure: Licensed physician. Barcelona, Spain. # 24.172.
- **Board certified in Gastroenterology (M.I.R).** Speciality in Gastroenterology and Hepatology. Certification: Date of Issuance: July, 23th, 1993.
- **Accreditation for Research-Associate Professor.** Agència per a la qualitat del Sistema Universitari de Catalunya (AQU), Generalitat de Catalunya.
Report code: 1761042/2-495. Date: May-2004.
- **Accreditation for Associate Professor.** Mount Sinai School of Medicine, New York University, USA. (May 2005).
- **Accreditation for Research-Full Professor.** Agència per a la qualitat del Sistema Universitari de Catalunya (AQU), Generalitat de Catalunya.
Educational group: Professor of University (Recerca Avançada).
Reference code: U1446/6896433-67. Date: January 30th, 2008
- **Accreditation for Full Professor.** Mount Sinai School of Medicine, New York University, USA. (1st July 2009).
- **Accreditation for Associate Professor- ANECA, Ministry of Education, Spain.**
Educational group: Associate Professor of Medicine. (ANECA: 01/2011)
- **Accreditation for Full Professor- ANECA, Ministry of Education, Spain.**
Educational group: Professor of Medicine. (ANECA: 07/2011)

TRAINING RECORD AND TEACHING ACTIVITIES

PROFESSOR, GRADUATE DEGREES

- **Professor, Degree in Medicine**

- 1993-95, ***Autonomous University of Barcelona*** Training of residents in the Digestive Disease Department, Hospital Germans Trias i Pujol.
- 1990-95, ***Autonomous University of Barcelona***. Post-doctoral courses. 1990-91: "Inflammatory bowel disease." 1991-92. "New aspects in the management of nutrition in liver diseases". 1993-94. "Nutrition disorders in Digestive Diseases". 1994-95. "Professional improvement in Digestive Diseases".
- 1995-2003. ***University of Barcelona***. Training of residents and research fellows in the Liver Unit and the Hepatic Oncology group in the Hospital Clínic. Grand Rounds and Journal Clubs of the Liver Unit and Transplantation Institute.
- 2003-07, ***MSSM-New York University***. Teaching responsibilities in the Mount Sinai School of Medicine: Grand Rounds and Journal Clubs of Division Liver Diseases, Transplantation Institute, Hemato/Oncology and Internal Medicine.
- 2018-2022. ***University of Barcelona***: Coordinator, Subject: Basic Principles of Translational Medicine. (4 credits). 3rd Course of Medicine
- 2018-2024 ***University of Barcelona***: Subject: Oncology (5th Course) Lecture: Hepatic Oncology

- **Professor, Degree in Biomedicine**

- 2011-20. ***University of Barcelona***. 3rd course classes and seminars. Subjects: 1) Translational medical research in oncology (seminar), 2) Organs and systems molecular pathology, and 4th course: Molecular biology of cancer and aging.
- 2012-24 ***University of Barcelona***. Coordinator. Subject: Translational medical research in oncology. 4th course, (3 credits).

PROFESSOR, POST-GRADUATE DEGREES.

- **Master's Director**

- Master in Translational Medicine*** University of Barcelona. (2013-26) (<https://web.ub.edu/en/web/estudis/w/masterdegree-m2804>)
Number of students 2024-2025: **37** ; 60 CME credits
 - Director of Master since 2013
 - Coordinator, Translational Medicine - (2010-26). 8 credits (150 hours/year).
 - Coordinator, Principles in Clinical Medicine (2018-2020) 3 credits
 - Coordinator, Clinical Trials Design and Evaluation of Molecular Therapies since (2019-2020) 3 credits
 - Coordinator, Master Research Work Project.(2014-26). 24 credits (500 hours/year)
- Master in Translational Oncology - Applications: Human models of translational research in oncology.*** Icahn School of Medicine at Mount Sinai
Number of students 2017-2019: **5**
Number of credits: 3
 - Director of the course since 2017
- Master in Cancer Research*** – University of Barcelona (2025-present)
 - Director of Master since 2025
 - Coordinator, Principles of Clinical Trial Design in Cancer – (2025-present) 3 credits

- **Master's Professor**

1. **Master in Biomedicine** University of Barcelona. Hepatocellular carcinoma. Molecular pathogenesis and targets for therapies. (2007-08-09). (2h/year).
2. **Master in Research in Liver Diseases** University of Barcelona. Subject: liver cancer : pathogenesis and treatment. - (2006-07-08-09-12-13). (10 hours/year).
3. **Master in Molecular Biology and Cancer** University of Barcelona Signal transduction pathways and molecular classification of HCC. (2008-09) 2h/year.
4. **Master in Molecular Pathology** Centro Nacional de Investigaciones Oncológicas-Madrid: Hepatocellular carcinoma, (2008-13). 2h/year.

- **Annual Performance Data**

Annual Performance Data (PDA)

Year	PDA Score	Total Inputs	Total Outputs	Input Quartile	Output Quartile
2025	87.00	1,143.00	1,143.00	A	A+
2024	80.00	1,186.00	1,186.00	A	A+
2023	67.00	1,123.00	1,123.00	A	A+
2022	77.00	904.00	904.00	A	A+
2021	79.40	686.00	686.00	A	A

- **PhD Thesis Director**

1. Marta Burrel, MD. "Angiography and magnetic resonance imaging in the study of hepatocellular carcinoma", University of Barcelona., 2001-06. Lecture: January, 2006. Excellent "Cum Laude" by unanimous decision.
2. Maria Isabel Real, MD. "Chemoembolization in hepatocellular carcinoma". University of Barcelona, 2003-06. Lecture: October, 2007. Excellent "Cum Laude" by unanimous decision.
3. Augusto Villanueva, MD. "Role of PI3k/Akt/mTOR signaling pathway in hepatocellular carcinoma: Evidence of its blockade and antineoplastic effect with a novel dual tyrosine kinase inhibitor (AEEH788) and a mTOR inhibitor (RAD001, everolimus)". University of Santiago de Compostela. Lecture: April, 2008. Excellent "Cum Laude" by unanimous decision.
4. Clara Alsina, PhD. "Signaling pathways and experimental models in liver cancer". University of Barcelona, 2013. Excellent "Cum Laude" by unanimous decision.
5. Helena Cornellà, International PhD. "Molecular pathogenesis of rare hepatic tumors". U. of Barcelona, (2015). Excellent "Cum Laude" by unanimous decision.
6. Agrin Moeini, PhD. Molecular classification of Cholangiocarcinoma, (2017).
7. Iris M-Quetglas. PhD. "Identification of oncogenes and tumor suppressor genes mutated in poor prognosis hepatocellular carcinoma". (2018)
8. Sara Torrecilla. PhD. "Early molecular events in the pathogenesis of HCC" (January 8th, 2020)
9. Robert Montal, MD. "Molecular characterization of extrahepatic cholangiocarcinoma". (October 7th, 2020)
10. Laura Torrens, PhD. "Molecular Characterization and novel Therapeutic Approaches in Hepatocellular Carcinoma" (March 7th, 2022)
11. Carla Montironi, MD. "Immunogenomic characterization of HCC and etiology-dependent response to immunotherapies". (June 20th, 2022)
12. Roger Esteban, PhD student "Structural genomic alterations in hepatocellular carcinoma and novel combination therapies" (February 13th, 2023).
13. Carmen Andreu, PhD. "Genomic and epigenomic alterations driving non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma" (April 14th,

2023

14. Jordi Abril, PhD Towards precision therapy for liver cancer: exploring new targeted therapeutic strategies in hepatocellular carcinoma and hepatoblastoma (October 11th, 2024)
15. Marta Piqué, PhD "Molecular profiling of hepatocellular carcinoma developed in patients with metabolic dysfunction-associated steatotic liver disease and biomarkers of treatment response" (November 11, 2025)
16. Agavni Mesropian, PhD "Identification of molecular mechanisms driving immune response and resistance to immunotherapies in HCC and development of biomarkers and new treatment strategies to overcome resistance". (expected 2025)
17. Ugnė Balaseviciute, PhD "Molecular characterization of HCC pathogenesis, with a special focus on NASH-HCC" (expected 2025)
18. Júlia Hugué. PhD "Characterization of the immunogenomic mechanisms of response and resistance to immunotherapies and development of new therapeutic strategies to overcome resistance in HCC, with special focus in NASH-HCC". (expected 2026-7).
19. David Camell. PhD. "Immunogenomic mechanisms of response and resistance to immune therapies and novel drug combinations in fatty liver-related hepatocellular carcinoma" (expected 2027-8).
20. Anna Vila. PhD "Characterization of tumor-host interactions in patients with hepatocellular carcinoma and study of predictive markers of response to immune therapies. " (expected 2028-29)
21. Guillem Cano, PhD. "Role of CAF cells in the TME and response to immunotherapies in HCC" (expected 2028-29)

- **Master Thesis Director**

1. Sara Torrecilla. Chemopreventive efficacy of a multikinase inhibitor in a mouse model of HCC. 2014.
2. Sergi Bonilla: Role of IGF2 as oncogene in HCC. 2015
3. Robert Montal, MD: Molecular predictors of response to sorafenib as adjuvant therapy after resection in hepatocellular carcinoma (HCC). 2016
4. Laura Torrens: Experimental models of cholangiocarcinoma and assessment of molecular therapies. 2016
5. Carmen Andreu: Molecular characterization and novel therapeutic drivers in NASH-HCC. 2017
6. Roger Esteban: Impact of aneuploidy on hepatocellular carcinoma progression and immune silencing. 2018
7. Carla Montironi, MD: The immune-mediated cancer field as target for hepatocellular carcinoma chemoprevention. 2018
8. Jordi Abril: Role of TGF-beta signalling in hepatocarcinogenesis. 2019
9. Marta Piqué: Combination therapy with TKI and checkpoint inhibitors in experimental models of HCC. 2019
10. Ugnė Balaseviciute: Molecular characterization of hepatoblastoma. 2020
11. Agavni Mesropian: Decoding the HCC immunology Landscape. 2020
12. Florian Castet, MD. Biomarkers predicting response to checkpoint inhibitors in HCC. 2021
13. Júlia Hugué: Determining the anti-tumoral efficacy of adding anti-CTLA4 therapy to the combination of cabozantinib with anti-PD-1 in preclinical models of hepatocellular carcinoma. 2022
14. Maria Esteve: Determining the anti-tumour and immunomodulatory effect of regorafenib in combination with anti-PD-1 in preclinical models of hepatocellular carcinoma 2023
15. Martí Torres: "Anti-tumoral and immunological effects of combining the Wnt pathway inhibitor E7386 with lenvatinib and anti-PD1 in preclinical models of HCC". 2024
16. Anna Vila. PhD. Title: Characterization of tumor-host interactions in patients with

hepatocellular carcinoma and study of predictive markers of response to immune therapies. June 2025

17. Guillem Cano, PhD. "Role of CAF cells in the TME and response to immunotherapies in HCC". June 2025

- **Degree of Medicine, Final Project's Director**

1. Ana Maria Corraliza: In vitro evaluation of a candidate molecular targeted therapy in Intrahepatic Cholangiocarcinoma. Biomedical Sciences Degree 2013
2. Roger Collet: Exploring the role of Alphafetoprotein in HCC. Medicine Degree. 2017
3. Mireia Llevadot: Combination therapy with TKI and checkpoint inhibitors in experimental models of HCC. Medicine Degree. 2019
4. Paolo Rodi (Erasmus Student, Milan). Molecular characterization of NASH-HCC. 2019

- **Jury Member, Thesis Committee**

1. Dr. Pau Sort, 2000. " Spontaneous bacterial peritonitis in cirrhotic patients". University of Barcelona.
2. Dr. Fco Rodriguez Moranta, UB 2010 "Prevencion del cancer colorectal: nuevas estrategias de cribado, vigilancia y quimioprofilaxis".
3. Dr. Raksha Mudbhary, 2013. PHD thesis on "UHRF1 is an oncogene in HCC". Mount Sinai School of Medicine.
4. Santiago Gonzalez. Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Univ. Barcelona 2016
5. Shing Kam, MPhil. "Qualitative & Functional Characterization of Platelets in Chronic. Liver Disease & Liver Cancer: Consequences for Diagnosis and Therapy?" University of Heidelberg, Faculty of Bioscience (online) 2021. 1st Thesis Advisory Committee.
6. Chaofan Fan "Novel approaches to improve immunotherapy for NASH-induced HCC" 1st Thesis Advisory Committee October 2022, Chaofan Fan "Novel approaches to improve immunotherapy for NASH-induced HCC" 2nd Thesis Advisory Committee. November 2022.
7. Shing Kam, MPhil. "Qualitative & Functional Characterization of Platelets in Chronic. Liver Disease & Liver Cancer: Consequences for Diagnosis and Therapy?" University of Heidelberg, Faculty of Bioscience (online) 2022. 2nd Thesis Advisory Committee.
8. Patricia de la Cruz Ojeda "Regulación de la expresión de miRNAs durante el tratamiento con Sorafenib en el carcinoma hepatocelular. Desarrollo de una nueva estrategia terapéutica". Sevilla University (online). April 17, 2023
9. Manuel Molina García. "Integrative molecular and immune profiling in melanoma: tumoral transcriptomic signatures associated with prognosis and markers of response to immunotherapy". Barcelona, Universitat de Barcelona. December 15, 2025

- **Tribunal Member, Master Thesis:**

Chair, Master Thesis Final Project Committee (2014-15, 2015-16, 2016-17, 2017-18, 2018-19, 2019-20, 2020-21, 2021-22, 2022-23, 2023-24, 2024-2025)

Assessment of Final projects of Master work

- **Chair, Committee for Extraordinary Award from the Master in Translational Medicine:** 2013-14 (Sara Torrecilla), 2014-15 (Marti Ortega), 2015-2016 (Robert Montal) , 2016-2017 (Carmen Andreu), 2017-2018 (Roger Esteban), 2017-2018 (Carla Montironi) 2018-2019 (Arturo Vega) , 2019-2020 (Agavni Mesropian), 2020-21 (Cinta Gomis), 2021-2022(Joan Sebastian Serrano Marín), 2022-2023 (Maria Esteve), 2023-2024 (Mar González), 2024-2025 (Guillem Cano).

- **Tribunal Member, Extraordinary Thesis Award Committee**
Medicine PhD 2013-14 Promotion
- **Tribunal Member, Bachelor's Degree Final project**
Medicine Degree, Faculty of Medicine, course 2021-22 (19/01/2022)

OTHER TEACHING ACTIVITIES

- 1990-2024. Lectures and Seminars in Meetings of Scientific Societies, Postgraduate Courses and Consensus Conferences. Most of these activities include CME courses (see section Visiting professorship and invited lectures).

MENTORSHIP

I have mentored 67 investigators (MD and PhD students, fellows, residents, and young faculties) and 9 Lab managers in my two Labs

NAME AND INCLUSIVE DATES OF TRAINING	LEVEL OF TRAINEE Graduate student, Postdoctoral fellow, Resident, etc.	ROLE IN TRAINING Mentor, research collaborator, thesis supervisor,	TRAINING VENUE Laboratory, etc.	TRAINEE'S CURRENT STATUS & INSTITUTION EMPLOYED List trainees' current academic status if possible
1.Ramon Bartolí (1991-1994)	Graduate Student	Mentor	Hosp Germans Trias Barcelona	Post-doctoral fellow, CIBERhd. Autonomous University of Barcelona
2.Javier Bustamante (1997-2000)	Postdoctoral fellow	Mentor	BCLC Group Barcelona	Faculty Hepatology, University of Bilbao
3.Margarita Sala (1999-2005)	Resident	Mentor	BCLC Group Barcelona	Faculty Hepatology, H Germans Trias (Barcelona)
4.Maria Isabel Real (2003-2006)	Faculty	Thesis director	BCLC Group Barcelona	Faculty Radiology, H Clinic Barcelona (retired)
5.Marta Burrel (2001-2006)	Faculty	Thesis director	BCLC Group Barcelona	Faculty Radiology, H Clinic Barcelona
6.Yingbei Chen (2004-2005)	Postdoctoral fellow	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty Pathology, Memorial Sloan Kettering Cancer Center
7.Elisa Wurmbach (2004-06)	Junior Faculty	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty, MSSM
8Augusto Villanueva (2005-2011)	Doctor	Thesis director	BCLC Group Barcelona	Associate Prof, Hepatology, MSSM
9.Sasan Roayaie (2005-08)	Junior Faculty	Mentor	Mount Sinai Liver Cancer Program, NYC	Full Professor, Surgery, White Plains, NYC
10.Steve Yea (2005-06)	Graduate Student	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty, Pathology, UCLA, Los Angeles
11.Eric Lemmer (2005-06)	Junior Faculty	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty Hepatology, MSSM; (Deceased, 2006)
12.Patricia López (2005-07)	Junior Faculty	Mentor	Mount Sinai Liver Cancer Program, NYC	Senior Scientist, Novartis
13.Stijn Van Laarhoven (2006)	Graduate Student	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty, Surgery, Royal Free, London

14.Pruthvi Patel (2006)	Resident	Mentor	Mount Sinai Liver Cancer Program NYC	Resident, MSSM
15.Pippa Newell (2006-07)	Resident	Mentor	Mount Sinai Liver Cancer Program NYC	Faculty, Surgeon. University of Portland, Oregon.
16.Victoria Tovar (2006-2012)	Postdoctoral fellow	Mentor	Liver Cancer Translational Research Group.Barcelona	Medical Advisor, Bayer Pharmaceuticals
17.Clara Alsinet (2007-2012)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Senior Post-doctoral CNAG-CRG
18.Beatriz Minguez (2007-2009)	Postdoctoral fellow	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty Hepatology, Hosp Vall Hebron Barcelona
19.Sara Toffanin (2007-2012)	Postdoctoral fellow	Mentor	Mount Sinai Liver Cancer Program, NYC	Research Coordinator, Munich (Germany)
20.Yujin Hoshida (2008-2012)	Postdoctoral fellow	Mentor	Dana-Farber, Harvard Univ.	Associate Prof, Hepatology, UTS , Texas
21.Rad Savic (2009-2011)	Postdoctoral fellow	Mentor	Mount Sinai Liver Cancer Program	Assistant Prof, MSSM
22.Anja Lachenmayer (2008-2011)	Postdoctoral fellow	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty,Surgeon. University of Bern, Switzerland
23.Helena Cornellà (2009-2014)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Post-doctoral fellow, Denmark
24.Daniela Sia (2009-2017)	Postdoctoral fellow	Mentor	Liver Cancer Translational Research Group. Mt Sinai Liver Cancer Program, NYC	Assistant Professor, Liver Cancer Program, MSSM
25.Andrew Harrington (2010-2012)	MD Student	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty Brookdale Hospital NY
26.Oriana Miltiadous (2011-2013)	MD	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty MSKCC, NYC Pediatric Oncology,
27.Agrin Moeini (2011-2018)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Post-doc Manchester Univ ,UK
28.Kate Revill (2012-2014)	Post-Doctoral fellow	Mentor	Mount Sinai Liver Cancer Program, NYC	Adjunt Director, Biotech
29.Virginia Hernández-Gea (2012-2013)	Post-Doctoral fellow	Mentor	Liver Cancer Translational Research Group. Barcelona	Faculty, Hepatology. Liver Unit- Hospital Clínic Barcelona
30.Iris Martinez-Quetglas (2013-2017)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Consultant, Biotech
31. Roser Pinyol (2013-2017)	Post-doctoral fellow	Mentor	Liver Cancer Translational Research Group. Barcelona	Assistant Researcher Liver Cancer Translational Research Group. IDIBAPS
32.Sara Torrecilla (2013- 2019)	PhD Student (CIBEREHD)	Thesis Director	Liver Cancer Translational Research Group. Graduate Student,HCC	Merck.Inc, Amsterdam, Holland

			Research Lab	
33.Yang Jiao (2013-17)	Post-Doc	Mentor	Mount Sinai Liver Cancer Program, NYC	Post-Doc, MIT, Boston
34.Amaia Lujambio (2015-)	Junior Faculty	Mentor	Oncological sciences, MSSM;NYC	Associate Professor, Oncological Sciences, MSSM
35.Martina Gambato (2015)	PhD	Mentor	Mount Sinai Liver Cancer Program, NYC	Faculty,Hepatology-. Padova University Hospital
36.Robert Montal (2015-2019)	MD, PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Faculty, Oncology. Hospital Lleida
37.Laura Torrens (2015-2022)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Post-Doc, IARC-Lyon
38.Olga Kuchuk (2015-2017)	Postdoctoral fellow	Mentor	Mount Sinai Liver Cancer Program, NYC	
40.Carmen Andreu (2016-2022)	PhD student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Consultant, Biotech
41.Laia Bassaganyas (2016-2018)	Postdoctoral fellow	Mentor	Liver Cancer Translational Research Group. Barcelona	Post-Doc, Cambridge, UK
42.Wei Qiang Leow (2017-2018)	Research Fellow	Mentor	Liver Cancer Translational Research Group. Barcelona	Faculty, Pathology. Singapore General Hospital
43.Roger Esteban (2017-2023)	PhD student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	PhD student, Liver Cancer Research Lab. IDIBAPS
44.Carla Montironi (2017-2022)	MD, PhD student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	Facuklty Dep Pathology, Hosp ClínicBarcelona
45.Beth Harrod (2016-2018)	MD, Liver Cancer Fellow	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	Lecturer, Univ London
46.Jordi Abril (2018-2024)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	PhD student, Liver Cancer Research Lab. IDIBAPS
47.Marta Piqué (2018-2025)	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	PhD student: Liver Cancer Research Lab. IDIBAPS
48.Marc Puigvehi (2017-2018)	MD	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	Faculty, Hepatology. Hospital del Mar IMIM, UAB-UPF
49.Carlos Montezuma (2017-2018)	MD,Liver Cancer Fellow	Mentor	Mount Sinai Liver Cancer Program.	Faculty,HepatologyMexico City, Mexico.

			Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	
50.Catherine Willoughby (2018- 2022)	Post- doc, PhD	Mentor	Liver Cancer Translational Research Group. Barcelona	Post-doc .IRB-Barcelona
51.Philip Haber (2018-2021)	MD	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	Faculty, Charité Hospital, Berlin
52.Miguel Torres (2019-2022)	Post-doc,PhD	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	Post-doc, CRG
53.Christopher Schrecker (2019-2020)	MD	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	Post-doc MSKCC
54. Vennis Lourdasamy (2018-2020)	MD. Liver Cancer Fellow	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	Faculty, Brandon Florida
55. Florian Castet (2019-2021)	MD, PhD Student	Master Thesis	Liver Cancer Translational Research Group. Barcelona	Faculty, Oncology, Hosp Vall d'Hebron
56. Ugne Balaseviciute (2019-	PhD student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	
57. Agavni Mesropian (2019-	PhD student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	
58. Júlia Huguet (2021-	PhD student	Thesis Director	Liver Cancer Translational Research Group Barcelona	
59. Maria Esteve (2022-2023	Master student	Master Thesis	Liver Cancer Translational Research Group . Barcelona	
60.Marcus Zeithoeffer (2023 -	MD	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	
61. Ieva Keraite (2023-2024)	Post-Doc, PhD	Mentor	Liver Cancer Translational Research Group. Barcelona	

62. Martí Torres (2023-2024)	Master student	Master Thesis	Liver Cancer Translational Research Group. Barcelona	
63. David Camell	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	
64. Anna Vila	Master student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	
65. Ezequiel Mauro	MD	Mentor	Liver Cancer Translational Research Group. Barcelona	
66. Tiago De Castro	MD	Mentor	Mount Sinai Liver Cancer Program. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai	
67. Guillem Cano	PhD student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	
68. Anna Vila	PhD Student	Thesis Director	Liver Cancer Translational Research Group. Barcelona	
69. Dylan Aitken	Master Student	Master Thesis Director	Liver Cancer Translational Research Group. Barcelona	
70. Laia González	Master Student	Master Thesis Director	Liver Cancer Translational Research Group. Barcelona	
Lab Managers (9 positions)	Judit Peix Laia Cabellos Vidalba Rocher Maria Milla Mònica Higuera Genis Campreciós Miho Maeda Marty Whithaegels Elisa Fernández		NYC-Barcelona NYC-Barcelona Barcelona Barcelona-NYC NYC NYC NYC NYC Barcelona Barcelona-NYC	

3. ACADEMIC AND HOSPITAL APPOINTMENTS

PRESENT POSITIONS

- 2006-present **Professor of Research-ICREA (Institució Catalana de Recerca i Estudis Avançats). Head, Translational Research Group.** IDIBAPS, Liver Unit, Hospital Clínic Barcelona, University of Barcelona.
- 2009-present **Professor of Medicine (Academic Track).** Division of Liver Diseases.

Department of Medicine. Icahn School of Medicine at Mount Sinai New York.

- 2005-present. **Director, Mount Sinai Liver Cancer Program.** Tish Cancer Institute (since 2010). Mount Sinai Liver Cancer Program. Icahn School of Medicine at Mount Sinai New York.
- 2013-present **Director, Master in Translational Medicine.** University of Barcelona.
- 2017-present **Director, Mount Sinai Liver Cancer Fellowship Program**
- 2020-present **Professor of Medicine-Hepatic Oncology.** Faculty of Medicine. University of Barcelona
- 2022-2024 **EASL Educational Committee.** European Association for the Study of the Liver.
- 2023-2024 **Member of the AASLD Special Interest Group (SIG) Advisory Task Force.**
- 2023- **Editor -in-Chief , *Journal of Hepatology Reports*** (Official journal of EASL;IF: 9.5)
- 2024 **Member of the academic committee for undergraduate degrees** at the Faculty of Medicine. University of Barcelona
- 2024- **AASLD- Past SIG Chairs Committee**

PAST POSITIONS

- 1989-1992. **Residency in Gastroenterology (M.I.R).** Speciality in Gastroenterology and Hepatology. Germans Trias i Pujol University Hospital (Head: Prof. M.A. Gassull). Certification: Date of Issuance: July, 23th 1993.
- 1993-94. **Research fellow in Hepatology.** Hospital Germans Trias i Pujol. Research Director: Dr. Ramón Planas.
- 1995-1997. **Faculty member of the Liver Unit, Hospital Clínic of Barcelona** Head of Unit: Prof. Joan Rodés. Responsibility in the hospitalization area of the Liver Unit, and the management of patients with liver tumors.
- 1995-1996. **Faculty member of the Intensive Care Liver Unit,** Hospital Clínic.
- 1993-2003. **Faculty in Digestive Diseases.** Catalan Institute of Health, Area of Barcelona (Area 8, Manso). June 1993- 2003. Resignation date in September 2005.
- 1998-2003 **Senior Researcher IDIBAPS-Hospital Clínic Barcelona.** Liver Unit, (Head: Prof Joan Rodés), Hepatic oncology group (Director: Dr. Jordi Bruix). Centre: IDIBAPS. Research Area: Liver, digestive system and metabolism.
- 2003-2004. **Senior Scientist, Mount Sinai School of Medicine (New York).** Division of Liver Diseases (Chief: Prof Scott Friedman), Transplantation Institute.
- 2005-2009 **Associate Professor of Medicine.** Division of Liver Diseases. Department of Medicine. Recanati Miller Transplantation Institute. Mount Sinai School of Medicine, New York.
- 2006-2015. **Executive Secretary (2006-2011), President (2011-13) and Educational Councilor (2013-15).** International Liver Cancer Association. (ILCA)
- 2009-2016 **Visiting Professor,** Fudan University, Shanghai.
- 2019-20 **Chair, Special Interest Group (SIG)- Hepatobiliary Tumors, AASLD**

4. MAIN ACHIEVEMENTS

The research activity in liver cancer started in 1995, after the obtention of the Doctoral Thesis degree, and involves two periods: one in the BCLC- Liver Unit–Hospital Clinic in Barcelona, (1995- 2002), mostly devoted to clinical research, a second period devoted to genomic and translational studies along with clinical research , first with the creation of the Mount Sinai Liver Cancer program (2003-2023), and afterwards by combining a dual

appointment in Mt Sinai as Professor of Medicine and Director of the Liver Cancer Program, and as Professor of Research-ICREA, Liver Unit, Hospital Clínic in Barcelona (2007-2023).

Scientific and managerial positions:

1. **Professor of Research-ICREA. Head, Liver Cancer Translational Research Group. IDIBAPS, Liver Unit, Hospital Clínic Barcelona, University of Barcelona (1995-2023).** Since 1995, Dr Llovet has carried out most of the clinical research in liver cancer in the setting of the Barcelona-Clínic Liver Cancer group, where he is leading the Liver Cancer Translational lab (<http://translationalhcc.idibaps.org/>). He has been leading more than 100 studies as PI, with an overall funding above 61M€.
 
2. **Founder (2005) and Director of the Mount Sinai Liver Cancer Program (2005-2019).** Mount Sinai Liver Cancer Program. Icahn School of Medicine at Mount Sinai New York. Dr Llovet formally organized the Liver Cancer Program in Mt Sinai in 2005, which currently includes more than 40 faculty with around \$ 7M of annual NIH funding (in 2024 : 8 RO1 or UO1). This program is the leading referral center for HCC management and research in the US. **The Liver Cancer Program was awarded with NCI designation in the setting of the NCI-designated Tisch Cancer Center in 2015.** This is the only program in Liver Cancer recognized by NCI in the US.
 
3. **Founder (2006), Executive Secretary (2007-2011) and President (2011-2013), and Educational councilor (2013-15) of the International Liver Cancer Association (ILCA),** the first multidisciplinary international association devoted to liver cancer research. The association has organized 10 annual meetings (Europe, US and Asia) with around 500-950 attendees per year, and provided CP Guidelines (ICCA, 2014).
4. **Leadership of International Consortia (2003-2020).** Dr. Llovet leads the *HCC Genomic Consortium*, which includes several academic centers (initially: USA: Mt Sinai, Dana-Farber Cancer Institute; Europe: Barcelona-BCLC Group; Milan NCI). It has been awarded with the AACR-Landon International Award in 2009. He is also the leader of *HEPTROMIC Consortium*, the first European multinational network for translational research in HCC supported by competitive funding from the European Commission (FP7- HEALTH, 2010-2013 www.heptromic.eu/). It involves 6 academic centers and 2 small-medium enterprises. Also Dr Llovet is partner of the *HEP-CAR Consortium* (Horizon 2020, 2016-2019), which is aimed to explore co-morbidities associated with HCC. This consortium includes 10 academic centers and SME and received a funding of 5,6M.
5. **Director, Master in Translational Medicine (2013-24).** Official Master, Faculty of Medicine, U.Barcelona (60 ECTS). Duration: 1-2 years, Students:30-60/year.
6. **Executive Committee of IDIBAPS (2012-23).** Member of the Executive Committee of IDIBAPS and the Advisory Committee of the Director. Chair of Talent Committee
7. **NCI-designated Tisch Cancer Center-Leadership Committee.** Member since 2015 as Director of the Liver Cancer Program.
8. **Executive Committee of Postgraduate and Masters Studies (2016-2018).** Faculty of Medicine and Health Sciences. University of Barcelona.
9. **Executive Committee of Postgraduate and Master Studies (2016-2020).** UFR Medicina-Clínic.

10. **Executive Committee of IDIBAPS Strategic plan (2018-2024).** Coordinator of the strategic line "Excellence in research" and Chair of Talent's Committee
11. **Participation in CIBERehd Network Research (2006-19).** My participation at CIBERehd begins after arriving from the US in 2006 as a researcher affiliated to the Hepatic Oncology group. Overall, I have published with the CIBERehd affiliation about 75 articles in Q1, of which in ~ 2/3 I am the principal investigator.

Main scientific achievements

Short Summary: a) *Establishing therapies as standard of care for advanced –sorafenib, regorafenib and ramucirumab- and intermediate –chemoembolization, and TACE plus Lenvatinib plus pembrolizumab- hepatocellular carcinoma (HCC); b) Defining molecular and immune classes of HCC and cholangiocarcinoma (CCA) and c) discovery of drivers as therapeutic targets (i.e mTOR, IGF signalling) for HCC and FGFR2 fusion (CCA) d) Proposal of BCLC staging for classification of HCC and mRECIST for assessment of response to therapies (adopted by guidelines)*

During the 30 years of my academic career, I have contributed to advancing scientific knowledge in liver cancer with the following achievements.

Translational research

1. Proposal of a molecular and immune classification of HCC:

A) A final proposal of a **molecular classification** of HCC is based on the results reported in different publications (Wurmbach, *Hepatology* 2007; Hoshida, *New Engl J Med*, 2008, Chiang, *Cancer Res*, 2008; Hoshida, *Cancer Res* 2009, Villanueva, *Gastroenterology* 2011, Hoshida *Gastroenterology* 2013, Nault JC, *Gastroenterology* 2013). This classification has been reviewed in Llovet, *Nat Rev Dis Primers* 2021 and *Nat Rev Clin Oncol* 2018

B) A proposal of **immune classification** of HCC (Sia et al, *Gastroenterology* 2017) was recently refined (Montironi, *Gut* 2022) and has been reviewed in Llovet, *Nat Rev Dis Primers* 2021 and *Nat Rev Clin Oncol* 2022 and predictors of response to immunotherapies (Harber P, *Gastroenterology* 2023)

2. Identification of oncogenic drivers as targets for therapies in HCC. Several studies led to the identification of **Akt/mTOR pathway** [Villanueva *Gastroenterology*, 2008], **Ras pathway** (Newell, *J Hepatol* 2009), **EGFR pathway** (Keng, *Nature Biotech* 2009), **IGF pathway** ([Tovar, *J Hepatol*, 2011, Martinez-Quegtlas *Gastroenterology* 2016], **Wnt Pathway** (Lachenmeyer, *CCR* 2012), **Notch pathway** (Villanueva, *Gastroenterology* 2012), AEG (Yoo, *J Clin Invest* 2009), **UHRF1** (Cancer Cell 2014), **IDH** (Saha, *Nature* 2014) and **miRNAs** (Viswanathan, *Nat Genetics* 2009, Toffanin, *Gastroenterology* 2011. Mutations signatures (Shultzze, *Nat Gen*, 2015), **chemoprevention** (Moeini, *Gastroenterology* 2019)

3. Pathogenesis of NASH-HCC and defining anti-tumoral and immunomodulatory effect of new combination treatments . We recently established the mechanism of diminished immune surveillance in HCC associated to NASH (Pfitzer, *Nature* 2021) and the decreased impact of immune therapies in this disease (Harber, *Gastroenterology* 2021, Llovet *Nat Rev Gastro Hepatology* 2022, in press). In addition, we have explored alternative approaches in experimental models using combinations therapies to overcome primary resistance and explore improved therapeutic approaches (Torrens, *Hepatology* 2021, Esteban *CCR* 2022)

4. Molecular classification of iCCA and drivers: We proposed a molecular classification of iCCA (Sia, *Gastroenterology* 2013) and identified **IDH** mutations as oncogenic in progenitor cells (Saha, *Nature*, 2014) and **FGFR2** fusion proteins as targetable drivers (Sia, *Nature Communications* 2015).

5. **Establishment of a molecular diagnosis of HCC:** Gene-set based diagnosis of HCC reported in Llovet, *Gastroenterology* 2006, accepted by EASL guidelines.

Clinical research

6. **Establishment of sorafenib, ramucirumab and regorafenib as standard of care in advanced HCC** (Llovet, *New Engl J Med* 2008). International RCT showing survival benefits for sorafenib vs placebo, presented at plenary session, ASCO. This breakthrough achievement establishes sorafenib as first line treatment for advanced HCC. Identified by *Nature Medicine* as the most cited paper in oncology 2008-2010. Adopted by American (AASLD) and European (EASL, ESMO) guidelines of HCC management. I have also co-authored the papers establishing ramucirumab (*Lancet Oncology*, 2019) and regorafenib (*Lancet*, 2017) as second-line therapies for advanced HCC.
7. **Guidelines of management of HCC and iCCA:** Chair of EASL-EORTC HCC Guidelines, 2012 (*J Hepatol*, 2012, *Eur J Cancer* 2012), and committee member panellist of guidelines of EASL (2001, 2018), ESMO (2018) and AASLD (2023). Leading author of AASLD guidelines for design of clinical trials in HCC (Llovet, *J Natl Cancer Institute*, 2008), and 2020 (*Hepatology*). Guidelines of management of iCCA (*J Hepatol*, 2014)
8. **Proposal of mRECIST for assessment of radiological end-points in HCC.** We reported the seminal paper describing the mRECIST assessment for radiological end-points (PFS, TTP and ORR) in HCC trial design. The study has received more than 1600 citations (Lencioni et al, *Semin Liv Dis* 2010), and mRECIST have been adopted by EASL guidelines and several phase III as the tool for measuring these end-points. Up-dated in 2020 (Llovet JM et al, *J Hepatol* 2020)
9. **Clinical classification of HCC:** with the acronym BCLC (Barcelona-Clínica Liver Cancer) classification, first published in Llovet, *Semin Liv Dis* 1999, and then further modified in Llovet, *Lancet* 2003; Llovet, *J Natl Can Inst*, 2008 and Forner, *Lancet* 2012, Llovet, *Nat. Cancer* 2022). This classification has been adopted by American (AASLD) and European (EASL-EORTC and ESMO) guidelines of HCC.
10. **Establishment of chemoembolization (associated with Lenvatinib plus pembrolizumab) as standard of care** in patients with intermediate HCC. Evidence-based establishment through randomized controlled trials [Llovet, *Lancet* 2002] and meta-analysis [Llovet, *Hepatology* 2003] of chemoembolization as standard of care in patients with intermediate HCC. Adopted by American (AASLD) and European (EASL-EORTC) guidelines. At ESMO 2024 we reported the LEAP012 study that showed superiority for lenvatinib+pembrolizumab+TACE vs TACE in terms of PFS (Llovet JM, *Ann Oncol* 2024, and *Lancet* 2025 -in press).

5. PUBLICATIONS

PERSONAL CITATION INDEX

- Number of articles: 397 (Scopus, January 2026): 87% Q1.
- Impact Factor (JCR update 2022): **8590,716**;
- Total number of citations: ~ **136,899** (Scopus, January 2026); ~ 173,156 (Google Scholar, January 2026).
- **H-index: 147** (Scopus, January 2026) ; **159** (Google Scholar)
- i1000 (papers with >1000 citations): **31**; i100: **172**
- **Top-1% most highly cited researcher** each year from 2014 to 2024. Clarivate Analytics (Thomson Reuters).



- # 996 top scientist in the world by Research.com in 2022, and #1318 in 2025
- #10 top scientist in Spain by Research.com in 2025;

Josep M. Llovet

University of Barcelona
Spain

D-Index & Metrics

Discipline name	D-index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	143	1318	1223	11	10	478	137974

- **Top 0.013% scientist globally, 675 out of ~7M scientists as per Stanford University 2024** (Ioannidis J et al, Plos Biology 2019) **#4 in Spain**
- **40 articles listed as *highly cited articles* by Clarivate Analytics (2018).**
- **Listed as top #3** of the Spanish 2018 HiCited Clarivate Researchers by Google Scholar.
- **Listed as top #8** Ranking of Spanish researchers and researchers working in Spanish Institutions

World	National	Scholar		D-Index	Citations	Publications
1223	10		Josep M. Llovet University of Barcelona, Spain	143	137.974	478

SUMMARY OF ARTICLES IN PEER-REVIEWED JOURNALS

Summary of scientific production and impact factor

JOURNAL	IF	Total Articles	Originals	Reviews	Editorials	Summary of IF*
LANCET	202,731	5	2	3		1013,655
NEW ENGLAND J. OF MEDICINE	176,079	2	2			352,158
NATURE MEDICINE	87,241	1	1			87,241
NAT REV GASTRO HEPAT	73,082	6		3	3	438,492
NATURE	69,504	2	2			139,008
NATURE BIOTECHNOLOGY	68,164	1	1			68,164
NATURE REVIEWS DISEASE PRIMER	65,038	2		2		130,076
NATURE REVIEWS CLINICAL ONCOLOGY	65,011	7		7		455,077
LANCET ONCOLOGY	54,433	8	5	2	1	435,464
ANNALS OF ONCOLOGY	51,769	2	2			103,538
JOURNAL OF CLINICAL ONCOLOGY	50,769	5		2	3	253,845
NATURE GENETICS	41,379	2	2			82,758
CANCER CELL	38,585	7	3	3	1	270,095
CANCER DISCOVERY	38,272	2	2			76,544
GASTROENTEROLOGY	33,883	32	19	14	1	1152,022
GUT	31,84	15	14		1	477,60
J HEPATOL	30,083	52	32	10	10	1564,316
JOURNAL CLINICAL INVEST	19,456	2	2			38,912
NATURE COMMUNICATIONS	17,694	2	2			35,388
HEPATOLOGY	17,298	41	33	4	4	709,218
ANNUAL REVIEW OF MEDICINE	16,048	1		1		16,048
CLINICAL CANCER RESEARCH	13,801	14	6	6	2	193,214
JOURNAL OF THE NATIONAL CANCER INSTITUTE	13,757	3	2	1		41,271
CANCER TREATMENT REVIEWS	13,608	2		2		27,216
CLIN GASTRO HEPAT	13,576	1	1			13,576
PROCEEDINGS OF NATIONAL ACADEMY OF SCIENCE	12,779	1	1	-	-	12,779
CANCER RESEARCH	12,701	2	2			25,402
AMERICAN JOURNAL OF GASTRO	12,045	4	4			48,18
CELL REPORTS	9,995	1	1			9,995
ONCOGENE	8,756	5	4	1		43,78
MOL CANCER THER.	6,311	2	2			12,622
SEMIN LIV DIS	6,115	9		9		55,035
LIVER TRANSPLANTATION	6,112	11	4	5	2	67,232
OTHERS		96				140,795
TOTAL		346	149	73	28	8590,716

Distribution of articles according to the scientific impact (last checked February 2023; letters excluded).

TOP MOST CITED ARTICLES. [(citations > 2500) as per Scopus, September 2024]

Title: Sorafenib in advanced hepatocellular carcinoma . Author(s): Llovet, JM. ; Ricci, Sergio; Mazzaferro, Vincenzo; et al. Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 359 Issue: 4 Pages: 378-390	11212
Title: EASL Clinical Practice Guidelines; Management of Hepatocellular Carcinoma . Author(s): Galle PR, Forner A, Llovet, JM. ; et al. Source: JOURNAL OF HEPATOLOGY 2018; 69 Issue: 1 Pages: 182-236 3073	7491
Title: EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma Author(s): Llovet, JM ; Ducreux, M; Lencioni, R. ; Di Bisceglie, A.M.; Galle, et al. Source: JOURNAL OF HEPATOLOGY 2012 Volume: 56 Issue: 4 Pages: 908- 943	5145
Title: Hepatocellular Carcinoma Author(s): Llovet, JM. ; et al. Source: NATURE REVIEWS DISEASE PRIMERS 2021;7:6	5014
Title: Hepatocellular Carcinoma Author (s): Forner A., Llovet JM , Bruix J. Source: THE LANCET 2012 Volume: 379 Issue: 9822 Pages: 1245-1255	4068
Title: Hepatocellular carcinoma Author(s): Llovet, JM ; et al. Source: LANCET 2003 Volume: 362 Issue: 9399 Pages: 1907-1917	3971
Title: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference . Author(s): Bruix, J; Sherman, M; Llovet, JM ; Group Author(s): EASL Panel Experts HCC. Source: JOURNAL OF HEPATOLOGY 2001 Volume: 35 Issue: 3 Pages: 421-430	3945
Title: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma . Author(s): Lencioni R, Llovet JM . Source: SEMINARS OF LIVER DISEASE 2010 Volume: 30 Pages: 52-60.	3842
Title: Prognosis of hepatocellular carcinoma: The BCLC staging classification . Author(s): Llovet, JM ; et al Source: SEMINARS IN LIVER DISEASE 1999 Volume: 19 Issue: 3 Pages: 329-338	3437
Title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial . Author(s): Llovet, JM ; Real, MI; Montana, X; et al. Source: LANCET 2002 Volume: 359 Issue: 9319 Pages: 1734-1739	3251
Title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial . Author(s): Bruix J, JM LlovetSource: LANCET 2017;389:56-66	3189
Title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival Author(s): Llovet, JM ; Bruix, J Source: HEPATOLOGY 2003 Volume: 37 Issue: 2 Pages: 429-442	2804

MOST CITED PAPERS EVER IN A GIVEN JOURNAL

1. **JOURNAL OF HEPATOLOGY** : EASL-EORTC Guidelines of management of HCC. Chair: JM Llovet): **5145 Citations**
2. **NEW ENGLAND JOURNAL OF MEDICINE** Llovet JM, Ricci S, Mazzaferro V, et al. N Engl J Med. 2008;359:378-90. Sorafenib in advanced hepatocellular carcinoma. Most cited article in NEJM for 2005-2015 and most cited article in the topic area of CANCER 2008-09, Nature Medicine (March, 2011)" **11212 citations**
3. **SEMINARS IN LIVER DISEASES**: Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC classification Semin Liv Dis 1999. **3437 citations**
4. **NATURE REVIEW DISEASE PRIMERS** : Llovet JM et al. Hepatocellular carcinoma. Nature Reviews Disease Primers 2021;7:6. **5014 citations**

MOST CITED MANUSCRIPTS IN LIVER CANCER EVER

1. The 100 most influential manuscripts on hepatocellular carcinoma: a bibliometric analysis. Hwang, JW. J Int Med Res. 2019 . JM Llovet: most cites articles # 15 out of top 100 articles.
2. Top100 articles in the area of Gastroenterology & Hepatology from 1950-2013 (Tang X, J Gastro & Hep 2016): JM Llovet 4 out 100 articles
3. Top 100 cited Meta-analysis by Uthman O et al, Plos One 2013. Paper: Llovet JM , Hepatology 2003 (63rd)
4. Llovet JM: #1 Most cited investigator in Spain, period 1997-2011. Top cited papers and authors in the field of Biomedicine in Spain, 1997-2011. Mendez-Vasquez, RI; Sunen-Pinyol, E; Pons, JMV; Cami, J. Barcelona, 2014.

MOST CITED PAPERS IN SPECIFIC YEARS

1. Llovet JM, Real MI, Montaña X, et al.. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-39 Llovet JM, Real MI, Montaña X, et al. The Lancet 2002;359: 1734-39. From "10 most cited articles in Lancet, 2002" **3251 citations**
2. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442 "Most cited article in Hepatology, 2003" . **2804 citations**

ORCID (Open Researcher and Contribution ID



RESEARCH GATE PROFILE http://www.researchgate.net/profile/Josep_M_Llovet



PUBLICATIONS IN INTERNATIONAL JOURNALS

ORIGINALS

1. Fernández-Bañares F, Esteve-P M., Humbert P, De Leon R, **Llovet JM**, Gassull MA. Sugar malabsorption in functional bowel disease: clinical implications. *Am J Gastroenterol* 1993;88:2044-50 (D1 PMID 8249972)
2. Abad-Lacruz A, Cabré E, González-Huix F, Fernández-Bañares F, Esteve M, Planas R, **Llovet JM**, Quer JC, Gassull MA. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics. *Am J Gastroenterol* 1993;88: 382-387 (D1 PMID 8438845)
3. **Llovet JM**, Planas R, Morillas R, Quer JC, Cabré E, Boix J, Humbert P, Guilera M, Domènech E, Bertran X, Gassull MA. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. *Am J Gastroenterol* 1993;88: 388-392 (D1 PMID 8438846)
4. Follo A, **Llovet JM**, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. *Hepatology* 1994;20: 1495-1501 (D1 PMID 7982650)
5. **Llovet JM**, Bartolí R, Planas R, Cabré E, Ibañez A, Urban A, Ojanguren I, Ibañez A, Arnal J, Gassull MA.. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. *Gut* 1994;35: 1648-1652 (D1 PMC1375630)
6. **Llovet JM**, Bartolí R, Planas R, Viñado B, Perez J, Cabré E, Arnal J, Ojanguren I, Ausina V, Gassull MA. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. *Hepatology* 1996;23: 781-787 (D1 PMID 8666332)
7. Sánchez-Tapias JM, Forns X, Ampurdanés S, Titó L, Planas R, Viver JM, Acero D, Torres M, Mas P, Morillas R, Forné M, Espinós J, **Llovet JM**, Costa J, Olmedo E, López-Labrador FX, Jiménez de Anta MT, Rodés J.. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. *Gut* 1996;38: 603-609 (D1 PMC1383123)
8. Navasa M, Follo A, **Llovet JM**, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forné M, Planas R, Bañares R, Castells L, Jimenez de Anta MT, Arroyo V, Rodés J. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. *Gastroenterology* 1996;111: 1011-1017 (D1 PMID 8831596)
9. **Llovet JM**, Rodriguez-Iglesias MP, Moitinho E, Planas R, Bataller R, Navasa M, Menacho R, Pardo A, Castells A, Cabré E, Arroyo V, Gassull MA, Rodés J.. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. *J Hepatol* 1997;26: 88-95 (D1 PMID 9148028)
10. Cubiella J, Sans M, **Llovet JM**, Bustamante J, Ferrer A, Arroyo V, Rodés J. . Pulmonary abscess as a complication of transarterial embolization of multinodular hepatocellular carcinoma. *Am J Gastroenterol* 1997;92: 1942-1943 (D1 PMID 9382078)
11. **Llovet JM**, Bartolí R, March F, Planas R, Viñado B, Cabré E, Arnal J, Coll P, Ausina V, Gassull MA. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. *J Hepatol* 1998;28:307-313 (D1 PMID 9580278)
12. Bruix J, **Llovet JM**, Castells A, Montaña X, Brú C, Ayuso MC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology* 1998;27: 1578-1583 (D1 PMID 9620330)
13. **Llovet JM**, Bruix J, Fuster J, Castells A, García-Valdecasas JC, Grande L, França A, Brú C, Navasa M, Ayuso MC, Solé M, Real MI, Vilana R, Rimola A, Visa J, Rodés J. . Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. *Hepatology* 1998;27:1572-1577 (D1 PMID 9620329)

14. **Llovet JM**, Fuster J and Bruix J, for the BCLC Group. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999;30: 1434-1440 (D1 PMID 10573522)
15. **Llovet JM**, Bustamante J, Castells A, Vilana R, Ayuso MC, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999;29:62-67 (D1 PMID 9862851)
16. **Llovet JM**, Moitinho E, Sala M, Bataller R, Rodríguez-Iglesias MP, Castells A, Planas R, Navasa M, Bruix J, Rodés J.. Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. *J Hepatol* 2000;33:423-429 (D1 PMID 11019998)
17. **Llovet JM**, Sala M, Castells LI, Suarez J, Vilana R, Bianchi LI, Ayuso C, Vargas V, Rodés J and Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. *Hepatology* 2000;31: 54-58 (D1 PMID 10613728)
18. Gimenez M, Franco S, Suárez Y, Forns X, Ampurdanés S, Puig-Basagoiti, Sanchez-Fueyo A, Barrera JM, **Llovet JM**, Bruix J, Sánchez-Tapias JM, Rodés J, Sainz JC. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. *Hepatology* 2001;34:158-167 (D1 PMID 11431747)
19. **Llovet JM**, Vilana R, Brú C, Bianchi LI, Salmeron JM, Sala M, Ayuso C, Pagès M, Boix L, Ganau S, Solé M, Rodés J, Bruix J. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. *Hepatology* 2001;33: 1124-1129 (D1 PMID 11343240)
20. Sarasin F, Majno P, **Llovet JM**, Mentha J, Bruix J, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. *Hepatology* 2001;33:1073-1079 (D1 PMID 11343234)
21. **Llovet JM**, Ruff P, Tassopoulos N, Bruix J, El-Hariry I, Peachey M. A phase II trial of oral eniluracil plus 5-fluorouracil in patients with inoperable hepatocellular carcinoma. *Eur J Can* 2001;37:1352-1358 (Q1 PMID 11435064)
22. **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte JJ, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J for the Barcelona-Clínic-Liver Cancer Group. . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002;359:1734-39 (D1 PMID 12049862)
23. Forns X, Ampurdanès S, **Llovet JM**, Aponte J, Quintó LI, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 2002;36:986-992 (D1 PMID 12297848)
24. **Llovet JM**, Mas X, Aponte J, Fuster J, Navasa M, Christensen E, Rodés J and Bruix J. BCLC Group.. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. *Gut* 2002;50:123-8 (D1 PMC1773063)
25. Armengol C, Boix L, Bachs O, Solé M, **Llovet JM**, Rodés J, Bruix J. p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. *J Hepatol* 2003;38:591-7 (D1 PMID 12713869)
26. Burrel M, **Llovet JM**, Ayuso C , Sala M, Iglesias C, Solé M, Caralt T, Ayuso JR, Brú C, Bruix J. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. *Hepatology* 2003;38:1034-42 (D1 PMID 14512891)
27. **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003;37: 429-442 (D1 PMID 12540794)
28. Ayuso JR, Ayuso C, Bombuy E, De Juan C, **Llovet JM**, De Caralt TM, Sánchez M, Pagés M, Bruix J, García-Valdecasas JC.. Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. *Liver Transpl* 2004;10: 1391-1397 (Q1 PMID 15497156)


29. Sala M, Fuster J, **Llovet JM**, Navasa M, Solé M, Varela M, Pons F, Rimola A, García-Valdecasas JC, Brú C, Bruix J; Barcelona Clinic Liver Cancer (BCLC) Group.. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. *Liver Transpl* 2004;10:1294-1300 (Q1 PMID 15376311)
30. Sala M, **Llovet JM**, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J; Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology* 2004;40: 1352-60 (D1 PMID 15565564)
31. Garcia-Retortillo M, Forns X, **Llovet JM**, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-Valdecasas JC, Rimola A.. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. *Hepatology* 2004;40:699-707 (D1 PMID 15349910)
32. Rimola A, **Llovet JM**, Navasa M, Bruix J, Londoño MC, Fuster J, García-Valdecasas JC.. Applicability of adult-to-adult living donor liver transplantation. *J Hepatol* 2005;43:104-109 (D1 PMID 15876470)
33. Mazzaferro V, Romito R., Schiavo M, Mariani L, Camerini T, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, **Llovet JM**. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. *Hepatology* 2006;44:1543-54 (D1 PMID 17133492)
34. **Llovet JM**, Chen Y, Wurmbach W, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman S. A molecular signature to discriminate dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis. *Gastroenterology* 2006;131: 1758-1767 (D1 PMID 17087938)
35. Vilana R, Bianchi L, Varela M, Nicolau C, Sánchez M, Ayuso C, García M, Sala M, **Llovet JM**, Bruix J, Bru C; BCLC Group.. Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?. *Eur Radiol* 2006;16: 2454-62 (Q1 PMID 16710666)
36. Bräu N, Fox R, Xiao P, Marks K, Naqvi Z, Taylor L, Trikha A, Sherman M, Sulkowski M, Dieterich D, Rigsby M, Wright T, Hernandez M, Jain M, Khatri G., Sterling R, Bonacini M, Martyn C, Aytaman A, **Llovet JM**, Brown S, Bini. Presentation and Outcome of Hepatocellular Carcinoma in HIV-Infected Patients. A U.S.-Canadian Multicenter Study. *J Hepatol* 2007;47:527-537 (D1 PMID 17692986)
37. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, **Llovet JM**, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. *J Hepatol* 2007;46: 474-481 (D1 PMID 17239480)
38. Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Benzeno S, Lee JS, Schwartz M, Thung S, Fiel MI, Yea S, Banck M, Zimran E, Thorgeirsson S, Mazzaferro V, Bruix J, Martignetti JA, **Llovet JM**, Friedman S. Downregulation of KLF6 is an Early Event in Hepatocarcinogenesis, and Stimulates Proliferation while Reducing Differentiation. *J Hepatol* 2007;46:645-54 (D1 PMC3533246)
39. Wurmbach E, Chen Y, Khitrov G, Roayaie S, Fiel I, Schwartz M, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, **Llovet JM**. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. *Hepatology* 2007;45: 938-47 (D1 PMID 17393520)
40. A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore Wrobel MJ, Lerner J, Reich M, Chan J, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, **Llovet JM**, Golub TR. Gene Expression in fixed tissue and Outcome in Hepatocellular Carcinoma. *N Engl J Med* 2008;359:1995-2004 (D1 PMID:18923165)



J,

(D1

41. **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Cosme A, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten T, Galle P, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J, for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378-90 (D1 PMID 18650514)
42. **Llovet JM**, Di Bisceglie A, J Bruix J, Kramer B, Lencioni R, Zhu A, Sherman M, Schwartz M, Lotze M, Talwalkar J, and Gores GJ on behalf of Panel of Experts in HCC. Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 2008;100: 698-711 (D1 PMID 18477802)
43. Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Martignetti J, Marsh W, **Llovet JM**. Liver Transplantation for hepatocellular carcinoma: extended indications based on molecular markers. *J Hepatol* 2008;49:581-8 (D1 PMC2646906)
44. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Sala M, Varela M, **Llovet JM**, Bru C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. *Hepatology* 2008;47: 97-104 (D1 PMID 18069697)
45. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, , **Llovet JM**. Pivotal role of mTOR signaling in HCC. *Gastroenterology* 2008;135:1972-83 (D1 PMC2678688)
46. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Akita K, Shirasawa S, Sasazuki T, Margignetti J, Llovet JM, Friedman S. Ras Promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. *Gastroenterology* 2008;2008;134:1521-31 (D1 PMC2600656)
47. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, **Llovet JM**. Focal gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. *Cancer Research* 2008;68:6779-88 (Q1 PMC2587454)
48. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhi R, Azam M, Teixeira J, Meyerson M, Hughes TP, **Llovet JM**, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ Lin28 enhances transformation and is associated with advanced human malignancies. *Nature Genetics* 2009;41:843-8 (D1 PMC2757943) PMID:19483683
49. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, Silverstein KA, Sarver A, Starr TK, Akagi K, Tessarollo L, Collier LS, Powers S, Lowe SW, Jenkins NA, Copeland NG, **Llovet JM**, Largaespada DA. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. *Nature Biotech* 2009;27:264-74 (D1 PMC2712727) PMID:19234449
50. Mazzaferro V, **Llovet JM**, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group.. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009;10:35-43 (D1 PMID 19058754)
51. Newell P, Toffanin S, Villanueva A, Chiang D, Minguez B, Cabellos L, Savic R, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel M, Thung S, Alsinet C, Tovar V, Hoshida Y, Bruix J, Roayaie S, Mazzaferro V, Schwartz M, Friedman S, **Llovet JM**. Ras Pathway Activation in Hepatocellular Carcinoma and anti-tumoral effect combined Sorafenib and Rapamycin in vivo. *J Hepatol* 2009;51:725-33 (D1 PMC2970800)



52. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, **Llovet JM**, Brenner DA, Schwabe RF. CCR1 and CCR5 promote hepatic fibrosis in mice . *J Clin Invest* 2009;119: 1858-70 (D1 PMC2701864)
53. Yoo B, Emdad L, Su Z, Villanueva A, Chiang D, Mukhopadhyay ND, Mills AS, Waxman S, Fisher R, **Llovet JM**, Fisher P, Sarkar D. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. *J Clin Invest* 2009;119:465-77 (D1 PMC2648696)
54. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, **Llovet JM**, Schwartz M. Novel A system of classifying microvascular invasion to predict outcome after resection in patients with HCC. *Gastroenterology* 2009;137:950-5. (D1 PMC2739450)
55. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, **Llovet JM**, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-Fetoprotein, Des-gamma Carboxyprothrombin, and Lectin-Bound alpha-Fetoprotein in Early Hepatocellular Carcinoma. *Gastroenterology* 2009;137:110-118 (D1 PMC2704256)
56. Hoshida Y, Nijman S, Kobayashi M, Chan J, Jean- Brunet P, Chiang D, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman S, Kumada H, **Llovet JM**, Golub T. Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. *Cancer Research* 2009;69:7385-92 (Q1 PMC3549578)
57. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer A, Rodriguez C, Reig M, Bianchi L, **Llovet JM**, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. *Cancer* 2009;115:616-623 (Q1 PMID 19117042)
58. Tovar V, Alsinet C, Villanueva A, Chiang D, Solé M, Thung S, Moyano s, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. *J Hepatol* 2010;52:550-9 (D1 PMC3662876)
59. Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung Swan, Mandeli John, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Golub TR, Friedman SL, **Llovet JM**. Gene-expression signature of vascular invasion in hepatocellular carcinoma. *J Hepatol* 2011;55:1325-1331 (D1 PMC3624094)
60. Paris AJ, Snapir Z, Christopherson CD, Kwok SY, Lee UE, Ghiassi-Nejad Z, Kocabayoglu P, Sninsky JJ, **Llovet JM**, Kahana C, Friedman SL. A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. *Hepatology* 2011;54(6):2198-207 (D1 PMC3760215)
61. Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, **Llovet JM**, Friedman SL. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma, associated with p53 pathway deregulation. *Hepatology* 2011;54:522-31 (D1 PMC3144998)
62. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung S, Bruix J, Newell P, Roayaie S, Mazzaferro V, Schwartz M, Golub T, **Llovet JM**. Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. *Gastroenterology* 2011;140:1501-1512 (D1 PMC3081971)
63. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A., Cabellos L, Mínguez B, Savic R, Ward S, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, April C, Fan JB, Schwartz M, Bruix J, Friedman SL, Golub T, Mazzaferro V, **Llovet JM**. MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. *Gastroenterology* 2011;140:1618-1628 (D1 PMC3680790)
64. Wang PR, Xu M, Toffanin S, Li Y, **Llovet JM**, Russell D. Induction of hepatocellular carcinoma by in vivo gene targeting. *Proceedings of National Academy of Science* 2012;109:11264-9 (D1 PMC3396480)
65. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis

- D, **Llovet JM**. Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC): subanalysis of a Phase III Trial. *J Hepatol* 2012;57:821-9 (D1 PMID:22727733)
66. Burrel M, Reig M, Forner A, Barrufet M, Lope CR, Tremosini S, Ayuso C, **Llovet JM**, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using DC Beads. Implications for clinical practice and trial design. *J Hepatol* 2012;57:213-8 (D1 PMID 22314428)
 67. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, **Llovet JM**. Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. *J Hepatol* 2012;56:1343-50 (D1 PMC3355195)
 68. Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S, Ricci S, Nadel A, Moscovici M, Voliotis D, **Llovet JM**. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. *J Hepatol* 2012;56:100-1088 (D1 PMID 22245896)
 69. EASL-EORTC Guidelines of clinical management of HCC (Chair: **JM Llovet**). European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012;56:908-43 (D1 PMID 22424438)
 70. Vetter D, Cohen-Naftaly M, Villaneuva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, **Llovet JM**, Thung SN, Friedman SL. Enhanced hepatocarcinogenesis in mouse models and human HCC by coordinate KLF6 depletion and increased mRNA splicing. *Hepatology* 2012;56:1361-70 (D1 PMC3412196)
 71. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Sole M, Thung S, Stanger B, **Llovet JM**. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. *Gastroenterology* 2012;143: 1660-69 (D1 PMC3505826)
 72. EASL-EORTC Guidelines of clinical management of HCC (Chair: **JM Llovet**). European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Eur J Can* 2012;48:599-641 (Q1 PMID 22424278)
 73. Lachenmayer A, Savic R, Alsinet C, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward S, Bruix J, Mazzaferro V, Schwartz M, Friedman S, **Llovet JM**. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. *Clin Cancer Res* 2012;15;18:4997-5007 (Q1 PMC3446854)
 74. **Llovet JM**, Pena C, Lathia C, Shan M, Meinhardt G, Bruix J.. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. *Clin Cancer Res* 2012;18:2290-2300 (Q1 PMID 22374331)
 75. **Llovet JM**, Decaens T, Raoul J-L, Boucher E, Kudo M, Chang C, Kang Y.-K, Assenat E, Lim H.-Y, V., P., Fartoux L, Lin D.-Y., Bruix J, R.T., M. Sherman, Blanc J.-F., Finn, R.S., Tak W.-Y., Chao Y., R., D., Walters I., Park J.-W. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. *J Clin Oncol* 2013;31:3509-16 (D1 PMID 23980090)
 76. Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, **Llovet JM**, Largaespada DA. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. *Hepatology* 2013;57:120-30 (D1 PMC3511635)
 77. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow d, **Llovet JM**, Schwartz M, Mazzaferro V. Resection of HCC ≤ 2 cm: results from two western centers. *Hepatology* 2013;1426-35 (D1 PMC3442120)

78. Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, **Llovet JM**, Powers S. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. *Gastroenterology* 2013;145:1424-1435 (D1 PMC3892430)
79. Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, **Llovet JM**, Zucman-Rossi J. A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. *Gastroenterology* 2013;145:176-187 (D1 PMID 23567350)
80. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Lavarone M, Friedman SL, Colombo M, **Llovet JM**, Golub TR. Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis Gene-Expression Signature and Outcome in Liver Cirrhosis. *Gastroenterology* 2013;144:124-30 (D1 PMID 26045137)
81. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung S, Fuster J, Garcia-Valdecasas JC, Bruix J, Schwartz M, Beroukhi R, Mazzaferro V, **Llovet JM**. Integrative molecular analysis of human intrahepatic cholangiocarcinoma reveals 2 classes that have different outcome. *Gastroenterology* 2013;144:829-40 (D1 PMC3624083)
82. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, **Llovet JM**, Wong KK, Ramaswamy S, Bardeesy N. Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. *Nature* 2014;513:110-4 (D1 PMID: 25043045)
83. Bridgewater J, Galle PR, Khan SA, **Llovet JM**, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *J Hepatol* 2014;60:1268-89 (D1 PMID 24681130)
84. Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, Senbanerjee S, Ukomadu C, **Llovet JM**, Sadler KC. UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. *Cancer Cell* 2014;25:196-209 (D1 PMC3951208)
85. Schulze K, Imbeaud S, Letouzé E, Alexandrov L, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton M, **Llovet JM**, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nature Genetics* 2015;47:505-11 (D1 PMC4587544)
86. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo M, Pinyol R, Roayaie S, Thung S, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, **Llovet JM**. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nature Communications* 2015;6:6087 (D1 PMID 25608663)
87. **Llovet JM**. Molecular markers predicting outcome in hepatocellular carcinoma treated by liver transplantation. *Liver Transpl* 2015;21 Suppl 1:S25-6 (Q1 PMID 26335803)
88. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, **Llovet JM**; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2015;16:1344-54 (D1 PMID 26361969)
89. Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, **Llovet JM**. Progenitor cell markers predict outcome of patients with Hepatocellular Carcinoma beyond Milan criteria undergoing liver transplantation. *J Hepatol* 2015;63:1368-77pii (D1 PMID 26220754)

90. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, **Llovet JM**, Leberre M, Jensen M, Meinhardt G, Kang Y. . SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. *J Clin Oncol* 2015;33:559-66 (D1 PMID 25547503)
91. Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, Pinyol R, Solé M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, **Llovet JM**. DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma. *Hepatology* 2015;61:1945-56 (D1 PMID 25645722)
92. Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Iavarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, **Llovet JM**, Hoshida Y, Friedman SL. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. *Gut* 2015;65:1754-64 (D1 PMID 26045137)
93. King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, **Llovet JM**, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. *Gut* 2015;64:1296-302 (D1 PMC4336233)
94. Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Vila-Casadesús M, Villanueva A, Thung S, C. Ward S, Rodriguez-Carunchio L, Imbeaud S, Lachenmayer A, Quaglia A, M. Nagorney D, Minguez B, Carrilho F, R. Roberts L, Mazzaferro V, Schwartz M, Esteller M, D. Heaton N, Zucman-Rossi J, **Llovet JM**. Unique genomic profile of fibrolamellar hepatocellular carcinoma. *Gastroenterology* 2015;148:806-18.e10 (D1 PMC4521774)
95. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, **Llovet JM**, Morrissey D, Raj L, Bardeesy N. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. *Cell Rep* 2015;S2211-1247:00173-4 (Q1 PMC4565791)
96. Lencioni R, **Llovet JM**, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. *J Hepatol* 2016;64:1090-8 (D1 PMID 26809111)
97. Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Bonilla S, Portela A, Tovar V, Alsinet C, Villanueva A, Rodriguez-Carunchio L, Solé M, Esteller M, Zender L, Llovet JM. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. *Gastroenterology* 2016;151:1192-1205 (D1 PMID 27614046)
98. Bollard J, Miguela V, Ruiz de M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, **Llovet JM**, Hoshida Y, Lujambio A. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. *Gut* 2017;66:1286-1296 (PMID 27849562)
99. Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileskin L, Sia D, Tothill R, Tabernero J, **Llovet JM**, Esteller M. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. *Lancet Oncol*. 2016;17:1386-1395 (PMID:27575023).
100. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Alsinet C, Martinez-Quetglas I, Solé M, Domingo-Domenech J, Villanueva A, **Llovet JM**. Tumor initiating cells and IGF/FGF signaling contribute to sorafenib resistance in Hepatocellular Carcinom. *Gut*. 2017;66:530-540 (D1 PMID 26658144)

101. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, **Llovet JM**. Objective Response by mRECIST as a Predictor and Potential Surrogate End Point of Overall Survival in Advanced HCC. *J Hepatol*. 2017;66:1166-1172 (PMID:28131794)
102. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, **Llovet JM**, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017 Jan 7;389(10064):56-66 PMID:27932229
103. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Quetglas IM, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, **Llovet JM**. Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity . *J Hepatol*. 2017;66:952-961 (PMID 28126467)
104. Nakagawa S, Wei L, Song W, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu M, Chuang W, Dai C, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, **Llovet JM**, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwartz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. *Cancer Cell* 2016;30:879-890 (PMID:27960085).
105. Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, **Llovet JM**. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma:preliminary results. *Eur Radiol*. 2017;27:4472-4481 (PMID:28439654).
106. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta Martin C,, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung S, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, **Llovet JM**. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. *Gastroenterology* 2017;153:812-826 (PMID:28624577).
107. Torrecilla S, Sia D , Harrington AN, , Zhang Z, Cabellos L , Cornella H, Moeini A ,Camprecios G, Leow WO , Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz M, **Llovet JM**. Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. *Journal of Hepatology* 2017;67:1222-1231 (PMID:28843658).
108. Goretsky T, Bradford EA, Ye Q, Vanagunas T, Keller PC, Moyer MP, Sinh P, **Llovet JM**, Gao T, She QB, Li L, Barrett T. Beta-catenin cleavage enhances transcriptional activation. *Scientific Reports* 2018;8:671 (PMID: 29330435)
109. **Llovet JM**, Pavel M, Rimola J, Diaz M A, Colmenero J, Saavedra D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Valdecasas JC. Pilot study of living donor liver transplantation for patients with HCC exceeding Milan criteria (BCLC extended criteria). *Liver Transplantation* 2018;3:369-379 (29140601).
110. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, **Llovet JM**. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. *Journal of Hepatology* 2017;67:999-1008
111. Labgaa I, Villacorta-Martin C, D'Avola D, Craig A, Martins S, Sia D, Stueck A, Ward S, Fiel MI, Mahajan M, Tabrizian P, Thung S, Ang C, Friedman S, **Llovet JM**, Schwartz M, Villanueva A. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. *Oncogene* 2018;37:3740-3752. (PMID: 29628508).
112. Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, **Llovet**

- JM.** Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma. *CCR* 2018;24:4650-4661 (PMID:29950351)
113. Galle P, Forner A, **Llovet JM**, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Association for the Study of the Liver. *J Hepatol.* 2018;69:182-236 (PMID 29628281).
 114. Vogel A, Cervantes A, Chau I, Daniele B, **Llovet JM**, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *ESMO Guidelines. Annals of Oncology* 2019;30:871-873. (PMID 30715202)
 115. Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martín Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia J, Molina MÁ, Juan M, **Llovet JM**, Reguart N, Arance A, Prat A. *Ann Oncol.* 2018;29:2121-2128 (PMID: 30165419)
 116. Kamath GR, Taioli E, N Egorva N, **Llovet JM**, Perumalswami PV, Weiss JJ, Schwartz M, Ewala S, Bickell Na. Liver Cancer Disparities in New York City: A neighborhood view of risk and harm reduction factors. *Frontiers of Oncology.* 2018;8:220 (PMID:29963497)
 117. Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U de la Mata E, Lupo L, Strasser S, JW Park, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, **Llovet JM**. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. *Gut* 2019;68:1065-1075 (PMID 30108162)
 118. Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, **Llovet JM**, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M.. Platelet GPIIb/IIIa is a mediator and potential interventional target for NASH and subsequent liver cancer. *Nat. Med.* 2019;25:641-655 (PMID:30936549).
 119. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, **Llovet JM**, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019;20:282-296. (PMID:30665869)
 120. Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. *Gastroenterology.* 2019;156:1731-1741 (PMID:30738047)
 121. Montal R., Andreu-Oller, C, Bassaganyas L, Esteban-Fabré R, Moran S, Montironi C, Moeini A, Pinyol R, Peix J, Cabellos L, Villanueva A, sia D, Mazzaferro V, Esteler M, **Llovet JM**. Molecular Portrait of High Alpha-Fetoprotein in Hepatocellular Carcinoma; Implications for Biomarker-Driven Clinical Trials. *British Journal of Cancer.* 2019; 121:340-343.(PMID:31285588).
 122. Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, **Llovet JM**, Merad M, Lujambio A. A. β -Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. *Cancer Discov.* 2019;9:1124-1141. PMID: 31186238

123. Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, **Llovet JM**. An Immune gene expression signature associated with developments of human HCC identifies mice that respond to chemopreventive agents *Gastroenterology*. 2019;157:1383-1397 (PMID:31344396)
124. Conboy CB, Velez-Reyes, Germán L, Tschida BR, Hu H, Kaufmann, NK, Koes N, Keller B, Alsinet C, Cornella H, Pinyol R, Abrahante JE, Temiz NA, Linden MA, Amin K, Kuka TP, Keng VW, **Llovet JM**, Starr TK, Largaespada. R-sponding 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner. *Hepatology Communications*. 2019;3:1496-1509. (PMID: 31701073)
125. Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Zioli M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, **Llovet JM**, Seror O, Letouzé E, Zucman-Rossi J. Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. *Hepatology* 2020;71:164-182. (PMID: 31206197)
126. Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, **Llovet JM**, Saberi B. Liver Transplant for Hepatocellular Carcinoma in the United States; Evolving Trends over the Last Three Decades. *Am J Transplant*. 2020;20:220-230. (PMID:31437349)
127. Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, **Llovet JM**, Manooogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. First-in-Human Phase I Study of Fisetinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma. *Cancer Discov*. 2019;9:1696-1707 (PMID: 31575541)
128. Losic B, Craig AJ, Villacorta-Martin C, Martins-Filho SN, Akers N, Chen X, Ahsen ME, von Felden J, Labgaa I, D'Avola D, Allette K, Lira SA, Furtado GC, Garcia-Lezana T, Restrepo P, Stueck A, Ward SC, Fiel MI, Hiotis SP, Gunasekaran G, Sia D, Schadt EE, Sebra R, Schwartz M, **Llovet JM**, Thung S, Stolovitzky G, Villanueva A. Intratumoral heterogeneity and clonal evolution in liver cancer. *Nat Commun*. 2020;11:291. (PMID: 31941899)
129. Franch-Expósito S, Bassaganyas L, Vila-Casadesús M, Hernández-Illán E, Esteban-Fabrá R, Díaz-Gay M, Lozano JJ, Castells A, **Llovet JM**, Castellví-Bel S, Camps J. CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications. *Elife*. 2020;15:e50267 (PMID: 31939733)
130. Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabrá R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J; Cabellos L; Maeda M; Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR; Sole M; Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, **Llovet JM**, . Molecular Classification and Therapeutic Targets in Extrahepatic Cholangiocarcinoma. *Journal of Hepatology* 2020;73:315-327 (PMID: 32173382)
131. Carrillo-Reixach J, Simon-Coma M, Akers N, 3,4, Royo L, Torrens L, Arnal M, Villamanzo N, Cairo S, Villanueva A, Kappler R, Domingo-Sàbat M, Garrido M, Guerra L, Sábado C, Guillén G, Mallo M, Piñeyro D, Vázquez-Vitali M, Kuchuk O, Mateos ME, Ramírez G, Lopez Santamaría M, Mozo Y, Soriano A, Grotzer M, Branchereau S, García de Andoin N, López-Ibor B, López-Almara R, Salinas JA, Torres B, Hernández F, Uriz JJ, Fabre M, Blasco J, Paris C, Bajciová V, Laureys G, MAsnou E, Belendez C, Guettier C, Sumoy L, Planas R, Jorda M, Nonell L, Czauderna P, Morland B, SalaM, Sia D, Losic B, Sarrias MR, Buendia MA, **Llovet JM**, Armengol C, Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications. *Journal of Hepatology*. 2020;30:S0168 -8278:30187-2. (PMID: 32240714)
132. Kudo M, Galle PR, **Llovet JM**, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Ubreva ND, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. *Liver Int*. 2020; 40:2008-2020 (PMID: 32279446)

133. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi K, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, **Llovet JM**. Phase 1b Study of Lenvatinib + Pembrolizumab in patients with unresectable Hepatocellular Carcinoma. *J. Clin. Oncol.* 2020;38:2960-2970. (PMID: 32716739)
134. Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, Franch-Expósito S, Vila-Casadesús M, Salaverria I, Montal R, Mazzaferro V, Camps J, Sia D, **Llovet JM**. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. *Clin Cancer res.* 2020;26:6350-6361 (PMID: 32873569)
135. Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, **Llovet JM**, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. *JHEP Rep.* 2020; 13:100215 (PMID:33392490)
136. Reig M, Galle PR, Kudo M, Finn R, **Llovet JM**, Mett AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. *Liver Int.* 2021;41:598-607. (PMID: 33188713)
137. Hernandez-Meza G, von Felder Johann, Gonzalez-Kozlova EE, Garcia-Lezana T, Peix J, Portela A, Craig AJ, Sayols S, Schwartz M, Losic B, Mazzaferro V, Esteller M, **Llovet JM**, Villanueva A. DNA methylation profiling of human hepatocarcinogenesis. *Hepatology.* 2021;74:183-199 (PMID:33237575)
138. von Felden J, Craig AJ, Garcia-Lezana T, Labgaa I, Haber PK, D'Avola D, Asgharpour A, Dieterich D, Bonaccorso A, Torres-Martin M, Sia D, Sung MW, Tabrizian P, Schwartz M, **Llovet JM**, Villanueva A. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. *Oncogene.* 2021;40:140-151 (PMID: 33097857)
139. Meunier L Hirsch TZ, Caruso S, Imbeaud S, Bayard Q, Roehrig A, Couchy G, Nault JC, **Llovet JM**, Blanc JF, Calderaro J, Zucman-Rossi J, Letouzé E. DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. *Hepatology* 2021;74:816-834 (PMID: 33713365)
140. Dalwadi DA, Torrens L, Abril-Fornaguera J, Pinyol R, Willoughby C, Posey J, **Llovet JM**, Lanciault C, Russell DW, Grompe M, Naugler WE. Liver injury increases the incidence of HCC following AAV Gene therapy in mice. *Mol Ther.* 2021;3:680-690 (PMID: 33554867)
141. Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, **Llovet JM**, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. *Br J Cancer.* 2021;124:1388-1397 (PMID: 33531690)
142. Pfister D, Gonzalo Núñez N, Pinyol R...**Llovet JM**, Heikenwalder M et al. NASH Limits anti-tumours surveillance in immunotherapy treated HCC. *Nature* 2021;592:450-456. (PMID: 33762733)
143. Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee Y, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, **Llovet JM**. Molecular characterization of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *J Hepatol.* 2021;75:865-878 (PMID 33992698)
144. Torrens L, Montironi C, Puigvehí M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqué-Gili M, Torres-Martín M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann DA, Sia D, **Llovet JM**. Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma. *Hepatology.* 2021; 74:2652-2669 (PMID:33992698)

145. Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Toucheffeu Y, Koh SJ, Sirmimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab in patients with previous treated advanced hepatocellular carcinoma: Impact of liver disease etiology. *Liver Int.* 2021;41:2759-2767. (PMID: 34173317)
146. Craig AJ, García-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozova EG, Martins-Filho SN, von Felden J, Ahsen ME, Bresnahan E, Hernandez-Meza G, Labgaa I, D'Avola D, Schwartz M, **Llovet JM**, Sia D, Thung S, Losic B, Lujambio A, Villanueva A. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. *PLoS Genet.* 2021;17:e1009589 (PMID: 34166362).
147. Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, Decker A, Workey J, Caviglia JM, Yu L, Yin D, Saito Y, Savage T, Wells RG, Mack M, Zender L, Arpaia N, Remotti HE, Rabadan R, Sims P, Leblond AL, Weber A, Riener MO, Stockwell BR, Gaublot J, **Llovet JM**, Kalluri R, Michalopoulos GK, Seki E, Sia D, Chen X, Califano A, Schwabe RF. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer Cell* 2021;39:883. (PMID: 34129825)
148. Vogel A, Martinelli E, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. *Ann Oncol.* 2021;32:801-805. (PMID: 33716105)
149. Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Lim E, Villanueva A, Schwartz M, **Llovet JM**. Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). *Gastroenterology* 2021;161:879-898 (PMID:34126063)
150. Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, **Llovet JM**, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). *Liver Cancer* 2021;10:451-460 (PMID: 34721507)
151. Von Felden J, Garcia-Lezana T, Dogra N... **Llovet JM**, Cordon-Cardo C, Tewari A, Schwartz M, Stolorovitzky G, Losic B, Villanueva A. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. *Gut* 2021. Online ahead of print, (PMID: 34321221).
152. Gallon J, Coto-Llerena M, Ercan C... **Llovet JM** et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. *Mol Oncol.* 2022;16:665-682. (PMID: 34863035)
153. **Llovet JM**, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. *Cardiovasc Intervent Radiol.* 2022; 45:405-412..(PMID: 35119481)
154. **Llovet JM**, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX. Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trial. *Clin Cancer Res.* 2022;28:2297-2305. .(PMID: 35247922)
155. Esteban-Fabro R, Willoughby CE, Piqué-Gili M, Montironi C, Abril-Fornaguera J, Peix J, Torrens L, Mesropian A, Balaseviciute U, Miró-Mur F, Mazzaferro V, Pinyol R, **Llovet JM**. Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. *Clin Cancer Res.* 2022;28:2449-2460(PMID;35302601)
156. Torrens L, Puigvehí M, Torres-Martín M, Wang H, Maeda M, Haber PK, Leonel T, García-López M, Leow WQ, Montironi C, Torrecilla S, Varadarajan AR, Taik P, Campreciós G, Enkhbold

- C, Taivanbaatar E, Yerbolat A, Villanueva A, Pérez-del-Pulgar S, Thung S, Chinburen J, Letouzé E, Zucman-Rossi J, Uzilov A, Neely J, Forns X, Roayaie S, Sia D, **Llovet JM**. Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents. *Clin Cancer Res*. 2022;28:4509-4520(PMID:35998012)
157. Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabrá R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, **Llovet JM**, Carlin LM, Bird TG, Sansom OJ, Mann DA. CXCR2 inhibition enables NASH-HCC immunotherapy. *Gut*. 2022 71:2093-106. (PMID: 35477863).
 158. Kudo M, Montal R, Finn RS, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, **Llovet JM**. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. *Clin Cancer Res*. 2022;28:3443-3451. (PMID: 34907081)
 159. Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS Jr, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, **Llovet JM**. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma. *JAMA Surg*. 2022;157:779-788. (PMID: 35857294)
 160. Buckstein M, Kim E, Ozbek U, Tabrizian P, Gunasekaran G, Facciuto M, Rosenzweig K, **Llovet JM**, Schwartz M. Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results from a Prospective Phase 2 Trial. *Int J Radiat. Oncol Biol Phys*. 2022;114:221-230. (PMID: 35643250).
 161. Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, **Llovet JM**, Thung SN, Tsankov AM, Sia D. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. *Gut*. 2023; 72:736-748. (PMID: 35584893)
 162. Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, **Llovet JM**. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. *Gut* 2023;72:129-140 (PMID: 35197323)
 163. Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehi M, Miho M, Radu P, Dufour JF, Verslype C, Czauderna C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Beijani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, **Llovet JM**. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. *Gastroenterology*. 2023;164:72-88. (PMID: 36108710)
 164. Abril-Fornaguera J, Torrens L, Andreu-Oller.....**Llovet JM**. Identification of IGF2 as genomic driver and actionable therapeutic target in hepatocellular carcinoma. *Mol Cancer Ther*. 2023;22:485-498 (PMID:36780225)
 165. Singal AG, Sanduzzi-Zamparelli M, Nahon P.... **Llovet JM**, Parikh ND, Villanueva A. International Liver Cancer Association (ILCA) White paper on Hepatocellular Carcinoma Risk Stratification and Surveillance. *J Hepatol* 2023;79:226-239 (PMID:3685445).
 166. Singal A, **Llovet JM**, Yarchoan M, et al. AASLD Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. *Hepatology* 2023;78:1922-1965. (PMID: 37199193)
 167. Rialdi A, Duffy M, Scopton AP....**Llovet JM**. WNTinib is a multi-kinase inhibitor with specificity against B-catenin mutant hepatocellular carcinoma. *Nat Cancer* 2023;4:1157-1175 (PMID:37537299)

168. Ortiz-Barahona V, Soler M, Davalos V, **Llovet JM**, Esteller M. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver Cancer. *Mol Cancer* 2023;22:83 (PMID:37173708)
169. Vucur M, Ghallab A, Schneider AT.... **Llovet JM**...Luedde T. Sublethal necroptosis signaling promotes inflammation and liver cancer. *T Immunity*. 2023;56:1578-1595 (PMID:37329888).
170. **Llovet JM**, Kudo M, Merle P. et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomized, double-blind, phase 3 trial. *Lancet Oncology*. 2023;24:1399-1410 (PMID: 38039993).
171. Kudo M, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Meyer T, Nagao S, Saito K, Mody K, Ramji Z, Dubrovsky L, **Llovet JM**. A phase 1b study of Lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: extended analysis of study 116. *Liver Cancer*. 2023;13:451-458. (PMID: 39114764)
172. O'Rourke, Salati MR, Carpino G.... **Llovet JM**... et al. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. *Gut*. 2024;73:496-508. (PMID: 37758326).
173. Tanabe KK, Zahrieh D, Strand CA, Hoshida Y, Flotte TJ, Della'Zanna G, Umar A, Chavin KD, Cleary S, Kubota N, **Llovet JM**, Patel T, Siegel C, Limburg PJ. Epidermal growth factor receptor inhibition with erlotinib in liver: dose de-escalation pilot trial as an initial step in chemoprevention strategy. *Gastro Hep Adv*. 2024;29;3:426-439. (PMID: 39131140).
174. Wu, Y. L., Cappuyns, S., Loh, A., Sun, S., Lewis, S., Sung, M. W., Schwartz, M., **Llovet JM**, Cohen, D. J. Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. *BJC Rep*. 2024;2:8. (PMID: 39516245)
175. Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutkus C, Dubrovsky L, Siegel AB, Finn RS, **Llovet JM**; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. *Lancet*. 2025;405:203-215. PMID: 39798578.
176. Cappuyns S, Piqué-Gili M, Esteban-Fabrá R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C, Bassaganyas L, Peix J, Zeithoeffer M, Mesropian A, Huguet-Pradell J, Haber PK, Figueiredo I, Ioannou G, Gonzalez-Kozlova E, D'Alessio A, Mohr R, Meyer T, Lachenmayer A, Marquardt JU, Reeves HL, Edeline J, Finkelmeier F, Trojan J, Galle PR, Foerster F, Mínguez B, Montal R, Gnjatich S, Pinato DJ, Heikenwalder M, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, **JM Llovet**. Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma *J Hepatol*. 2025;3:426-439 (PMID:39709141)
177. Piqué-Gili M, Andreu-Oller C, Mesropian A, Esteban-Fabrá R, Bárcena-Varela M, Ruiz de Galarreta M, Montironi C, Martínez-Quetglas I, Cappuyns S, Peix J, Keraite I, Gris-Oliver A, Fernández-Martínez E, Mauro E, Torres-Martin M, Abril-Fornaguera J, Lindblad KE, Lambrechts D, Dekervel J, Thung SN, Sia D, Lujambio A, Pinyol R, **JM Llovet**. Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF- β activation in HCC. *JHEP Reports* 2024; 7;6:101212. (PMID: 39524206).
178. Tabrizian P, Marino R, Bhoori S, Zeithoeffer M, Mehta N, Banz V, Gruttadauria S, Iavarone M, Mazzarelli C, Simonotti N, Yao F, Mazzaferro V, **Llovet JM**. Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma" *JHEP Reports* 2024; 7:101246 (PMID: 39911942)
179. Müller, M., May, S., Hall, H., Kendall, T.J., McGarry, L., Blukacz, L., Nuciforo, S., Georgakopoulou, A., Jamieson, T., Phinichkusolchit, N., Dhayade, S., Suzuki, T., Huguet-Pradell, J., Powley, I.R., Officer-Jones, L., Pennie, R.L., Esteban-Fabrá, R., Gris-Oliver, A.,

- Pinyol, R., Skalka, G.L., Leslie, J., Hoare, M., Sprangers, J., Malviya, G., Mackintosh, A., Johnson, E., McCain, M., Halpin, J., Kiourtis, C., Nixon, C., Clark, G., Clark, W., Shaw, R., Hedley, A., Drake, T.M., Tan, E.H., Neilson, M., Murphy, D.J., Lewis, D., Reeves, H.L., Le Quesne, J., Mann, D.A., Carlin, L.M., Blyth, K., **Llovet, JM.**, Heim, M.H., Sansom, O.J., Miller, C.J., Bird, T.G. Human-correlated genetic HCC models identify combination therapy for precision medicine. *Nature*. 2025;639:754-764 (PMID: 39972137)
180. Hernandez CA, Verzeroli C, Roca-Suarez AA, Farca-Luna AJ, Tonon L, Esteban-Fabrá R, Pinyol R, Plissonnier ML, Chicherova I, Dubois A, Bellaud P, Seffals M, Turlin B, Fautrel A, Ichim G, Rivoire M, Passot G, Macek-Jilkova Z, Decaens T, Viari A, Testoni B, Rebouissou S, **Llovet JM**, Zoulim F, Parent R. Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptors. *JHEP Rep*. 2024 Nov 12;7:101245. PMID: 39717507.
 181. Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, **Llovet JM**, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. *Lancet* 2025;406:731-778 (PMID 40744051)
 182. Vogel A, Chan SL, Dawson LA, Kelley RK, **Llovet JM**, Meyer T, Ricke J, Rimassa L, Sapisochin G, Vilgrain V, Zucman-Rossi J, Ducreux M; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2025;36(5):491-506 (PMID 39986353)
 183. Müller M, May S, Hall H, Kendall TJ, McGarry L, Blukacz L, Nuciforo S, Georgakopoulou A, Jamieson T, Phinichkusolchit N, Dhayade S, Suzuki T, Huguet-Pradell J, Powley IR, Officer-Jones L, Pennie RL, Esteban-Fabrá R, Gris-Oliver A, Pinyol R, Skalka GL, Leslie J, Hoare M, Sprangers J, Malviya G, Mackintosh A, Johnson E, McCain M, Halpin J, Kiourtis C, Nixon C, Clark G, Clark W, Shaw R, Hedley A, Drake TM, Tan EH, Neilson M, Murphy DJ, Lewis DY, Reeves HL, Le Quesne J, Mann DA, Carlin LM, Blyth K, **Llovet JM**, Heim MH, Sansom OJ, Miller CJ, Bird TG. Human-correlated genetic models identify precision therapy for liver cancer. *Nature* 2025;639(8055):754-764 (PMID 39972137)
 184. Kodali S, Kulik L, D'Allesio A, De Martin E, Hakeem AR, Lewinska M, Lindsey S, Liu K, Maravic Z, Patel MS, Pinato D, Rammohan A, Rich N, Sanduzzi Zamparelli M, Victor DW 3rd, Vinaxia C, Brombosz EW, Villanueva A, Meyer T, Selzner N, Ghobrial RM, Rela M, Sapisochin G; ILTS ILCA Consensus 2024 Group. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma. *Liver Transpl* 2025;31(6):815-831. (PMID 40014003)
 185. Taddei TH, Brown DB, Yarchoan M, Mendiratta-Lala M, **Llovet JM**. Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology* 2025;82(1):272-274 (PMID 39992051)
 186. Mesropian A, Gris-Oliver A, Balaseviciute U, Potdar AA, Kimura T, Shen J, Torres-Marcén M, Abril-Fornaguera J, Piqué-Gili M, Camell-Raventos D, Peix J, Fernández-Martínez E, Huguet-Pradell J, Hernández de Sande A, Keraite I, Esteban-Fabrá R, Barcena-Varela M, Lindblad KE, Lujambio A, Guccione E, Thung S, Ikeda M, Kudo M, Sia D, Pinyol R, **Llovet JM**. E7386 enhances lenvatinib's antitumor activity in preclinical models and human hepatocellular carcinoma. *Clin Cancer Res* 2025;31:5037-5050(PMID 40986544)
 187. Mauro E, de Castro T, Zeithoefler M, Hackshaw A, Lee M, Meyer T, Singal AG, **Llovet JM**. Strategies to address non-proportional hazards between survival curves – Lessons from phase III trials in hepatocellular carcinoma. *J Hepatol* 2025 Sep 22 (DOI 10.1016/j.jhep.2025.08.042) (Online ahead of print) (PMID 40992574)
 188. Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster JD, Rieder N, Dietmann G, Cannarile M, Cotter C, Hack SP, Cha E, Ishiguro T, **Llovet JM**, Zhu AX, Finn RS. Molecular subtypes of

hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy. *Cell Rep Med*. 2025 Nov 28;102473Epub ahead of print. (PMID: 41317730).

189. Seraphin TP, Mesropian A, Žigutytė L, Brooks J, Mauro E, Gris-Oliver A, Pinyol R, Montironi C, Balaseviciute U, Piqué-Gili M, Huguet-Pradell J, van Treeck M, Kallenbach M, Schneider AT, Roderburg C, Kather JN, Luedde T, **Llovet JM**. Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma. *JHEP Rep*. 2025;7:101592. (PMID: 41321933). Balaseviciute U, Huguet-Pradell J, Abril-Fornaguera J, Gris-Oliver A, Rialdi A, Fernández-Martínez E, Montironi C, Del Pozo V, Houghton P, Zanatto L, Mesropian A, Keraite I, Thung S, Armengol C, Sancho-Bru P, Guccione E, Pinyol R, **Llovet JM**. Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib. *Mol Oncol*. 2025. Epub ahead of print. (PMID: 41359441).

REVIEWS

1. Akriviadis E, **Llovet JM**, Efremidis S, Shouval D, Canelo R, Ringe B, Meyers W. Hepatocellular Carcinoma . *BRIT J SURG* 1998;85(10):1319-31 (D1 PMID 9782009)
2. **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Sem Liver Dis* 1999;19:329-338 (Q1 PMID 10518312)
3. **Llovet JM**, Sala M, Bruix J. Non-surgical treatment of hepatocellular carcinoma. *Liver Transpl* 2000;6: S11-S15 (Q1 PMID 11084079)
4. Suarez Y, França A, **Llovet JM**, Fuster J, Bruix J. The current status of liver transplantation for primary hepatic malignancy. *Clinics in Liver Disease* 2000;4: 3:591-605 (Q2 PMID 11232163)
5. Bruix J, Sherman M, **Llovet JM**, Beaugrand M, Lencioni R, Christensen E, Burroughs A, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001;35:421-430 (D1 PMID 11592607)
6. **Llovet JM**. Evidence-based medicine in the treatment of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2002;17 Suppl 13:S428-433 (Q1 PMID 12472976)
7. Bruix J, **Llovet JM**. Prognostic assessment and evaluation of the benefits of treatment. *J Clin Gastroenterol* 2002;35:S138-42 (Q2 PMID 12394217)
8. Bruix J, **Llovet JM**. Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology* 2002;35:519-524 (D1 PMID 11870363)
9. **Llovet JM**, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907-17 (D1 PMID 14667750)
10. **Llovet JM**, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. *J Hepatol* 2003;38 Suppl 1:S136-49 (D1 PMID 12591191)
11. Bruix J, **Llovet JM**. Hepatitis B virus and hepatocellular carcinoma. *J Hepatol* 2003;39: Suppl 1: S59-63 (D1 PMID 14708679)
12. M Varela, M Sala, **JM Llovet**, J Bruix. Treatment of hepatocellular carcinoma: is there an optimal strategy?. *Cancer treatment reviews* 2003;3:99-104 (Q2 PMID 12670452)
13. M Varela, M Sala, **JM Llovet**, J Bruix. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. *ALIMENT PHARM THER* 2003;17 (Suppl 2):1-5 (D1 PMID 12786620)

14. **Llovet JM**, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl* 2004;10 (Suppl 1):S115-20 (Q1 PMID 14762851)
15. **Llovet JM**. Viral hepatitis and hepatocellular carcinoma. *Hepatology* 2004;1:89-98 (D1)
16. Bruix J, Sala M, **Llovet JM**. Chemoembolization for hepatocellular carcinoma. *Gastroenterology* 2004;127: S179-S188 (D1 PMID 15508083)
17. Bruix J, Boix L, Sala M, **Llovet JM**. Focus on hepatocellular carcinoma. *Cancer Cell* 2004;5:215-219 (D1 PMID 15050913)
18. **Llovet JM**, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. *Sem Liver Dis* 2005;2: 181-200 (Q1 PMID 15918147)
19. Schwartz M, Roayaie S, **Llovet JM**. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. *J Hepatol* 2005;43: 584-9 (D1 PMID 16120468)
20. **Llovet JM**. Updated treatment approach to hepatocellular carcinoma. *J Gastroenterology* 2005;40: 225-35 (Q1 PMID 15830281)
21. Roayaie S, **Llovet JM**. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?. *Clinics in Liver Disease* 2005;9:315-28 (Q2 PMID 15831276)
22. **Llovet JM**, Schwartz M, Fuster J, Bruix J. Expanding criteria for HCC through downstaging prior liver transplantation: not yet ther. *Sem Liver Dis* 2006;26:248-53 (Q1 PMID 16850374)
23. Lemmer E, Friedman S, **Llovet JM**. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. *Sem Liver Dis* 2006;26: 373-384 (Q1 PMID 17051451)
24. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, **Llovet JM**. New aspects of diagnosis and therapy of hepatocellular carcinoma. *Oncogene* 2006;25: 3848-56 (Q1 PMID 16799626)
25. Lopez P, Villanueva A, Roayaie S, **Llovet JM**. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. *Liver Transpl* 2006;1747-54 (Q1 PMID 17133591)
26. **Llovet JM**. Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound. *Clinical Gastroenterology and Hepatology* 2006;4: 29-35 (D1 PMID 16431301)
27. Lopez P, Villanueva A, **Llovet JM**. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. *ALIMENT PHARM THER* 2006;23: 1535-47 (D1 PMID 16696801)
28. Villanueva A, Newell P, Chiang D, Friedman S, **Llovet JM**. Genomics and signaling pathways in hepatocellular carcinoma. *Sem Liver Dis* 2007;27: 55-76 (Q1 PMID 17295177)
29. **Llovet JM**. Clinical and molecular classification of hepatocellular carcinoma. *Liver Transpl* 2007;13 (Suppl 2): 13-6 (Q1 PMID 17969094)
30. Gennari R, Veronesi U, Andreoli C, Betka J, Castelli, Gatti G, Hudgosson J, **Llovet JM**, Melia J, Nakhosteen JA, Pastorino U, Sideri M, Stephan C, Veronesi P, Zurida S. Early detection of cancer: Ideas for a debate. *Critical Reviews in Oncology Hematology* 2007;61:97-103 (Q2 PMID 17113782)
31. Wilhelm SM, Adnane L, Newell P, Villanueva A, **Llovet JM**, Lynch M. Preclinical overview of sorafenib – a multi-kinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. *Mol Cancer Ther* 2008;7:3129-40 (Q1 PMID 18852116)
32. Newell P, Villanueva A, Friedman S, Koike K, **Llovet JM**. Experimental models in hepatocellular carcinoma. *J Hepatol* 2008;48:858-879 (D1 PMC2990959)
33. **Llovet JM**, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. *Hepatology* 2008;48:1312-27 (D1 PMC2597642)

34. Villanueva A, Toffanin S, **Llovet JM**. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. *Curr Opin Oncol* 2008;20:444-53 (Q1 PMC3678124)
35. **Llovet JM**, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. *J Hepatol* 2008;48: S20-S37 (D1 PMID 18304676)
36. Bruix J, **Llovet JM**. Major achievements in hepatocellular carcinoma. *Lancet* 2009;373:614-16 (D1 PMID 19231618)
37. Hoshida Y, Villanueva A, **Llovet JM**. Molecular profiling to predict hepatocellular carcinoma outcome. *Expert Rev Gastroenterol Hepatol* 2009;3:101-3 (Q3 PMC3668659)
38. Mínguez B, Tovar V, Chiang D, Villanueva A, **Llovet JM**. Pathogenesis of hepatocellular carcinoma and molecular therapies. *Curr Opin Gastroenterol* 2009;25:186-94 (Q1 PMID 19387255)
39. Lachenmayer A, Alsinet C, Chang CY, **Llovet JM**. Molecular approaches to treatment of hepatocellular carcinoma. *Digest Liver Dis* 2010;42 Suppl 3:S264-72 (Q2 PMC3693074)
40. Bruix J, **Llovet JM**. Two decades of advances in hepatocellular carcinoma research. *Sem Liver Dis* 2010;30 (1):1-2 (Q1 PMID 20175028)
41. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Mínguez B, **Llovet JM**. Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. *Sem Liver Dis* 2010;30:35-51 (Q1 PMC3668687)
42. Lencioni R, **Llovet JM**. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. *Sem Liver Dis* 2010;30(1):52-60 (Q1 PMID 20175033)
43. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, **Llovet JM**. Cancer gene discovery in hepatocellular carcinoma. *J Hepatol* 2010;52:921-9 (D1 PMC295725)
44. Toffanin S, Villanueva A, **Llovet JM**. miRNA delivery: emerging therapy for hepatocellular carcinoma. *Gastroenterology* 2010;138:1202-4 (D1 PMID 20102759)
45. Lachenmayer A, Hoshida Y, **Llovet JM**. Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma. *Gastroenterology* 2010;139:692-4 (D1 PMID 20600057)
46. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, **Llovet JM**. New strategies in hepatocellular carcinoma: genomic prognostic markers. *Clin Cancer Res* 2010;16:4688-94 (Q1 PMC3395071)
47. Toffanin S, Fiedman SL, **Llovet JM**. Obesity, Inflammatory Signaling, and Hepatocellular Carcinoma- An Enlarging Link. *Cancer Cell* 2010;17 (2):115-117 (D1 PMID 20159605)
48. Villanueva A, Mínguez B, Forner A, Reig M, **Llovet JM**. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. *Annu Rev Med* 2010;1:317-28 (D1 PMC3677155)
49. **Llovet JM**, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates in hepatocellular carcinoma. *Liver Transpl* 2011;suppl 2:67-71 (Q1 PMC3164216)
50. Toffanin S, Alsinet C, Cornella H, Sia D, **Llovet JM**. microRNAs and the MYC network: a major piece in the puzzle of liver cancer. *Gastroenterology* 2011;140:2138-2140 (D1 PMID 21515272)
51. Villanueva A, **Llovet JM**. Targeted therapies for hepatocellular carcinoma. *Gastroenterology* 2011;140:1410-26 (D1 PMC3682501)
52. Villanueva A, Hoshida Y, **Llovet JM**. Hepatocellular carcinoma enters the sequencing era. *Gastroenterology* 2011;141:1943-5 (D1 PMC3679498)

53. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. *Lancet Oncol* 2012;13:11-22 (D1 PMC3417764)
54. Forner A, **Llovet JM**, Bruix J. Hepatocellular carcinoma. *Lancet* 2012;379:1245-55 (D1 PMID 22353262)
55. Sia D, Tovar V, Moeini A, **Llovet JM**. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. *Oncogene* 2013;32:4861-70 (Q1 PMC3718868)
56. Villanueva A, Hernandez-Gea V, **Llovet JM**. Medical therapies for hepatocellular carcinoma: a critical watch of the evidence. *Nat Rev Gastro & Hepatol* 2013;10:34-42 (D1 PMID 23147664)
57. Hernandez-Gea V, Toffanin D, Friedman S, **Llovet JM**. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. *Gastroenterology* 2013;144:512-27 (D1 PMC3578068)
58. Pinyol R, Nault JC, Quetglas IM, Zucman-Rossi J, **Llovet JM**. Molecular profiling of liver tumors: classification and clinical translation for decision making. *Sem Liver Dis* 2014;34:363:75 (Q1 PMID 25369299)
59. Villanueva A, **Llovet JM**. Liver Cancer 2013: Mutational landscape of HCC-end of the beginning. *Nat Rev Clin Oncol* 2014;11:73-74 (D1 PMID 24395088)
60. **Llovet JM**. Liver cancer: Time to evolve trial design after everolimus failure. *Nat Rev Clin Oncol* 2014;11:506-7 (D1 PMID 25091613)
61. **Llovet JM**, Hernández-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. *Clin Cancer Res* 2014;20:2072-9 (Q1 PMID 24589894)
62. **Llovet JM**. Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. *Cancer Cell* 2014;25:560-2 (D1 PMC4071286)
63. Quetglas I, Moeini A, Pinyol R, **Llovet JM**. Integration of genomic information in the clinical management of HCC. *Best Pract Res Cl Ga* 2014;28:831-42 (Q2 PMID 25260311)
64. **Llovet JM**, Villanueva A, Lachenmayer A, Finn R. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. *Nat Rev Clin Oncol* 2015;12:408-24 (D1 PMID 26099984)
65. Torrecilla S, **Llovet JM**. New molecular therapies for hepatocellular carcinoma. *Clinics and Research in Hepatology and Gastroenterology* 2015;39, S80-S85 (Q4 PMID 26206572)
66. Bruix J, Han KH, Gores G, **Llovet JM**, Mazzaferro V. Liver cancer: Approaching a personalized care. *J Hepatol* 2015;62:S144-S156 (D1PMC4520430)
67. Zucman-Rossi J, Villanueva A, Nault JC, **Llovet JM**. Genetic landscape and biomarkers of hepatocellular carcinoma. *Gastroenterology* 2015; 149:1226-1239 (D1 PMID 26099527)
68. Moeini A, Sia D, Bardeesy N, Mazzaferro V, **Llovet JM**. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. *Clin Cancer Res* 2016;22:291-300 (Q1 PMID 26405193)
69. **Llovet JM**, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. *Nat Rev Disease Primers* 2016;2:16018 (PMID:27158749)
70. Sia D, Villanueva A, Friedman SL, **Llovet JM**. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. *Gastroenterology*. 2017;152:745-761 (PMID:28043904)
71. Sia D, **Llovet JM**. Translating ‘-omics’ results into precision medicine for hepatocellular carcinoma. *Nature reviews Gastroenterology and Hepatology*. 2017;14:571-572 (PMID:28765583)

-
72. **Llovet JM**, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine in hepatocellular carcinoma. *Nature Reviews Clinical Oncology*. 2018;15:599-616. (PMID:30061739)
 73. **Llovet JM**, Translational medicine in Catalonia: the case of liver oncology. *Contributions to Science*. 2017;13;37-40.
 74. Pinyol R, Sia D, **Llovet JM**. "Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC". *Clin Cancer Res*. 2019;25:2021-2023 (PMID: 30617138)
 75. **Llovet JM**, Montal R, Villanueva A. Randomized trials and end points in advanced HCC: Role of PFS as a surrogate of survival. *J Hepatol*. 2019;70:1262-1277. (PMID: 30943423)
 76. Puigvehí M, Moctezuma-Velázquez C, Villanueva A, **Llovet JM**. The Oncogenic role of hepatitis delta virus in hepatocellular carcinoma. *J Hep Reports*. 2019; 16:120-130
 77. Galle PR, **Llovet JM**, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. *Liver International* 2019 39:2214-2229.(PMID: 31436873)
 78. Montironi C, Montal R, **Llovet JM**. New drugs effective in the systemic treatment of hepatocellular carcinoma. *Clinical Liver Disease*. 2019; 14:56-61 (PMID: 31508221)
 79. Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, **Llovet JM**, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. *Cancer Res*. 2019;79:4326-4330
 80. **Llovet JM**, Lencioni R. mRECIST for HCC: Performance and novel refinements. *J Hepatol*. 2020;72:288-306. (PMID: 31954493)
 81. Nault JC, Cheng AL, Sango B, **Llovet JM**. Milestones in the pathogenesis and management of primary liver cancer. *J Hepatol* 2020;72:209-214 (PMID: 31954486)
 82. **Llovet JM**, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR, AASLD Panel of Experts on Trial Design in HCC. *Hepatology*. 2021;73:158-191. (PMID: 32430997)
 83. **Llovet JM**, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2021;18:293-313 (PMID: 33510460)
 84. Castet F, Willoughby CE, Haber PK, **Llovet JM**. Atezolizumab plus Bevacizumab: A novel breakthrough in Hepatocellular Carcinoma. *Clin Cancer Res*. 2021;27:1827-1829 (PMID: 33472912)
 85. **Llovet JM**, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2021;7:6. (PMID: 33479224)
 86. **Llovet JM**, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. *Nat Rev Clin Oncol*. 2022;19:151-172 (PMID: 34764464)
 87. **Llovet JM**, Pinyol R, K. Kelley R, El-Khoueiry A, L. Reeves H, Wang XW, J. Gores G, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. *Nature Cancer* 2022;3:386-401. (PMID: 354844).
 88. **Llovet JM**. Exploring a new pathway for biomarker-based approval of immunotherapies. *Nat Rev Clin Oncol*. 2023;20;279-280 (PMID:3670778)

89. **Llovet JM**, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL. Non-alcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. *Nat Rev Gastroenterol Hepatol*. 2023;20:487-503 (PMID: 36932227).
90. **Llovet JM**, Heikenwälder M. Atezolizumab plus bevacizumab in advanced HCC: efficacy in NAS-specific etiology. *Gastroenterology*. 2023. Online ahead of print (PMID: 37116832)
91. Singal AG, Kanwal F, **Llovet JM**. Global trends in hepatocellular carcinoma epidemiology: implications for screening prevention and therapy. *Nat Rev Clin Oncol*. 2023;20:864-884. (PMID:37884736).
92. **Llovet JM**, Heikenwalder M. Atezolizumab plus bevacizumab in advanced HCC efficacy in NASH-specific etiology. *Gastroenterology*. 2023;165:1308-1310.(PMID:37116832)
93. Cappuyns S, Corbett V, Yarchoan M, Finn RS, **Llovet JM**. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma. *JAMA Oncol*. 2024;10:395-404. (PMID: 37535375).
94. **Llovet JM**, Pinyol R, Yarchoan M, Singal AG, Maroon TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. *Nat. Rev. Clin. Oncol*. 2024;21:294-311. (PMID: 38424197).
95. **Llovet JM**, Cappuyns S, Finn RS. Himalaya overall survival prominence and other routes to peak-reply. *Jama Oncol*. 2024;10:1. (PMID: 38206615).
96. Banerjee S, Booth CM, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, **Llovet JM**, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J, Wechselbaum RR, Weller M, Wu Yi-Long. Two decades of advances in clinical oncology – lessons learned and future directions. *Nature Reviews Clinical Oncology*. 2024;21:771-780. (PMID: 39354161)
97. Forns X, **Llovet JM**. The first year of the new Editorial Team of JHEP Reports. *JHEP Rep* 2025;7:101292 (PMID 39872236)
98. **Llovet JM**. Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma. *Nat Rev Clin Oncol* 2025;22(9):625-626 (PMID 40588495)

Mauro E, de Castro T, Zeithoefler M, Sung MW, Villanueva A, Mazzaferro V, **Llovet JM**. Hepatocellular carcinoma: Epidemiology, diagnosis and treatment. *JHEP Rep*. 2025;7:101571. (PMID: 41244300)**Editorials / Comments**

1. **Llovet JM**, Bruix J, Gores G. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. *Hepatology* 2001;31:1019-1021 (D1 PMID 10733561)
2. Bruix J, **Llovet JM**. Hepatocellular carcinoma: Is surveillance cost-effective?. *Gut* 2001;48 149-150 (D1 PMC1728216)
3. Bruix J, Fuster J, **Llovet JM**. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. *Liver Transpl* 2003;9:700-702 (Q1 PMID 12827556)
4. Bruix J, **Llovet JM**. HCC surveillance: who is the target population?. *Hepatology* 2003;37:507-9 (D1 PMID 12601346)
5. **Llovet JM**, Wurmbach E. Gene expression profile in hepatocellular carcinoma: not yet there. *J Hepatol* 2004;4: 336-9 (D1 PMID 15288485)
6. Bruix J, **Llovet JM**. Prognostic prediction in HCC: did anybody expect it to be easy?. *Hepatology* 2004;39: 551-552 (D1)
7. Lencioni R, **Llovet JM**. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?. *J Hepatol* 2005;43: 377-80 (D1 PMID 16005537)

8. **Llovet JM**. Expanding HCC criteria for liver transplant: The urgent need for prospective, robust data. *Liver Transpl* 2006;12: 1741-3 (Q1 PMID 17133574)
9. Fattovich G, **Llovet JM**. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. *J Hepatol* 2006;44:1013-1016 (D1 PMID 16678654)
10. **Llovet JM**, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. *J Natl Cancer Inst* 2008;100:1121-3 (D1 PMC2720710)
11. Newell P, Villanueva A, **Llovet JM**. Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. *J Hepatol* 2008;49:1-5 (D1 PMID 18486262)
12. Forner A, **Llovet JM**, Bruix J. Sunitinib and the benefits of a negative study. *Lancet Oncol* 2009;10:743-44 (D1 PMID 19647195)
13. **Llovet JM**, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. *J Clin Oncol* 2009;27:833-5 (D1 PMID 19139428)
14. Villanueva A, Savic R, **Llovet JM**. Lymphotoxins: Novel targets for HCC. *Cancer Cell* 2009;16:272-273 (D1 PMC3677157)
15. Sherman M, **Llovet JM**. Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma. *J Natl Cancer Inst* 2011;103: 1-2 (D1 PMID 22021668)
16. Mínguez B, Sia D, **Llovet JM**. Reply to: "Network-based discovery of gene signature for vascular invasion prediction in HCC". *J Hepatol* 2012;56:1424 (D1)
17. Forner A, **Llovet JM**, Bruix J. Chemoembolization for intermediate HCC: Is there proof of survival benefit?. *J Hepatol* 2012;56:984-6 (D1 PMID 22008737)
18. Alsinet C, Villanueva A, **Llovet JM**. Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. *J Hepatol* 2012;56:1198-200 (D1 PMID 22173155)
19. Villanueva A, Forns X, **Llovet JM**. Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. *J Hepatol* 2012;57:213-4 (D1 PMID 22282033)
20. Toffanin S, Cornella H, Harrington A, **Llovet JM**. HCC is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. *Hepatology* 2012;56: 1998-2000 (D1 PMID 23115011)
21. Villanueva A, **Llovet JM**. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. *Hepatology* 2012;56: 2416-9 (D1 PMID 23212778)
22. Toffanin S, Cornella H, Harrington A, **Llovet JM**. Next-Generation Sequencing: Path for Driver Discovery in Hepatocellular Carcinoma. *Gastroenterology* 2012;143:1391-93 (D1 PMID 23006809)
23. **Llovet JM**, Villanueva A. Second-line therapies in HCC: emergence of resistance to sorafenib. *Clin Cancer Res* 2012;18: 1824-6 (Q1 PMC3336075)
24. Hernandez-Gea V, Alsinet C, **Llovet JM**. Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies?. *J Hepatol* 2013;59:882-4 (D1 PMID 23673136)
25. Pinyol R, **Llovet JM**. Hepatocellular Carcinoma. Genome-scale metabolic models for hepatocellular carcinoma. *Nat Rev Gastro & Hepatol* 2014;11:336-337 (D1 PMID 24840704)
26. **Llovet JM**, Johnson PJ. Reply to X. Qi et al " Brivanib for Hepatocellular Carcinoma Trials: Selection Bias From Barcelona Clinic Liver Cancer Stage?". *Journal of Clinical Oncology* 2014;32:968-969 (D1 PMID 24516037)

27. Pinyol. R, Tovar V, **Llovet JM**. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. *J Hepatol* 2014;61:685-7 (D1 PMID 24859456)
28. Villanueva A, **Llovet JM**. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. *Nature Reviews Gastroenterol and Hepatol* 2016;13:561-2 (PMID: 27580683).
29. Montal R, Lencioni R, **Llovet JM**. Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made". *J Hepatol*. 2017;67:196-197 (PMID 28315709)
30. Zhu AX, Fin RS, Galle PR, **Llovet JM**, Kudo M. "Ramucirumab in advanced hepatocellular carcinoma in REACH-2: The true value of a-fetoprotein" *Lancet Oncol*.2019;20:e191 (PMID: 30942178)
31. Castet F, Willoughby CE, Haber PK, **Llovet JM**. Atezolizumab plus bevacizumab: a novel breakthrough in hepatocellular carcinoma. *Clin Cancer Res*. 2021. Online ahead of print. (PMID: 33472912)
32. Vogel A, Martinelli E, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. *Ann Oncol*. 2021; 32: 801-805 (PMID: 33716105)
33. Cappuyns S, **Llovet JM**. Combination therapies for advanced HCC: biomarkers and unmet needs. *Clin Can Res* 2022;28:3405-3407. (PMID: 35727695)
34. Kudo M, Ren Z, Finn RS, **Llovet JM**; LEAP-012 Investigators. Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial – Authors' reply. *Lancet* 2025;406:694 (PMID 40818849)

Letters and case reports

99. Fernández-Bañares F, Esteve-P M., Humbert P, De Leon R, **Llovet JM**, Gassull MA. Role of Fructose-Sorbitol malabsorption in Irritable Bowel Syndrome. *Gastroenterology* 1991; 101:1453-1454.
100. **Llovet JM**, Castells A, Bruix J. Transcatheter arterial chemoembolization in hepatocellular carcinoma *Hepatology* 1998;28:1441-43.
101. **Llovet JM**, Miquel R. Sclerosing hepatic carcinoma in non-cirrhotic liver resembling metastatic adenocarcinoma. *J Hepatol* 1999: 30:161.
102. Suarez Y, De Lacy A., **Llovet JM**. Intrahepatic bleeding due to undifferentiated (embryonal) hepatic sarcoma. *J Hepatol* 2000;32: 361.
103. **Llovet JM**, Bruix J. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. *Hepatology* 2000; 32:679-80.
104. **Llovet JM**, Vilana R, Brú C, Bianchi L, Bruix J. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. *Hepatology* 2001;31: 608-611.
105. Bruix J, **Llovet JM**, for the EASL Panel of Experts on HCC. Reply. *J Hepatol* 2003;37:875.
106. Forns X, **Llovet JM**, Ampurdanés S, Sanchez-Tapias JM, Rodés J. Non-invasive prediction of fibrosis in patients with chronic hepatitis C. *Hepatology* 2003; 37: 1221-1222.
107. **Llovet JM**, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. *Radiology* 2004;230:300-302.

108. **Llovet JM**, Bruix J. Sorafenib in HCC. *New Engl J Med* 2008;359:2497-2499.
109. **Llovet JM**, Finn RS. Negative phase 3 study of 90Y microspheres versus sorafenib in HCC. *Lancet Oncol.* 2018;19:30025-1 (PMID 29413470)
110. Moctezuma-Velázquez C, Lewis S, Lee K, Amodeo S, **Llovet JM**, Schwartz M, Abalde JG, Villanueva A. JHEP Rep. 2021;3 (PMID: 34712933)

OTHER PUBLICATIONS

Originals

1. Bertrán X, Fernández-Bañares F., Planas R., Cabré E, Morillas R, De León R, Guilera M, Quer JC, **Llovet JM**, Doménech E y Gassull MA. Repercusión sobre el estado nutricional energético-proteico de la paracentesis total asociada a la infusión de albúmina o dextrano-70 en el tratamiento de la ascitis a tensión en la cirrosis hepática. *Rev Esp Enferm Digest* 1991;79,5:320-324 (Q4)
2. JC Quer, J Boix, R. Planas, M. Domínguez, A Abad-Lacruz, P. Humbert, R. Morillas, M. Guilera, **JM Llovet**, MA Gassull. Prophylactic sclerosis of esophageal varices. Results of a controlled prospective study. *Med Clin (Barc)* 1991;96:241-244 (Q2 PMID 2038216)
3. JC Quer, R Planas, J Boix, E Cabré, MA Broggi, P Humbert, N Rodriguez, R Morillas, **JM Llovet**, E Doménech, B Oller y MA Gassull. Influencia del tratamiento de la hipertensión portal en la aparición de ascitis y sus complicaciones. Comparación entre la anastomosis portocava y la esclerosis endoscópica. *Gastroenterol y Hepatol* 1994;17:1-6 (Q4)
4. Heinemann LA, Thomas DB, Möhner M; MILTS Collaborative Study Team. Multicentre international liver tumour study protocol of the case-control study on hepatocellular cancer. *Pharmacoepidemiology and drugs safety* 1996;5: 173-186 (Q2 PMID 15073834)
5. The Collaborative MILTS Project Team. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). *Contraception* 1997;56: 275-284 (Q2 PMID 9437555)
6. Vilana R, **Llovet JM**, Bianchi L, Sanchez M, Pagés M, Sala M, Gilabert R, Ayuso C, Bruix J, Bru C.. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. *J Clin Ultras* 2003;31:119-28 (Q3 PMID 12594796)
7. Fuster J, **Llovet JM**, Garcia-Valdecasas JC, Grande L, Fondevila C, Vilana R, Palacin J, Tabet J, Ferrer J, Bruix J, Visa J. Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. *Hepato-gastroenterology* 2004;51: 536-40 (Q4 PMID 15086197)

Editorials

1. **JM Llovet**, X Bertrán, R Planas. Hepatitis C. *Annals de Medicina Interna (Barc)* 1993;3:53-58
2. **JM Llovet**, J Fuster. Liver resection in the treatment of hepatocellular carcinoma. *Gastroenterol y Hepatol* 2001;24: 511-513 (Q4 PMID 11730622)

Reviews

1. R. Planas, **JM Llovet**, R Morillas. Prespectivas terapéuticas en la hepatitis crónica C. *Gastroenterología práctica* 1994;10:1-2
2. **JM Llovet**, R Bartolí, R Planas. Intestinal bacterial translocation. *Gastroenterol y Hepatol* 1996;19:374-382 (Q4 PMID 8963909)
3. **JM Llovet**. Les aportacions científiques de Joan Rodés i la Unitat d'Hepatologia de l'Hospital Clínic. *Annals de Medicina Interna (Barc)* 1998;82:98-100
4. **Llovet JM**, Real M Isabel, Bruix J. BCLC Group. Does transarterial embolization have survival benefit for patients with non-surgical hepatocellular carcinoma?. *Current topics of hepatocellular carcinoma* 1999;pp3-13
5. Bruix J, **Llovet JM**. BCLC Group. Locoregional treatments for hepatocellular carcinoma. *Bailliere Clin Gastr* 1999;13: 611-622 (Q2 PMID 10654923)

6. Suarez Y, Sala M, **Llovet JM**, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. *ACTA GASTRO-ENT BELG* 1999;62:410-4 (Q4 PMID 10692771)
7. Y Suarez, M Sala, **JM Llovet**, J Bruix. Diagnóstico y tratamiento del carcinoma hepatocelular. *Timely Topics in Medicine* 2000;1-7
8. **Llovet JM**, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. *Bailliere Clin Gastr* 2000;14:991-1008 (Q2 PMID 11139351)
9. **JM Llovet**. Estrategia terapéutica del carcinoma hepatocelular. *Gastroenterología práctica* 2001;10:27-32
10. **JM Llovet**, R Vilana, LI Bianchi, C Brú. Radiofrecuencia en el tratamiento del carcinoma hepatocelular. *Gastroenterol y Hepatol* 2001;34:303-311 (Q4 PMID 11459568)
11. **JM Llovet**, J Fuster, J Bruix. Resecció versus trasplantament hepatic en el tractament del carcinoma hepatocel.lular de petit tamany. Anàlisi segons intenció de tractament. *Butlletí de trasplantament* 2001;Oct: 6-9
12. **Llovet JM**, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma. *Hepato-gastroenterology* 2002;49: 7-11 (Q4 PMID 11941987)
13. **JM Llovet**, J Bruix. Tratamiento médico del carcinoma hepatocelular. *Gastroenterologia continuada* 2002;1:278-283
14. M Sala, **JM Llovet**, J Bruix. Considerations of the Barcelona Conference on the diagnosis and treatment of hepatocellular carcinoma. *Gastroenterol y Hepatol* 2002;25:570-574 (Q4 PMID 12435309)
15. Forns X, Sanchez Tapias JM, Parés A, **Llovet JM**, Bruix J, Rodés J. Expected developments in hepatology. *Best Pract Res Clin Gastroenterol* 2002;16:957-970 (Q2 PMID 12473301)
16. **JM Llovet**. Tratamientos preventivos del HCC. *Timely Topics in Medicine* 2003
17. Pons F, **Llovet JM**. Hepatocellular carcinoma. A clinical up date. *Medscape General Medicine* 2003;5: 11 (PMID 14600648)
18. M Varela, M Sala, **JM Llovet**, J Bruix. Prevención del desarrollo de carcinoma hepatocelular. *Gastroenterol y Hepatol* 2003;26:40-4 (Q4)
19. F Pons, **JM Llovet**. Actitud ante una lesión focal hepática. *Rev Esp Enferm Digest* 2004;96:567-577 (Q4)
20. M Varela, **JM Llovet**. Quimioembolizacion en el tratamiento del carcinoma hepatocelular. *Gastroenterologia continuada* 2004
21. **Llovet JM**. Treatment of hepatocellular carcinoma. *Curr Opin Gastroenterol* 2004;7: 431-441 (Q1 PMID 15527709)
22. Fuster J, Charco R, **Llovet JM**, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. *Transplant Int* 2005;18:278-82 (PMID 15730486)
23. M Sala, **JM Llovet**, J Bruix. Tratamiento actual del carcinoma hepatocelular. *Rev Esp Pat Dig* 2005
24. Pons F, Varela M, **Llovet JM**. Staging systems in hepatocellular carcinoma. *HPB (Oxford)* 2005;7:35-41 (Q2 PMC2023920)
25. **Llovet JM**, Sala M. Non-surgical treatments for hepatocellular carcinoma. *EUR J GASTROEN HEPAT* 2005;17:505-13 (Q3 PMID 15827440)

26. B Minguez, A Villanueva, **JM Llovet**. La firma genética para el diagnóstico molecular del hepatocarcinoma. *GH continuada* 2007;6:274-278
27. **Llovet JM**. Emerging agents for the medical therapy of hepatocellular carcinoma. *Gastroenterology & Hepatology* 2007;3:600-602 (PMC3099295)
28. V Tovar, A Villanueva, **JM Llovet**. Biología celular y genética del carcinoma hepatocelular. *Gastroenterol y Hepatol* 2007;30:360-69 (Q4)
29. Forner A, Ayuso C, Real MI, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, **Llovet JM**, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. *Med Clin (Barc)* 2009;132:272-87 (Q2 PMID 19248879)
30. Zhu AX, El-Khoueiry A, **Llovet JM**. Accomplishments in 2008 in the management of hepatobiliary cancers. *Gastrointest Cancer Res* 2009;3 (5 supplement 2): S28-36 (PMC2791389)
31. Villanueva A, **Llovet JM**. Tratamiento del carcinoma hepatocelular. *Gastroenterol y Hepatol* 2010;33: 79-81 (Q4)
32. Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmatí L, **Llovet JM**, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. *Med Clin (Barc)*. 2016;146:511.e1-511.e22.
33. Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, **Llovet JM**, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix. *J.Med Clin (Barc)*. 2021;156:463-463 (PMID:33461840)


BOOK CHAPTERS

Editor

1. Ed: **Josep M Llovet**. Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3

Guest Editor:

1. Ed: PA.Clavien; S Breitenstein, J Belghiti, R Chari, **JM Llovet**. CH Lo, M Morse, T Takayama, JN Vauthey. Malignant Liver Tumors current and emerging therapies. Wiley-Blackwell Publishers, Sudbury, USA, 2009. Vol 23 Print ISBN: 781405179768 Online ISBN: 9781444317053
2. Ed: P Berk. Guest Editors: J Bruix, **JM Llovet**. Hepatocellular carcinoma. Seminars in Liver Disease, Feb 2010. vol30, number 1. ISSN: 0272-8087. Thieme, New York.
3. Ed: Elsevier. Guest Editors: **JM Llovet**, Al Cheng, JC Nault and B Sangro. Liver Cancer. Journal of Hepatology, Feb 2020





Author

1. R Morillas, **JM Llovet**, R Planas. Biopsia hepática. In: P. Humbert, MA Gassull, eds. *Pruebas complementarias en Gastroenterología y Hepatología*. Barcelona: Ediciones Doyma, 1996: 39-45.
2. R Planas, **JM Llovet**, E Doménech. El riñón en la insuficiencia hepática. Tratamiento de la ascitis. In: JM. Herrerias, A Diaz, M Jiménez, eds. *Tratado de Hepatología* Volumen 2, 1st ed. Sevilla: Universidad de Sevilla, 1996:731-748.
3. J. Bruix, **JM Llovet**, C Brú, J Rodés: Clinical presentation. In: T. Livraghi, M Makuuchi,

- Buscarini L, eds. *Diagnosis and treatment of Hepatocellular Carcinoma*. 1st ed. London: Oxford University Press, 1997:53-58
4. J.Bruix, **JM Llovet**, C Brú: Tumores primitivos del hígado. In: F Vilardell, J Rodés, JR Malagelada, JM Pajares, A Perez Mota, E Moreno, J Puig LaCalle, eds. *Tratado de Gastroenterología*. Volume 3. 2nd ed. Madrid: Biblioteca Aula Médica, 1998;3:2246-2256.
 5. **JM Llovet**, A Castells, J Bruix: Hígado metastásico. En: F Vilardell, J Rodés, JR Malagelada, JM Pajares, A Perez Mota, E Moreno, J Puig LaCalle, eds. *Tratado de Gastroenterología*. Volume 3. 2nd ed. Madrid: Biblioteca Aula Médica, 1998;3:2257-2265.
 6. J Fernandez, **JM Llovet**, JM Salmerón: Dolor abdominal, fiebre y escalofríos. In: M Gomis, J García y A Sitges-Serra, eds. *Libro de médicos internos residentes en enfermedades infecciosas*. Madrid: Grupo Luzán, 1998:82-83.
 7. **JM Llovet**, A Castells, J Bruix: Metastatic liver disease. In: J Bircher, JP Benhamou, N McIntyre, M Rizzetto and J Rodés, eds. *Oxford Textbook of Clinical Hepatology*. Volume 2. 2nd ed. New York: Oxford University Press, 1999;1551-1560.
 8. **JM Llovet**, R Bartolí, R Planas: Bacterial infection of the ascitic fluid in rats with carbon tetrachloride-induced cirrhosis. In: V Arroyo, P Ginès, J Rodés, R Schrier, eds. 1st ed. *Ascites and renal disfunction in liver diseases. Pathogenesis, diagnosis and treatment*. Malden: Blackwell Science, 1999:397-408.
 9. X. Aldaguer, R Vega, **JM Llovet**, R Planas: Prognosis of spontaneous bacterial peritonitis. In: H Conn, M Navasa, J Rodés, eds. 1st ed. *Spontaneous Bacterial Peritonitis. The disease, pathogenesis and treatment*. Marcel Dekker, Inc. 1999.
 10. **JM Llovet**, J Bruix: Medical treatment of advanced hepatocellular carcinoma. In: V Arroyo, J Bosch, M Bruguera, J Rodés, JM Sanchez Tapias, eds. *Treatments in Hepatology*. Barcelona: Masson, 1999:345-354.
 11. **JM. Llovet**, MI. Real, J. Bruix. Does transarterial arterial embolization have a survival benefit for patients with non-surgical HCC? En: Y. Itai, M. Kudo eds. Current topics of hepatocellular carcinoma. Axel Springer Japan, Publishing Inc. Tokyo. 1999.
 12. J Bruix, **JM Llovet**: Risk of hepatic malignancies in primary biliary cirrhosis and autoimmune hepatitis. Treatment schedule. In: Moreno-Otero, Clemente, Garcia-Monzon, eds, 1st ed. Madrid: Aran S.A., 2000:229-234.
 13. Suarez Y, França A, **Llovet JM**, Fuster J, Bruix J. Advances in liver transplantation. The current status of liver transplantation for primary hepatic malignancy. In: Rosen H, Martin P, Gitlin N, eds. *Clinics in Liver Disease. Advances in Liver Transplantation*. Philadelphia: W.B. Saunders Company. 2000;Volume 4: Number 3:591-605.
 14. J. Bruix, **JM Llovet**, C. Brú. Tumores hepáticos malignos. In: Asociación Española para el Estudio del Hígado (AEEH). *Tratamiento de las enfermedades hepáticas y biliares*. 2a Ed. Madrid, 2001:247-255.
 15. J Bruix, **JM Llovet**. Hepatitis C virus and hepatocellular carcinoma. In: M Buti, R Esteban, J Guardia, eds. *Viral hepatitis*. Barcelona: Acción Médica S.A. 2000;133-143.
 16. J Bruix, M Sala, **JM Llovet**. Interferon for the prevention of hepatocellular carcinoma. En: A.J. Zuckerman, I.K. Mushahwar, eds. Perspectives in Medical Virology E. Tabor, ed. *Viruses and liver cancer*. Elsevier Science B.V, 2002:159-167.
 17. J Bruix, M Sala, **JM Llovet**. Prevention of Hepatocellular Carcinoma. In: V Arroyo, J Bosch, J Bruix, P Ginès, M Navasa, J Rodés, eds. *Therapy in Hepatology*. Barcelona: Medicina stm Editores, SL. 2001: 359-366.
 18. **JM Llovet**. Prevention of recurrence for hepatocellular carcinoma after surgical treatments. In: Berr F, Hauss J, Falk H. "Malignant liver tumours: basic concepts and clinical management". Falk Workshop. Leipzig, 2002:191-200
 19. J Bruix, **JM Llovet**. Treatment of patients with suspected or proven hepatocellular carcinoma. IASL-EASL Post-Graduate course. "Prevention and intervention in Liver disease. Madrid, 2002:188-197.
 20. **JM Llovet**. Natural history of hepatocellular carcinoma. In: Colombo M, Schiff E. "Update in Hepatology: Hepatocellular carcinoma". Milan, 2002: 9-18.
 21. J Bruix, **JM Llovet**. Is there an optimal locoregional therapy for hepatocellular carcinoma? In:

- Perry MC, eds. *ASCO 2002 Educational book*. Lippincott Williams & Wilkins, Baltimore. 2002:316-320.
22. **JM Llovet**. Carcinoma Hepatocelular. In: E Cabré, A Abad. *Manual de Enfermedades digestivas*. Ed Viguera Editores. Barcelona, 2002; 469-484.
 23. J Bruix, **JM Llovet**. Hepatitis B virus infection and hepatocellular carcinoma. Consensus Conference on HBV. EASL. Syllabus. 2002:
 24. J Bruix, MI Real, **JM Llovet**. Transarterial embolization for patients with hepatocellular carcinoma. Ed: PA.Clavien. *Malignant Liver Tumors current and emerging therapies..* Jones and Bartlett Publishers, Sudbury, USA, 2003:111-119.
 25. **JM Llovet**. Systematic review of treatment for HCC. In: V Arroyo, X Forns, JC Garcia-Pagan, J Rodés, eds. *Progress in the treatment of liver diseases*. Barcelona: Medicina STM Editores, SL. 2003: 341-350.
 26. M Sala, **JM Llovet**, J Bruix. Enfermedades quísticas no parasitarias del hígado y absceso piógeno. En: J Guardia, V Arroyo. *Tratado de Medicina Interna (2a Ed)*. Barcelona, 2002.
 27. J Bruix, M Sala, **JM Llovet**, J Bruix. Tumores hepáticos. In: J Guardia, J Rodés. *Medicina Interna (2a Ed)*. Barcelona: Masson, 2004: 1525-1529
 28. **JM Llovet**, J Bruix. Nuevas expectativas en la investigación del carcinoma hepatocelular. In: M. Romero, M. Castro, eds. *Carcinoma hepatocelular*; Ergon, 2004:11-14
 29. **JM Llovet**. J Bruix. Prognostic evaluation and assessment of the benefits of treatment. In: J Bruix, ed. *Hepatocellular carcinoma*. Barcelona: Permanyer Publications, 2004:85-104
 30. J Bruix, C Bru, **JM Llovet**. Tumors of the Liver: hepatocellular carcinoma. In : T Boyer, T Wright, M Manns, eds. *Zakim and Boyer's Hepatology . A textbook of Liver Diseases*. Fifth Edition. Saunders Elsevier 2006:1109-1132.
 31. **JM Llovet**. Clinical and molecular classification of hepatocellular carcinoma. In: Grunberg S, ed. *ASCO 2006 Gastrointestinal symposium Proceedings..* Lippincott Williams & Wilkins, Baltimore. 2006:53-54
 32. J Bruix, A Forner, M Varela, C Ayuso, **JM Llovet**. Hepatocellular carcinoma. In: JP Benhamou, N McIntyre, M Rizzetto and J Rodés, eds. *Textbook of Clinical Hepatology*. 3rd ed. London. Blackwell, 2005.
 33. J Schwartz and **JM Llovet**. Molecular Biology and Targeting in Hepatocellular Carcinoma. In *Molecular Targeting in Oncology*. Eds Wadler S, Antman K, Kaufman H. Humana Press. 2006.
 34. A Villanueva, P Newell, A Forner, V Tovar, SL Friedman, J Bruix, **JM Llovet**. Molecular pathogenesis of hepatocellular carcinoma and targeted therapies. In: V Arroyo, A Sanchez, J Fernandez, X Forns, P Gines, J Rodés, eds. *Advances in the therapy of liver diseases*. Ars Medica (Barcelona), 2007: 193-208.
 35. J Bruix, M Sala, **JM Llovet**. Hepatocellular carcinoma. In: *Surgery of the Liver, biliary tract and pancreas*, 4th edition. Ed: Blumgart, Belghiti, Jarnagin, DeMateeo, Chapman, Buchler, Hann and D'Angelica. Elsevier (Philadelphia, USA) 2006:1152-1158.
 36. J Bruix, **JM Llovet**, C Bru. Tumores del hígado. En. *Medicina Interna*, 16th Edition. Ed: Farreras-Rozman. Elsevier, Barcelona 2008
 37. A Villanueva, **JM Llovet**. Evidence-based management of hepatocellular carcinoma and design of clinical trials. In: J G-Abraldes, P Gines, JM Sanchez Tapias, X Forns, R Bataller, J Rodés, eds. *Treatment of liver diseases*. Ars Medica (Barcelona), 2009: 261-272.
 38. A Villanueva, C Alsinet, **JM Llovet**. Signaling Pathways and Rationale for molecular targeted therapies in Hepatocellular Carcinoma. Ed: PA.Clavien. *Malignant Liver Tumors current and emerging therapies*. Wiley-Blackwell. A John Wiley & Sons, Ltd Publication (West Sussex, UK) 2010: 368-381.
 39. M Morse, **JM Llovet**. Emerging therapies in HCC. Introduction. In *Malignant Liver Tumors current and emerging therapies*. Ed: PA.Clavien. Wiley-Blackwell. A John Wiley & Sons, Ltd Publication (West Sussex, UK) 2010: 349-351.
 40. A Villanueva, B Minguez, **JM Llovet**. Emerging therapies beyond sorafenib for hepatocellular carcinoma. In: P Gines, X Forns, JG Abraldes, J Fernández, R Bataller, J Rodés, V Arroyo eds. *Therapy in Liver Diseases*. Elsevier (Barcelona), 2011:315-323

41. V. Hernández-Gea, C. Alsinet, H. Cornellà, **JM. Llovet**. Molecular Classification and Pathogenesis of Hepatocellular Carcinoma. In: P Gines, X Forns, JG Abraldes, J Fernández, R Bataller, J Rodés, V Arroyo eds. Therapy in Liver Diseases. Elsevier (Barcelona), 2013:289-298
42. Villanueva A, Hoshida Y, Chiang DY, **Llovet JM**. Hepatocellular carcinoma. Book: Molecular Oncology. Causes of Cancer and targets for treatment. . 2014:569-578. Publisher: Cambridge University Press (Editors: Drs Gelmann, Sawyers and Rauscher)
43. Sara Torrecilla, Iris Martínez-Quetglas, Roser Pinyol, **Josep M. Llovet**. Genomic alterations for guiding personalized clinical management of HCC. Publisher: Ars Media a Barcelona (Therapy in Liver Diseases 2015)
44. L Torrens, R Pinyol, W Jimenez and **JM Llovet**. Overview of Translational Medicine. In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3
45. R Pinyol, A Martinez-Cardus, M Esteller and **JM Llovet**. Genomics and Epigenomics. In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3
46. V Tovar and **JM Llovet**. Molecular basis of cancer. In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3
47. S Torrecilla, C Fillat, S Puig, M Potrony and **JM Llovet**. Translational Medicine in oncology. In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3
48. R Montal, M Brunet and **JM Llovet**. Discovery and validation of biomarkers. In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3
49. R Montal, F Torres and **JM Llovet**. Design of clinical trials in the genomic era. In: Handbook of Translational Medicine. Edicions de la Universitat de Barcelona, Barcelona-B-16.985-2016. ISBN: 978-84-475-4030-3
50. **JM Llovet**. Tumors of the Liver and Biliary Tree. In: Harrison's Principles of Internal Medicine (20th Edition). Ed: Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Joseph Loscalzo. Chapter 78; 144-157- 2018.
51. **JM Llovet**. Tumors of the Liver and Biliary Tree. In: Harrison's Principles of Internal Medicine (21st). Ed: Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Joseph Loscalzo. Chapter 82; pg...2021
52. A Villanueva, ME Schwartz, **JM Llovet**, Liver Cancer (Chapter 8). Mount Sinai Expert Guides Oncology. ISBN: 798-11-191-8955-8



6. PROFESSIONAL ASSOCIATIONS AND EDITORIAL ACTIVITY

Executive positions in Scientific Institutions, Universities and Scientific Societies

- Executive Secretary, Interim Governing Board. International Liver Cancer Association (ILCA). 2006-07
- Executive Secretary, International Liver Cancer Association (ILCA). 2007-11
- President, International Liver Cancer Association (ILCA). 2011-13
- Executive Committee member, IDIBAPS. 2012-2024
- Advisory Committee of the Director, IDIBAPS 2012-24
- Educational Councilor, International Liver Cancer Association (ILCA). 2013-15
- Executive Committee, Senior Leadership, Tisch Cancer Institute. ISMMS. 2008-18.
- Vice-Chair, Special Interest Group (SIG)- Hepatobiliary Tumors, AASLD. 2016-18
- Chair, Special Interest Group (SIG)- Hepatobiliary Tumors, AASLD. 2019-20
- Chair, Talent's Committee, IDIBAPS 2018-2024

Executive positions in Corporative Associations

- Vicepresident, Association of Professors and Investigators of Advanced Research in Catalunya. 2007-2011
- President, Association of Professors and Investigators of Advanced Research in Catalunya (APIRAC) . 2011-12

Founding Member of Scientific Societies and Corporative Associations

- International Liver Cancer Association (ILCA). 2006
- Association of Professors and Investigators of Advanced Research in Catalunya. 2007.

Membership in Professional Societies

- 1993- Catalan Society Digestive Diseases, Digestive Endoscopy and Transplantation. *Active*
- 1995- Spanish Association for the Study of the Liver (AEEH). *Active*
- 1995- European Association for the Study of the Liver (EASL). *Active*
- 1998- American Association for the Study of Liver Diseases (AASLD). *Active*
- 2001- Reial Acadèmia de Medicina de Catalunya. *Corresponding Member*.
- 2004- American Association for Cancer research-AACR. *Active*.
- 2004-10 The New York Academy of Sciences.
- 2006- International Liver Cancer Association (ILCA). *Regular member*

Elected appointments

- 1985-1986. Council Elected Member, Governing Board, University of Barcelona. (Dean: Prof. Badia), representing the Student's stratum, Faculty of Medicine- Hospital Clínic,
- 1998-2005 Elected Member. Representative of physicians in the presidential elections of the College of Physicians, Barcelona. 1998-2001, and 2002-2005.
- 2008-2012 AASLD- Special Interest Group, Hepatobiliary Neoplasia. Steering Committee Member.
- 2017-2018 (Vice-Chair) and 2019-2020 Chair. AASLD- Special Interest Group, Hepatobiliary Neoplasia

Service to Public and Non-Profit Scientific Agencies

Ad hoc reviewer for peer-reviewed journals

Alimentary Pharmacology and Therapeutics	Hepatology
American Journal of Cancer	Journal National Cancer Institute
American Journal of Transplantation	Journal of Hepatology
Annals of Internal Medicine	Journal of Clinical Oncology
Annals of Oncology	JAMA
Cancer Chemotherapy and Pharmacology	JAMA Oncology
Cancer Cell	Lancet Oncology
Cancer Research	The Lancet
Cell	Liver Transplantation
Clinical Cancer Research	Liver International
Digestive and Liver Disease	Nature
European Journal of Clinical Investigation	Nature Reviews Clinical Oncology
European Journal of Gastroenterology Hepatology	Nature Communications
Expert Opinion on Investigational Drugs	Nature Genetics
FEBS letters	Nature Medicine
Gastroenterology	Nature Reviews Gastro & Hepatology
Gastroenterología y Hepatología	New England Journal of Medicine
Gastroenterology & Hepatology	Proceedings of the National Academy of Science

Editor in Chief, Associate Editor and Editorial Board

- 2000- 2006. Editorial Board of Gastroenterología Práctica.
- 2004 (June) -2009 (October). **Associate Editor**. Journal of Hepatology. Official Journal of the European Association for the Study of the Liver (EASL). Editor in Chief: Prof Massimo Colombo, Milan. Area: Liver cancer.
- 2006 (June)- 2009 (December). **Associate Editor**. Liver Transplantation. Official Journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). Editor in Chief: Jorge Rakela, MD. John Fung, MD Area: Liver cancer.
- 2006- 2011. Member of the Editorial Board of Hepatology. Official Journal of the American Association for the Study of the Liver (AASLD)
- 2006-2016. Member of the Editorial Board of Journal of Hepatology. Official Journal of the European Association for the Study of the Liver (EASL). Area: Liver cancer.
- 2009-2012. **Special Editor**. Selected Summaries. Gastroenterology. Official Journal of the American Gastroenterology Association (AGA). Editor in Chief: Prof Rustgi. Area: Liver cancer.
- 2009-2014. **Special Editor**- Hepatology International. Journal of Hepatology. Official Journal of the European Association for the Study of the Liver (EASL). Editor in Chief: Prof Didier Samuel. Area: Liver cancer.
- 2009 - 2023 **Senior Editor**. Clinical Cancer Research. Official Journal of the American Association of Cancer Research (AACR). Editor in Chief. K. Anderson.& Keith Flaherty
- 2010. **Guest-Editor**. Seminars in Liver Diseases. Monographic in Liver Cancer.
- 2020. **Guest-Editor**. Journal of Hepatology. Special Issue in Liver Cancer.
- 2020- . **Advisory Board member**. Nature Reviews Clinical Oncology
- 2023- . **Editor in Chief**. Journal of Hepatology Reports.
- 2023- **External Advisory Board member**. VCU HCC P01

Scientific Meeting Organizer

a) Scientific Societies

- Director, American Association of the Study of The Liver (AASLD) (2006). Single Topic Conference. Design of clinical trials in hepatocellular carcinoma. Atlanta, USA. Attendees~200
- Executive Secretary and President of Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Barcelona, 2007. Attendees~600
- Executive Secretary and President of Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Chicago, 2008. Attendees~600
- Executive Secretary and President of Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Milan 2009,. Attendees~650
- Chairperson-Director, EASL-AASLD-ALEH-APASL Special Conference in HCC, Croatia 2010. Attendees~700
- Executive Secretary and President of Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Montreal 2010. Attendees~700
- Executive Secretary and President of Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Hong-Kong 2011. Attendees~850
- President ILCA. Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Berlin 2012. Expected attendees~700
- President ILCA. Organizing Committee of the Meeting of the International Liver Cancer Association (ILCA), Washington 2013. Expected attendees~650
- Director, American Association of the Study of The Liver (AASLD) (2018). Single Topic Conference. Advances in trial design and molecular therapies in hepatocellular carcinoma. Atlanta, USA. Attendees~200
- Director, AACR-Special conference on “Advances in the Pathogenesis and Molecular therapies of Liver Cancer. Boston, USA, May 2022

b) Academic Institutions

- Course Director, First Anniversary of the Mount Sinai Liver Cancer Program, New York (2006). Sponsor: Bayer Pharmaceuticals. Attendees~80
- Course Director, Second Anniversary of the Mount Sinai Liver Cancer Program, New York (2007). Sponsor: Bayer Pharmaceuticals. Attendees~80
- Course Director, Third Anniversary of the Mount Sinai Liver Cancer Program, New York (2008). Sponsor: Bayer Pharmaceuticals. Attendees~100
- CME Course Director, Fourth Anniversary of the Mount Sinai Liver Cancer Program, New York (2009). Sponsor: Bayer Pharmaceuticals. Attendees~100
- Course Director, Fifth Anniversary of the Mount Sinai Liver Cancer Program, New York (2010). Sponsor: Bayer Pharmaceuticals. Attendees~100

- Course Director, Sixth Anniversary of the Mount Sinai Liver Cancer Program, New York (2011). Sponsor: Bayer Pharmaceuticals and Onyx. Attendees~100
- Course Director, Seventh Anniversary of the Mount Sinai Liver Cancer Program, New York (2013). Sponsor: Onyx. Attendees~100
- Director, First ILCA school of liver cancer, ISMMS, New York
- Course Director, Eighth Anniversary of the Mount Sinai Liver Cancer Program, New York (2014). Sponsor: Bayer Pharmaceuticals and Onyx. Attendees~160
- Course Director, Observership program in a center of excellence, New York. 2nd and 3rd October 2014 (Accredited with 2,8 credits by Consell Català de Formació Continuada de les Professions Sanitàries, Generalitat de Catalunya) – Top High Rated lecturer at the Scientific Evaluation Results.
- Course Director, 10th Anniversary of the Mount Sinai Liver Cancer Program, New York (2015). Sponsor: Bayer HealthCare, Blueprint Medicines, BTG International, Gilead Sciences. Attendees~150
- Course Director, 11th Anniversary of the Mount Sinai Liver Cancer Program, New York (2016). CME accredited (7 AMA PRA Credits) Attendees~150
- Course Director, 12th Anniversary of the Mount Sinai Liver Cancer Program, New York (2017). CME accredited (7 AMA PRA Credits) Inc. Attendees ~150
- Course Director, 13th Anniversary of the Mount Sinai Liver Cancer Program, New York (2018). CME accredited (7 AMA PRA Credits) Attendees~150
- Course Director, 14th Anniversary of the Mount Sinai Liver Cancer Program, New York (2019). CME accredited (7 AMA PRA Credits) Attendees~175
- Course Director, 15th Anniversary of the Mount Sinai Liver Cancer Program, New York (2020). Virtual meeting. CME accredited (7 AMA PRA Credits) Attendees~250
- Course Director, 16th Anniversary of the Mount Sinai Liver Cancer Program, New York (2021). Virtual meeting. CME accredited (7 AMA PRA Credits) Attendees~250
- Course Director, 17th Anniversary of the Mount Sinai Liver Cancer Program, New York (2022). CME accredited (7 AMA PRA Credits) Attendees ~100
- Course Director, 20th Anniversary of the Mount Sinai Liver Cancer Program, New York (2025), CME accredited (7 AMA PRA Credits) Attendees ~97.
- Chair, Molecular Tumor Board, Tisch Cancer Institute. ISMMS.

Reviewer

a) Scientific Societies

- 2001. Expert investigator for the European Association for the Study of the Liver (EASL), for Grant assessment.
- 2002. Jury member of the European Association for the Study of the Liver (EASL), for grants and communication awards. 37th Annual Meeting. Madrid.
- 2005- Reviewer for the AIRC (Associazione Italiana per la Ricerca sul Cancro), Italy

- 2005- 2021. EASL Reviewer, Communications to the EASL Annual Meetings of Vienna (2006), Barcelona (2007), Milan (2008), virtual (2021). Topic: Liver Tumors.
- 2005-13 AASLD Reviewer, Communications to DDW, Los Angeles (2006). Topic: Clinical: HCC and Cholangiocarcinoma; Clinical Hepatobiliary Neoplasia and Liver Imaging: Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma; Liver Imaging Modules abstract review committee. Digestive Disease Week (AASLD).
- 2006, 2007, 2008. AASLD Reviewer. Communication to Annual Meeting, Boston.
- 2007-2018. ILCA Reviewer. Treatments of HCC. Annual Meetings.
- 2013: AACR.GI Symposium: Pancreas, Small Bowel, and Hepatobiliary Tract Abstract Reviewer
- 2014, 2016: AASLD Reviewer. Topic: Hepatobiliary Neoplasia: Experimental Hepatocarcinogenesis; Biomarkers; Clinical Hepatocellular Carcinoma and Cholangiocarcinoma
- 2015: The Liver Meeting Abstract Reviewer. Topic: Hepatobiliary Neoplasia: Hepatocellular Carcinoma and Cholangiocarcinoma
- 2017. Panelist, EASL Clinical Practice Guidelines of Management of HCC
- 2018. Panelist, ESMO Clinical Practice Guidelines of Management of HCC
- 2018-19. NEJM Reviewer, Manuscript Review CME Program.
- 2021. Reviewer EASL-ILC Abstracts
- 2021-2022 Panelist, AASLD Guidance of management of HCC

b) Funding Agencies

- 2001- Expert Investigator for Agencia Nacional de Evaluación (ANEP), of Spain.
- 2003- Reviewer for the Council for Development Research (RUF), Policy and Planning Department, Danish Ministry of Foreign Affairs.
- 2003- Reviewer for International Union Against Cancer (UICC). ICRETT Projects.
- 2004- Reviewer of the Council for Grant support, University Grants Committee of Hong Kong.
- 2006-Reviewer, Research Projects, FIS. Instituto Carlos III. Ministry of Health Spain.
- 2006-Reviewer, Research projects, AGAUR. Generalitat de Catalunya, Spain.
- 2007-Reviewer, Research projects, INSERM. French Government, Paris, France.
- 2007. Grant Reviewer. Institut National du Cancer, France.
- 2009- Reviewer. National Cancer Institute (NCI-NIH). Grant U01. On site review, Hepatitis B foundation and Drexel University.
- 2009- National Cancer Institute- Early Detection research network (EDRN). Panel of Experts-auditor. Discovery of biomarkers in HCC.

- 2009. Grant Reviewer. AGAUR, Government of Catalonia, Spain.
- 2016. Grant Reviewer. Call for Ideas. AAI-BRIO-Bordeaux, France.
- 2021. Reviewer, FIS evaluation Grants, 2021 Call. Instituto Carlos III. Ministry of Health Spain
- 2021. Reviewer, NIH-NCI intramural for the Laboratory of Human Carcinogenesis. National Cancer Institute, USA
- 2025. Member of the jury 'Margarita Salas,' 2025 Research Awards of the Community of Madrid, September 2025. Ministry of Education, Science and Universities.

Member of Scientific Committees

a) Scientific Societies

- 2000. Member of the Panel of Experts in hepatocellular carcinoma for the EASL.
- 2001. Member of the "International Task Force on Early Diagnosis of Cancer". European School of Oncology.
- 2002. Member, Academic Committee, Spanish Association of the Study of the Liver.
- 2005- Advisor, PDQ-National Cancer Institute. Guidelines on hepatocellular carcinoma.
- 2005. Member, Panel of Experts in hepatocellular carcinoma for the EASL-AASLD-JSH.
- 2006- Director, AASLD Single Topic Conference. Design of Clinical trials in hepatocellular carcinoma.Co-directors: Gregory Gores and Adrian DiBisceglie. Atlanta,USA
- 2006-Secretary- AASLD Panel of Experts in Design and End-point in clinical trials in HCC. Atlanta,USA.
- 2007-Speaker. Standing Committee on Risk Analysis Issues and Reviews. Workshop: Mouse liver tumors: benefits and constraints on use in human health risk assessment, qualitative and quantitative aspects. National Research Council of the National Academies, USA.
- 2008- . AASLD- Special Interest Group in Liver tumors. Steering Committee Member.
- 2009- Chairman, EASL-EORTC Practice Guidelines in Hepatocellular Carcinoma.
- 2010- Chairman. EASL-AASLD-APASL-ALEEH International meeting on Liver cancer, Dubrovnik.
- 2010-2014 Steering Committee member- Hepatobiliary Neoplasia Special Interest Group (AASLD)
- 2011-13 – ILCA – Member, Special Interest Group "Molecular Pathogenesis of HCC"
- 2011-13 – ILCA – Member, Special Interest Group "Molecular Target Therapies in HCC"
- 2014- Scientific Committee, Josep Trueta Award. Academia Ciències Mèdiques Catalunya
- 2015-2017 Scientific Review Committee. AACR-Fellowship in HCC.

- 2016-2018 Scientific Program Committee. ASCO-GI
- 2018-2019 AASLD Content Advisor for the 2019 Gastrointestinal Cancers Symposium Program Committee.
- 2023-2025 Member of the AASLD Special Interest Group (SIG) Advisory Task Force.

b) Academic Institutions

- 2004- Member of the Strategic Planning Initiative for Mount Sinai Medical Center.
- 2005- Member, Research Advisory Panel, Department of Medicine. Mount Sinai School of Medicine.
- 2005-Member, Steering Committee of the Early Detection Research Network (EDRN). National Cancer Institute, USA.
- 2005. Member, Search Committee for Director of Department of Medicine Biostatistics Core. MSSM. New York
- 2005. Member, Search Committee for Director of Cancer Programs. MSSM, NY
- 2006-Panel Member. Editors Forum: to publish in liver-related research papers. Shanghai International Liver Congress, China.
- Director, Mount Sinai Liver Cancer Program Meeting, 1st (2006), 2nd (2007), 3rd (2008), 4th (2009), 5th (2010), 6th (2011). 7th (2012), 8th (2014)
- 2009- Member, Executive Management Committee, Tisch Cancer Institute, MSSM.
- 2010-Member, Basic Tisch Cancer Institute Translational Research Committee, MSSM
- 2011- Member, Developmental Funds Committee, Tisch Cancer Institute, MSSM.
- 2011- Member, Basic and Translational Research Committee, Tisch Cancer Institute, MSSM.
- 2012- Executive Committee Leadership member, IDIBAPS-Barcelona.
- 2012- Tisch Cancer Institute, Senior Leadership Committee, MSSM.
- 2013- Co-chair, Liver Cancer Disease Focus Group, The Tisch Cancer institute, MSSM.

c) Others

- 2004-2007. Principal investigator and member of the Steering Committee of the SHARP trial.
- 2005- Member, list of trustees of Lancet Oncology.
- 2005- Chairman, Safety Monitoring Committee. Prospective randomized study of doxorubicin in the treatment of HCC by drug eluting bead embolization. Biocompatibles PRECISION V.
- 2007-2014. Principal investigator, and member of the Steering Committee of the STORM trial (Bayer Pharmaceuticals).
- 2007-2008. Jury Member, Excellence in Research Award. College of Physicians, Barcelona.

- 2008-2012 Principal investigator, and member of the Steering Committee of the SPACE (TACE-sorafenib) trial (Bayer Pharmaceuticals).
- 2008-2012 Principal investigator, and member of the Steering Committee of the Brivanib Phase III trial. (Bristol-Meyers-Squibb)
- 2008-2011. Member, Steering Committee of SEARCH -The Tarceva-Sorafenib Phase III RCT (Bayer Pharmaceuticals).
- 2008- Organizing Committee. CIBERehd International Meeting. Liver and Colon Cancer molecular pathogenesis and treatment.
- 2008.- Member, Executive Committee and Scientific Board, CIBERehd, Instituto Carlos III, Spain.
- 2010-2014 Chair, IDMC, Data Safety and Monitoring Committee. Phase III study, ramucirumab vs placebo in second-line advanced HCC (Imclone-Lilly)
- 2010-2014 Chair, Data Safety and Monitoring Committee. Biospheres vs conventional TACE in intermediate HCC (Merit-Biospheres)
- 2011-2014. Member, Steering Committee of the Regorafenib vs placebo in 2nd line therapy. Phase III RCT (Bayer Pharmaceuticals).
- 2015-2018 Chair, Data Safety and Monitoring Committee. OPTIMA phase III study: Thermodox plus+RFA vs Dummy+RFA (Celsion)
- 2015-2018. Steering Committee member. Ramucirumab vs Placebo in 2 line study. Phase III RCT. (Eli – Lilly).
- 2016-2018 Chair, Data Safety and Monitoring Committee. Nivolumab vs sorafenib in advanced HCC. Phase III RCT. (BMS)
- 2017-2020 Chair, Data Safety and Monitoring Committee. Nivolumab vs placebo as adjuvant therapy after resection/local ablation. Phase III RCT. (BMS)
- 2017-2020 Chair, Data Safety and Monitoring Committee. Nivolumab + ipilimumab vs sorafenib for advanced hepatocellular carcinoma. Phase III RCT. (BMS)
- 2018-2023. International Principal Investigator. Glycotest clinical trial to define early detection predictors in HCC
- 2019-2022. International Principal Investigator. (LEAP 002). Phase III RCT Lenvatinib+pembrolizumab vs pembrolizumab in advanced HCC. Merck-Eisai
- 2019-2023 Steering Committee member.(LEAP 012) Phase III RCT Lenvatinib+pembrolizumab+TACE vs TACE in intermediate HCC. Merck-Eisai
- Steering Committee member. KEYNOTE-937 (Merck): Safety and efficacy of Pembrolizumab (MK-3475) Versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (MK-3475-937/KEYNOTE-937).
- REPLACE/TRIO041 Trial (Trioncology) Independent Data Monitoring Committee (IDMC). Phase III, Multicenter, Randomized, Open-Label Trial to Evaluate Efficacy and Safety of Regorafenib in Combination With Pembrolizumab Versus TACE for First-Line Treatment of Intermediate-Stage HCC With Beyond Up-to-7 Criteria – 2023

- Steering committee member: IMBRAVE 152 (Roche-Genentech): A study Evaluating Atezolizumab and Bevacizumab, with or without Tiragolumab, in participants with untreated locally advanced or metastatic Hepatocellular Carcinoma.

Pharmaceutical and biotechnology Consulting- Conflict of Interest.

2025

•**Research support:** Genentech, Roche

***Consultancy/Sponsored Lectures:** Eisai Inc., Merck, Roche, Genentech, AstraZeneca, Bayer Pharmaceuticals, Abbvie, Sanofi, Moderna, Glycotest, Exelixis and Boehringer Ingelheim

***Data Safety Monitoring Board for Industry or Commercial Enterprise:** Bristol Myers Squibb.

Previous years (2004-2024)

Bayer HealthCare Pharmaceuticals, Germany. 2004-2021; MDS Nordion, Ottawa, Canada. 2005-2007; Biocompatibles Ltd, United Kingdom. 2003-09; Almirall Prodespharma, Spain. Medical advisor, 2003.; Genzyme Corporation, USA. Consultant. DENSPM in advanced HCC. 2005.; Bristol-Meyers-Squibb. 2008-18; Novartis. Research grant, 2007. Consultancy 2008-13; Arqule, USA. Consultant, 2007-09; Exelixis. Research grant on new molecular targets in HCC. 2006-09. 2017-2020 Johnson and Johnson. Consultant, 2008; Abbot, USA: Consultant, 2009; Jennerex, USA, Consultant 2010-14; Imclone-Lilly 2010-. Chair, Data Safety Monitoring Committee; Biosphere Medical-Merit, 2010-16. Chair, Data Safety Monitoring Committee ; Glaxo-SmithKlein. Consultant, 2011-; Onyx, USA. Consultant, 2011-12; Boehringer Ingelheim Pharma. Germany. Consultant, 2011-2017; Eisai and H3, Consultant, 2012-18; Daishi-Sanko, Japan. Consultant, 2012; Genentech, USA. Consultant, 2012-; Blueprint Medicines. Consultant 2013-17; Celision, Consultant, Speaker and Advisory Board. 2013-18; Acceleron Pharma. Consultant 2013; Celonova Biosciences Inc. Consultant 2013; Celgene. Consultant 2013; Med- iQ. Faculty 2013; Nanostring. Consultant 2013; Vaximm AG. Consultant 2013; Ysios Capital. Consultant 2013; -Heron Therapeutics, Consultant 2014; Threshold Pharmaceuticals, 2015; Incyte Pharmaceuticals 2016; Eli Lilly 2015-20.; Eisai, 2016-; Merck 2017-; Roche & Genentech, 2018; Exelixis, 2018; Mina Alpha Ltd 2018-2021, Navigant, Leerink Swann LLC, Midatech Ltd, Sirtex, Fortress Biotech, Sprink Pharmaceuticals-2019; Nucleix, 2018-21; Iylon 2021; Scientia 2021;

7.INTERNATIONAL RESEARCH CONSORTIUMS

Principal investigator of the HCC Genomic Consortium

- **Icahn School of Medicine at Mount Sinai New York, USA.** : Scott Friedman (Director of Division of Liver Diseases), Myron Schwartz and Sander Florman (Transplantation Institute), Eric Schadt (Genomics Institute), Samuel Waxman (Hemato-Oncology Department) Swan Thung, Isabel Fiel (Pathology Department). Kirsten Sadler, PhD, Yujin Hoshida, MD and Augusto Villanueva MD (Liver Diseases), Amaia Lujambio (Oncological Sciences), Uzilov (Sema 4). Liver Cancer Lab: Daniela Sia, Marc Puigvehí, Philip Harber, Miho Maeda. Past: Yinbei Chen, Beatriz Minguez, Sarra Toffanin, Rad Savic, Anja Lachenmayer, Oriana Miltiadous, Yang Jiao, Martina Gambato, Olga Kuchuk, Genís Campreciós
- **AACR-Landon International Award: Dana-Farber Cancer Institute/MIT Broad Institute (Harvard University, Boston, USA).** Matthew Meyerson and Derek Chiang; Todd Golub and Yujin Hoshida.
- **Hospital Clínic-IDIBAPS, University of Barcelona** Liver Cancer Translational Research Group: Active: Roser Pinyol, Catherine Willoughby, Judit Peix, Josep Fuster, Manel Solé, Joana Ferrer. Previous BCLC: Conxita Brú, Carmen Ayuso, Jordi Bruix, Ramon Vilana, Lluís Bianchi, Marta Burrel.
- **Instituto Nazionale di Tumori, Milano** : Dr. Vincenzo Mazzaferro, Carlo Battiston.

Principal investigator (Coordinator) of the HEPROMIC Consortium:

- FP7 Health grant on genomic predictors and oncogenic drivers of hepatocellular carcinoma:
- Principal coordinator: Josep M Llovet
- Partners: Manel Esteller (IDIBELL), Jessica Zucman-Rossi (INSERM), Vincenzo Mazzaferro (INT, Milan), Lars Zender (University of Hannover), Todd Golub (Harvard, Boston), 2 Small medium enterprises (Diagenode and TCLand)
- Scientific advisors: Scott Friedman, (MSSM, NYC) and Massimo Colombo (Milan)
- Funding: 3 million Euros.
- Period: Nov 2010, Nov 2013.

Principal investigator (Partner) of the HEP-CAR Consortium:

- Call H2020-PHC-2015. Proposal number 667273-2. Acronym: HEP-CAR. Title: Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities.
- Total budget: 5,698,310.00 €.
- Duration: 48 months.
- Partners (10): H2020 HEP-CAR: Prof. Thiemme (U. Freiburg), P. Schirmacher (U. Heidelberg), M. Lebrero (INSERM). 1-Universitätsklinikum Freiburg, Germany; 2- Consorci IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Spain; 3-The Babraham Institute, United Kingdom; 4-The University of Birmingham, United Kingdom; 5-Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GMBH, Germany; 6-Deutsches Krebsforschungszentrum, Germany; 7-Universitätsklinikum, Heidelberg Germany; 8-Università degli Studi di Roma, La Sapienza Italy; 9-Institut National de la Santé et de la Recherche Médicale (INSERM), France; 10-Alta Ricerca e Sviluppo in Biotecnologie SRLU, Italy

Principal Investigator (partner) HUNTER-Accelerator award (CRUK, AECC):

- HUNTER - Hepatocellular Carcinoma Expediter Network". Proposal No: C18873/A26813.
- Total budget: £4,963,702.35.
- Duration: 60 months: 2019-2023 (Non-cost extension until Nov 2025).
- Partners: Prof H Reeves (Newcastle), T Meyer (Riyal Free), Mala Maini (UCL)

Principal investigator (Coordinator) of the TRIVE Consortium:

- HORIZON-MISS.2023-CANCER-01-01 (Proposal: 101136622)
- Title: Tumour-host interactions in live cancer of childhood and adults
- Principal coordinator: Josep M Llovet
- Partners: Manel Esteller (IDIBELL), Jessica Zucman-Rossi (INSERM), Vincenzo Mazzaferro (INT, Milan), Lars Zender (University of Hannover), Todd Golub (Harvard, Boston), 2 Small medium enterprises (Diagenode and TCLand)
- Scientific advisors: Scott Friedman, (MSSM, NYC) and Massimo Colombo (Milan)
- Funding: 3 million Euros.
- Period: Nov 2010, Nov 2013.

Principal investigator: Consortium for assessment fo biomarkers of response to checkpoint inhibitors in HCC

1. MSSM/IDIBAPS, NYC/Barcelona: Josep M Llovet ;
2. Kings College, London: D. Sarker
3. Royal Free Hosp, London : T. Meyer
4. UCLA, Los Angeles: R. Finn
5. Mayo Clinic, Rochester: L. Roberts
6. INT, Milan: V. Mazzaferro
7. Vall d'Hebron, Barcelona: B. Minguez
8. Univ Bern: JF. Dufour
9. Univ. Lausanne: I. Labgaa
10. Univ. Leuven: C. Verslype
11. Univ. Mainz: P. Galle

Other collaborators:

Manel Esteller, MD, PhD, IDIBELL, Barcelona
 Roger Gomis, PhD, IRB, Barcelona
 Xavi Forns, Hosp Clinic-IDIBAPS, Barcelona
 Anja Lachemeyer, Univ Bern
 Mathias Heikenwalder , DKFZ, Heidelberg, Germany
 Nabeel Bardesy, Mass General Hospital, Harvard Univ, USA
 Ben Stanger, Penn University, USA.
 Massimo Colombo,MD. Hospitale Maggiore, University of Milan.Italy.
 David Russel, Univ Washington, Seattle, USA
 David Laragespada, PhD. University of Minesota.
 Jorge Rakela, MD. Mayo Clinic-Scottsdale, USA
 Flair Carrilho,MD. University of Sao Paulo, Brasil
 Sasan Roayaie, White PlainsNew York
 Lewis Roberts, Mayo Clinic, Rochester, Minnessota
 Robert Schwabe, Columbia Univ, NYC
 Mashatoshi Kudo, Univ Osaka, Japan

8.PATENTS

United States Patents

1. **Title: *Methods and compositions for the diagnosis of early hepatocellular carcinoma (MSSM Ref. 050904)***
 Inventors: Josep M Llovet,MD, Myron Schwartz,MD, Scott Friedman, MD.
 Application number: 11/735,402
 Application filed on April, 13th, 2007; confirmation number 1891.
 Issued patent on October, 4th, 2011: US 8,030,013
 Attorney Docket Number: 29636/40936A
2. **Title: *Compositions, Kits, and methods for identification, assessment, prevention and therapy of hepatic disorders" (MSSM Ref. To be determined)***
 Inventors: Todd Golub, MD, Yujin Hoshida ,MD, Josep M Llovet, MD and Augusto Villanueva, MD , Bryan Fuchs and Ken Tanabe
 International Application Number: WO2010/045470 A2
 Application number: PCT/US2009/060859
 Application filed on October 15th, 2009
 Converted in US application on October 27th, 2011: US 2011/0263441 A1
3. **Title: *Methods for Diagnosing and Treating Intrahepatic Cholangiocarcinoma***
 Inventors: D Sia PhD, B Losic PhD, V Mazzaferro MD, JM. Llovet MD,
 Application Number: 61/876,451
 Application filed on October, 9th 2013, confirmation number 1914
 Attorney Docket Number: 27527-0130P01
 Foreign Filing License Granted: 10/01/2013
 Country code and number of your priority application: US 61/876,451
4. **Title: *Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features***
 Inventors: Josep M. Llovet, MD, Daniela Sia, PhD, Augusto Villanueva, MD
 Application Number: 62/519,711
 Application filed on June 14th 2017, confirmation number 170101G-P
5. **Title: *Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy***
 Inventors: Josep M Llovet, MD, Daniela Sia, PhD, Augusto Villanueva, MD.
 Application Number: PCT/US2018/037579
 Application filed on February 12, 2018. Tech No. 17010G-P2
 International filing date: June 14th, 2018
 International Application number: WO2018/232142A1
6. **Title: *Methods for the detection and treatment of immune classes of hepatocellular carcinoma***
 Inventors: Josep M Llovet, MD, Daniela Sia, PhD
 Application Number: 63/248.653
 Application filed on September 28, 2021, confirmation number 506892503
7. **European Patents**

Title: *Methods for the prognosis of Hepatocellular Carcinoma*

Inventors: Josep M. Llovet, MD, Augusto Villanueva, MD, Manel Esteller, MD, Anna Portela, PhD, Sergi Sayols, PhD
 European Application Number: EP14382535.4
 Reference Number: P3156EP00 Date: 18th December 201

9. PROJECTS AND GRANT SUPPORT

PUBLIC GRANTS – PI: Prof Josep M Llovet

1. Horizon-Miss-2023-Cancer-01. Proposal number: 101136622. Proposal Acronym: **THRIVE**. Type of Model Grant Agreement: HORIZON Action Grant Budget-Based. Title: Tumour-host interactions in liver cancer of childhood and adults. (PI: Llovet, Josep M). Total budget: 12,068,185€. Duration 60 months. Project start: Dec 2023.
2. NCI-R01. Grant Number: 1 **R01** CA273932-01 Proposal Title: Determinants of immunotherapy response in NASH Hepatocellular carcinoma (07/01/2023-06/30/2028) PI: JM Llovet. Budget. (total: \$3,092,679€) Duration: 5 years
3. Horizon 2020. Call H2020-PHC-2015. Title: “Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities”. Proposal No: 667273. Acronym: **HEP-CAR**. (PI/Partner: JM Llovet). Total budget: 5,698,310.00 EUR.. Duration: 48 months: 2016-19.
4. FP7-2010-Health European Commission Title: “Genomic predictors and oncogenic drivers in hepatocellular carcinoma”. Proposal No: 259744-2. Acronym: **HEPTROMIC**. (PI/Coordinator: Josep M Llovet). Total budget 3,000,000 Euros. Period: 2010-14
5. National Institute of Health-USA (NIDDK). **R01**. Grant Number 5R01DK076986-05. Project Period: 08/10/2007 to 07/31/2012. “Integrative genomic analysis in hepatocellular carcinoma”. PI: Josep M Llovet. Total budget \$1,250,000, non-cost extension 2013
6. National Health Institute, Spain. **I+D Program** “Immunogenomic mechanisms of response and resistance to immune therapies and novel drug combinations in fatty liver-related hepatocellular carcinoma”. PI: Josep M Llovet. 01/09/2023-31/08/2026. Awarded Total budget: 499,750€
7. Grup de Recerca Consolidat — Recerca Translacional en Oncologia Hepàtica. **AGAUR** (Generalitat de Catalunya). Grant number: SGR-CAT 2021. PI: Josep M Llovet. Període 2022-2024.- Total Budget: 60,000€.
8. National Health Institute, Spain. **I+D Program** Grant number: PID2019-105378RB-I00. “Molecular characterization of obesity/diabetes/NASH-related hepatocellular carcinoma”. PI: Josep M Llovet. Period: 1/6/2020-31/5/23. Total budget: 338,800€
9. Grup de Recerca Consolidat — Recerca Translacional en Oncologia Hepàtica. **AGAUR** (Generalitat de Catalunya), SGR 1358. PI: Josep M Llovet. Period: 2017-2021. Total budget: 61.192€.
10. **EUIN. Mineco**. “Identificación de biomarcadores de respuesta a inmunoterapias en carcinoma hepatocellular” Total budget: 10,000€. PI: Josep M Llovet. Period: 01/01/2017-12/31/2017
11. National Health Institute, Spain. **I+D Program** (Grant number: SAF2016-76390-R). “Mecanismos de Resistencia a TKI en el carcinoma hepatocellular”. PI: Josep M Llovet. Period: 30/12/2016-29/12/2019. Total budget: 338,800€
12. DOD Team Grant. “Mechanisms of acquired resistance to sorafenib in HCC”. (CA150272P1). PI: S. Friedman. Co-PI: JM Llovet, A Villanueva, A Lujambio and S Lowe (MSKCC). Total budget: \$406,762.00 Duration: September 1st 2016 – August 31st 2019.
13. Grup de Recerca Consolidat — Recerca Translacional en Oncologia Hepàtica. **AGAUR** (Generalitat de Catalunya), SGR 1162. PI: Josep M Llovet. Període 2014-2017.- Total Budget: 30,000€.
14. National Health Institute, Spain. **I+D Program** (Grant number: SAF-2013-41027).

- “Oncogenic drivers and poor prognosis signatures”. PI: Josep M Llovet. Period: 1/2014-12/2017. Total budget: 220,000€
15. National Health Institute, Spain. **I+D Program** “Predictores genomicos pronosticos y nuevas dianas moleculares en el carcinoma hepatocelular” (Grant number: SAF-2010-16055). PI: Josep M Llovet. Period: 2010-2013. Total budget: 300.000€
 16. Grup de Recerca Singular- Recerca Translacional en Oncologia Hepàtica. **AGAUR** (Generalitat de Catalunya), SGR 1186. PI: Josep M Llovet. Període 2009-2014.- Total Budget: 41,600€.
 17. National Health Institute, Spain. **I+D Program** (Grant number: SAF-2007-61898). “Role of IGF signaling in HCC”. PI: Josep M Llovet. Period 2007-2010. Total budget: 224.000€.
 18. Member of CIBEREHD network- Instituto Carlos III– Oncologia Hepatica . Period: since 2006-2019. Funding: support for 2 staff positions : Judit Peix (Lab Manager) and Senior Post-doc (Augusto Villanueva, up to 2024); 1 PhD students: (Iris Martinez: 2015-16; Laura Torrens 2017-18 and Sara Torrecilla 2018-19)
 19. National Health Institute-Spain. **FISS project**-2002-2005. Report PI020596. “Analysis of clonality and chromosomal aberrations in preneoplastic lesions and hepatocellular carcinoma in cirrhotic patients suitable for liver transplantation.” PI: Josep M Llovet (2002-04). Total budget:\$126,000

PRIVATE GRANTS – PI:Prof Josep M Llovet

1. Asociación Española Contra el Cáncer (AECC). Reto AECC 70% Supervivencia. Ttitle: "ASPIRE-AECC: Mejorar la supervivencia de los pacientes de cáncer de hígado combinando inmunoterapia y cirugía". Acronym: **ASPIRE**. Coordinators: Dr. Josep M Llovet, Dr. Xose Bustelo. Project duration: 01/07/2024-01/07/2030. Total budget: 8.000.000€.
2. Fundació La Caixa. Translational Research in Cancer Program. (Coordinator: Llovet, Josep M) Multidisciplinary Research Programmes (MRP). Project duration: 01/05/2023-01/05/2027. Total budget: 400,000€.
3. Asociación Española Contra el Cáncer (AECC) “Identification of biomarkers predicting response and resistance to immunotherapy in advanced hepatocellular carcinoma”. Official code: PRYGN223117LLOV. Role PI.. Project duration: 30/11/2022-29/11/2025. Total budget: 300,000€.
4. Asociación Española Contra el Cáncer (AECC). AECC-IDIBAPS **Excellence Programme** – Immunotherapy against Cancer. Official code: EPAEC246711CLIN. Acronym: AECC_ProdExcel24. Project duration: 1/12/2024-30/11/2028. Total budget: 1.995.015,00€. Dr Josep M Llovet’s budget: 288.833,33€.
5. Research Groups – Research Area Cancer. IDIBAPS. Period: TBC. Total: 125,000€
6. Eisai. Exploring the anti-tumoral and immunological effects of combining the Wnt pathway inhibitor E7386 with lenvatinib in preclinical models of HCC . PI: Josep M Llovet,MD . Budget: \$800,000
7. Genenetch. Characterizing the tumor microenvironment of mash-related hcc to unravel determinants of response and/or resistance to atezolizumab + bevacizumab PI: Josep M Llovet,MD . Budget: \$1,097,824
8. Genenetch. A Feasibility Clinical Trial of Atezolizumab and Bevacizumab in Combination with Y90 Radioembolization for Patients with Hepatocellular Carcinoma for Liver Transplantation. PI: Parissa Tabricin, MD & Josep M Llovet,MD . Budget: \$1,190, 287
9. Academia – Basic Research Grant – Fundació Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears. Title: “Discovery of biomarkers predictive of

- response and/or resistance to anti-PD1 immune checkpoint inhibitors in advanced hepatocellular carcinoma” Project duration: 01/02/2021 – 30/05/2023. Grant number: BECA-ACADEMIA21-001 Total budget: 30,000€
10. Accelerator Award (CRUK; AECC; AIRC; C9380/A26813.). Title: “HUNTER - Hepatocellular Carcinoma Expediter Network”. Proposal No: C18873/A26813. Acronym: HUNTER. (PI/Partner: JM Llovet). Project duration 48 months: 2019-2023 (+2 years non-cost extension until Nov 2025). Total budget: £4,963,702.35.
 11. Tish Cancer Institute Grant. “Clinical and molecular risk factors for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease ”. (Received a TCI development grant award). PIs: Chang, Boffeta, Llovet. Project duration: 9/1/2015 – 12/31-2016. Total budget: \$50,000
 12. The Tisch Cancer Institute of Mount Sinai. B cell regulation of HCC progression. (PI: Miriam Merad-Josep M Llovet). Project duration: 01/01/2012 – 12/31/2012. Total budget: \$50,000
 13. Asociación Española Contra el Cáncer (AECC): “Integrative genomic analysis of intrahepatic cholangiocarcinoma”. (PI: Josep M Llovet). Project duration: 2011-2018 Total budget: 1,200,000 Euros.
 14. Mount Sinai School of Medicine (MSSM). RMTI Grant: “Molecular markers defining at risk populations fo liver transplantation from HCC”. (PI: Josep M Llovet). Project duration: 07/14/2011 to 07/13/2012 Total budget: \$200,000.
 15. Marató of TV3 Foundation, 1999. “Cost-effective analysis of adjuvant treatment of hepatocellular carcinoma for patients on the waiting list for liver transplant.” Scientific research projects on organ transplants. PI: Josep M Llovet. Project duration: 2001-2002. Total budget: \$ 58,000
 16. Identification of subpopulations of HCC patients predisposed to respond to GPC3-targeting bispecific antibodies and NK-based therapy. Cytovia Therapeutics. Project duration: 01/03/2023-28/02/2024. Budget 338,000\$.
 17. Molecular and genomic characterization of human hepatocellular carcinoma with high FASN expression. Sagimet. Project duration: 01/01/23-30/06/2023. Budget: 220,000\$
 18. Immuno-molecular effects of regorafenib + anti-PD1 after front-line atezolizumab + bevacizumab in preclinical models of HCC and NASH-HCC (second-line study). Bayer Healthcare. Project duration: Jan 1, 2022 – Dec 31, 2023 Budget: 249,986€ .
 19. Anti-tumour and immunomodulatory effect of Regorafenib in combination with anti-PD1 in preclinical models of HCC and, specifically, in NASH-HCC. Bayer Pharmaceuticals. Project duration: Feb 9, 2021 - 2024 Budget: 249,986€
 20. Exploring the anti-tumoral and immunological effects of combining the Wnt pathway inhibitor E7386 with lenvatinib in preclinical models of HCC. Eisai. Project duration: 15/01/2021-23/12/2024. Total budget: \$825,767
 21. Determining the efficacy and immune-modulatory effects of adding anti-ctla4 therapy to the combination of cabozantinib and anti-pd1/anti-pdl1 in preclinical models of HCC. Ipsen Pharma S.A.S. Project duration: 2021-2023. Budget: 188,650€
 22. Role of Xentuzumab for the treatment of hepatoblastoma overexpressing IGF2. Boehringer-Ingelheim. Project duration: April 1, 2019 – April 1, 2023. Budget: 81,741€
 23. Discovery of biomarkers predictors of response and/or resistance to anti-PD1-based immune checkpoint inhibitors in advanced HCC. Bayer Pharmaceuticals. Project duration: March 7, 2019- March 4, 2022. Budget: 400,000€
 24. Impact of cabozantinib alone or in combination with anti-Pd1 on the immune system in HCC and assessment of the synergistic anti-tumoral effect in experimental models. Ipsen. Project duration: Dec 3, 2018- Dec 31, 2021. Budget: 205,254€

25. Impact of lenvatinib alone or in combination with anti-PD1 on the immune system in HCC and assessment of the synergistic anti-tumoral effect in experimental models. Eisai. Project duration: 2018-2021. Budget: \$175,298
26. Impact of lenvatinib alone or in combination with anti-PD1 on the immune system in HCC and assessment of the synergistic anti-tumoral effect in experimental models. Funding agency: Eisai Inc. Project duration: 2018-2019. Budget: \$187,298
27. Molecular characterization of the immune cells in HCC. Funding agency: BMS. Project duration: 2017-2018. Budget: \$1,166,189
28. JAK/STAT3 signaling pathway selective targeting in liver cancer. Funding agency: Incyte Corporation. GCO 14-1242. Project duration: 2014-2017. Budget: \$50,000
29. Measuring and correlating FGF19 amplification and expression in HCC. Funding agency: Blueprint Medicines Corporation. GCO 4-0996. Project duration: 2014-2017. Budget: \$171,000
30. Assessment of Jak inhibitors in HCC. Funding agency: Incyte/Novartis. Project duration: 2014-15 Budget: \$7.000(Mt Sinai)
31. Assessment of FGF19 amplification in HCC. Funding agency: Blueprint. Project duration: 2013-15. Budget: \$170.000(Mt Sinai)
32. IGF Signaling in Hepatocellular Carcinoma: Assessment of Anti-tumoral Efficacy of BI 836845. Funding agency: Boehringer Ingelheim. Project duration: 2013-2014. Budget: 50,000.00€.
33. BIBF 1120 Therapy for acquired resistance to sorafenib and chemoprevention in HCC. Funding agency: Boehringer Ingelheim. Project duration: 2012-2014. Budget: 300,000€.
34. BIOSTORM study, biomarkers predicting response to sorafenib therapy. Funding agency: Bayer Pharmaceuticals. PI: JM Llovet, J Bruix . Project duration: 2009-2017. Budget: 734,499 €
35. Role of FGF signaling in hepatocellular carcinoma and pre-clinical effect of brivanib. Funding agency: BMS. PI: JM Llovet. Project duration: 2009-2011. Budget: 190,000€
36. Role of c-MET signaling in human hepatocellular carcinoma. Pre-clinical evaluation of JNJ-38877605. Funding agency: Johnson & Johnson). PI: JM Llovet. Project duration: 2008-9. Budget: 65,000 €.
37. Molecular targeted therapies with a novel dual PI3K/mTOR TK inhibitor. Funding agency: Exelixis. (PI: Josep M Llovet). Project duration: 2007-2009. Budget: \$150,000
38. Molecular targeted therapies with a novel IGF-1R TK inhibitor. Funding agency: Exelixis. (PI: Josep M Llovet). Project duration: 2007-09. Budget: \$60,000
39. Targeted molecular combined therapy of Hepatocellular carcinoma (HCC) with a RAF kinase and VEGFR inhibitor (sorafenib) associated with a m-TOR inhibitor (rapamycin). Funding agency: Bayer Pharmaceutical, USA. Project duration: 2006-08. \$60,000.
40. Targeted molecular therapy for hepatocellular carcinoma with a dual tyrosine kinase receptor inhibitor (AEE788) and a mTOR inhibitor (RAD001). Funding agency: Novartis, 2006
41. Analysis of the tumor microenvironment in Hepatocellular Carcinoma using Tumor bank Samples from Mount Sinai.. Project duration: 2017-2021. Budget \$1,166,189
42. Phase II Assessment of Refametinib in RAS mutant HCC. Sponsor: Bayer Healthcare.. Role: International PI (Mt Sinai) Project duration: 2012-2015, Budget: \$204,293

43. Phase III randomized, placebo-controlled study of sorafenib vs placebo in the adjuvant setting after curative resection or ablation (STORM trial). Sponsor: Bayer Pharmaceuticals. (Mt Sinai): PI: Josep M Llovet, MD. Project duration: 2008-2012. Budget: \$ 707,000
44. Phase II randomized, placebo-controlled study of TACE-sorafenib vs TACE-placebo in HCC patients (SPACE trial). Sponsor: Bayer Pharmaceuticals PI: Josep M Llovet, MD. (Mt Sinai) Project duration: 2008-2012. Budget: \$ 152,000
45. Phase III randomized, study of brivanib vs placebo in patients failing sorafenib treatment in HCC (BRISK trial) . Sponsor: Bristol-Myers Squibb PI: Josep M Llovet, MD. Project duration: 2008-2012. Budget: \$ 490,000
46. Therasphere for the treatment of advanced HCC: Randomized controlled trials versus best supportive care. Pilot study. (Mt Sinai) Sponsor :MDS Nordion. Project duration: 2006. Budget: \$68,000
47. Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma (SHARP). Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet, MD. (Mt Sinai). Project duration: 2004-2007. Budget: \$ 750,000
48. 20th Anniversary of the Mount Sinai Liver Cancer Program 2025 "Liver Cancer: Novel clinical and translational advances". \$66,000
49. 17th Anniversary of the Mount Sinai Liver Cancer Program 2022 "Liver cancer: Updated review of clinical management and translational science"
50. 16th Anniversary of the Mount Sinai Liver Cancer Program 2021. "Liver cancer: Advances in science and clinical management"
51. 15th Anniversary of the Mount Sinai Liver Cancer Program 2020. "Liver cancer: Advances in science and clinical management"
52. 14th Anniversary of the Mount Sinai Liver Cancer Program 2019. Sponsor: Bayer HealthCare, Merck, Bristol-Myers Squibb, BTG International, Eisai, Glycotest. PI: Josep M Llovet, MD. Budget \$104,500
53. Management of Hepatocellular Carcinoma and Novel Therapies. Funding agency: Period: 2018. Exelixis: \$148,500
54. 13th Anniversary of the Mount Sinai Liver Cancer Program 2018. Sponsor: Bayer HealthCare, Bristol-Myers Squibb, BTG International, Eisai, Glycotest. PI: Josep M Llovet, MD. Budget \$80,000
55. 12th Anniversary of the Mount Sinai Liver Cancer Program 2017. Sponsor: Bayer HealthCare, Eisai, BMS, Blueprint Medicines, BTG International, Celis, Gilead Sciences. PI: Josep M Llovet, MD. Budget \$80,000
56. 11th Anniversary of the Mount Sinai Liver Cancer Program 2016. Sponsor: Bayer HealthCare, Blueprint Medicines, BTG International, Gilead Sciences, Incyte. PI: Josep M Llovet, MD. Budget \$70,000
57. Tenth Anniversary of the Mount Sinai Liver Cancer Program 2015. Sponsor: Bayer HealthCare, Blueprint Medicines, BTG International, Gilead Sciences PI: Josep M Llovet, MD. Budget \$70,000
58. First-ILCA School of Liver Cancer. Mount Sinai Liver Cancer Program. Icahn School of Medicine at Mount Sinai, 2014 . PI: Jm Llovet, S Friedman, M Schwartz. \$41,000.
59. Eighth Anniversary of the Mounts Sinai Liver Cancer Program 2014. Sponsor: Bayer Pharmaceuticals and Onyx. PI: Josep M Llovet, MD. Budget \$45,000
60. Seventh Anniversary of the Mount Sinai Liver Cancer Program-2012. Sponsor: Onyx. PI: Josep M Llovet, MD . Budget: \$40,000
61. Sixth Anniversary of the Mount Sinai Liver Cancer Program-2011. Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet, MD . Budget: \$55,000

62. Fifth Anniversary of the Mount Sinai Liver Cancer Program-2010. Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet,MD . Budget: \$55,000
63. Fourth Anniversary of the Mount Sinai Liver Cancer Program-2009. Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet,MD . Budget: \$55,000
64. Third Anniversary of the Mount Sinai Liver Cancer Program-2008. Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet,MD . Budget: \$55,000
65. Second Anniversary of the Mount Sinai Liver Cancer Program-2007. Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet,MD . Budget: \$40,000
66. First Anniversary of the Mount Sinai Liver Cancer Program-2006. Sponsor: Bayer Pharmaceuticals. PI: Josep M Llovet,MD . Budget: \$40,000
67. SWCRF- Mt Sinai Liver Cancer Program project. 2005. \$65,000
68. SWCRF Mt Sinai Liver Cancer Program project 2006. \$50,000
69. SWCRF Mt Sinai Liver Cancer Program project 2007. \$107,800
70. SWCRF Mt Sinai Liver Cancer Program project 2008. \$115,000
71. SWCRF Mt Sinai Liver Cancer Program project . 2009. \$112500
72. SWCRF Mt Sinai Liver Cancer Program project. 2010. \$ 120,000
73. SWCRF Mt Sinai Liver Cancer Program project 2011. \$120,000
74. SWCRFMt Sinai Liver Cancer Program project . 2012. \$60,000
75. SWCRF Mt Sinai Liver Cancer Program project. 2013. \$110,000
76. SWCRF Mt Sinai Liver Cancer Program project 2014. \$110,000
77. SWCRF Mt Sinai Liver Cancer Program project. 2015. \$105,000
78. SWCRF Mt Sinai Liver Cancer Program project. 2016 . \$62,500
79. SWCRF Mt Sinai Liver Cancer Program project. 2017. 27,500\$
80. SWCRF Mt Sinai Liver Cancer Program project . 2018. 25,000\$
81. SWCRF Mt Sinai Liver Cancer Program project 2019. 25,000\$
82. SWCRF Mt Sinai Liver Cancer Program project. 2020. 25,000\$
83. SWCRF Mt Sinai Liver Cancer Program project 2021. 25,000\$
84. SWCRF Mt Sinai Liver Cancer Program project 2022. 25,000\$
85. SWCRF Biomarkers predictors of response/primary resistance to checkpoint inhibitors in HCC. 2023. 25,000\$
86. SWCRF Biomarkers predictors of response/primary resistance to checkpoint inhibitors in HCC. 2024. 25,000\$
87. SWCRF Mt Sinai Liver Cancer Program project 2025. 66,000\$

OTHER PUBLIC & PRIVATE FUNDING AS CO-INVESTIGATORS

1. National Institute of Health-USA (NIDDK). Hepatic stellate cells in NASH fibrosis and HCC. R01-NIH. (PI: Friedman, Scott). Total budget: \$1,979,818. Project number: 1 R01 DK128289-02. Duration: 2021-2026
2. National Cancer Institute (NCI). 1P30CA165979-01. The Tisch Cancer Institute: Cancer Center. Project period: 09/01/2015 to 09/01/2020. PI: Steven J. Burakoff. Role: Director, Liver Cancer Program PI. Total budget: \$8,500,000.
3. National Institute of Health-USA (NIDDK). 1R01DK DK099558. "Molecular Prognostic Indicators in Liver Cirrhosis and Cancer". Mount Sinai School of Medicine, USA. Grant 2013-2017. (PI: Yujin Hoshda). Total budget: \$696,850
4. National Institute of Health-USA. Training Grant, Division of Liver Diseases. Mount Sinai School of Medicine, USA. Ref. 5T32DK007792 Grant 2012-2017. (PI: Scott Friedman). Total budget: \$1,250,000
5. National Institute of Health-USA (NIDDK). R01. Grant Number 1R01DK080789-01A1. Project Period: 12/01/2008 to 11/30/2013. "Role of UHRF1 in liver development, regeneration and carcinogenesis". (PI: Kirsten Sadler). Total budget \$2,100,000
6. Alex's Lemonade Stand- Foundation for Childhood Cancer. "IND-enabling studies for WNTinib, a novel selective therapeutic for CTNNB1 mutant hepatoblastomas". Total Budget: 250,000\$ Period: 01/11/2021-31/10/2023.
7. HCC Phase III randomized, double blinded study comparing regorafenib vs placebo promoter: Bayer Pharmaceuticals. 2012-2015. PI: Jordi Bruix
8. National Cancer Institute-NIH. Validation of serum markers for the early detection of hepatocellular carcinoma. PI: Jorge Marrero, MD. (University of Michigan). Budget: \$ 60,000 (Mt Sinai). (2005-2007)
9. Phase III randomized, double-blinded study of sorafenib+erlotinib vs sorafenib in patients with advanced hepatocellular carcinoma (SEARCH). Promoter: Bayer Pharmaceuticals. 2004-2007. PI: Charissa Chiang. Total budget: \$52,563. (2004-2007)
10. "Pharmacokinetic Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma (HCC) by Drug-Eluting Bead Embolisation. Phase I/II study". Europe. Promoter: Biocompatibles Limited. (2003- 2004)
11. PEG-Intron como tratamiento de mantenimiento en comparación con un grupo control en sujetos adultos con cirrosis compensada (Metavir F4) secundaria a hepatitis crónica C, que no han respondido al tratamiento con interferón alfa y ribavirina. Código P02569. Promoter: Shering-Plough. (2003-2006)
12. Program for promotion of biomedical research and health sciences. Instituto de Salud Carlos III. "Analysis and comparison of efficacy, tolerance and cost of radiofrequency vs alcohol injection in patients with small hepatocellular carcinoma" (nº 02/10072). -PI: Dr. R Vilana. (2002-2004)
13. Study EBC 9802 INT, "Treatment of advanced hepatocellular carcinoma. Randomized multicentre controlled trial comparing serocalcitol vs symptomatic treatment "Promoter: Leo Pharmaceutical. (1999-2006)
14. Study EBC 9801 INT, "Prevention of recurrence of hepatocellular carcinoma after curative treatment: Randomized multicentre controlled trial comparing serocalcitol vs symptomatic treatment". PI: M Beuagrand. Promoter: Leo Pharmaceutical Products. (1999-2004)
15. Project of Agency for Assessment of Technologies.. "Treatment of small hepatocellular carcinoma by radiofrequency ablation". PI: Dra Concepció Brú. (1999-2001)
16. National Health Institute. Project of investigation and technological development I+D: CYCIT (SAF 004/98). "Natural history of hepatocellular carcinoma. Analysis of factors related to proliferation and dissemination.". PI: Dr. Jordi Bruix. (1998-2000)
17. "Phase II study to assess oral 5-FU and 776C85 in patients with unresectable hepatocellular carcinoma. Promoter. Glaxo-Wellcome. (1997-1999)
18. "Treatment of hepatocellular carcinoma with embolization associated or not with doxorubicin vs control. Multicenter, randomized controlled phase IV study." Promoter. Pharmacia -Upjohn. (1995-1999)

19. Multicentre International Liver Study Protocol of case-control study on Hepatocellular Carcinoma The MILTS Collaborative Study Team. Promoter: Center for Epidemiology and Health Research, Germany, (1995-1997)
20. "Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma". Promoter: Shering-Plough. (1995-1997)
21. Open-labeled, randomized, multicentre, controlled trial comparing norfloxacin vs rifloxacin in the prevention of spontaneous bacterial peritonitis in cirrhotic patients. (1993-1996)
22. Randomized controlled trial comparing ofloxacin vs cefotaxime in cirrhotic patients with spontaneous bacterial peritonitis. PI: M Navasa. Promoter: Hoechst Ibérica. (1990-1992)
23. Cooperative research network of Cancer Centers. Center: IDIBAPS, group Hepatic Oncology. PI: Dr. J Bruix.
24. Cooperative research network of Hepatology and Gastroenterology. Center: IDIBAPS, group Hepatic Oncology. PI: Dr. J Bruix
25. National Health Institute. FISS project, report 92/0764: "Intestinal bacterial translocation in liver cirrhosis with ascites. Implication in the pathogenesis of spontaneous bacterial peritonitis: Clinical study and in animal experimentation". PI: Dr. R. Planas. (1992-1994)
26. National Health Institute. FISS project, report 90/0039: "Study of the antioxidant micronutrients in plasma and of fatty polyunsaturated acids in plasma, intestinal mucosa and platelets functionalism in premalignant colon diseases". PI: Dr. MA. Gassull. (1990-1992)

10.HONORS AND AWARDS

1994

- PIAR 92/93 Award (Institutional Research Program): granted by the Catalan Health Studies Institute, for international journal publications. Article published: "Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis." **Llovet JM**, Bartolí R, Planas R, et al. *Gut*, 1994;35:1648-1652.
- PIAR 93/94 Award (Institutional Research Program): granted by the Catalan Health Studies Institute): **JM Llovet** Relationship between bacterial translocation and spontaneous bacteria peritonitis in ascitic cirrhotic rats. (IASL, Scientific Meeting). May 19-24, 1994. Cancun, México.
- IASL Best Communication Award: "Somatostatin vs endoscopic sclerotherapy in the treatment of acute variceal bleeding: final results of a prospective randomized trial". R Morillas, JC Quer, R Planas, J Boix, P Humbert, E Cabré, **JM Llovet**, E Domènech, MA Gassull. Congress of the IASL. Cancún, México. 1994.

1998

- Doctoral Thesis EXTRAORDINARY award: March, 1998. Thesis: "Spontaneous bacterial peritonitis in cirrhosis: pathogenesis and prognosis."

2000

- Best Article Award 1999-2000: Catalan Foundation for Transplant and the Royal Academy of Medicine of Catalonia. **Llovet JM**, Fuster J, Bruix J, for the BCLC Group. Intention-to-treat analysis for surgical treatment of hepatocellular carcinoma: resection vs transplantation. *Hepatology* 1999;30:1434-1440.
- Philips Award of Ultrasonography Diagnosis (14th edition, 2000). Vilana R, Bianchi L, Sánchez M, Pagés M, **Llovet JM**, et al. "Color Doppler and signal enhancer in the pre- and post percutaneous treatment of small HCC. A Comparative study with spiral CT"

2001

- Best Poster Award: XXVI Congress of the Spanish Association for the Study of the Liver, 2001. M Sala, **JM Llovet**, et al. High risk of tumor dissemination after radiofrequency in HCC patients".
- Best Communication award. Spanish Society of Interventional Vascular Radiology, 2001. Montañá X, **Llovet JM**, Real M, et al. "Quimioembolización vs control en el tratamiento del carcinoma hepatocelular avanzado".

2002

- Best published article in international peer-reviewed journals by a Spanish researcher, 2002. Ediciones MAYO. **Llovet JM**, Arterial embolization or chemoembolization vs symptomatic treatment in patients with unresectable HCC: a randomized controlled trial. *The Lancet* 2002;359:1734-39

2003

- Award of the Spanish Association for the Study of the Liver (AEEH) "Carlos Hernández Guío". Support research in foreign countries. "Gene expression profile in pre-neoplastic lesions and hepatocellular carcinoma". Mt Sinai Hospital, New York.
- Award for long-term stay for research in foreign countries. Societat Catalana de Digestologia. 2003-2004. "Gene expression profile in pre-neoplastic lesions and hepatocellular carcinoma". Mt Sinai Hospital, New York.
- Award for Doctors to support long-term stay for research outside Catalunya (BE). AGAUR 2003BEAI00138 (2003-04). "Gene expression profile in pre-neoplastic

lesions and hepatocellular carcinoma". Mt Sinai Hospital, New York.

- Award of Sociedad Española de Radiología Médica, 2003. "Assessment of efficacy of second generation contrast ultrasound agent in the evaluation of response after percutaneous treatment of hepatocellular carcinoma.". PI: Dr. Ramon Vilana.

2004

- Award to the best research article in peer-review journals, 2003. Burrell M, **Llovet JM**, Ayuso C, et al. MRI angiography is superior to triphasic helical CT for detection of small HCC prior liver transplantation. Comparison with pathologic correlation. *Hepatology* 2003;38:1034-42.
- Award for Doctors to support long-term stay for research outside Catalunya (BE), AGAUR 2004BE 00226 (2004-05). "Gene expression profile in pre-neoplastic lesions and hepatocellular carcinoma". Mt Sinai Hospital, New York.

2006

- Award of Professional Excellence in Research. Official College of Physicians-Barcelona.

2007

- Award, Mount Sinai Faculty Convocation Program. Appointment awarded: Executive Secretary, International Liver Cancer Association.

2008

- ICREA scientific evaluation: outstanding
- Award, Best communication J.L.Raoul, L. Bolondi, A. Craxi, M. Moscovici, M. Shan, D. Voliotis, J. Bruix, J.M. Llovet. *Potential impact of macroscopic vascular invasion (MVI), ECOG performance status and extrahepatic spread (EHS) on sorafenib safety and efficacy in patients with advanced hepatocellular carcinoma: SHARP trial subset analyses*. ILC meeting, 2008.
- Award, Best paper 2008 (Diario Médico): Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan J, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, **Llovet JM**, Golub TR. Gene Expression Profiles of Adjacent Liver Predict Outcome in Hepatocellular Carcinoma. *N Engl J Med*. 2008;359:1995-2004.
- Award, Best article published in 2008, AEEH. Villanueva A, De Feo A, Chen Y, Yea S, Fiel I, Thung S, Schwartz M, Roayaie S, Schwartz M, Friedman SL, **Llovet JM**. Role of dual TKI and an mTOR inhibitor in blocking PI3K pathway in HCC. *Gastroenterology* 2008; 135:1972-83.

2009

- Visiting Professor Award, University of Fudan, Shanghai (China). February 2009.
- AACR-Landon INNOVATION Award for International Collaborations (PI: Josep M Llovet, MD, on behalf of the HCC Genomic Consortium. AACR Annual Meeting, Denver, USA: (PI: Josep M Llovet). Total budget \$100,000.
- Excellence accreditation in research: Grup de Recerca Singular (PI Josep M Llovet), according to the Catalan Government (Generalitat de Catalunya), June 2009-2014. 45000Euros.
- SHARP awarded as the Best International Trial-2009 Award. The Clinical Research Excellence Award. GCPJ Publishers.

2010

- Award, best oral communication. Spanish Association for the Study of the Liver. Asociación Española para el estudio del Hígado. XXXV Congreso Nacional Anual AEEH. Título: La firma genética de proliferación-G3 identifica los pacientes.

- Award, best poster communication. Spanish Association for the Study of the Liver Asociación Española para el estudio del Hígado. XXXV Congreso Nacional Anual AEEH. Título: Nueva diana terapéutica en el carcinoma hepatocelular: Complejo 2 de MTOR
- August Pi i Sunyer Award of Excellence in Research, IDIBAPS-Hospital Clínic-2010-2012

2011

- Award, best oral communication. Spanish Association for the Study of the Liver. Asociación Española para el estudio del Hígado. XXXVI Congreso Nacional Anual AEEH. Title: Molecular classification of intrahepatic cholangiocarcinoma
- Award, best poster communication. Spanish Association for the Study of the Liver Asociación Española para el estudio del Hígado. XXXVI Congreso Nacional Anual AEEH. Title: FGF signaling in HCC.
- AECC award, coordinated study: 1.2 Million Euro: “Integrative genomic analysis of intrahepatic cholangiocarcinoma.”

2012

- International Hans Popper Award 2012, for excellence in basic and experimental Hepatology. Falk Symposium, Mainz, October 5th 2012.
- Awards, best oral communication, AEEH. Anti-tumoral efficacy of HDAC in combination with sorafenib in preclinical models of HCC.

2013

- Josep Trueta award, Best scientist. Acadèmia Ciències Mèdiques de Catalunya. May 2013.

2014

- Best Oral Communication, Spanish Association for the Study of the Liver. Asociación Española para el estudio del Hígado. XXXVI Congreso Nacional Anual AEEH. Helena Cornellà, PhD Student, Title: Molecular characterization of fibrolamellar HCC
- ILCA School of Liver Cancer in 2014 (Director) .Designation of the **Liver Cancer Program** at Icahn School of Medicine at Mount Sinai (MSSM) as the Center of Excellence hosting the very first edition of ILCA Liver Cancer School.
- Highly Cited Researchers 2014. Thomson Reuters (refers to 1% most cited researchers in science).
- Award, Top cited investigators in the country. Department of Medicine , University of Barcelona
- Recognition of dedicated membership. American Association for the Study of the Liver Diseases (member since 2004).
- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2014”. Thomson Reuter (using its Web of Science and InCites platforms to determine which researchers have produced work that is most frequently acknowledged by peers).

2015

- ICREA scientific evaluation: outstanding
- Tisch Cancer Institute awarded with NCI-designated Cancer Center recognition 2015-2020. Funding 8,5M\$. TCI research programs ‘Liver Cancer’ led by Scott Friedman and Josep Llovet are recognized as 1st Liver Cancer program ever awarded by NCI.
- Award, Best oral AASLD presentation on liver cancer. “Molecular heterogeneity in multinodular Hepatocellular Carcinoma”, San Francisco.
- AASLD Fellowship Award. 2015

- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2015”. Thomson Reuter (using its Web of Science and InCites platforms to determine which researchers have produced work that is most frequently acknowledged by peers).
- Recognition as the spanish author with most top-cited articles in digestive disease system from 1950-2013 (Font: Journal of Gastroenterology and Hepatology 31 (2016) 107–111)

2016

- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2016”. Thomson Reuter (top 1% most cited investigator)
- Vice-Chair-AASLD-SIG Hepatobiliary tumors.

2017

- Award, Best oral EASL presentation “Molecular Characterization of the immune class of hepatocellular carcinoma” Amsterdam.
- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2017”. Thomson Reuter (top 1% most cited investigator)
- Recognition as “working hard professors” among the world’s most cited researchers in 2017. ICREA

2018

- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2018”. Clarivate Analytics (top 1% most cited investigator)
- Chair-AASLD SIG Hepatobiliary tumors.

2019

- 18th Annual Dr Richard W. Sherbaniuk & Dr Ronald H.Wensel Lectureship Award in Gastroenterology, University of Alberta. Edmonton, Canada.
- Leon Schiff State-of-the-Art Lecture “Molecular Pathogenesis and Management of Hepatocellular Carcinoma –” AASLD The Liver Meeting 2019. Boston, US. 12th November 2019.
- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2019”. Clarivate Analytics (top 1% most cited investigator)

2020

- ICREA scientific evaluation: outstanding
- Award, best oral communication. Asociación Española para el estudio del Hígado. XLV Congreso Nacional Anual AEEH. Título: Caracterización del Sistema immune en el microambiente de los carcinomas hepatocelulares. Madrid.
- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2020”. Clarivate Analytics (top 1% most cited investigator)

2021

- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2021”. Clarivate Analytics (top 1% most cited investigator)
- Recognition as one of the best worldwide researchers, best 100,000 (position 726). Stanford University. Clarivate Analytics.

2022

- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2022”. Clarivate Analytics (top 1% most cited investigator)

2023

- CVIR Most cited article: Study protocol for publication. “Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus

Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment” 2023

- Award, Best oral EASL presentation “Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures” 2023
- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2023”. Clarivate Analytics (top 1% most cited investigator).

2024

- Award, best oral XXXIII Congrés de la Societat Catalana de Digestologia Award for publication: Identificació de dos mecanismes de resposta a atezolizumab + bevacizumab en carcinoma hepatocel·lular avançat mitjançant single-cell RNA sequencing”
- Award, best Oral Communication 49th Annual Congress AEEH 2024. “Identificación de dos mecanismos de respuesta a atezolizumab + bevacizumab en carcinoma hepatocelular avanzado mediante single-cell RNA sequencing”
- Award for Outstanding Service to the CVIR Journal for the Most Cited Study Protocol in 2023 for the paper “Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization with or without Lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment”.
- Recognition as one of “The WORLD’s Most Influential Scientific Minds 2022”. Clarivate Analytics (top 1% most cited investigator)
- University of Stanford-Elsevier 2% scientist 2024: # 675 globally
- Award HCC-LIVE’s Distinguished Lecture Series: A career Story. Lecture: “Distinguished Lecture Series: A career Story” HCC-LIVE, Austin, TX, USA. February 2025

11.VISITING PROFESSORSHIP, INVITED LECTURES,PRESENTATIONS

TOP VISITING PROFESSORSHIP

USA/Canada

- Columbia University, New York, 2004
- Mayo Clinic, Rochester, Minnesota, USA. 2004 & 2012.
- Cornell University. New York, USA, 2004.
- Yale University, Connecticut, USA 2004
- Northwestern University of Chicago, Chicago USA. 2004.
- Memorial Sloan-Kettering Cancer Center. NYC, USA; 2004.
- Ann Harbor, University of Michigan, 2006
- Univ. of Pennsylvania. Philadelphia, 2010
- Mayo Clinic – Arizona, 2014.
- MD Anderson, Houston, USA, 2016.
- MGH and Dana-Farber, Harvard University, 2018
- The Rockefeller University Hospital, New York, US, 2018
- University of Alberta, Edmonton, Canada. 2019
- University of Vermont, USA, 2021
- UCLA JCCC Leaders in the Field Seminar Series. USA, 2022

Asia

- Yonsei University, Seoul, Korea, 2004.
- Fudan University, Shanghai, China (2009-2016)

- Second Military Hospital, Shanghai, 2019.

Europe

- University Hospital Zurich, Switzerland, 2007
- Newcastle University, United Kingdom. 2016

South America

- University of Sao Paulo, 2015.

TOP ORAL COMMUNICATIONS IN SCIENTIFIC MEETINGS (PLENARY SESSION)

1. **JM Llovet**, X Mas, J. Aponte, J Fuster, M Navasa and J Bruix. BCLC Group Radical treatment of hepatocellular carcinoma during the waiting list for orthotopic liver transplantation: a cost-effectiveness analysis on an intention-to-treat basis. *Hepatology* 1999;30:223A .50th Congress of **AASLD**. Dallas, 1999. (Plenary Session)
2. **Llovet JM**, Vilana R, Brú C, Bianchi LI, Salmeron JM, Sala M, Ayuso C, Pagès M, Bruix J, Rodés J. Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma. *Hepatology* 2000; 32:206A. 51th Congress of **AASLD**. Dallas, 2000. (Plenary session).
3. **JM Llovet**, M Real, R Vilana, R Planas, S Coll, JJ Aponte, C Ayuso, M Sala, J Muchart, R Solà, J Rodés, J Bruix. Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma . *J Hepatol* 2001;34 (Suppl 1):11A .36th European Congress of **EASL**. Prague, 2001. (Plenary session)
4. **JM Llovet**, M Real, R Vilana, R Planas, S Coll, JJ Aponte, C Ayuso, M Sala, J Muchart, R Solà, J Rodés, J Bruix. Chemoembolization versus conservative management in patients with unresectable hepatocellular carcinoma . *J Clin Oncol* 2002;21 (Part 1):132A .38th Annual Meeting of the American Society of Clinical Oncology **ASCO**. Orlando, 2002. (Paralel Session).
5. **JM Llovet**, J Bruix. Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma. *Hepatology* 2002;36:387A. 5^{3th} Congress of **AASLD**. Boston,, 2002. (Paralel Session).
6. **Llovet JM**, Chen Y, Wurmbach W, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman S. A molecular signature to discriminate dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis. 57th Congress of **AASLD**. St Francisco, 2005 (Paralel Session)
7. **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J, for the SHARP Investigators. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial. *J Clin Oncol* 2007: LBA1 **ASCO**, Plenary Session. Chicago 2007
8. **Llovet JM**, Peña C, Shan M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Presidential Plenary Session, **AASLD** 59th Annual Meeting, San Francisco. 2008
9. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Peix J, Solé M, Tovar V, Cornellà H, Alsinet C, Pellegrinelli A, Cotsoglou C, Molino E, Citterio D, Lachenmayer A, Thung S, Fuster J, Garcia-Valdecasas JC, Bruix J, Schwartz M, Mazzaferro V, **Llovet JM**. Molecular classification of human intrahepatic cholangiocarcinoma defines two classes with distinct biology and outcome. *Hepatology* 2010; 52:320A-421A. 61th Congress of **AASLD**. Boston, 2010 (Presidential Plenary session).
10. Villanueva A, Zong Y, Hoshida Y, Yange K, Cabellos L, Thung S, Stanger B, **Llovet JM**. Genomic and functional characterization of Notch as oncogenic driver in liver. *Hepatology* 2010; 52:320A-421A. 61th Congress of **AASLD**. Boston, 2010 (Plenary session).
11. **Llovet JM**, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn R, Tal WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS Study. 47th Annual Meeting of the **EASL**. Barcelona 18-22 April 2012. *Journal of Hepatology* 2012;56 (Suppl 2):S549 (Late breaker session), and **ILCA** Presidential plenary session, Berlin 2012.
12. D. Sia , B. Losic, K. Revil, K. Hao, L. Cabellos, Z. Zhang , Y. Hoshida, S. Roayaie , S. Thung , M. Schwartz , S. Waxman , V. Mazzaferro, E. Schadt, **J. M. Llovet**. Discovery Of A Tyrosine

Kinase Fusion Gene In Intrahepatic Cholangiocarcinoma. **ILCA Presidential plenary session, Washington 2013.**

13. **Josep M. Llovet**, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jia-Mei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T. Poon, Kwang-Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabricio Souza, Marie-Aude Le Berre, Gerold Meinhardt Jordi Bruix,. A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Adjuvant Sorafenib After Resection or Ablation to Prevent Recurrence of HCC, **ILCA Presidential plenary session**, Kyoto, Japan 5th -7th September 2014
14. Pinyol R, Montal R, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Poon RT-P, Kokudo N, Zhang Z, Bassaganyas L, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata, M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, **Llovet JM**. Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial, **EASL, Presidential plenary session**, Amsterdam, The Netherlands 19th-23rd April 2017.
15. Robert Montal, Wei Qiang Leow, Carla Montironi, Laia Bassaganyas, Agrin Moeini, Daniela Sia, Roser Pinyol, Laia Cabellos, Judit Peix, Miho Maeda, Parissa Tabrizian, Beatriz Minguez, Timothy Pawlik, Ismail Labgaa, Lewis Roberts, Manel Sole, Maria Isabel Fiel, Swan Thung, Sasan Roayaie, Augusto Villanueva, Myron Schwartz, **Josep M. Llovet**. Integrative molecular classification of extrahepatic cholangiocarcinoma, **EASL .Plenary**, Paris, France 11th-15th April 2018.
16. Robert Montal, Wei Qiang Leow, Carla Montironi, Laia Bassaganyas, Agrin Moeini, Daniela Sia, Roser Pinyol, Laia Cabellos, Judit Peix, Miho Maeda, Carlos Villacorta, Parissa Tabrizian, Christine Sempoux, Beatriz Minguez, Tim Pawlik, Ismail Labgaa, Lewis Roberts, Manel Sole, Maria Isabel Fiel, Swan Thung, Sasan Roayaie, Augusto Villanueva, Myron Schwartz, **Josep M Llovet**. Integrative molecular classification of extrahepatic cholangiocarcinoma. Plenary session, EASL 2018; Presidential plenary session, ILCA Annual Conference, London, United Kingdom 14th-16th September 2018; **AASLD-Presidential plenary** (St Francisco 2018).
17. Tabrizian P, Holzner M, Halazun K, Agopian V, Busuttil R, Yao F, Roberts J, Florman S, Schwartz M, Emond J, Samstein B, Brown R., Najjar M, Chapman W, Doyle M, **Llovet JM** and Mehta N. A US multicenter analysis of 2529 HCC patients undergoing liver transplantation: 10year outcome assessing the role of downstaging to within Milan criteria. Hepatology 2019;(in press). Congress of **AASLD**. Boston, 2019 (Presidential *Plenary session*).
18. **Josep M. Llovet**; Richard S. Finn; Zhenggang Ren et al. LEAP-012: A Phase 3 Study of Lenvatinib Plus Pembrolizumab Plus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. ESMO Congress. Presidential Plenary, Barcelona 2024

Visiting Professorships and Invited Lectures : Total 775 (as per December 2025)

Recent period 2008-2025: 5968

Previous period 1995-2007: 177

	Country	Number (n=752)
Europe (295)	Spain (90% Barcelona) + Virtual lectures held in Barcelona	235
	Italy	29
	Germany	20
	Switzerland	23
	France	19
	Rest of Europe	73

America (210)	USA	197
	Canada	11
	Center/South	22
Asia (110)	Japan	47
	China	56
	Korea	14
	Australia/NZ	9
	Rest of Asia	10
Africa /Middle East (10)	Africa & Middle East	10

VISITING PROFESSORSHIP AND INVITED LECTURES (RECENT 2008-2025)

2008

1. Invited lecture. "Novel advancements in HCC: From loco-regional to molecular targeted therapies". ASCO-GI Satellite Symposium, Orlando, FL, 2008.
2. Invited lecture. "Molecular targeted therapies in HCC: the sorafenib case". AISF (Italian Association for the Study of the Liver). Rome, Italy, 2008.
3. Seminar. "Evidence-based treatment for HCC". BSP Symposium. 6th Annual Meeting of the JSMO. Fukuoka, Japan, 2008.
4. Invited lecture. "Molecular pathogenesis and targeted therapies in HCC". Special ASCO-JSMO Joint Symposium. Translation of research findings to clinical trials. 6th Annual Meeting of the JSMO. Fukuoka, Japan, 2008.
5. Chair. "New therapeutic approach to HCC". 18th Conference APASL, Seoul, Korea. 2008
6. Invited lecture. "A new evidence-based approach for the treatment of HCC". 18th Conference APASL, Seoul, Korea. 2008
7. Chair. Poster Presentation HCC (III). 18th Conference APASL. Seoul, Korea. 2008
8. Invited lecture. "Clinical data with sorafenib in patients with advanced HCC". Targeted therapy in advanced HCC: working towards improved treatment options BSP symposium. 18th Conference APASL, Seoul, Korea. 2008
9. Invited lecture. "Advancements in the treatment of HCC". IX Jornadas de Invierno. Granada, 2008.
10. Chair. "New advancements in HCC". EASL-Symposium on HCC. Milan, Italy 2008.
11. Chair. "The molecular targeted therapies in advanced HCC". BSP symposium. Marrakech, Morocco, 2008
12. Invited lecture. "Targeted systemic therapies". European Conference on Interventional Oncology (ECIO). Florence, Italy, 2008
13. Invited lecture. "Targeting molecular pathways in the adjuvant setting after locoregional treatment" ILCA-ECIO. Florence, Italy, 2008
14. Invited lecture. "Sorafenib as the standard of care in HCC: implications for earlier stages in HCC and future directions". European Conference on Interventional Oncology (ECIO). Florence, Italy, 2008
15. Invited lecture. "Molecular targets for HCC". AACR Symposium on molecular pathogenesis of HCC. AACR 2008 Annual Meeting. San Diego, USA, 2008.
16. Invited lecture. "Molecular pathogenesis of HCC and signaling pathways". Program for the Advancement of Therapy in HCC (PATH) Preceptorship- BCLC. Barcelona, 2008
17. Invited lecture. "Current Evidence based practice and research trial design". EASL-ILCA Meeting. EASL Annual Meeting 2008. Milan, Italy, 2008.

18. Chair. Clinical Symposium: "Novel advancements in HCC". EASL Annual Meeting 2008. Milan ,Italy, 2008.
19. Chair. "Targeted therapies: from clinical trials to clinical practice-progress in the management of HCC". BSP Satellite Symposium EASL Annual Meeting 2008. Milan ,Italy, 2008.
20. Invited lecture. "New strategies for targeted therapies in HCC: focus on Sorafenib". BSP Satellite Symposium EASL Annual Meeting 2008. Milan ,Italy, 2008.
21. Invited lecture. "Mt Sinai Liver Cancer Research Program in 2007". Samuel Waxman Cancer Research Foundation. New York, 2008.
22. Chair. Director of Course."Translating New Developments in Solid Tumors into Clinical Practice". EORTC 2008. Barcelona 2008.
23. Invited lecture. "Targeted therapies in hepatocellular carcinoma". EORTC 2008. Barcelona, 2008.
24. Chairn. "Molecular Mechanisms". 3rd Biannual Spring Conference. AEEH. Santander, Spain, 2008.
25. Invited lecture. "Molecular classification of HCC" 3rd Biannual Spring Conference. AEEH. Santander Spain ,2008.
26. Invited lecture. "Current situation of ILCA ". 44th Annual Meeting of Liver Cancer Study Group of Japan. Osaka, Japan, 2008.
27. Invited lecture. "Molecular targeting therapy for HCC". 44th Annual Meeting of Liver Cancer Study Group of Japan. Osaka, Japan, 2008.
28. Invited lecture. "Sorafenib in HCC: whom to treat,whom not to treat". ASCO Annual Meeting 2008. Chicago, USA,2008.
29. Invited lecture. "Sorafenib, the new standard for advanced HCC". EASL Monothematic Conference-Liver Cancer: from molecular pathogenesis to new therapies. Prague, 2008.
30. Chair. "Liver Cancer: from molecular pathogenesis to new therapies". Local Therapies. EASL Monothematic Conference. Prague, 2008.
31. Director"3rd Aniversary Mount Sinai Liver Cancer Program meeting". New York, 2008.
32. Invited lecture. "Rationale for adjuvant therapy in HCC: STORM trial". BSP meeting. Barcelona, 2008.
33. Invited lecture. "Molecular targeted therapies in HCC". EORTC South European Meeting, Taormina, Sicily, 2008.
34. Invited lecture. "Molecular Pathogenesis of HCC". Post Graduate Course. AASLD Annual Meeting, San Francisco, 2008.
35. Invited lecture. "Molecular tools for the diagnosis of HCC". Special Interest Group Symposium. AASLD, Annual Meedting, San Francisco, 2008.
36. Invited lecture. "Genetics and genomics in HCC". Early Morning Workshop AASLD. Annual Meedting, San Francisco, 2008.
37. Invited lecture. "Novel agents in advanced HCC". Chemotherapy Foundation Symposium (Special lecture), New York, 2008.
38. Invited lecture. "Staging systems in hepatocellular carcinoma". NIH-NCI Special Meeting on Hepatocellular Carcinoma (SOTS Meeting). Bethesda, 2008.

2009

39. Invited lecture. "Molecular classification of HCC". Instituto Carlos III (IDIBAPS-IRB) Barcelona, 2009.
40. Invited lecture. "Molecular pathogenesis and targeted therapies in HCC" (Special lecture) IARC, Lyon, 2009.
41. Visiting Professorship lecture. "Management of HCC". Fudan University, Shangai, 2009.
42. Visiting Professorship lecture. "Molecular pathogenesis of HCC and Targeted therapies". Fudan University, Shangai, 2009.
43. Visiting Professorship workshop. "Design of clinical trial in HCC". Fudan University, Shangai,

2009.

44. Invited lecture. "Rationale for sorafenib in the adjuvant therapy of HCC". STORM Investigators meeting. Hong-Kong, 2009.
45. Invited lecture. "Rationale for the combination of TACE and sorafenib in HCC". SPACE Investigators meeting. Hong-Kong, 2009.
46. Invited lecture. "Design of RCT and treatment options of early-stage HCC". BRISK investigators meeting. Florida, USA, 2009.
47. Invited lecture. "Sorafenib, biomarkers and future prospects in HCC". AEEH, Madrid, 2009.
48. Chair. "Therapy for HCC". 2009 International symposium on Viral hepatitis and Liver Diseases. Bethesda, USA, 2009.
49. Invited lecture. "Treatment of HCC". 2009 International symposium on Viral hepatitis and Liver Diseases. Bethesda, USA, 2009.
50. Seminar. "Diagnosis and prognosis of HCC". Auckland, New Zealand, 2009.
51. Seminar. "Treatment strategies in HCC". Auckland, New Zealand, 2009.
52. Seminar. "Biomarkers and response to sorafenib". Sidney, Australia, 2009.
53. Seminar. "Overview of pathogenesis and management of HCC". Sidney, Australia, 2009.
54. Award Ceremony. AACR Landon International award ceremony. AACR, Denver, USA
55. Chair. "Novel targets in HCC". EASL- ILCA joint meeting. Copenhagen, Denmark, 2009
56. Invited lecture. "How can molecular profiling improve the diagnosis and therapy of HCC" Postgraduate course. EASL, Copenhagen, Denmark, 2009
57. Invited lecture. "Markers and surrogate markers of tumor biology". Session: Liver Transplantation in HCC. EASL, Copenhagen, Denmark, 2009
58. Invited lecture. "Design of RCT and treatment options of early-stage HCC". BRISK investigators meeting. Barcelona, 2009.
59. Invited lecture. "Molecular pathogenesis and the role of molecular targeting therapies". Japan Society of Hepatology. Kobe, Japan, 2009.
60. Chair. "Genomics and Signaling pathways in HCC". Japan Society of Hepatology-ILCA joint meeting. Kobe, Japan, 2009.
61. Invited lecture. "Molecular classification of HCC". Japan Society of Hepatology-ILCA joint meeting. Kobe, Japan, 2009.
62. Invited lecture. "Subanalysis results of the SHARP trial". IKLS Official symposium. Kobe, Japan, 2009.
63. Invited lecture. "¿Deben expandirse los criterios de trasplante en el hepatocarcinoma?". III Curso de Cirugía hepática Avanzada. Barcelona, 2009.
64. Invited lecture. "Molecular therapies for advanced HCC". XV Congreso Argentino de Hepatología. Buenos Aires, Argentina, 2009
65. Invited lecture. "Molecular pathogenesis of HCC". XV Congreso Argentino de Hepatología. Buenos Aires, Argentina, 2009
66. Invited lecture. "Assessing candidacy for orthotopic liver transplantation. Prediction of tumor biology." The state of liver transplantation-International Liver Transplantation Society (ILTS). New York, 2009.
67. Director, 4th Anniversary Mount Sinai Liver Cancer Program meeting. Novel targets and drugs in HCC. New York, 2009.
68. Invited lecture. "Achievements of the Mount Sinai Liver Cancer Program". 4th Anniversary Mount Sinai Liver Cancer Program meeting. Novel targets and drugs in HCC. New York, 2009.
69. Invited lecture. "Current Molecular therapies in HCC and design of trials". 4th Anniversary Mount Sinai Liver Cancer Program meeting. Novel targets and drugs in HCC. New York, 2009.
70. Chair. "Hepatocellular carcinoma: identifying targets for novel therapies." ILCA Symposium International Liver Cancer association (ILCA), Milan, 2009.

71. Invited lecture. "Linking signalling pathways and molecular therapies in HCC". International Liver Cancer association (ILCA), Milan, 2009.
72. Invited lecture. "Future prospects on molecular therapies in HCC". International Liver Cancer association (ILCA), Milan, 2009.
73. Chair. "Symposium on Hepatocellular carcinoma and renal cancer". BSP symposium. Istambul, Turkey, 2009.
74. Chair/ Invited lecture. "Sorafenib in HCC, a paradigm shift in clinical practice". Istambul, Turkey, 2009.
75. Chair/ Invited lecture. "Future prospects and ongoing and planned trials with sorafenib in HCC". Istambul, Turkey, 2009.
76. Invited lecture. "General Hepatology Update. Liver Cancer Screening: modalities and benefits. Are we there yet?" AASLD Postgraduate course. Boston, 2009.
77. Chair. "Keeping the patient with end-stage disease alive". Postgraduate course. AASLD 60th Annual Meeting. Boston, 2009.
78. Meet-the-Professor-luncheon. "HCC: novel targets and therapies". AASLD 60th Annual Meeting. Boston, 2009.
79. Chair. "International management strategies for HCC in patients with advanced disease". AASLD 60th Annual Meeting. Boston, 2009.
80. Chair. "Risk factors and rationale for chemoprevention in HCC". Eight Annual Conference on Frontiers in Cancer Prevention Research. New York, 2009.
81. Invited lecture. "Rationale for molecular targeted therapy in HCC". Columbia Grand Rounds. New York, 2009.

2010

82. Chair. "Genomics in HCC research" Mount Sinai School of Medicine – HCC Retreat 2010. New York, 2009.
83. Chair. "Estrategias de mejora para el tratamiento de las complicaciones de la cirrosis" XXXV Congreso Annual de la Fundación/Asociación Española para el Estudio del Hígado. Madrid, 2010.
84. Invited lecture. "Cancer". EASL Monothematic Conference. Signalling the liver. Amsterdam, 2010.
85. Invited lecture. "Molecular Pathogenesis of HCC and Signaling Pathways" Program of the Advancement of Therapy in Hepatocellular Carcinoma (PATH). Barcelona, 2010.
86. Invited lecture. "Biología molecular del hepatocarcinoma y tratamiento personalizado" 5o. Curso avanzado de Oncología – 8o. Curso de Doctorado Investigación Aplicada y Traslacional en Neoplasias Digestivas. Barcelona, 2010.
87. Invited lecture. "Future Prospects on Molecular Targeted Therapies in HCC" 20th Conference of the APASL Beijing, China, 2010.
88. Invited lecture. "HCC treatment evolution and brivanib's potential role in meeting unmet needs and shaping the future of HCC landscape.audience:BMS global and regional medical and marketing teams".BMS.20th Conference of the APASL. Beijing, China, 2010.
89. Invited lecture. "Molecular Targeted Therapy in Hepatocellular Carcinoma" The 20th Conference of the APASL. Beijing, China, 2010.
90. Invited lecture. "Angiogenic Resistance in HCC: An Emerging Need for Novel treatment" 20th Conference of the APASL Beijing, China, 2010.
91. Chair. "HCC management: progress through scientific exploration" Bayer Schering Expert Symposium on Targeted Therapies (BESTT 2010). Geneva, 2010.
92. Invited lecture. "Signalling pathways and enhancing patient outcomes: next steps" Bayer Schering Expert Symposium on Targeted Therapies (BESTT 2010). Geneva, 2010.
93. Chair. "New Advancements in HCC research" EASL-ILCA Joint Symposium. 45th Annual Meeting of the European Association for the Study of the Liver.EASL. Vienna, 2010.

94. Chair. "New directions in HCC: an overview of current and future management options". 45th Annual Meeting of the European Association for the Study of the Liver.EASL. Vienna, 2010.
95. Invited lecture. "New directions in HCC: an overview of current and future management options". 45th Annual Meeting of the European Association for the Study of the Liver.EASL. Vienna, 2010
96. Invited lecture. "Hepatocarcinoma". Master 110 curso avanzado de Oncología. Centro de Investigaciones Oncológicas. Madrid, 2010.
97. Invited lecture. "Liver Cancer Collaborative Program". 2010 Scientific Review. The Samuel Waxman Cancer Research Foundation Institute without walls.Mount Sinai Medical Center. New York, 2010.
98. Invited lecture. "Targeted Molecules for systemic Therapy of HCC:Sorafenib and Beyond". 2010 World Conference on Interventional Oncology Conference. WCIO. Philadelphia, 2010.
99. Chair. "Epidemiology and suverillance". EASL-AASLD-APASL-ALEH Special Monothematic conference in HCC.Dubrovnik- Croacia, 2010.
100. Chair. "Current systemic therapies in HCC". EASL-AASLD-APASL-ALEH Special Monothematic conference in HCC.Dubrovnik, Croacia, 2010.
101. Invited lecture. "Sorafenib: Implications in management and trial design". EASL-AASLD-APASL-ALEH Special Monothematic conference in HCC. Dubrovnik, Croacia, 2010.
102. Invited lecture. "Molecular changes occurring in pathogenesis of HCC". 12th World Congress on Gastrointestinal Cancer.ESMO. Barcelona, 2010.
103. Invited lecture. "Hepatocellular carcinoma". Young European Hepatologist Workshop. Bendor Island.,2010France.
104. Invited lecture. "As the systemic refence in HCC, has sorafenib changed the approach to the study of HCC management and were do we go from here?". Bayer Satellite Symposium.ILCA. Montreal, 2010.
105. Chair. "Treating HCC patients-Can We Do Better?" Bristol Myers Squibb Symposium.ILCA. Montreal, 2010.
106. Invited lecture. "Improving Patient Outcomes: Combining Targeted Treatments in Hepatocellular Carcinoma". Novartis. 4th ILCA General Assembly. Montreal 2010.
107. Invited lecture. "Molecular pathogenesis of HCC and signalling pathways". Program for the advancement for therapy in Hepatocellular Carcinoma. PATH. Barcelona, 2010.
108. Invited lecture. "Biologically based therapy of HCC" (Visiting Professor). University of Pennsylvania School of Medicine. Philadelphia, 2010.
109. Invited lecture. "Staging & Treatment of suspected HCC" CIRSE 2010 Annual Meeting. Valencia, 2010.
110. Invited lecture. "Broadening horizons in the treatment of hepatocellular carcinoma". ESMO 2010 Annual Meeting Bayer Schering Pharma Satellite Symposium. Milan, 2010.
111. Invited lecture. "Systemic Therapy of HCC". Symposium on the integration of interventional oncology in the treatment of liver malignancies. ITLT Essen 2010. Dusseldorf, 2010.
112. Invited lecture. "Systemic treatment of advanced HCC- beyond sorafenib". 18th United European Gastroenterology Week.UEGW. Barcelona, 2010.
113. Invited lecture. "HCC-Medical Treatment before and after liver transplantation". Malignancies.AASLD/ILTS Transplant Course. AASLD. Boston, 2010.
114. Seminar. "What information molecular markers may bring?". 2010 Consensus Conference on Liver Transplantation for HCC. Zurich, 2010

2011

115. Invited lecture. "Molecular Markers in cancer cells and stroma". 7th International Meeting Hepatocellular Carcinoma Easter and Western Experiences. Paris, 2011.
116. Chair. "Neo and adjuvant approaches: can medical treatment improve curative approaches". 7th International Meeting Hepatocellular Carcinoma Easter and Western Experiences. Paris,

2011.

117. Invited lecture. "Local Regional Approach". 4th Paris Hepatitis Conference. Paris, 2011.
118. Invited lecture. "Incorporación de nuevos medicamentos en el tratamiento del hepatocarcinoma". 9º Curso avanzado de oncología. Investigación aplicada y traslacional en neoplasias digestivas. Barcelona, 2011.
119. Invited lecture. "Potential rationale for systemic therapy with antiangiogenic properties in intermediate HCC". Global expert series meeting. Berlin, 2011.
120. Invited lecture. "Neoplasia and liver transplantation". Postgraduate Course. EASL. Berlin, 2011.
121. Invited lecture. "Improving Liver Research Funding from EU". EU Framework programs. EASL. Berlin, 2011.
122. Invited lecture. "Medical therapy: Some issues solved but many open for discussion". EASL Clinical Symposium. Berlin, 2011.
123. Invited lecture. "TACE in combination with antiangiogenic therapy in the treatment of intermediate HCC: data, issues and controversies". BSP Symposium at EASL. Berlin, 2011.
124. Invited lecture. "Molecular pathogenesis and target therapies in liver cancer". 102nd Annual Meeting. AACR. Orlando, 2011.
125. Lecture "Molecular pathways relevant to diagnosis and treatment of HCC". Grand Rounds Comprehensive Cancer Center. Vienna, 2011.
126. Lecture "Liver cancer collaborative program". The Samuel Waxman Cancer Research Foundation Institute without walls. 2011 Scientific review. New York, 2011.
127. Invited lecture. "Opportunities of collaborative research: Liver". First workshop on Collaborative actions MD Anderson Cancer Center-Clinic Barcelona Hospital Universitari-Idibaps. Barcelona, 2011.
128. Invited lecture. "Specific malignancies and procedures. Cancer of GI Tract and Liver: Liver". First workshop on Collaborative actions MD Anderson Cancer Center-Clinic Barcelona Hospital Universitari-Idibaps. Barcelona, 2011.
129. Invited lecture. "Workshop in specific areas of collaborative research. Cancer of GI Tract and Liver". First workshop on Collaborative actions MD Anderson Cancer Center-Clinic Barcelona Hospital Universitari-Idibaps. Barcelona, 2011.
130. Invited lecture. "New approaches in determining tumor biology: applications for liver transplantation". Global Challenges and controversies in liver transplantation Symposium. The 2011 Joint International Congress of ILTS, ELITA & LICAGE. Valencia, 2011.
131. Invited lecture. "Outcomes with OLT and LDLT in HCC". ELITA Symposium: liver Transplantation in HCC: Recent advancements. The 2011 Joint International Congress of ILTS, ELITA & LICAGE. Valencia, 2011.
132. Invited lecture. "Introducción a la patología molecular/hepatocarcinoma". CNIO Meeting. Madrid, 2011.
133. Chair. "Molecular pathogenesis and signalling pathway". The 2nd Asia-Pacific primary liver cancer expert Meeting. Osaka, 2011.
134. Invited lecture. "Advanced HCC: Future directions in HCC - An overview of current and future management options". Bayer Luncheon Seminar. The 2nd Asia-Pacific primary liver cancer expert Meeting. Osaka, 2011.
135. Chair. "Systemic therapy and treatment response in HCC". The 2nd Asia-Pacific primary liver cancer expert Meeting. Osaka, 2011.
136. Seminar. "Treatment Challenge of Advanced HCC in Asia. Case presentation and Panel discussion". The 2nd Asia-Pacific primary liver cancer expert Meeting. Osaka, 2011.
137. Invited lecture. "Molecular targeted therapy: Sorafenib and beyond". Meet the professor breakfast Seminar. The 2nd Asia-Pacific primary liver cancer expert Meeting. Osaka, 2011.
138. Invited lecture. "Trial design and endpoint" The 2nd Asia-Pacific primary liver cancer expert Meeting. Osaka, 2011.
139. Seminar. "What are the unmet needs for HCC in Asia". The 2nd Asia-Pacific primary liver

cancer expert Meeting. Osaka, 2011.

140. Invited lecture. "Evidence based management of HCC". MSSM Grand Rounds in Medicine, New York.
141. Invited lecture. "Progress in addressing challenges in early HCC and future direction in the management of HCC". Bayer evening local symposium. ILCA 2011. Hong kong, 2011.
142. Invited lecture. "Progress in addressing challenges in early HCC and future directions in the management of HCC". Bayer lunch symposium. ILCA 2011. Hong Kong, 2011.
143. Invited lecture. "Changing the treatment paradigm in HCC: The western prespective". Nexavar 5th Anniversary gala Dinner. ILCA 2011. Hong Kong, 2011.
144. Co-chair. "Managing Unresectable HCC for Optimal Outcomes: Preparing for the Future" and Moderator "Q&A session". BMS symposium. ILCA 2011. Hong Kong, 2011.
145. Chair. "Clinical trials. Design and pitfalls". ILCA symposium 3. ILCA 2011. Hong Kong, 2011.
146. Chair/ Invited lecture. "Management of intermediate HCC with sorafenib and drug-Eluting Bead doxorubicin (DEBDOX)". Biocompatibles Symposium. ILCA2011. Hong Kong, 2011.
147. Invited lecture. "An overview of HCC management and rationale for SPACE trial" . Biocompatibles Symposium. ILCA2011. Hong Kong, 2011.
148. Invited lecture. "Design of clinical trials in HCC - Lessons for the future". PATH Conference 2011. Shanghai, 2011.
149. Invited lecture. "Emerging therapies beyond sorafenib". 9thl International Meeting on therapy in liver Diseases. Barcelona, 2011.
150. Chair. "The challenges of solid tumors with high unmet need: progress and futuredirections with TKIs". Bayer HealthCare Satellite Symposium. The European Multidisciplinary Cancer Congress ECCO/ESMO 2011. Stockholm, 2011.
151. Invited lecture. "Tumor progression and recurrence in early stages of HCC: is there a role for TKIs?" Bayer HealthCare Satellite Symposium. The European Multidisciplinary Cancer Congress ECCO/ESMO 2011. Stockholm, 2011.
152. Invited lecture. "Current and future directions in clinical trial design in HCC". Bayer global Expert Series Meeting. The European Multidisciplinary Cancer Congress ECCO/ESMO 2011. Stockholm, 2011.
153. Chair. "Hepatocellular Carcinoma: Novel Advancements in Diagnosis and treatment". Scientific Symposium. The European Multidisciplinary Cancer Congress ECCO/ESMO 2011. Stockholm, 2011.
154. Invited lecture. "New molecular targeted therapies". Scientific Symposium. The European Multidisciplinary Cancer Congress ECCO/ESMO 2011. Stockholm, 2011.
155. Invited lecture. "Linking molecular profiling with HCC development, treatment, and outcome". PATH Conference 2011. Barcelona, 2011.
156. Invited lecture. "Molecular targeted therapies in HCC". Current status and future of anti-cancer targeted therapies. Interamerican Oncology Conferences. Buenos Aires, 2011.
157. Invited lecture. "Systematic therapy of HCC". 2nd ITLT 2011- Interdisciplinary Treatment of Liver Malignancies. Essen, 2011.
158. Address. "Achievements of Mount Siani Liver Cancer Program 05-11". 6th Aniversary Mount Sinai Liver Cancer Program meeting. Translational and clinical advancements in liver cancer. New York, 2011.
159. Invited lecture. "What does molecular profiling offer in current clinical decission making?" EASL Special Conference on Liver Transplantation. Lisbon, 2011.

2012

160. Invited lecture. "Understanding cancer: from the molecular base to the disease". 46th ICREA Colloquium. Barcelona, 2012.
161. Invited lecture. "Translating genetics into clinical practice". Hepatology Perspectives. Indicators and predictors of treatment success. The Sixth Expert Forum. Madrid, 2012.

162. Invited lecture. "Molecular Signature of Prognosis and outcomes in HCC". ASCO-Gastrointestinals Cancers Symposium. San Francisco, 2012.
163. Seminar. "Final results of SPACE trial in patients with intermediate HCC". HCC Research Meeting. Mount Sinai School of Medicine. New York, 2012.
164. Invited lecture. "Incorporación de nuevos medicamentos en el tratamiento del hepatocarcinoma". 10º Curso Avanzado de Oncología. Investigación aplicada y transnacional en neoplasias digestivas. Barcelona, 2012
165. Invited lecture. "El Càncer hepatic: importància i tractament". 42º Convención Anual y reunión estatutaria de socios de la Asociación Española Contra el Cáncer (AECC). Barcelona, 2012.
166. Chair/ Invited lecture. "Emerging therapies in HCC". Symposium Pathogenesis and treatment of liver tumors. AACR Annual Meeting, Chicago, 2012.
167. Invited lecture. "Linking molecular profiling with HCC development, treatment, and outcome". PATH Symposium, Barcelona, 2012.
168. Chair/ Invited lecture. "Liver Cancer: Pathogenesis and Treatment". AACR Annual Meeting, Chicago, 2012
169. Invited lecture. "Strategies for the management of HCC: Paths to progress". CBCE CME Activity. AACR Annual Meeting, Chicago, 2012.
170. Invited lecture. "Future outlook: What's next for HCC management". Bayer Satellite Symposium: The challenge of diagnosing and managing patients with HCC: How far have we come in 5 years? EASL Annual Meeting. Barcelona, 2012.
171. Chair. EASL-ILCA Joint Workshop. EASL Annual Meeting, Barcelona, 2012.
172. Invited lecture. "Emerging drugs for first and second line in advanced HCC". EASL-IASL Postgraduate Course. EASL Annual Meeting. Barcelona, 2012.
173. Chair. HEPROMIC Mid Term Meeting, Barcelona, 2012.
174. Invited lecture. "Navigating Hepatocellular Carcinoma: Applying Clinical Trials Data to Patient Care" Grand Round Gastro-Hepatology. Quintiles Medical Education. SUNY Downstate Medical Center. New York, 2012.
175. Seminar. Samuel Waxman Cancer Research Foundation meeting. New York, 2012.
176. Invited lecture. "Hepatocellular carcinoma: molecular classes and overview of management". Medical Ground Rounds. Department of Medicine. Mayo Clinic, Rochester, Minnesota, 2012.
177. Invited lecture. "Pathologic and molecular changes occurring in HCC". Session IV: Cancer of the Liver". 14th World Congress on Gastrointestinal Cancer. ESMO 2012, Barcelona, 2012.
178. Invited lecture. "Evidence Based regional approaches to patient care". Lilly Symposium: Hepatocellular Carcinoma - Regional Best Practices in Staging and Management of HCC. 14th World Congress on Gastrointestinal Cancer. ESMO 2012, Barcelona, 2012.
179. Symposia. "Treatment landscape Evolution and path to personalized medicine" (your stream is Gastrointestinal cancer). Novartis Lead Summit 2012, Barcelona, 2012.
180. Invited lecture. "Evidence Based regional approaches to patient care". Lilly Symposium: Hepatocellular Carcinoma - Regional Best Practices in Staging and Management of HCC. 14th World Congress on Gastrointestinal Cancer. ESMO 2012, Barcelona, 2012.
181. Invited lecture. "Molecular prediction of response to targeted therapy in HCC". Liver cancer. From molecular pathogenesis to targeted therapies. International Research Conference on Liver Cancer (DFG, EASL, EACR). Heidelberg, 2012.
182. Chair. "Profiling/high throughput/screening". Liver cancer. From molecular pathogenesis to targeted therapies. International Research Conference on Liver Cancer (DFG, EASL, EACR). Heidelberg, 2012.
183. Invited lecture. "Evidence based treatment of HCC: an overview of the current guideline". Bayer Symposium. APPLE 2012. Shanghai, China, 2012.
184. Chair. "Session 9: Systemic and Molecular Targeted Therapy in HCC". APPLE 2012. Shanghai, China, 2012.
185. Invited lecture. "Session 11: Novel therapy and ongoing trials in HCC". APPLE 2012. Shanghai, China, 2012.

186. Co-chair and commentator. "Session 12: Panel discussion for HCC Algorithm Consensus". APPLE 2012. Shanghai, China, 2012.
187. Invited lecture. "Current & future usefulness of HCC molecular profiling". PATH 2012. Shanghai, China, 2012.
188. Invited lecture. "Phase III study comparing brivanib vs placebo in second-line in HCC: final results". Grand Rounds Mount Sinai Liver Cancer Program. Mount Sinai School of Medicine. New York, 2012.
189. Invited lecture. "Management of HCC". Department of Medicine. Division of Liver Diseases. The Page and William Black Post-Graduate School. Mount Sinai School of Medicine. New York, 2012.
190. Symposia. "Understanding EASL-EORTC 2012 Guidelines: what does the future hold for HCC management?" Bayer HealthCare Symposium. ILCA 2012. Berlin, 2012.
191. Chair. "Brivanib vs placebo in patients with advanced HCC who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS Study". Plenary Session. ILCA 2012. Berlin, 2012.
192. Chair. "New compounds in early clinical trial in HCC". ILCA Symposium. ILCA 2012. Berlin, 2012.
193. Invited lecture. "Hepatocellular carcinoma: The BCLC approach to clinical and translational research". Presentation of the International Hans Popper Award Falk Symposium: Challenges of Liver Cirrhosis and tumors: Prevent it, treat it and manage consequences. Mainz, 2012.
194. Invited lecture. "Linking molecular profiling with HCC prognosis and target identification". PATH. Barcelona Clinic Liver Cancer. Barcelona, 2012.
195. Invited lecture. "Clinical and molecular classification of hepatocellular carcinoma". Management of hepatocellular carcinoma Congress. Israel Association for the Study of the Liver. Tel Aviv, 2012.
196. Invited lecture. "Novel molecular targeted therapy in hepatocellular carcinoma: recent advancements". Management of hepatocellular carcinoma Congress. Israel Association for the Study of the Liver. Tel Aviv, 2012.
197. Seminar. "Clinical case presentation". Management of hepatocellular carcinoma Congress. Israel Association for the Study of the Liver. Tel Aviv, 2012.

2013

198. Invited lecture. "Achievements of Mount Sinai Liver Cancer Program 05-12", Hans Popper's Perspective. Seventh Anniversary of Mount Sinai Liver Cancer Program. Liver Cancer: Management and Challenges. The Icahn School of Medicine at Mount Sinai School of Medicine, New York, 8th February 2013.
199. Chair. "Management of Advanced Liver Cancer". Challenges in systemic management: why Phase III studies are failing?. Seventh Anniversary of Mount Sinai Liver Cancer Program. Liver Cancer: Management and Challenges. The Icahn School of Medicine at Mount Sinai School of Medicine, New York, 8th February 2013.
200. Symposia. "Molecular mechanisms in Preclinical Models and Genomic Profiling". The Barcelona Clinic Liver Cancer Program for the Advancement of Therapy in Hepatocellular Carcinoma (PATH), Barcelona, 18th-19th February 2013.
201. Invited lecture. "Hepatocarcinoma". Digestive Neoplasms- Applied and Translational Research Course 2013. Institut Germans Trias i Pujol Hospital, Barcelona, 14th-15th March 2013.
202. Chair. American Association of Cancer research (AACR) Annual Meeting: Classification and Pathogenesis of Liver Cancer, Washington, 6th-10th April 2013.
203. Invited lecture "Molecular signature of prognosis and outcomes in HCC". 3rd ITLT Essen Interdisciplinary Treatment of Liver Tumors, Essen, 18th April 2013.
204. Invited lecture. "Molecular targeted therapy in HCC: Why phase III trials are failing and what is the future. EASL-ILCA Joint Symposium. EASL Annual Meeting, Amsterdam. 24th -28th April 2013.

205. Invited lecture. Samuel Waxman Cancer Research Foundation Annual Review and Symposium (Special Programs). New York, 13th -14th May 2013.
206. Invited lecture. "Multidisciplinary State-of-the-Art Session: HCC (Early Stage): Staging and Triage". WCIO Conference, New York, 16th -19th May 2013
207. Invited lecture. "Multidisciplinary State-of-the-Art Session: HCC (Intermediate-Advanced Stage)". WCIO Conference, New York, 16th -19th May 2013
208. Invited lecture. "El Càncer: de la Biomedicina al pacient". Grans reptes de la Biomedicina, Debats ICREA-CCCB. Centre de Cultura Contemporània de Barcelona 5th June 2013
209. Invited lecture. "Systematic Therapy - Clinical Focus Session: CF 201 Intermediate-advanced HCC". ECIO Conference, Budapest, 19th June 2013
210. Invited lecture. "Milestones in HCC research: where do we go from here? ". ECIO Conference, Budapest, 19th June 2013
211. Moderator. "ECIO meets ILCA – Open issues in the management of liver cancer. ECIO Conference, Budapest, 19th June 2013
212. Panel of Experts. Novartis Oncology Lead Summit XI. Budapest, 28th -29th June 2013
213. Chair. "HCC session IV: Cancer of the Liver". ESMO World Congress Barcelona, 3th -5th July 2013.
214. Invited lecture. "Pathologic and molecular changes occurring in HCC". Session IV: Cancer of the liver. ESMO World Congress Barcelona, 3th -5th July 2013
215. Invited lecture. "Workshop on Molecular Classification and Biomarkers in HCC", ILCA-EASL-NCI-AASLD endorsed by AASLD and EASL. ILCA Washington, 13th -15th September 2013
216. Invited lecture. "Criteria for accepting subclasses/biomarkers in HCC Guidelines". ILCA Washington, 13th -15th September 2013
217. Chair. "Translating knowledge into Guidelines and Practice". ILCA Washington, 13th -15th September 2013
218. Invited lecture. "Exploring the infrastructure for personalised management of HCC" Personalized Treatment of HCC: Seeking Solutions Through Multidisciplinary Collaboration (Prime Oncology Symposium), ILCA Washington, 13th -15th September 2013
219. Chair. "Novel Opportunities for Treatment in HCC" ILCA SYMPOSIUM 3. ILCA Washington, 13th -15th September 2013
220. Chair. "Revisiting Data from Phase III Trial Failures in HCC" (Dr Llovet and Dr Lencioni) ILCA Washington, 13-15th September 2013.
221. Invited lecture. "Overview of Management of HCC Patients According to Guidelines" Celsion Symposium: Directions in Early-Intermediate HCC. ILCA Washington, 13-15th September 2013
222. Invited lecture. "Molecular Pathogenesis of HCC". 10th International Meeting on Therapy in Liver Disease, Barcelona, 20th September 2013
223. Invited lecture. "Molecular classification and drivers as target for therapies in HCC". OMICS Meet translational research" IDIBELL. Session I. Genomics and epigenomics. Barcelona, 25th September 2013
224. Invited lecture. "Diretrizes, Tratamento. Cenário Atual – Guideline EASL-EORTC 2012". Simpósio Satélite Bayer HCC. XXII Congresso Brasileiro Hepatologia e XXII Semana de Fígado do Rio de Janeiro. Rio de Janeiro, 2nd -5th October 2013.
225. Invited lecture. "Tratamento de HCC: considerações sobre etiologia e biologia molecular". XXII Congresso Brasileiro Hepatologia e XXII Semana de Fígado do Rio de Janeiro. Rio de Janeiro, 2nd -5th October 2013.
226. Invited lecture. "Molecular classification of intrahepatic cholangiocarcinoma and discovery of a novel oncogenic fusion" VII Jornadas Científicas CIBERehd, Barcelona, 21th -22th October 2013
227. Invited lecture. "New Anti-tumor agents in Development for HCC". The Liver Meeting. The 64th Annual Meeting of the American Association for the Study of Liver Diseases. Early Morning Workshops. Washington, 1st – 2nd November 2013.

- 228. Invited lecture. "Patogénesis molecular de HCC (Bloque 1: Patogénesis del HCC)". Madrid-CIBER sponsored meeting. BCLC con el soporte de CIBEREHD y de Bayer. Madrid 25th November 2013
- 229. Invited lecture. "Past, Present and Future of Cancer" (roundtable). AECC Catalunya Contra el Càncer. Barcelona, 27th November 2013.

2014

- 230. Chair (with Gores) "General Session 4: Advances in the Management of Liver Cancer". Gastrointestinal Cancers Symposium. ASCO (American Society of Clinical Cancer), San Francisco 16th-18th January 2014
- 231. Invited lecture. "Hepatocellular Carcinoma" GLG Conference. Gastrointestinal Cancers Symposium. ASCO (American Society of Clinical Cancer), San Francisco 16th -18th January 2014
- 232. Invited lecture. "Achievements of Mount Sinai Liver Cancer Program 05-14". General Meeting. 8th Anniversary Mount Sinai Liver Cancer Program. Liver Cancer: Management and Challenges. New York. 7th February 2014
- 233. Address. "Hans Popper Lecture". General Meeting. 8th Anniversary Mount Sinai Liver Cancer Program. Liver Cancer: Management and Challenges. New York. 7th February 2014
- 234. Chair. "Management of Advanced Liver Cancer". 8th Anniversary Mount Sinai Liver Cancer Program. Liver Cancer: Management and Challenges. New York. 7th February 2014
- 235. Invited lecture. "RCT in HCC after sorafenib success: what's next?". 8th Anniversary Mount Sinai Liver Cancer Program. Liver Cancer: Management and Challenges. New York. 7th February 2014.
- 236. Chair. "Session 4: Curative treatments II". HCC Summit. Geneva 13th -16th February 2014
- 237. Invited lecture. "Status of Joint Molecular classification effort of HCC". Joint session 8/1 (ILCA-EASL). HCC SUMMIT, Geneva, 13th -16th February 2014.
- 238. Invited lecture. "Molecular Mechanisms in Preclinical Models and Genomic Profiling". Program for the Advancement of Therapy in Hepatocellular Carcinoma (PATH). Barcelona, 3rd -4th March 2014.
- 239. Seminar. "Molecular pathogenesis of hepatocellular carcinoma". Program of the Master in Liver Cancer., University of Barcelona, 3rd March 2014.
- 240. Invited lecture. "Hepatocarcinoma". 12th Advanced course in oncology: applicated and translational research in digestive neoplasms. Hospital Universitari Germans Trias i Pujol, Badalona, 13th March 2014.
- 241. Invited lecture. "Molecular characterization of hepatocellular carcinoma". 41th Congress of the International Society of Oncology and Biomarkers. XIV International Symposium on Biology and Clinical Usefulness of Tumor Markers, Barcelona., 17th March 2014.
- 242. Invited lecture. "Novel drivers and targeted therapies in HCC". EASL International Liver Congress™, London, 9th -12th April 2014.,
- 243. Invited lecture. "HR Excellence in Research Award in UK and Europe: main challenges" Born centre Cultural, Barcelona, 28th April 2014.
- 244. Invited lecture. "Molecular pathogenesis and targeted therapies". Fundación Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) Seminars. 29th April 2014, Madrid
- 245. Symposia. "Molecular Pathogenesis and Targeted Therapies in HCC". Cancer Center Grand Rounds at Mayo Clinic – Arizona., 8th May 2014.
- 246. Lecture. Samuel Waxman Cancer Research Foundation. Scientific Symposium honoring Kenneth C. Anderson, MD and Musa Mayer, New York., 11th May 2014.
- 247. Symposia. Moderator: Alan Rosmarin, MD. Samuel Waxman Cancer Research Foundation.. New York, 11th May 2014.
- 248. Chair. "How to Manage Advanced HCC with Vascular Invasion?" 4th International Kyoto Liver Cancer Symposium. 8th June 2014

249. Invited lecture. "Systemic Therapy in HCC sorafenib" 4th International Kyoto Liver Cancer Symposium. 8th June 2014
250. Invited lecture. "Adjuvant Therapies After Resection / Local Ablation in HCC. Summary of the STORM trial" Luncheon Seminar. 4th International Kyoto Liver Cancer Symposium 8th June 2014
251. Symposia. "FGFR4 Inhibitor SAB". SAB NOVARTIS –BASEL, 12th -13th June 2014 Switzerland
252. Invited lecture. "Pathologic and molecular changes in HCC". Session VI: Cancer of the Liver 16th World Congress on Gastrointestinal Cancer (ESMO), Barcelona, 25th -28th June 2014.
253. Seminar. "Molecular Pathogenesis and Target Therapies in Liver Cancer". IDIBAPS-IN HOUSE SEMMINAR., IDIBAPS, Barcelona, 3rd July 2014.
254. Chair. "Sorafenib in Adjuvant HCC-STORM data". Optimizing outcomes in Hepatocellular Carcinoma with Sorafenib, The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014), , Taiwan, Taipei 12th July 2014.
255. Invited lecture. "Session 7: Can we find new therapeutic targets for HCC" The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014), , Taiwan, Taipei, 12th July 2014.
256. Seminar. "New molecular therapies, biomarkers and companion diagnostics", AMRF HCC, Las Vegas 22th July 2014.
257. Seminar. "Liver Diseases Research Semminar: Medical Therapies for Hepatocellular Carcinoma (HCC)", Icahn Medical Institute, Grand Rounds in Medicine, , New York, 13th August 2014.
258. Invited lecture. "Molecular pathogenesis and targeted therapies in HCC", CGIBD Research Seminar, Icahn Medical Institute , , New York, 14th August 2014.
259. Invited lecture. "Major Advancements in HCC management obtained from RC - Session 1. Principles of Trial Design in Cancer and in HCC", ILCA 2014 Annual Conference, Kyoto, Japan, 4th September 2014.
260. Invited lecture. "Trial Design in advanced HCC (first and second line) / Plenary Discussion", ILCA 2014 Annual Conference, Kyoto, Japan, 4th September 2014.
261. Chair. "Principles of Trial Design in Cancer and in HCC" ILCA 2014 Annual Conference, Kyoto, Japan, 4th September 2014.
262. Chair. "Novel Opportunities of Treatment in HCC", ILCA 2014 Annual Conference, Kyoto, Japan, 6th September 2014.
263. Invited lecture. "Trial Design in Advanced HCC (First and Second Line)". Authors: Llovet JM, Galle P, Finn R. Plenary Discussions. ILCA Annual Conference, Kyoto Japan 4th – 7th September 2014.
264. Invited lecture. "Achievements of Mount Sinai Liver Cancer Program 2005-2014". Observership program in a center of excellence in Hepatology, New York, 2nd - 3rd October 2014.
265. Invited lecture. "Advanced HCC: What's next?" Observership program in a center of excellence in Hepatology, New York, 2nd - 3rd October 2014.
266. Invited lecture. "Molecular Mechanisms in Preclinical Models and Genomic Profiling". PATH Congress 2014, Barcelona 6th - 7th October 2014.
267. Symposia. "Management of Advanced HCC, results of phase III trials". Global Nintedanib (BIBF 1120) Advisory Board Meeting HCC, Frankfurt Germany 17th October 2014.
268. Invited lecture. "Evento Carcinoma Hepatocelular aCHC 2014 2a.Edición"- Organised by Bayer, Madrid, 29th November 2014.
269. Invited lecture. "Achievements of Mount Sinai Liver Cancer Program 2005-2014". ILCA School of Liver Cancer - New York Academy of Medicine, New York, 11th - 12th December 2014 .
270. Invited lecture. "Overview of Management of HCC and Therapeutic Challenges". ILCA School of Liver Cancer – New York Academy of Medicine, New York, 11th - 12th December 2014.
271. Invited lecture. "Advanced HCC: RCT in HCC After Sorafenib Success, What's Next?" ILCA School of Liver Cancer - New York Academy of Medicine, New York, 11th -12th December

2014.

- 272. Chair. "Management of Liver Cancers" ILCA School of Liver Cancer - New York Academy of Medicine, New York, 11th -12th December 2014.
- 273. Chair. "Retreat on Clinical Trials – Liver Cancer Program" ILCA School of Liver Cancer - New York Academy of Medicine, New York, 11th - 12th December 2014.

2015

- 274. Invited lecture. "Tasquinimod in Hepato cellular carcinoma". AD BOARD (IPSEN), Paris, 12th March 2015.
- 275. Symposia. "Unmet Medical Needs in the Management in HCC: Opportunities for Immune Therapies" Fibrosis, Tumor Microenvironment, Genomics and Biomarkers in Liver Cancer (Bristol-Myers Squibb), New York, 27th March 2015.
- 276. Invited lecture. "Molecular Mechanisms in Preclinical Models and Genomic Profiling". Program for the Advancement of Therapy in Hepatocellular Carcinoma (PATH), Barcelona, 30th-31th March 2015.
- 277. Invited lecture "Targeting Liver Cancer". Samuel Waxman Cancer Research Foundation Annual Scientific Review and Symposium, New York 3rd -4th May 2015.
- 278. Invited lecture. "Tumor biology (ED: Understanding the targets in immunotherapy)". ASCO Annual Meeting, Chicago 29th May - 2nd June 2015.
- 279. Invited lecture. ASTRAZENECA Round table discussion. ASCO Annual Meeting, Chicago 29th May - 2nd June 2015.
- 280. Invited lecture "Biología y tratamiento del Hepatocarcinoma". XIII curso avanzado de oncología Investigación traslacional y neoplasias digestivas. BCIN Badalona. 14th- 15th May 2015.
- 281. Invited lecture "What are we learning when looking at the genetic diversity in humans? The research of ICREA's director in the last years". 67th ICREA Colloquium. Barcelona. 16th May 2015.
- 282. Invited lecture "The hepatologist's role: treatment of hepatitis and management of liver disease". HCC program – Epatocarcinoma e Colangiocarcinoma intraepatico: Cosa c'è di nuovo?.. Treviso, Italy. 18th -19th June 2015.
- 283. Moderator "Early HCC" Epatocarcinoma e Colangiocarcinoma intraepatico: Cosa c'è di nuovo?.. Treviso, Italy, 18th -19th June 2015.
- 284. Chair "Session VIII: Liver Malignancies". ESMO 2015. 17th World Congress on Gastrointestinal Cancer. Barcelona. 2nd July 2015.
- 285. Invited lecture "Tandem talk: Hepatocellular carcinoma" ESMO 2015. 17th World Congress on Gastrointestinal Cancer. Barcelona. 2nd July 2015.
- 286. Invited lecture "Session 7 Systemic Therapy I - Molecular Therapies for HCC: Current and Future Direction". The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015). Osaka, Japan, 3rd –5th July, 2015.
- 287. Invited lecture "State-of-the-Art Lecture II - Design of Clinical Trials in Advanced HCC: Trial Enrichment and Stratification". The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015). Osaka, Japan, 3rd –5th July, 2015.
- 288. Chair "Session 8 Systemic Therapy II" The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015). Osaka, Japan, 3rd –5th July, 2015.
- 289. Chair "ILCA Symposium 2: Controversies in Liver Cancer (Pros and Cons Session)". ILCA Annual Conference 2015. Paris, France, 4th -6th September 2015.
- 290. Lecture "Why Target Therapies Fail in HCC: Drug Features or Study Designs?" ILCA Annual Conference 2015. Paris, France. 4th -6th September 2015.
- 291. Lecture "Molecular profiling of liver cancer: Current Application and future prospects". 11th International Meeting on Therapy in Liver Diseases. Barcelona. September 16th -18th 2015.
- 292. Lecture "Specific Indications. Hepatocellular Carcinoma and Living Donor Liver

- Transplantation". International meeting on living donor liver transplantation. Barcelona 28th - 29th September 2015.
293. Lecture "New Insights on Treatments of HCC". The 10th International Symposium on Alcoholic liver and Pancreatic Diseases and Cirrhosis (ISALPD/C). Sao Paulo, Brazil. 30th September - 1st October 2015.
 294. Roundtable "Liver tumor: resection or transplantation". 10th International Symposium on Alcoholic liver and Pancreatic Diseases and Cirrhosis (ISALPD/C). Sao Paulo, Brazil. 30th September - 1st October 2015.
 295. Lecture "Intermediate irresectable HCC: Current treatments and future perspective". 10th International Symposium on Alcoholic liver and Pancreatic Diseases and Cirrhosis (ISALPD/C). Sao Paulo, Brazil. 30th September - 1st October, 2015.
 296. Roundtable "New drugs for hepatocellular carcinoma". Session VI: Management of HCC and Liver Transplantation. The 10th International Symposium on Alcoholic liver and Pancreatic Diseases and Cirrhosis (ISALPD/C). Sao Paulo, Brazil. September 30th September - 1st October, 2015.
 297. Roundtable "Molecular diagnosis of HCC and its clinical application". The 10th International Symposium on Alcoholic liver and Pancreatic Diseases and Cirrhosis (ISALPD/C). Sao Paulo, Brazil. September 30th September - October 1st, 2015.
 298. Lecture "From Emerging phase I to failing III phase trials. at the Session VII Liver Cancer: Molecular pathogenesis and treatment. Falk Symposium 199. Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma. Freiburg, Germany. October 14th -15th October 2015.
 299. Lecture "Molecular mechanisms and genomic profiling in HCC patients". Program for the Advancement of Therapy in Hepatocellular Carcinoma (PATH). Barcelona, CAT, 19th -20th October 2015.
 300. Lecture "Benign liver tumors: optimal management in 2015". 23th United European Gastroenterology Week (UEG Week), Barcelona 24th -28th October 2015.
 301. Chair "Update on management strategies in hepatocellular carcinoma (HCC)". 23th United European Gastroenterology Week (UEG Week), Barcelona 24th -28th October 2015.
 302. Seminar "Genetic and Other Molecular Markers Predicting Outcome". Hepatic Malignancies: Saga Continues, To Be or Not to Be?. AASLD Liver Meeting/ILTS Transplant Course. San Francisco, USA, 13th to 17th November 2015.
 303. Lecture "La Biopsia líquida" Sessió 4: perspectives futures". Programa de Actualización en Hepatocarcinoma Celular, Madrid 27th November 2015.
 304. Invited lecture "Achievements of Mount Sinai Liver Cancer Program 2005-15". 10th Anniversary of the Mount Sinai Liver Cancer Program. Liver Cancer: from bench to clinic. New York, EEUU 18th December 2015.
 305. Invited lecture "Overview of Novel Agents in Phase II and Phase III-Opportunities in HCC". 10th Anniversary of the Mount Sinai Liver Cancer Program. Liver Cancer: from bench to clinic. New York, EEUU 18th December 2015.

2016

306. Invited lecture "New Therapies & Biomedical Research: Accelerated drug approval for oncology drugs" XXV Congrés de la Societat Catalana de Digestologia. Reus, Tarragona. 28th-30th January 2016.
307. Seminar "Molecular pathogenesis and targeted therapies in HCC", Seminar at Instituto de Biomedicina de Sevilla (IBIS). Sevilla, 11th February 2016.
308. Roundtable WP1 "Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of comorbidities" HEP-CAR Kick-off meeting. Freiburg, Germany, 15th February 2016.
309. Invited lecture "State of the art lecture: Molecular targeted therapies in advanced HCC". DOHA Hepatocellular Carcinoma 2016 Conference, Doha Qatar, 4th -5th March 2016.
310. Invited lecture "Molecular profiling of intrahepatic cholangiocarcinoma: The next challenge", ILCA School of Liver Cancer 2016, Barcelona, 7th - 8th March 2016.

311. Invited lecture "Molecular classification and profiling of HCC: is there a clinical link for prognosis and treatment?". The International Liver Congress 2016 - EASL, Barcelona 13th - 17th April 2016.
312. Invited lecture "Liver biopsy in clinical trials – needless or necessity?". The International Liver Congress 2016 - EASL, Barcelona 13th - 17th April 2016.
313. Invited lecture "H2020 HEPCAR: understanding, prevention and management of HCC". The International Liver Congress 2016 - EASL, Barcelona 13th - 17th April 2016.
314. Invited lecture "Role of cTACE in guidelines of management of HCC across the world". Satellite Symposium ECIO 2016, Dublin 18th -19th April 2016.
315. Invited lecture "Molecular pathogenesis & targeted therapies in HCC". SIOPEL Spring Meeting. Barcelona 21th April 2016.
316. Invited lecture "Liver Cancer Program Update". Samuel Waxman Cancer Research Foundation, New York 1st May 2016.
317. Invited lecture "Hepatocarcinoma: Patogenia molecular y terapias dirigidas. XIV curso avanzado de oncología – Investigación traslacional y neoplasias digestivas 2016 BCIN, Badalona 12th -13th May 2016.
318. Invited lecture " Why some targeted therapies fail in HCC and future perspectives on study design?.Rencontres en Oncologie. Lyon, France, 20th -21th May 2016.
319. Invited lecture "TACE consensus guideline review and how to develop in real practice (Plenary Session)". The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
320. Invited lecture "Guideline recommendation for treatment of HCC with sorafenib". Bayer Sponsored Satellite Symposium. The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
321. Invited lecture "Review the all guideline including 2016 APASL Update". Bayer Sponsored Satellite Symposium. The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
322. Invited lecture "Treatment of Advanced HCC in BCLC B/C treatment".Bayer Breakfast RTM session. The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
323. Invited lecture "Rescue Therapies for Transarterial Chemoembolization Failure and Clinical Outcomes" – Multidisciplinary Approach to Patients with Transarterial Chemoembolization Failure (Plenary Session). The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
324. Invited lecture "Review Current Treatment Strategies to Optimize Outcome and p of Patients with uHCC". Bayer Luncheon Symposium. The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
325. Workshop "Challenges in HCC: BCLC and Asian Guidelines". Nexavar Breakfast Workshop. The Liver Week 2016, Incheon, Korea, 16th -18th June 2016.
326. Invited lecture "State of the art: pathogenesis and targeted therapies in HCC". Bayer Auditorium, New York, USA, 8th August 2016.
327. Invited lecture "Medical Therapies for HCC". Division of Liver Diseases Lecture Series, New York, USA, 9th August 2016.
328. Invited lecture "Molecular Pathogenesis and Targeted therapies in Hepatocellular Carcinoma". DoCM Grand Rounds - MD ANDERSON, Houston, USA, 15th - 16th August 2016.
329. Roundtable "Pre-conference workshop on preclinical Trial Models of HCC: From target identification to Clinal Trials". ILCA 2016 Annual Conference, Vancouver, Canada , 8th- 9th September 2016.
330. Chair "State-of-the-Art lecture 2: Assessing Hepatocellular Carcinoma Risk". ILCA 2016 Annual Conference,Vancouver, Canada, 8th - 9th September 2016.
331. Chair "What is new in liver cancer?". ESMO 2016, Copenhagen, Denmark. 7th -11th October 2016.
332. Lecture "Stage-dependent management of HCC and news in systemic treatment". ESMO 2016, Copenhagen, Denmark. 7th -11th October 2016.
333. Lecture "Molecular pathogenesis and targeted therapies for HCC". NICR Seminar: Molecular pathogenesis and targeted therapies in HCC. Newcastle, United Kingdom. 17th October 2016.

334. Lecture "Personalized Management of HCC". Session IV: Personalized Management of Liver Diseases. Postgraduate course - Challenges in the Management of Common Liver Diseases. The AASLD Liver Meeting 2016 ,Boston, USA. 12th November 2016.
335. Moderator "Management of Unresectable HCC: Time to move the goalposts" MEDSCAPE SYMPOSIUM. The AASLD Liver Meeting 2016, Boston, USA. 12th November 2016.
336. Lecture "Achievements of Mount Sinai Liver Cancer Program 2005-16". Liver cancer: discoveries and management. The Mount Sinai Liver Cancer Program 11th Anniversary, New York, USA, 16th December 2016.
337. Chair "Hans Popper Lecture" Introduction. Liver cancer: discoveries and management. The Mount Sinai Liver Cancer Program 11th Anniversary, New York, USA, 16th December 2016.
338. Chair "Management of Liver Cancer (II)". The Mount Sinai Liver Cancer Program 11th Anniversary, New York, USA, 16th December 2016
339. Lecture "Role of regorafenib in the management of HCC (short report)". Management of Liver Cancer (II). The Mount Sinai Liver Cancer Program 11th Anniversary, New York, USA, 16th December 2016.

2017

340. Chair "Enabling of replicative immortality, genomic instability and mutation". HCC Summit 2017, Geneva, Switzerland 2-5 February 2017.
341. Lecture "Molecular classification and drivers of cholangiocarcinoma". Session: Enabling of replicative immortality, genomic instability and mutation. HCC Summit 2017, Geneva, Switzerland 2-5 February 2017.
342. Lecture "Optimizando la terapia sistémica contra el Cáncer Hepatocelular". La Evolución en el Manejo del Carcinoma Hepatocelular. Nexa10. Guatemala 10th February 2017.
343. Lecture "Ten Years of Multikinase Inhibitor (MKI) Treatment in Unresectable HCC: what Have We Learned?". Optimizing the Sequence of Multikinase Inhibitors in Unresectable HCC". The 26th Conference of Asian Pacific Association for the Study of the Liver. APASL Annual Meeting 2017. Shanghai, China, 15th-19th February 2017
344. Lecture "Molecular Targeted Therapies in HCC". Current Session 12: New Concept and Therapy for Liver Cancer. The 26th Conference of Asian Pacific Association for the Study of the Liver. APASL Annual Meeting 2017. Shanghai, China. 15th-19th February 2017
345. Lecture "Molecular targeted therapies in HCC". Post Graduate Course "Carcinoma Hepatocelular". Portuguese congress of Hepatology. Oporto, Portugal 30th – 1st April 2017.
346. Lecture "Trasplante hepático. Deben expandirse los criterios de Milán? Papel del Down-staging". Programa marco "Preceptorship" en Hepatocarcinoma. Barcelona, 3rd – 5th April 2017.
347. Lecture "Management of HCC after progression or intolerance to sorafenib" Post Graduate Course: A multidisciplinary approach to patients with liver disease. EASL International Liver Congress 2017. Amsterdam, The Netherlands 19th - 23rd April 2017.
348. Lecture "Molecular immune class of HCC and potential implications in precision medicine". Samuel Waxman Cancer Research Foundation. Annual Scientific Review and Symposium, New York, USA. 30th April-1st May 2017
349. Lecture "Systemic Therapies for Advanced HCC: What to Expect After Sorafenib" Digestive Disease Week. AASLD Clinical Symposium. Chicago, USA. 8th May 2017.
350. Invited Lecture "Patogénesis y terapias dirigidas en hepatocarcinoma" XV Jornadas Investigación traslacional y neoplasias digestivas. IGTP Santa Coloma de Gramanet, Barcelona. 18th-19th May 2017
351. Invited Lecture I "Raising the bar in the treatment of unresectable HCC: 10 years and beyond for multikinase inhibitors" HCC Meet-the-Expert Session – Bayer 10th anniversary of Sorafenib. National Cancer Center Singapore. 24th May 2017.
352. Invited Lecture II "Raising the bar in the treatment of unresectable HCC: 10 years and beyond for multikinase inhibitors" HCC Meet-the-Expert Session – Bayer 10th anniversary of Sorafenib. Singapore. 24th May 2017
353. Invited Lecture I "Raising the bar in the treatment of unresectable HCC: 10 years and beyond

- for multikinase inhibitors” HCC Meet-the-Expert Session – Bayer 10th anniversary of Sorafenib. National Cancer Institute, Putrajaya, Malaysia. 25th May 2017.
354. Invited Lecture II “Raising the bar in the treatment of unresectable HCC: 10 years and beyond for multikinase inhibitors” HCC Meet-the-Expert Session – Bayer 10th anniversary of Sorafenib. Aloft Kuala Lumpur Sentral, Kuala Lumpur, Malaysia. 25th May 2017
 355. Invited lecture “Trial Design and Endpoints”. CPG HCC. Frankfurt 28th July 2017
 356. Invited lecture “Future directions”. CPG HCC. Frankfurt 28th July 2017
 357. Invited lecture “Challenges in Hepatology from an International Perspective”. 2017 ALA Masterclass. Gastroenterological Society of Australia. Melbourne 27th July 2017
 358. Invited lecture “Clinical and Molecular Classification of HCC and Intrahepatic Cholangiocarcinoma”. 2017 ALA Masterclass. Gastroenterological Society of Australia. Melbourne 28th July 2017.
 359. Invited lecture “Chemoembolization as Standard of Care” 2017 ALA Masterclass. Gastroenterological Society of Australia. Melbourne 28th July 2017.
 360. Invited lecture “The future: Drivers of Oncogenesis as Targets for Therapies”. 2017 ALA Masterclass. Gastroenterological Society of Australia. Melbourne 28th July 2017
 361. Invited lecture “Medical management of HCC, novel effective therapies” Division of Liver Diseases Seminar Series. ICAHN School of Medicine at Mount Sinai. New York 2nd August 2017.
 362. Round table discussion. “Data review of clinical data of regorafenib (RESORCE)”. Sorafenib 10-year anniversary Symposium. Japan 19th August 2017.
 363. Invited lecture - NEXT Symposium. “Management of HCC patients with systemic therapies”. Sorafenib 10-year anniversary Symposium. Japan 20th August 2017.
 364. Round table discussion. “Sumando experiencias en el manejo de Cáncer de Hígado”. Costa Rica 1st september 2017
 365. Round table discussion “Taller para el desarrollo de una estrategia nacional para el manejo del Cáncer de Hígado. Costa Rica 1st September 2017
 366. Chair. Advisory Board HCC. Costa Rica. 2nd September 2017.
 367. Invited lecture “HCC-Cholangiocarcinoma and Mixed Tumours: a Molecular Continuum?”. 11th ILCA Annual Conference. Seoul, South Korea, 15th September 2017.
 368. Invited lecture “Future directions for HCC treatment: Preclinical and clinical aspects” Global HCC Advisory board meeting, Seoul, South Korea, 17th September 2017.
 369. Invited lecture “Molecular profiling and clinical management: The awaited link” 21th International Meeting on Therapy in Liver Diseases. Barcelona 22nd September 2017.
 370. Invited lecture “Molecular pathogenesis and targeted therapies in HCC”. CRCL 3rd International Cancer Symposium of the Cancer Research Center of Lyon. Lyon, 25th September 2017.
 371. Panelist. “Novel Therapeutics in the Post Genomic Age” SinaInnovations – ICAHN School of Medicine at Mount Sinai. New York, 18th October 2017
 372. Invited lecture “The expanding role of the hepatologist in interdisciplinary hepatocellular carcinoma management: achieving the full potential of targeted therapy and immunotherapy advances”. Medical Learning Institute and PVI, PeerView Institute for Medical Education. The AASLD Liver Meeting. Washington, 21st October 2017
 373. Invited lecture “Hepatocellular Adenoma: Bridging Molecular Classification to Clinical Practice” Early Morning Workshop. The AASLD Liver Meeting. Washington, 23rd October 2017
 374. Invited lecture “Advances in systemic therapies of HCC”. Synergy Meeting. Miami, 11th November 2017.
 375. Invited lecture “Impact of molecular profiling in prognosis prediction and clinical decision making”. PATH. Barcelona, 13th November 2017
 376. Invited lecture “el metge investigador”. Dia de la Ciència. Barcelona, 15th November 2017
 377. Invited lecture “Molecular drivers and targeted therapies in HCC” Hepatobiliary Cancers:

Pathobiology and translational advances. 15th December 2017, Richmond, US.

378. Invited lecture "Achievements of Mount Sinai Liver Cancer Program 2005-17" The Mount Sinai Liver Cancer Program 12th Anniversary, New York, USA, 15th December 2017.
379. Invited lecture "Hans Popper Lecture" The Mount Sinai Liver Cancer Program 12th Anniversary, New York, USA, 15th December 2017.
380. Invited lecture "Positive Lenvatinib and Regorafenib Data in HCC Management" The Mount Sinai Liver Cancer Program 12th Anniversary, New York, USA, 15th December 2017.
381. Chair "Management of Liver Cancer (II)" The Mount Sinai Liver Cancer Program 12th Anniversary, New York, USA, 15th December 2017.

2018

382. Chair "General Session: Emerging options for HCC-A global perspective". ASCO-GI 2018. San Francisco, USA. 19th January 2018.
383. Invited lecture "What do we understand by Translational Medicine?" EIT Health – Barcelona, 1st February 2018
384. Invited lecture "Molecular Targeted Therapies for HCC". Harvard Medical School. Seminars in Vascular Biology. Boston, USA. 15th February 2018.
385. Chair "General Session 4 – From molecular defects to new targeted therapies in HCC". EASL SUMMIT 2018. Geneva, Switzerland, 2nd March 2018.
386. Lecture "Development of tumour makers for diagnosis, prognosis and tumour response prediction" – Session 6: Scores and Biomarker. EASL SUMMIT 2018. Geneva, Switzerland, 2nd March 2018.
387. Lecture "Big data approaches to identify targetable pathways in liver cancer" – Session Basic Science Seminar – Targetable pathways in liver disease: Identifying targetable pathways in liver disease. EASL 2018. Paris, France, 11th April 2018.
388. Panelist. GPG Session. "EASL Clinical Practice Guideliness: Management of hepatocellular carcinoma". EASL 2018. Paris, France, 11th April 2018.
389. Lecture "Achievements of Mount Sinai Liver Cancer Program 05-17". Liver Cancer Program at Mount Sinai. New York, 26th April 2018
390. Lecture "Overview of Management of HCC and Therapeutic Challenges" Liver Cancer Program at Mount Sinai. New York, 26th April 2018
391. Chair "Management of Liver Cancer" Liver Cancer Program at Mount Sinai. New York, 26th April 2018
392. Lecture "Advanced HCC: Overview of molecular targeted therapies in HCC" Liver Cancer Program at Mount Sinai. New York, 27th April 2018
393. Lecture "Molecular pathogenesis and targeted therapies in hepatocellular carcinoma" Genomics and Personalized Medicine , ZENCODE International Training Network Symposium, IDIBAPS, Barcelona 7th May 2018.
394. Lecture "Upcoming systemic treatment approaches for liver cancer". 12th Annual Conference of the International Liver Cancer Association, London, 13th September 2018.
395. Chair "General Session 2 - Clinical Trials" 12th Annual Conference of the International Liver Cancer Association, London, 14th September 2018.
396. Lecture "Molecular Pathogenesis and Targeted Therapies in Hepatocellular Carcinoma" Seminars in Clinical Research. The Rockefeller University Hospital, New York, US, 3rd October 2018.
397. Lecture "Ramucirumab as second-line treatment in patients with Hepatocellular Carcinoma (HCC) and Elevated alpha-fetoprotein (AFP) following sorafenib: pooled results from two global phase 3 studies (REACH-2 and REACH)" The AASLD Liver Meeting. San Francisco, 12th November 2018.
398. Lecture "New drugs effective in the systemic treatment of HCC" – Session: New Therapies in HCC: Mechanisms of Action and Indications. The AASLD Liver Meeting. San Francisco, 12th

November 2018.

399. Chair "SIG Program: New therapies in HCC: Mechanisms of action and indications" The AASLD Liver Meeting. San Francisco, 11th November 2018.
400. Lecture "Targeted Therapies" Session IV – Targeted Therapies for HCC. National Institute of Health, National Cancer Institute Bethesda, US, 6th November 2018.
401. Lecture "Molecular profiling and outcome prediction. What has been validated and challenges posed by heterogeneity" PATH. Barcelona, 20th November 2018
402. Lecture "Achievements of Mount Sinai Liver Cancer Program 2005-18" Mount Sinai Liver Cancer Program 13th Anniversary. New York, 14th December 2018
403. Chair "Hans Popper Lecture: HCC Incidence in the Era of DAA Drugs for HCV Infections" Mount Sinai Liver Cancer Program 13th Anniversary. New York 14th December 2018
404. Lecture "Molecular Targeted Therapies in Advanced HCC" Mount Sinai Liver Cancer Program 13th Anniversary. New York 14th December 2018.

2019

405. Chair "General Session 6: Advancements in Treatment of Cholangiocarcinoma and Hepatocellular Carcinoma" ASCO-Gastrointestinal Cancers Symposium. San Francisco 18th January 2019.
406. Lecture "Current and upcoming clinical trials" ASCO-Gastrointestinal Cancers Symposium. San Francisco 18th January 2019.
407. Round Table "HUNTER: Hepatocellular Carcinoma Expediter Network" Kick-off meeting. London, UK, 28th February 2019.
408. Chair "Hepatobiliary Neoplasia SIG". Emerging Trends Conference- AASLD. Atlanta, US. 22nd March 2019
409. Lecture "Advanced HCC, first, second line and beyond". Emerging Trends Conference- AASLD. 22nd March 2019, Atlanta
410. Moderator "Session II: Design and end-points in trails for HCC". Emerging Trends Conference- AASLD. 22nd March 2019, Atlanta
411. Lecture "Patogénesis y terapias dirigidas en hepatocarcinoma" XV Jornadas Investigación traslacional y neoplasias digestivas. IGTP Santa Coloma de Gramanet, Barcelona. 17th May 2019
412. Lecture "Molecular targeted therapies and trial design for advanced HCC" 55th Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan. 5th July 2019
413. Lecture "Considering optimal drug selection to prolong overall survival in the era of HCC sequential therapy" 55th Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan. 5th July 2019
414. Chair "International Symposium 2 Theme: Pros & Cons in molecular targeted agents" 55th Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan. 5th July 2019
415. Lecture "Advances in management and trial design in advanced HCC – Session: The new era begins. Evidence based sequential therapy for a patient with uHCC to prolong overall survival" 55th Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan. 4th July 2019.
416. Lecture "Advanced HCC- Trial design and end-points" Meet the expert session. 55th Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan. 3th July 2019.
417. Lecture "Clinical Research summary". Kick-off meeting for the Clinical Research. A randomized phase II trial of surgery plus sorafenib vs.sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombus. Shanghai, China. 5th September 2019
418. Lecture "Advances in HCC" Kick-off meeting for the Clinical Research. A randomized phase II trial of surgery plus sorafenib vs.sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombus. Shanghai, China. 5th September 2019
419. Lecture "Molecular Characterization of HCC in NAFLD" ILCA pre-conference workshop

"metabolism and liver cancer- from mechanism to treatment". ILCA 2019 Annual Conference. Chicago. US. 19th September 2019

420. Chair. AASLD Symposium. ILCA 2019 Annual Conference. Chicago. US. 22nd September 2019
421. Visiting Professor. Lecture "Molecular targeted therapies in HCC" 18th Annual Dr Richard Sherbaniuk and Ronald H. Wensel Lectureship. Edmonton, Canada. 27th September 2019
422. Lecture "Immunotherapeutic Strategies for Hepatocellular Cancers" 4th European Congress on Immunotherapies in Cancer. Barcelona 15th November 2019.
423. Lecture "Precision Medicine to Guide Therapy in Liver Cancer – Session: Post Graduate Course" AASLD The Liver Meeting 2019. Boston, US. 9th November 2019.
424. Lecture "Combination Therapies for Advanced HCC – Session: Early Morning Workshops". AASLD The Liver Meeting 2019. Boston, US. 10th November 2019.
425. Chair "Session: Hepatobiliary Neoplasia SIG". AASLD The Liver Meeting 2019. Boston, US. 10th November 2019.
426. Leon Schiff State-of-the-Art Lecture" Lecture "Molecular Pathogenesis and Management of Hepatocellular Carcinoma –AASLD The Liver Meeting 2019. Boston, US. 12th November 2019.
427. Chair. Systemic therapies in HCC. 14th-Liver Cancer Program, ISMMS, NYC, Dec 13th, 2019
428. Lecture "Achievements of the Mt Sinai Liver Cancer porram 2005-19". 14th annual meeting. Liver Cancer Program, ISMMS, NYC, Dec 13th, 2019
429. Lecture "Molecular targeted therapies in advanced HCC". 14th annual meeting. Liver Cancer Program, ISMMS, NYC, Dec 13th, 2019

2020

430. Lecture "Milestones in the development of systemic therapy for HCC". Spectrum 2020, Miami, Florida, Jan 19th 2020.
431. Moderator "Session VII: HCC Part II". Spectrum 2020, Miami, Florida, Jan 19th 2020.
432. Lecture "Key trends in HCC research: Where are we headed?" Spectrum 2020, Miami, Florida, Jan 19th 2020.
433. Panelist "Panel discussion: Immuno-oncology and HCC" Spectrum 2020, Miami, Florida, Jan 19th 2020.
434. Panelist "HCC Tumor Board" Spectrum 2020, Miami, Florida, Jan 19th 2020.
435. Lecture "Exploring the rationale for combination therapy in HCC". EASL Liver Cancer Summit. Feb 7th 2020.
436. Lecture "Biomarker and response prediction in HCC and CCA". Workshop Primary Liver Cancer Emerging Concets and Novel Treatments. Johannes Gutenberg-Universität, Mainz, Germany. Feb 14th 2020.
437. Lecture "Decoding HCC immunology by multi-omics" HCC-UK 2020 Annual Conference "Questioning current practice". *Virtual*. March 12th 2020.
438. Lecture "Atezolizumab plus bevacizumab in advanced HCC: implications of the phase III positive RCT. Liver Diseases Seminar. ICAHN School of Medicine at Mount Sinai. *Virtual*. May 20th 2020.
439. Lecture "Novel Molecular Targets, Agents and Biomarkers for HCC" ILCA 2020 Annual Conference Virtual Symposium. *Virtual*. Sept 14th 2020.
440. Lecture "Insinghts from the tumour microenvironment for the 2021 treatment landscape". ILCA 2020 Annual Conference Virtual Symposium. *Virtual*. Sept 11th 2020.
441. Lecture "Immune Classification of Hepatocellular Carcinoma" Samuel Waxman Cancer Research Foundation. New York. *Virtual*. Sept 14th 2020

442. Lecture "Clinical Trial Design in ICCA: Lessons Learned from HCC". AASLD The liver meeting 2020. *Virtual*. Sept 26th 2020.
443. Lecture: "Patogénesis Molecular y terapias dirigidas en hepatocarcinoma" XVIII Jornadas de investigacion traslacional y neoplasias digestivas. October 2nd 2020
444. Program Chair - Session I: Hot Topics in the Management of Liver Cancer - Pathogenesis and Treatment for Early Tumors – SIG Program. AASLD. *Virtual*. Nov 13th 2020.
445. Moderator & Program Chair – Session II: Hepatobiliary Neoplasia SIG & Liver Transplantation and Surgery – SIG Program. AASLD. *Virtual*. Nov 13th 2020.
446. Lecture: "Trial Design and End-points in Advanced HCC: OS and PFS" Session II: Hepatobiliary Neoplasia SIG & Liver Transplantation and Surgery – SIG Program. AASLD. *Virtual*. Nov 13th 2020.
447. Lecture; "Treatment landscape in advanced HCC- A new paradigm. Bayer Portugal. *Virtual*. Nov 20th 2020
448. Chair "Management of liver Cancer (Advanced stage)", 15th annual meeting. Liver Cancer Program, ISMMS, NYC, *Virtual*. Dec 11th, 2020
449. Lecture "Hans Popper Lecture". 15th annual meeting. Liver Cancer Program, ISMMS, NYC, *Virtual*. Dec 11th, 2020
450. Lecture "Molecular and Immune Therapies in Advanced HCC". 15th annual meeting. Liver Cancer Program, ISMMS, NYC, *Virtual*. Dec 11th, 2020
451. Lecture: "Evolution of treatment in advanced HCC" 30th Annual Conference Thailand. APASL 2020. *Virtual*. Dec 12th, 2020
452. Lecture: "Hepatocellular Carcinoma" APASL Hepatology Webinar. APASL *Virtual*. Dec 19th, 2020
453. Lecture: "Advocating for Action in HCC: Delivering Impartial and Personalized Care" AXIS. *Virtual*. 27th Jan 2021
454. Lecture; "Advances in molecular classification and precision oncology in HCC" APASL 2021. *Virtual*. 5th Feb 2021
455. Lecture: "Immune therapies for HCC: is NASH-HCC responding different" KeystoneSymposia Virtual Event on Fatty Liver Disease/Hepatobiliary Cancers. *Virtual*. 23rd March 2021.
456. Lecture: "Liver Tumours. ILC 2021: Wrap up session" EASL 2021. The International Liver Congress. *Virtual*. June 2021
457. Lecture: "Management of the Hepatocellular Carcinoma (Manejo del Carcinoma Hepatocelular)". 9th Interamerican Oncology Conference. Virtual Conference "Current status and future of anti-cancer Therapies. *Virtual*. July 2021
458. Lecture: "Molecular and immune therapies for advanced HCC" 9th Interamerican Oncology Conference. Virtual Conference. Roche Meet the Expert. *Virtual*. July 2021
459. Lecture: "Molecular, immune and precision oncology in HCC" 9th International Gastrointestinal and Liver and URO- Oncology Conference (IGILUC) Egypt. *Virtual*. July 2021
460. Lecture: "Immune classes and gene signatures associated with response to checkpoint inhibitors in HCC" Samuel Waxman Research Foundation. SWRF Annual Scientific Review. *Virtual*. September 2021
461. Chair: "The role of first-line monotherapy in a UHCC combination market". Eisai Sponsored symposium. ILCA 2021 Annual Conference Virtual Symposium. *Virtual*. Sept 2021.
462. Lecture: "Clinical trial design in the era of immune therapies" ILCA 2021 Annual Conference Virtual Symposium. *Virtual*. Sept 2021.
463. Lecture: "HCC management evolution and perspectives from the West" APAC 2021. Bayer Scientific Symposium Asia Pacific. *Virtual*. Sept 2021.
464. Lecture: "Overview of current IO combination trials in first-line uHCC as well as other trials of systemic treatment in combination/adjuvant setting with TACE" HCC Pioneers meeting (western/Eastern meeting) Eisai. *Virtual*. Sept 2021
465. Lecture: "Take aways on liver tumours" EASL 2021. The International Liver Congress. *Virtual*. October 2021

466. Lecture: "Caracterización molecular del CHC (Carcinoma Hepatocelular)" Formación Integral en Cancer Hepático. Asociación Española para el estudio del hígado. Virtual, pre-recorded lecture. October 2021.
467. Lecture: "Caracterización molecular del Cci (Colangiocarcinoma)" Formación Integral en Cancer Hepático. Asociación Española para el estudio del hígado. Virtual, pre-recorded lecture. October 2021.
468. Lecture: "Current status of the HCC Treatment Landscape and Clinical Trial design for novel therapies". TECH Annual Symposium. Cancer Prevention & Research Institute of Texas. *Virtual*. October 2021.
469. Lecture: "Actualidades en el manejo del Carcinoma Hepatocelular". XVI Congreso Nacional de Hepatología. *Virtual*. Oct 2021
470. Lecture: "Molecular and Immune Therapies for HCC". JSH International Liver Conference (Japan). *Virtual*. Oct 2021
471. Lecture: "Patogénesis Molecular y terapias dirigidas en hepatocarcinoma" XIX Jornadas de investigación traslacional y neoplasias digestivas. Oct 2021
472. Lecture: "Clinical trial design: outcomes, surrogates for overall survival". EASL-AASLD HCC Endpoints Conference. *Virtual*. Oct 2021
473. Chair: "Basket trials and molecular-based enriched populations". EASL-AASLD HCC Endpoints Conference. *Virtual*. Oct 2021
474. Lecture: "Emerging Therapies in Phase II and III - Session Hepatobiliary Neoplasia SIG" AASLD The liver meeting. *Virtual*. Oct 2021
475. Lecture: "Achievements of Mount Sinai Liver Cancer Program 2005-2021" Mount Sinai Liver Cancer Program 16th Anniversary. *Virtual*. Dec 2021
476. Chair: Session Management of Advanced Liver Cancer. Liver Cancer Program 16th Anniversary. *Virtual*. Dec 2021
477. Lecture: "Overview: Molecular and immune therapies in advanced HCC" Liver Cancer Program 16th Anniversary. *Virtual*. Dec 2021

2022

478. Lecture "Molecular and Immune Therapies in Hepatocellular Carcinoma". Virtual. University of Vermont. Feb 2022
479. Lecture "Molecular pathogenesis and systemic therapies in advanced hepatocellular carcinoma" Hospital Arnau de Vilanova. March 2022.
480. Lecture "Liver Cancer" HCC Presentation Steering Committee. ICAHN School of Medicine at Mount Sinai. *Virtual*. Mar 2022
481. Lecture NCI-CCR-LCP Seminar. Molecular Pathogenesis and Targeted Therapies for HCC. *Virtual seminar*. April 2022
482. Chair: ILCA webinar series "tips from the editors desk: how to succeed in the peer review process". *Virtual*. April 2022
483. Lecture "Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis" EASL Journal Club. *Virtual*, April 2022
484. Lecture: "Systemic Therapies – Past, Present and Future" Unresectable Hepatocellular Carcinoma Monothematic Meeting, Tata Memorial Hospital Mumbai, India. *Virtual*, June 2022.
485. Lecture "Biomarkers for HCC diagnosis" ILCA Single Topic Workshop. Paris June 2022.
486. Session Panelist "Case study discussion of Early-stage HCC" ESMO (supported by AstraZeneca) June 2022.
487. Session Panelist "Case study Discussion of Intermediate-stage HCC" ESMO (supported by AstraZeneca) June 2022.
488. Lecture "The evolving therapeutic landscape of unresectable/advanced HCC" ESMO (supported by AstraZeneca) June 2022.

489. Session Panelist “Case study Discussion of Unresectable/Advanced HCC” ESMO (supported by Astrazeneca) June 2022.
490. Session Panelist “Audience Discussion and Q&A” ESMO (supported by Astrazeneca) June 2022.
491. Lecture “Pathogenesis and subtypes of HCC” ESMO, June 2022.
492. Panelist “Cases with Panel Discussion: Management Strategy in HCC” ESMO, June 2022.
493. Chair Symposium: HCC screening and management in NASH patients. Liver tumours, metabolism, alcohol and toxicity. EASL, London. June 2022
494. Lecture “Advanced NASH-HCC: Response to TKI and checkpoint inhibitors. EASL, London. June 2022.
495. Panelist for the Education at EASL Workshop. EASL. London. June 2022.
496. Lecture “Diversidad Molecular en el Carcinoma Hepatocelular” Congreso Nacional de Hepatología. Mérida, Mexico, July 2022.
497. Lecture state of the art “Revisión de estadiaje y tratamiento del Carcinoma Hepatocelular” Congreso Nacional de Hepatología. Mérida, Mexico, July 2022.
498. Lecture “Tratamiento sistémico del carcinoma hepatocelular estadio avanzado: sistémico y secuenciación de tratamiento” Congreso Nacional de Hepatología. Mérida, Mexico, July 2022.
499. Lecture “Immunotherapies for hepatocellular carcinoma”. APPLE. Virtual conference. August 2022.
500. Lecture “What we have learned about biomarkers associated with response to IO”. ILCA Congress. Madrid, September 2022.
501. Lecture “The future landscape of HCC treatment”. Virtual. IASLD. Israel. September 2022
502. Lecture “Tratamiento Sistémico del Hepatocarcinoma”. BCIN. Badalona. October 2022.
503. Lecture “Molecular pathogenesis and systematic therapies in HCC”. Seminar leaders in Field. UCLA. Los Angeles, US. October 2022.
504. Lecture “Role of Lenvatinib in the Management of HCC” Beijing Health Promotion Association (BJHPA). Virtual. November 2022.
505. Lecture “Achievements of Mount Sinai Liver Cancer Program 205-2022” Mount Sinai Liver Cancer Program. 17th Anniversary. Liver Cancer: Updated Review of Clinical Management and Translational Science. New York, US. December 2022.
506. Hans Popper Lecture. Mount Sinai Liver Cancer Program. 17th Anniversary. Liver Cancer: Updated Review of Clinical Management and Translational Science. New York, US. December 2022.
507. Chair at Intermediate & Advanced Liver Cancer. Mount Sinai Liver Cancer Program. 17th Anniversary. Liver Cancer: Updated Review of Clinical Management and Translational Science. New York, US. December 2022.
508. Lecture “New Flowchart for molecular and immune therapies for advanced HCC” Mount Sinai Liver Cancer Program. 17th Anniversary. Liver Cancer: Updated Review of Clinical Management and Translational Science. New York, US. December 2022.
509. Lecture “Primary Results from the phase 3 LEAP-002 Study: Lenvatinib Plus Pembrolizumab versus Lenvatinib as First-line therapy for advanced Hepatocellular Carcinoma. Mount Sinai Liver Cancer Program. 17th Anniversary. Liver Cancer: Updated Review of Clinical Management and Translational Science. New York, US. December 2022.

2023

510. Chair Session: “Cambiando la perspectiva en Hepatocarcinoma”. Eisai. Barcelona Feb 3, 2023
511. Lecture State of the art “Panorama actual en el abordaje terapéutico del hepatocarcinoma irreseccable” Eisai. Barcelona Feb 3, 2023
512. Lecture “What’s the best comparator arm for trial design in 2022” HCC-TAG 2023 Conference. California, US. Feb 24, 2023

-
513. Lecture "The evolving landscape in the management of advanced HCC" HCC national dinner meeting. Virtual meeting March 29, 2023.
514. Chair at "Innovative therapeutical approaches to liver cancer" Plenary session. EASL Liver Cancer Summit. Estoril, Portugal. April 22, 2023
515. Lecture "New targeted therapies" Plenary session. EASL Liver Cancer Summit. Estoril, Portugal, April 22, 2023
516. Roundtable. Plenary session. EASL Liver Cancer Summit. Estoril, Portugal, April 22, 2023
517. Lecture "Innovations in HCC therapy" Session Plenary 1. Innovations in liver disease therapy: present and future. Global Hepatitis Summit. Paris, April 25, 2023
518. Lecture "Molecular and immune therapies for HCC" Virtual. Hepatobiliary Summit in China. May 28, 2023
519. Chair at "Postgraduate Course – session: Metabolism, alcohol and toxicity, Liver Tumours" EASL Congress, Viena. June 2023.
520. Lecture "Systemic therapies for HCC and role of etiology" at "Postgraduate Course – session: Metabolism, alcohol and toxicity, Liver Tumours". Viena, EASL Congress, June 2023.
521. Panellist at Symposium session group: General Hepatology. Viena, EASL Congress, June 2023.
522. Chair / Director at "Postgraduate Course – Session: From NAFLD to liver cancer – Management of HCC & cholangiocarcinoma in patients with NAFLD. Viena, EASL Congress, June 2023.
523. Lecture "The future of molecular guided therapy in HCC" . Session: Research Think Tank: How to guide systemic treatments for HCC and CCA. Viena, EASL Congress, June 2023.
524. Lecture "Systemic therapies for HCC and role of etiology. Session: from NAFLD to liver cancer – Management of HCC & cholangiocarcinoma in patients with NAFLD. Viena, EASL Congress, June 2023.
525. Chair at session: NAFLD to liver cancer – Management of HCC & cholangiocarcinoma in patients with NAFLD. Viena, EASL Congress, June 2023.
526. Chair at IDIBAPS Seminar Title of lecture: "Detection of driver gene and mutagen exposures in human cancer". IDIBAPS, Barcelona, July 2023
527. Lecture "Phase III trial design in advanced HCC" Mini Adboard. Osaka, Japan, July 2023
528. Lecture "Overview of management for advanced HCC with systemic therapies" 59th Annual Meeting of Japan Liver Cancer Association. Osaka, Japan. July 2023
529. Keynote lecture "Trial Design and endpoints in HCC. Including early-stage and Child-pugh B patients" Osaka, Japan, July 2023
530. Lecture "Immunotherapies for HCC: role of biomarkers" Osaka, Japan. July 2023.
531. Lecture "Immunotherapy for advanced HCC – From immune classification to 1st line immunotherapy selection" Kyoto, Japan. July 2023
532. Lecture "From bench to clinic: bridging the translational gap in current immunotherapeutic strategies for advanced HCC" TLCA. Taipei, Taiwan. July 2023.
533. Lecture "Current status and future perspective of immunotherapy combinations for HCC" Taipei. Taiwan. July 2023.
534. Lecture "Meet the expert – The evolving role of systemic treatment in HCC: across unresectable and resectable stages". Taipei, Taiwan. July 2023.
535. Chair at session "Basic State of Art" Presenting Myron Schwartz. ILCA 2023. Amsterdam, September 2023
536. Chair "deciphering NASH-HCC development and response to therapy" ILCA Webinar. Virtual. October 2023.
537. Lecture "Tratamiento Sistémico del Hepatocarcinoma". Curs Neoplasies Digestives. BCIN. Badalona. October 2023 Panel speaker.
538. Discussant for oral Abstract Sessions. ASCO-GI. San Francisco. January 2024.

-
539. Chair "Symposia – Update in systemic therapies for hepatocellular carcinoma". EASL Summit, Rotterdam. February 2024.
540. Lecture "From models to clinical trials" EASL Summit, Rotterdam. February 2024.
541. Lecture "Towards manipulation of responses to immunotherapy in HCC" PHC 2024. Institute Pasteur, Paris, France. March 2024
542. Chair – Session 3: Molecular stratification and trial endpoints for systemic therapy. ILCA Single Topic Workshop. Madrid, Spain. April 2024.
543. Lecture "Stratification factors and predictive biomarkers in HCC" ILCA Single Topic Workshop. Madrid, Spain. April 2024.
544. Lecture: Conferencia de Clausura: Como integrar la MPP en la práctica clínica en hepatología: su aplicación en la oncología hepática. Sevilla. May 2024.
545. Chair "Welcome and Introduction of JHEP Reports". J. Hep. Reports Symposium. EASL Milan. June 2024
- Lecture "JHep Reports: New team approach". EASL Milan. June 2024
546. Lecture "Performance of JHEP reports" EASL Milan. June 2024
547. Chair "EASL Studio - Advances in systemic treatments in liver cancer" EASL. Milan. June 2024.
548. Lecture "Medical Management of Hepatocellular Carcinoma (HCC). Ulaanbaatar, Mongolia. July 2024.
549. Lecture "Transarterial Chemoembolization (TACE) with or without Lenvatinib (len) + Pembrolizumab (pembro) for intermediate-stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 study. Presidential Symposium. ESMO. Barcelona. September 2024.
550. Round table discussion. AECC "Repte 70% supervivència. Impulsem la recerca oncològica a Barcelona. Barcelona. September 2024.
551. Lecture "Future of predictive biomarkers in HCC". XV International Meeting on Therapy in Liver Diseases. Barcelona. October 2024.
552. Chair: "Clinical State of the Art. Goals and endpoints in liver cancer clinical trials". 18th annual conference ILCA. October 2024.
553. Lecture: "Transarterial Chemoembolization (TACE) with or without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase III. General Session 4: Therapy & Miscellaneous. 18th annual conference ILCA. October 2024.
554. Lecture: "Molecular-based prediction biomarkers in HCC: Current status. Session – Treatment response biomarkers. 18th annual conference ILCA. October 2024.
555. Lecture "Tratamiento Sistémico del Hepatocarcinoma". Curs Neoplasies Digestives. BCIN. Badalona. November 2024 Panel speaker.
556. Lecture: "Transarterial Chemoembolization (TACE) with or without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase III LEAP-012 Study". Abstract Parallel Session 1. AASLD 2024. San Diego. November 2024.
557. Lecture: "Clinical trials in HCC: International vs Chinese RCT". Global week meeting- Roche. Virtual. December 2024.
558. Lecture: "Welcome and opening remarks" THRIVE Cluster First Annual Meeting. Barcelona, December 2024.
559. Lecture: "Overview and aims of the 6 cluster projects – THRIVE". Cluster First Annual Meeting. Barcelona, December 2024.
560. Lecture: "Immunotherapies in the Management of Hepatocellular Carcinoma" Department of Medicine Grand Rounds. New York. February 2025.
561. Chair: "Pre-meeting workshop" HCC-LIVE, Austin, TX, USA. February 2025
562. Lecture: "Critical Assessment: LEAP-012". HCC-LIVE, Austin, TX, USA. February 2025
563. Lecture: "Distinguished Lecture Series: A career Story" HCC-LIVE, Austin, TX, USA. February 2025
564. Chair: "Overview ASPIRE project" Neoadjuvant and adjuvant therapies to improve survival of HCC: ASPIRE project". Madrid, Spain. February 2025.

565. Chair: "Session 1- Presentation and discussion of the Clinical Trial. Study Design and Methodology (Aim #1). Neoadjuvant and adjuvant therapies to improve survival of HCC: ASPIRE project". Madrid, Spain. February 2025.
566. Chair: "Session 3: Translating research to therapeutics". Grifols Chair Symposium. Translating Science into the Clinic: Role of the Grifols Chair. Barcelona. March 2025
567. Chair: " Session I: Overview of the End Points and Trial Design. EASL Congress 2025. Amsterdam, Netherlands. May 2025.
568. Lecture: "Overview of the End-Points for intermediate stage HCC: os vs PFS". EASL Congress 2025. Amsterdam, Netherlands. May 2025.
569. Lecture: "Closing Remarks". EASL Congress 2025. Amsterdam, Netherlands. May 2025.
570. Chair: "THRIVE Networkig". EASL Congress 2025. Amsterdam, Netherlands. May 2025.
571. Lecture: "Addressing liver cancer challenges" EASL Congress 2025. Amsterdam, Netherlands. May 2025.
572. Lecture: "JHEP Reports Editorial Team meeting" 1.-Journal Performance 2.- Strategies to enhance readership, visibility and readiness 3.- JHEP reports participation at EASL 2025.
573. Lecture: "Avances en el tratamiento sistémico del carcinoma hepatocelular". XXIV Jornadas de Avances en Hepatología. Facultad de Medicina de Málaga. Online. May 2025.
574. Scientific Advisory Board Meeting. Lyon Hepatology Institute SAB Meeting. Online. May 2025
575. Chair: Liver Cancer Program Research Meeting Hybrid Meeting. "Role of Gut Microbiome in the response to Immunotherapy in HCC". ICAHN School of Medicine at Mount Sinai. New York. May 2025.
576. Lecture: "Translational Research in Liver Cancer: From Bench to Bedside". The Lancet Commission Forum – Strengthen the prevention and treatment of liver cancer to improve the quality of life. Online. September 2025.
577. Lecture: "Present and Future of immunotherapies in the management of HCC" 25th Annual Meeting. Interlaken. September 2025
578. Lecture: "From molecular pathways to precision medicine in HCC: state of the art". 11th Global Liver Forum (Bayer). Barcelona, September 2025.
579. Chair: Session III: New biomarkers and tratments for HCC. 11th Global Liver Forum (Bayer). Barcelona, September 2025.
580. Round table discussion "Clinical discussion and international collaboration in hepatocellular carcinoma" Guangzhou, China. September 2025
581. Lecture: "LEAP-012: A Paradigm Shift in Intermediate-Stage Hepatocellular Carcinoma Treatment & Latest BCLC Staging System Guideline Updates and Key Clinical Applications. ISMIO Meeting. Hangzhou, China. September 2025.
582. Lecture: Scientific exchange with local experts on HCC. Round table discussion. Hangzhou, China. September 2025.
583. Roundtable discussion & institutional visit at Southeast University Zhongda Hospital. Nanjing, China. September 2025.
584. Lecture: Latest BCLC Staging System Guideline Updates and Key Clinical Applications. Hospital Meeting (Zhongshan Hospital) Shanghai, China. September 2025.
585. Lecture: Translational & Precision Medicine in HCC. Shanghai, China. September 23
586. Roundtable discussion on HCC management Activity: Hospital visit. Xi'an, China. September 2025.
587. Lecture: LEAP-012: A Paradigm Shift in Intermediate-Stage Hepatocellular Carcinoma Treatment & Latest BCLC Staging System Guideline Updates and Key Clinical Applications CACA–ILCA–WAIO Liver Cancer Summit. Xi'an, China. September 2025.
588. Roundtable discussion "Lecture title: Expert discussion session". Xi'an, China. September 2025
589. Lecture title: Future Directions in Translational & Precision Medicine Research for Liver Cancer Based on LEAP-012 Study Design and Results. Activity: Beijing Meeting. Beijing,

China, September 2025

590. Lecture title: Recent Advances in Hepatocellular Carcinoma. Activity: CACA Meeting. Tianjin, China. September 2025.
591. Lecture: Integración de omicas para la clasificación molecular de los tumores hepáticos y predicción de la respuesta a tratamiento. 7ª. Reunión de Hepatología traslacional. FEEH – AEEH. Online. October 24, 2025.
592. Lecture: “Which one is the preferred conversion strategy for unresectable HCC: Concurrent TACE+Atezolizumab+Bevacizumab versus Sequential Atezolizumab+Bevacizumab” Roche. Shanghai. China. November 15, 2025.
593. Chair: “Second to None” Asia-Pacific HCC Perioperative Case Invitational Tournament Finals. Roche. Shanghai. China. November 15, 2025.
594. Lecture: “Advances in the Management of Intermediate and Advanced HCC Stages”. Roche. Shanghai. China. November 16, 2025
595. Lecture: “Career story: How to become an international leader in clinical trials and research in HCC”. Roche. Guangzhou. China. November 17, 2025.
596. Lecture: “Integrated approaches in HCC: Combining systemic and locoregional strategies” at Eisai Lunchtime Industry Symposium: Navigating complexity: Multimodal innovations in unresectable HCC. Hong Kong. November 21, 2025.
597. Lecture: “Overview of Guidelines of HCC management (EASL, AASLD, ESMO)” Paris International Liver Meeting. Paris. January 19, 2026
598. Chair: “Advances in the management of HCC”. Paris International Liver Meeting. Paris. January 19, 2026
599. Lecture: “Recent and ongoing pivotal phase III RCTs in HCC” Session: State of HCC. EASL Summit 2026. Edinburgh. January 23, 2026
600. Chair: “Loco-regional therapies: from ablation, TACE, TARE to combinations” EASL Summit 2026. Edinburgh. January 23, 2026
601. Chair: “Chair session: Hot topics”. EASL Summit 2026. Edinburgh. January 23, 2026

VISITING PROFESSORSHIP AND INVITED LECTURES (1995-2007)

1995

1. Invited lecture. “Bacterial translocation in the pathogenesis of spontaneous bacterial peritonitis”. Second Joint Spanish-Israeli Meeting on Liver Diseases. Toledo, 1995.
2. Invited lecture. “Mecanismos patogénicos en la peritonitis bacteriana espontánea”. Simposio “Infecciones en las enfermedades hepáticas”. Moderator: Dr. M Diago. XX Congreso de la AEEH. Madrid. 1995.
3. Invited lecture. “Carcinoma hepatocel.lular”., in “Diagnòstic diferencial de les lesions focals hepàtiques”. Moderator: Dra. C. Brú. Congrés de la Societat Catalana de Radiologia (ACRAM). Barcelona, 1995.
4. Invited lecture. “Translocación bacteriana”, in “Infecciones en la cirrosis hepática”. Curso de la Escuela de Patología Digestiva del Hospital de la Santa Creu i Sant Pau, Director: Prof. F. Vilardell. Barcelona, 1995.

1996

5. Invited lecture. “Translocació bacteriana”. Seminar on “Infeccions a la cirrosi hepàtica”. Moderator: Dr. Guarner. Ordinary session, Societat Catalana de Digestologia. Barcelona, 1996.
6. Invited lecture. “Tractament mèdic del carcinoma hepatocel.lular”. Seminar in “Carcinoma hepatocel.lular”. Moderator: Dr. Cirera. Ordinary session, Societat Catalana d'Oncologia. Barcelona, 1996.
7. Invited lecture. “Carcinoma Hepatocelular”. Curso de la Escuela de Patología Digestiva del Hospital de la Santa Creu i Sant Pau.. Director: Dr. Balanzó, Dr Monés. Barcelona 1996.
8. Invited lecture. “Carcinoma Hepatocelular: Diagnòstic i tractament”. Col·legi de Metges de

Mallorca. Palma de Mallorca 1996.

1997

9. Invited lecture. "Epidemiology and screening of patients at risk for HCC". European main session. Primary Hepatic Carcinoma (HCC) in Europe. Chairpersons: W Meyers. E Akriviadis. Panel: JM Llovet, S Efremidis, B Ringe, D Shouval. 7th European Congress of Surgery. Athens 1997.
10. Invited lecture. "Tratamiento local del carcinoma hepatocelular" Moderator: JR Germá Lluch. VI jornadas de Actualización en Oncología. Formigal 1997.
11. Invited lecture. "Diagnóstico del carcinoma hepatocelular" and "Tratamiento médico del carcinoma hepatocelular". XIV Curso de Actualización Médico-Quirúrgica en Gastroenterología. Valladolid 1997.
12. Invited lecture. "Tratamiento quirúrgico del carcinoma hepatocelular", "Tratamiento del carcinoma hepatocelular". VII Reunión de la Sociedad Aragonesa de Patología Digestiva. Zaragoza 1997.

1998

13. Invited lecture. "Radical therapies for Hepatocellular Carcinoma and Cholangiocarcinoma". B Ringe, T Livraghi, R Adam and R Steiner. Congress of Gastroenterology and Hepatology. Pörschach. Austria., 1998.
14. Invited lecture. "Cáncer hepatocelular: tratamiento". Moderator: J Rodés. Panel: A Rimola, A Mallat. Reunión Internacional de Enfermedades Digestivas. Barcelona, 1998
15. Invited lecture. "Alcoholització i embolització arterial", in "Estratègies diagnòstiques i terapèutiques del carcinoma hepatocel.lular". Moderator: Dr. J. Bruix. Ordinary session, Societat Catalana d'Aparell Digestiu. Barcelona, 1998.

1999

16. Invited lecture. "Medical treatment of advanced hepatocellular carcinoma". Chairman J Bruix. Ponents: M Sherman, JR Lake, T Livraghi, G Gores. "Treatment of hepatocellular carcinoma". 3rd International Meeting on therapy in liver diseases. Barcelona 1999.

2000

17. Invited lecture. "Therapeutic approach in patients with liver cancer". Percorsi diagnostico-terapeutici del paziente epatopatico. Università degli studi di Torino- Liver Unit. Hospital Clínic. Barcelona, 2000.
18. Invited lecture. "Medical treatment for hepatocellular carcinoma". M Colombo, T Livraghi, X Rogiers, H Verbaan XXXII Nordic Meeting of Gastroenterology. Göteborg .Sweden, 2000.
19. Invited lecture. "Natural history and prognostic assessment". Clinical Management of hepatocellular carcinoma. EASL Monothematic Conference. Barcelona, 2000.
20. Invited lecture. "Hormonal therapy". Clinical Management of hepatocellular carcinoma. EASL Monothematic Conference. Barcelona, 2000.
21. Invited lecture. "Treatment of hepatocellular carcinoma". Panel of experts Clinical Management of hepatocellular carcinoma. (JM Llovet and L Pagliaro). EASL Monothematic Conference. Barcelona, 2000.
22. Moderator. Clinical discussion. Symposium in MRI in Hepatology. Barcelona, 2000.
23. Invited lecture. "Tratamiento médico del carcinoma hepatocelular: impacto en la supervivencia". Moderator: A Rimola. Ponentes: J Bruix, M Solé, J Fuster. V Curso Iberoamericano de Hepatología. Barcelona, 2000
24. Invited lecture. "Actitud terapéutica ante el carcinoma hepatocelular". V Jornadas de Hepatopatías e Infecciones. Cadiz, 2000.
25. Invited lecture. "Estado actual del tratamiento del carcinoma hepatocelular". XXI Jornadas de la Sociedad Canaria de Patología Digestiva. Fuerteventura, 2000.

2001

26. Invited lecture. "The EASL guide lines for the management of patients with HCC". Critical evaluation of the criteria for defining the prognosis of patients affected with HCC. M Borzio, A Sangiovanni. Milan, Italy 2001.
27. Invited lecture. "The EASL guide lines for the management of patients with HCC". Authors: JM Llovet. T Livraghi. U Maggi. V Mazzaferro. Critical evaluation of the treatment of HCC. Milan, Italy 2001.
28. Chair. "Liver transplantation for malignant tumors". ILTS-ELTA-LIGACE Annual Meeting. Berlin, Germany 2001.
29. Invited lecture. "Estrategia terapéutica del carcinoma hepatocelular". II Simposio Multidisciplinario anual de cáncer. Santiago de Chile, Chile.2001.
30. Invited lecture. "Metástasis hepáticas y tumores primarios hepáticos". II Simposio Multidisciplinario anual de cancer. Santiago de Chile, Chile.2001.
31. Invited lecture. "Estrategia diagnóstica y terapéutica de los tumores hepáticos en pacientes cirróticos". Sociedad Aragonesa de Gastroenterología. Formigal, 2001.
32. Invited lecture. "Diagnóstico precoz, estadificación y tratamiento del carcinoma hepatocelular". Hepatology Day. Hospital Germans Trias i Pujol. Badalona. 2001.
33. Invited lecture. "Estrategia terapéutica del carcinoma hepatocelular". I Curso de hepatología: "Actualización en el diagnóstico y tratamiento de las enfermedades hepáticas". Santiago de Compostela, 2001.
34. Invited lecture. "Carcinoma hepatocelular: resecció o trasplantament". Real Academia de Medicina de Catalunya. Barcelona, 2001.

2002

35. Invited lecture. "Surgical Treatment and prevention of recurrence for hepatocellular carcinoma". Authors: P.Neuhaus. Ch. Broelsch. Falk workshop. Malignant liver tumors: basic concepts and clinical management. Leipzig, Germany 2002.
36. Invited lecture. "Loco-regional treatments for HCC: a meta-analytic review". 9th United European Gastroenterology Week-EASL Postgraduate Course. "Tumours in the Liver". Amsterdam, The Netherlands, 2002.
37. Invited lecture. "Natural history of hepatocellular carcinoma". 7th European Meeting on Hepatocarcinogenesis. From the basic science to treatment. Cagliari, Italy, 2002.
38. Invited lecture. "Early diagnosis of hepatocellular carcinoma". International Task Force on early diagnosis of cancer. European School of Oncology. Milan, Italy 2001/2002.
39. Chair/Invited lecture. "Evidence based treatment of HCC". Joint Meeting of the INASL (Indian Association for the Study of the Liver)-EASL. New Dehli, India,2002.
40. Chair. "Management issues in Hepatology". Joint Meeting of the INASL (Indian Association for the Study of the Liver)-EASL. New Dehli, India,2002.
41. Invited lecture. "Spontaneous bacterial peritonitis". Joint Meeting of the INASL (Indian Association for the Study of the Liver)-EASL. New Dehli, India, 2002.
42. Invited lecture. "Regional and systemic chemotherapy- better or worse than placebo?". 18th UICC International Cancer Congress. Oslo, Norway,2002. International Journal of Cancer 2002, S13: 11 (A).
43. Invited lecture. "BCLC Staging System". Staging of hepatocellular carcinoma. A Consensus Conference. AHPA. Boston, USA, 2002.
44. Invited lecture. "Prognostic and staging of HCC". 3rd International Meeting on HCC Eastern and Western Experiences. Lodi, , 2002.
45. Invited lecture. "Maneig clínic del carcinoma hepatocelular. Recomanacions de l'EASL". Societat Catalana Digestologia. Reus, 2002.
46. Invited lecture. "Tratamiento médico del carcinoma hepatocelular: impacto en la supervivencia". VI Curso Iberoamericano de Hepatología. Barcelona, 2002.
47. Invited lecture. "Estratègia terapèutica actual a l' hepatocarcinoma". Hospital Son Dureta. Palma de Mallorca, 2002.

48. Invited lecture. "Medicina basada en la evidencia en el tratamiento del carcinoma hepatocelular". Sociedad Asturiana de Hepatología. Oviedo, 2002.

2003

49. Invited lecture. "Systematic review of randomized controlled trials for unresectable HCC". Leo International Meeting of Investigators. Rome, Italy, 2003.
50. Invited lecture. "Hepatocellular carcinoma recurrence after transplantation". EASL-ELTA Meeting. 38th EASL Meeting. Geneva, Switzerland, 2003
51. Moderator. "Hepatocellular carcinoma". Early Morning Workshop. JM Llovet, V Mazzaferro 38th EASL Meeting. Geneva, Switzerland, 2003
52. Invited lecture. "Systematic review of treatment for HCC". Chairman J Bruix. Speakers: M Colombo, M Kojiro, Y Fong, M Schwartz, R Lencioni, JM Llovet, A Venook, G Gores. "Treatment of hepatocellular carcinoma". 5rd International Meeting on therapy in liver diseases. Barcelona 2003.
53. Invited lecture. "New trends in chemoembolization of Liver Tumors". Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe". Antalya, Turkey, 2003.
54. Invited lecture. "Treatment strategy for hepatocellular carcinoma". Hemato/Oncology Department. Mount Sinai School of Medicine, New York, USA. 2003.
55. Chair. Poster sessions for Congreso de la Asociación Española para el Estudio del Hígado (AEEH). Barcelona, 2003.
56. Chair. Jornada sobre tratamientos percutáneos de tumores. Aula Clínic. Barcelona, 2003.
57. Chair. Sesión Poster del Congreso de la AEEH. Rafael Bañares, JM Llovet. Barcelona, 2003.
58. Invited lecture. "Estrategia terapéutica del carcinoma hepatocelular. Papel de la quimioembolización". Sociedad Española de Angioradiología. Alicante, 2003.

2004

59. Invited lecture. "Radical therapies on hepatocellular carcinoma". Mount Sinai School of Medicine, New York, USA. 2004
60. Visiting Professor. "Treatment strategy in hepatocellular carcinoma. Rationale for the design of clinical trials": HB Neoplasia Retreat. Mayo Clinic, Rochester, Minnesota, USA. 2004.
61. Invited lecture. "Evidence-based medicine in the treatment of HCC". International Symposium of EASL/ALEH. IASL Meeting. Salvador de Bahía. Brasil, 2004.
62. Invited lecture. "Epidemiology, Natural history, Staging and prognosis of hepatocellular carcinoma". International Symposium of EASL/ALEH. IASL Meeting. Salvador de Bahía. Brasil, 2004.
63. Chair. "Extending criteria for living donor transplantation for hepatocellular carcinoma and cholangiocarcinoma". Early Morning workshop. M Schwartz, JM Llovet. American Society of Transplant Surgeons and the American Society of Transplantation, Boston, USA, 2004.
64. Visiting Professor. "Treatment strategy for hepatocellular carcinoma". Cornell University. New York, USA, 2004.
65. Invited lecture. "Chemoembolization and survival benefits". 1st International Symposium on diagnosis and treatment of HCC. Riyadh, Saudi Arabia, 2004.
66. Invited lecture. "Treatment of HCC: an overview". 1st International Symposium on diagnosis and treatment of HCC. Riyadh, Saudi Arabia, 2004.
67. Invited lecture. "Significance of pretransplant treatment and posttransplant adjuvant therapies for HCC patients". In: Liver transplantation for tumors. ILTS, Kyoto, Japan, 2004.
68. Visiting Professorship. Invited lecture. "Overview of treatments for HCC". Yonsei University, Seoul, Korea, 2004.
69. Invited lecture. "Staging systems and treatment strategy for hepatocellular carcinoma". National Cancer Institute, National Health Institute, Bethesda. USA. 2004
70. Invited lecture. "Radical therapies in the management of early HCC". RMTI. Mount Sinai, New York, USA, 2004
71. Invited lecture. "Approach to the management of hepatocellular carcinoma". Luke's and

Roosevelt Hospital, New York, USA. 2004.

72. Visiting Professor. "Treatment strategy for HCC: Rationale for the design of RCT". Yale University, New Haven, USA: 2004.
73. Invited lecture. "Treatment strategy for HCC: Rationale for the design of RCT". Mount Sinai School of Medicine, Grand Rounds in Medicine. New York, USA,; 2004.
74. Magistral lecture. "Overview of treatment in hepatocellular carcinoma". 2nd International Meeting on HCC. Milan, Italy, 2004.
75. Panelist. Panel on the treatment assessment. 2nd International Meeting on HCC. Milan, Italy, 2004.
76. Visiting Professor. "Hepatocellular carcinoma: review of AASLD Meeting –2004". Northwestern University of Chicago, Chicago USA. 2004.
77. Invited lecture. "Key developments in Hepatology: Hepatocellular carcinoma. Rationale for translational and clinical research". Northwestern University of Chicago, Chicago, USA, 2004.
78. Visiting Professor. "Treatment strategy for HCC: Rationale for the design of RCT". Memorial Sloan-Kettering Cancer Center. New York, USA; 2004.
79. Invited lecture. "Treatment strategy for HCC: Rationale for the design of RCT". Kaplan Comprehensive Cancer Center, New York University. New York, USA; 2004.
80. Invited lecture. "Treatment strategy for HCC: Rationale for the design of RCT". Image guided tumor therapy. College of Physicians and Surgeons. Columbia University, New York, USA. 2004.

2005

81. Invited lecture. "Treatment strategy for HCC. Rationale for the use of sorafenib". Investigator's meeting, Bay 43-9006 Phase III. Miami, USA.2005.
82. Invited lecture. "Local ablative therapy: Definitive treatment or bridge to transplantation". Canadian Association for the Study of the Liver. Banff, Canada, 2005.
83. Invited lecture. Early morning workshop on Hepatocellular carcinoma. 40th Annual meeting of EASL, Paris,2005..
84. Invited lecture. "Hepatocellular carcinoma". National Cancer Institute. Advisory Board.PDQ-HCC guidelines. Bethesda, USA,2005.
85. Invited lecture. "Treatment of hepatocellular carcinoma: Chemoembolization improves survival". Johns Hopkins University School of Medicine. Baltimore,USA,2005.
86. Invited lecture. "Current status of non-surgical treatment of HCC". DDW (AASLD-AGA Combined Clinical Symposium). Chicago, 2005.
87. Visiting Professor. "Treatment strategy for HCC: Rationale for the design of RCT". Oregon Health and Science University. Portland,USA,2005.
88. Invited lecture. "Design and methodology in therapeutic trials". Monothematic Conference EASL-AASLD-JSH "HCC: Towards molecular profiling of clinical management". Barcelona, 2005.
89. Invited lecture. "Treatment update in hepatocellular carcinoma". World Congress of Gastroenterology. Montreal, Canada, 2005.
90. Invited lecture. "Medical management of HCC". Science in the City, Division of Liver diseases NYC,New York, 2005.
91. Chair. "Short review lectures on hepatocellular carcinoma". 6th international meeting on therapy in liver diseases. Barcelona, 2005.
92. Invited lecture. "Diagnosis, primary and secondary prevention of HCC". Falk Symposium #150. Berlin, Germany, 2005.
93. Chair. "Session Liver IV. Hepatocellular carcinoma". Falk Symposium #150. Berlin, Germany, 2005.
94. Invited lecture. "Management of hepatocellular carcinoma in the West". The National Meeting on Liver Cancer (China). Shanghai, China. 2005

95. Invited lecture. "Treatment of early HCC". Continuing Education Course. Fudan University. Shanghai, China, 2005
96. Chair. "Hepatocellular cancer –screening and treatment". Early Morning workshop. AASLD, San Francisco 2005.
97. Chair. "Staging systems for HCC". 4th JSH Single Topic Conference. Hyogo, 2005. Japan.
98. Invited lecture. "Staging systems for HCC. Validation of the BCLC staging classification" 4th JSH Single Topic Conference. Hyogo, 2005. Japan.
99. Invited lecture. "Overview of loco-regional therapies in HCC". Yamagiwa Memorial Awaji Liver Symposium. Hyogo, 2005. Japan.

2006

100. Invited lecture. "Screening and treatment of HCC". Workshop on HIV-HCV coinfection. Amsterdam, 2006
101. Invited lecture. "Management of Hepatocellular carcinoma". Beth Israel Medical Center, NYC, 2006.
102. Invited lecture. "Staging systems for hepatocellular carcinoma: from clinical systems to molecular classification". ASCO-GI meeting. St Francisco, 2006.
103. Visiting Professor: "Evidence-based medicine in HCC". Ann Harbor, University of Michigan, 2006
104. Invited lecture. "Local treatment of HCC". College of Physicians and Surgeons, Columbia University. NYC, 2006
105. Invited lecture. "Novel targets in hepatocellular carcinoma". Challenges and advances in the management of Hepatitis B. Mt Sinai, New York, 2006.
106. Invited lecture. "Non-surgical therapies and novel therapeutic targets: TACE". Liver Cancer and Hepatitis. Shanghai-Hong Kong International Liver Congress 2006. Shanghai, 2006.
107. Chair. Session on "Screening, Diagnosis and treatment of hepatocellular carcinoma". Shanghai-Hong Kong International Liver Congress 2006. Shanghai, 2006.
108. Invited lecture. "Evidence-based approach on the treatments strategy for HCC". Liver Cancer and Hepatitis. Shanghai-Hong Kong International Liver Congress 2006. Shanghai, 2006.
109. Chair. "Complications of cirrhosis". 41st EASL Meeting, Vienna 2006.
110. State-of-the-art Lecture. "Liver Transplant for HCC". Digestive Disease Week. Los Angeles, USA May, 2006
111. Invited lecture. "HCC: an evidence-based approach: resection, transplant or ablation." Digestive Disease Week. Los Angeles, USA May, 2006.
112. Symposia. "Studies with signal transduction inhibitors in hepatocellular carcinoma". ASCO, Atlanta, 2006
113. Invited lecture. "Review and analysis of clinical trials of TACE". World Conference on Interventional Oncology, Como, Italy, 2006
114. Chair: "Hepatocellular carcinoma". Spanish Association of Digestive Diseases. Cordoba, 2006
115. Invited lecture. "Evidence-based treatment of HCC: The BCLC strategy". 20th Anniversary of the BCLC group. Barcelona, 2006
116. State-of-the-art lecture. "Molecular targeting agents in the treatment of HCC". 42nd Annual Meeting of Liver Cancer Study Group of Japan. Tokyo, 2006
117. Invited lecture. "Therapeutic management of the patient with liver cancer". CIRSE. Roma, 2006
118. Invited lecture. "Treatment of HCC in cirrhotic patients". Czech Society of Hepatology. Prague, 2006.
119. Visiting Professorship. State-of-the art lecture. "Clinical and molecular classification of HCC". Sao Paulo, Brasil, 2006.
120. Invited lecture. "Liver transplantation for hepatocellular carcinoma", Sao Paulo, 2006 Brasil.

121. Invited lecture. "Molecular targeted therapies in HCC". Grand Rounds Hem/Oncology , Mt Sinai School of Medicine. NYC, 2006
122. Invited lecture. "Diagnosis and Medical management of HCC". Science in the City, Division of Liver diseases.NYC, 2006
123. Chair. "Experimental hepatocarcinogenesis". 37th AASLD, Boston, USA,2006.
124. Invited lecture. "Diagnosis of HCC". Meet the Professor luncheon 37th AASLD, Boston, USA,2006.
125. Invited lecture. "Molecular targeted therapies in HCC. AACR-EORTC Meeting". Prague, 2006 Checoslovaquia.
126. Invited lecture. "Medical Treatment of HCC". I Hepatology Course. Liver Unit. Barcelona, 2006.
127. Invited lecture. "Randomized controlled trial with Y-90 in advanced HCC". Barcelona, 2006.
128. Director, "Design of clinical trials in hepatocellular carcinoma". AASLD Single Topic Conference. Atlanta, USA,2006.
129. Chair. "Design and end-points in clinical trials in Oncology". AASLD Single Topic Conference, Atlanta, USA,2006.
130. Invited lecture. "Principles of trial design in HCC: end-points and beyond". AASLD Single Topic Conference, Atlanta, USA,2006.

2007

131. Invited lecture. "Development of HCC: Molecular mechanisms". HCC: Eastern and Western experiences. Houston, Texas, USA,2007.
132. Invited lecture. "Prevention of HCC after surgical treatment". HCC: Eastern and Western experiences. Houston, Texas, USA,2007.
133. Chair. "Systemic therapy of HCC". HCC: Eastern and Western experiences. Houston, Texas, USA,2007.
134. Chair. "Molecular biology in HCC: Eastern and Western experiences. Houston, Texas, USA,2007.
135. Invited lecture. "Molecular classification of HCC and molecular targeted therapies". University Hospital Zurich,Zurich, 2007.
136. Chair/ Invited lecture. "Molecular diagnosis and therapies in HCC". 6th Hepatobiliary and GI Research retreat. Vulpera, Switzerland, 2007
137. Invited lecture. "New molecular targeted therapies in HCC". Postgraduate Course. AEEH, Madrid, 2007.
138. Invited lecture. "Expanded indications of liver transplantation for HCC". 9th Congress, Catalan Transplantation Society, Barcelona, 2007.
139. Invited lecture. "What is new for hepatocellular carcinoma, what to refer, how to treat?". New concepts in the management of Hepatitis B. MSSM, New York, 2007.
140. Invited lecture. "Treatment of HCC". Early morning workshop. EASL 42nd Meeting. Co-chaired V Mazzaferro. Barcelona, 2007.
141. Chair. "Pathogenesis of hepatocellular carcinoma". EASL 42nd Meeting. Barcelona, 2007.
142. Chair. "The role of molecular targeted therapy in the treatment of advanced hepatocellular carcinoma", EASL 42nd Meeting. Barcelona, 2007.
143. Invited lecture. "Molecular targeted therapies in HCC". Satellite Symposium., EASL 42nd Meeting. Barcelona, 2007.
144. Invited lecture. "Summary, HCC End-points Single Topic Conference-2006". AASLD highlights program.Washington, 2007.
145. Invited lecture. "Carcinoma hepatocelular. Situación actual y perspectivas de futuro". GECH. Estrategia terapéutica actual y nuevas dianas moleculares. Barcelona, 2007.
146. Invited lecture. "Molecular pathogenesis and signal transduction pathways in HCC". Samuel Waxman Cancer Research Foundation. New York, 2007.

147. Invited lecture. "Estrategia terapéutica del HCC. Diseno basado en la evidencia". Curso Actualización en el diagnóstico y tratamiento del HCC. Santiago de Compostela, 2007.
148. Invited lecture. "Molecular targeted therapies in HCC". EASL Clinical School of Hepatology. Barcelona, 2007.
149. Director, 2nd Mount Sinai Liver Cancer Program Meeting. Overview of the Mount Sinai Liver Cancer Program. NYC. 2007.
150. Director, 2nd Mount Sinai Liver Cancer Program Meeting. Molecular targeted therapies. NYC, 2007.
151. Symposia. Satellite Symposium. 9th World Congress on Gastrointestinal Cancer. Targeting the underlying molecular mechanisms of hepatocellular carcinoma. Barcelona, 2007.
152. Invited lecture. "How new treatment modalities impact on patient selection in HCC". CIRSE Annual Scientific meeting. Athens, Greece. 2007.
153. State of the art lecture: "Hepatic carcinogenesis: from dysplastic nodules to hepatocellular carcinoma". 7th international meeting on therapy in liver diseases. Barcelona, 2007.
154. Invited lecture. "Molecular targeted therapies". Symposium on HCC. 7th international meeting on therapy in liver diseases. Barcelona, 2007.
155. Invited lecture. "Clinical data with sorafenib in patients with advanced HCC". Symposium: Targeting multiple molecular pathways: a new dawn in the management of HCC. ECCO14 Annual Meeting, Barcelona, 2007.
156. State-of-the-art-lecture: "Current management of hepatic cancer". ECCO Annual meeting, Barcelona, 2007.
157. Invited lecture. "Clinical data with sorafenib in patients with HCC". ECCO Symposium. Targeting multiple molecular pathways: a new dawn in the management of hepatocellular carcinoma. Barcelona, 2007.
158. State of the art lecture: "Molecular classification of HCC and implications in the selection of patients prior liver transplantation." ESOT, Prague, 2007.
159. Invited lecture. "Results of the RCT sorafenib in advanced HCC". SHARP Investigators meeting. Lisbon, Portugal, 2007.
160. Invited lecture. "Principles of trial design and end-points in HCC research". International Liver Cancer Association (ILCA). Barcelona, 2007.
161. Invited lecture. "Management of HCC: recent advances and future prospects". Satellite symposium. ILCA Annual meeting, Barcelona, 2007.
162. Invited lecture. "An overview of clinical data with drug-eluting beads". Satellite symposium. ILCA Annual meeting, Barcelona, 2007.
163. State-of-the-art-lecture. "Targeting multiple molecular pathways: a new era in HCC". Japan Digestive Disease Week. Kobe, Japan 2007.
164. Invited lecture. "The role of molecular signaling in the pathogenesis of HCC". Meet the Experts Session. APDDW-Japan Digestive Disease Week. Kobe, Japan 2007.
165. Invited lecture. "Results of a phase III-SHARP trial". Meet the Experts Session. APDDW-Japan Digestive Disease Week. Kobe, Japan 2007.
166. Invited lecture. "Molecular pathogenesis of HCC". Early Morning Workshop AASLD 58th Annual Meeting, Boston, 2007.
167. Invited lecture. "Current management of HCC: going for a cure". Postgraduate course AASLD: Pathophysiologic basis on the therapy of liver diseases. AASLD 58th Annual Meeting, Boston, 2007.
168. Invited lecture. "Clinical and Molecular classification of HCC". ILTS/AASLD Transplant Course. AASLD 58th Annual Meeting, Boston, 2007.
169. Invited lecture. "New Molecular Targeted therapies in HCC". MSSM Grand Rounds in Medicine, New York, 2007.
170. Chair. "Targeting the Ras/Raf signaling pathway: implications in the management of HCC". Satellite Symposium, AASLD. New York, 2007.

171. Invited lecture. "Therapeutic implications of Ras/Raf signaling pathways. Targeted therapies in the treatment of HCC". Satellite Symposium, AASLD. New York, USA, 2007.
172. Invited lecture. "Epidemiology, diagnosis and treatment of liver cancer". National Academies Standing Committee on Risk Analysis, Bethesda, USA, 2007.
173. Invited lecture. "Molecular targeted therapies in HCC: Role of sorafenib". Chemotherapy foundation symposium XXV, New York, 2007
174. Invited lecture. "The vital role of molecular signalling in the pathogenesis of HCC". BESTT symposium. Vienna, Austria, 2007.
175. Invited lecture. "Drugs in development for HCC: phase III data". BESTT symposium. Vienna, Austria, 2007.
176. Invited lecture. "Extended indications for LDLT". A critical appraisal. Barcelona, 2007.
177. Invited lecture. "Bases moleculares para nuevos tratamientos en el HCC". II Curso de Hepatología. Barcelona, 2007.

PRESENTATIONS IN INTERNATIONAL SCIENTIFIC MEETINGS (SEE TOP ORAL IN SECTION 11TH)

- Abad-Lacruz A, González-Huix F, Cabré E, Boix J, Gomes-Vieira C, **Llovet JM**, Esteve-C M, Fernández-Bañares F, Humbert P, Gassull MA. Survival and prognostic factors of the first episode of encephalopathy in 91 patients with advanced liver cirrhosis. A multivariate analysis. *Gastroenterology* 1990; 98:A562. (Poster).
- Esteve-Comas M, Ramírez M, Boix J, Fdez-Bañares F, González-Huix F, Abad-Lacruz A, Gil A, Cabré E, Quer JC, **Llovet JM**, Gassull MA. The influence of the activity of the disease in polyunsaturated fatty acid pattern in inflammatory bowel disease. *Freiburg /Germany. Falk Symposium nº 60. Inflammatory Bowel Disease. 1990.*(Oral)
- Abad-Lacruz A, González-Huix F, Cabré E, Gomes-Vieira C, **Llovet JM**, Esteve-Comas M, Fdez-Bañares F, Humbert P, Gassull MA. Probability and prognostic factors of the first encephalopathy episode in advanced liver cirrhosis. A multivariate analysis. *J. Hepatol* 1990 (Suppl. 2): S68. (Poster)
- Esteve-Comas M, Ramirez M., Boix J, Fernández-Bañares F, González-Huix J, Abad-Lacruz A, Gil A, Cabré E, Quer JC, **Llovet JM**, Gassull MA. The influence of activity of the disease in polyunsaturated fatty acid (PUFA) pattern in inflammatory bowel disease (IBD). *Clinical Nutrition* 1990;9 (Suppl):62. *XII Congress of ESPEN. Athens. 1990.* (Oral)
- **Llovet JM**, Planas R, Morillas R, Quer JC, Cabré E, Boix J, Humbert P, Guilera M, Domènech E, Bertrán X, Gassull MA. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis (SBP). Multivariate study. *J Hepatol* 1991;13:S139. (Oral)
- González-Huix F, De León R, Acero D, Esteve M, Figa M, Abad A, Fdez-Bañares F, Guilera M, **Llovet JM**, Cabré E, Gassull MA. Total enteral nutrition with polymeric diets (TENP) as primary treatment of Crohn's disease (CD). Preliminary results of a controlled trial. *Clinical Nutrition* 1991; 10 (Suppl 2):47. *XII Congres of the ESPEN. Antwerp. Belgium. 1991.* (Oral)
- De León R, Cabré E, Esteve Pardo M, Fernández-Bañares F, **Llovet JM**, Esteve Comas M, Planas R, Boix J, Humbert P, Gassull MA. Body impedance analysis (BIA) in the diagnosis of protein-energy malnutrition (PEM) in liver cirrhosis (LC). *J Hepatol* 1991;13:S114. (Poster)
- **Llovet JM**, Planas R., Morillas R., Quer JC, Cabré E, Boix J, Humbert P, Guilera M, Domènech E, Bertran X, Gassull MA. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis (SBP). Multivariate study. *Gastroenterology* 1992;102: A844. (Poster)
- Cabré E, De Ramón, Planas R, Quer JC, Boix J, Pastor C, **Llovet JM**, Gassull MA. Effect of portocaval shunt (PCS) on plasma polyunsaturated fatty acids (PUFA) in liver cirrhosis (LC). *J Hepatol* 1992;16 (Suppl).1: S82. (Poster)
- Humbert P, Fernández-Bañares F, López de Soria P, Planas R, Bertrán X, Boix J, Domènech E, **Llovet JM**, et al. Oral magnesium hydrogen breath test (MgHBT) using end-expiratory sampling: a method to assess hipoclorhydria. *Gastroenterology* 1992;102:A86. *Digestive Disease Week of AGA. San Francisco. 1992.* (Oral)
- Cabré E, De Ramón M, Planas R, Quer JC, Boix J, Pastor C, **Llovet JM**, Gassull MA. Effect of portal-systemic shunting on the plasma lipid polyunsaturated fatty acid (PUFA) content in liver cirrhosis (LC). *Clinical Nutrition* 1992;11 (Suppl):90. *XIV Congress of ESPEN. Viena. 1992.* (Oral)
- Spanish Collaborative Group for the Study of Spontaneous Bacterial Peritonitis. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Preliminary results of a multicenter, randomized, comparative study. *Hepatology* 1992;16:594. (Oral)
- **Llovet JM**, Bartolí R, Planas R, Arnal J, Cabré E, Urban A, Ojanguren I, Ibañez A, Gassull MA. Relation of bacterial translocation (BT) with spontaneous bacterial peritonitis (SBP) in cirrhotic rats. *Gastroenterology* 1993;104:A942. *Digestive Disease Week of AGA. Boston. 1993.* (Poster)
- Planas R, Follo A, **Llovet JM**, Navasa M, Cabré E, Forns X, Rimola A, Domènech E, Arroyo V, Gassull MA. Incidence and prognosis of renal failure (RF) in cirrhotics with nosocomial spontaneous bacterial peritonitis (SBP). *Gastroenterology* 1993;104:A973. *Digestive Disease Week of AGA. Boston. 1993.* (Oral)
- Humbert P, López de Soria P, Fdez-Bañares F, J Juncà, Boix J, Quer JC, **Llovet JM**,

- Gassull MA. Oral magnesium hydrogen breath test (MgHBT) as compared to serum pepsinogen I levels in the screening for pernicious anemia. *Gastroenterology* 1993;104:A106. *Digestive Disease Week of AGA. Boston. 1993* (Poster)
- Fernandez-Bañares F, Esteve-P M, De Leon R, Humbert P, Cabré E, **Llovet JM**, Bertrán X, Gassull MA. Role of lactose and fructose plus sorbitol malabsorption in functional bowel disease (FBD). A controlled study. *Gastroenterology* 1993;104:A247. (Poster)
 - **Llovet JM**, Bartolí R, Planas R, Arnal J, Cabré E, Ibañez A, Gassull MA. Spontaneous bacterial peritonitis (SBP) in cirrhotic rats. Role of bacterial translocation. *J Hepatol* 1993;18 (Suppl).1: S140 (T-248). (Poster).
 - Follo A, Navasa M, **Llovet JM**, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Incidence, predictive factors and prognosis of renal impairment (RI) in Spontaneous bacterial peritonitis (SBP) in cirrhosis. *J Hepatol* 1993;18 (Suppl).1: S118 (T-148). *28th Meeting of EASL, 1993. París.* (Oral)
 - **Llovet JM**, Bartolí R, Planas R, Gimenez M, Cabré E, Arnal J, Galimany R, Bertran X, Ausina V, Gassull MA. Relationship between bacterial translocation (BT) and spontaneous bacterial peritonitis (SBP) in ascitic cirrhotic rats. *Gastroenterology* 1994;106:A932. (Poster).
 - **JM Llovet**, MP Rdguez-Iglesias, M Menacho, R Planas, E Cabré, MA Gassull. Spontaneous bacterial peritonitis: Comparison between cirrhotics with and without previous selective intestinal decontamination. *Gastroenterology* 1994;106:A933. *Digestive Disease Week of AGA. New Orleans, Louisiana. 1994.* (Poster)
 - R Planas, R Morillas, JC Quer, J Boix, P Humbert, E Cabré, **JM Llovet**, E Domènech, MA Gassull. Randomized controlled trial of somatostatin vs endoscopic sclerotherapy in the treatment of acute variceal bleeding: final results. *Gastroenterology* 1994;106:A962. *Digestive Disease Week of AGA.(Sessió plenària) New Orleans, Louisiana. 1994* (Oral).
 - **Llovet JM**, Bartolí R, Planas R, Gimenez M, Cabré E, Arnal J, Galimany R, Bertran X, Ausina V, Gassull MA. Relationship between bacterial translocation and spontaneous bacterial peritonitis in ascitic cirrhotic rats. *Hepatology* 1994;19:A227. *Congress of the IASL. Cancún, México. 1994.* (Oral)
 - R Morillas, JC Quer, R Planas, J Boix, P Humbert, E Cabré, **JM Llovet**, E Domènech, MA Gassull. Somatostatin vs endoscopic sclerotherapy in the treatment of acute variceal bleeding: final results of a randomized controlled trial. *Hepatology* 1994;19:A270. *Congress of the IASL. Cancún, México. 1994.(IASL Award)* (Oral).
 - **Llovet JM**, Bartolí R, Planas R, Gimenez M, Cabré E, Arnal J, Galimany R, Bertran X, Ausina V, Gassull MA. Relación entre la translocación bacteriana y la peritonitis bacteriana espontánea en la rata cirrótica con ascitis. *Rev Gastroenterol Mex* 1994;59:A24. *XII Jornadas Latinoamericanas de Hepatología. Mérida, México. 1994.* (Oral)
 - R Morillas, JC Quer, R Planas, J Boix, P Humbert, E Cabré, **JM Llovet**, E Domènech, MA Gassull. Somatostatina vs esclerosis endoscópica en la hemorragia aguda por varices esofágicas: resultados finales de un estudio prospectivo y aleatorio. *Rev Gastroenterol Mex* 1994;59:A23. *XII Jornadas Latinoamericanas de Hepatología. Mérida, México. 1994* (Oral)
 - Navasa M, Planas R, Clemente G, Vargas V, Guarner C, Follo A, Viver J, Obrador A, Rodrigo L, Rimola A, Arroyo V, Rodés J and members of the Collaborative Group for the Study of SBP. Oral ofloxacin versus intravenous cefotaxima in the treatment of non-complicated spontaneous bacterial peritonitis (SBP) in cirrhosis. Results of a multicenter, prospective, randomized trial. *J Hepatol* 1994;21(Suppl1):S11. (Oral)
 - **JM Llovet**, R Bartolí, R Planas, B Viñado, J Perez, E Cabré, J Arnal, I Ojanguren, V Ausina, MA Gassull. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. *Gastroenterology* 1995;4:1112 (A) *Digestive Disease Week of AGA. San Diego, California. 1995* (Poster).
 - **JM Llovet**, MP R-Iglesias, E Moitinho, M Menacho, R Bataller, R Planas, M Navasa, A Castells, E Cabré, V Arroyo, MA Gassull, J Rodés. Does spontaneous bacterial peritonitis (SBP) have a better outcome in patients with previous selective intestinal decontamination (SID)? *Gastroenterology* 1995;4:1111 (A). *Digestive Disease Week of AGA. San Diego, California. 1995* (Poster).
 - Navasa M, Planas R, Clemente G, Vargas V, Guarner C, Follo A, **Llovet JM**, Viver J,

Obrador A, Rodrigo L, Rimola A, Arroyo V, Rodés J and members of the Collaborative Group for the Study of SBP. Oral ofloxacin versus intravenous cefotaxima in the treatment of non-complicated spontaneous bacterial peritonitis (SBP) in cirrhosis. Results of a multicenter, prospective, randomized trial. *Gastroenterology* 1995;4:1132 (A). *Digestive Disease Week of AGA. San Diego, California. 1995* (Poster).

- JM Sanchez-Tapias, R Planas, X Forns, S Ampurdanés, LL Titó, JM Viver, R Morillas, D Acero, P Mas, **JM Llovet**, J Rodés. Low-Dose alpha-interferon therapy can be effective in chronic active hepatitis C. Results of multicenter randomized trial. *Gastroenterology* 1995;4:1162 (A). *DD Week of AGA. San Diego, California. 1995*. (Poster).
- M Navasa, E Moitinho, **JM Llovet**, R Bataller MP Rodríguez-Iglesias, A Castells, R Planas, J Bruix, MA Gassull, J Rodés. High prevalence and prognostic significance of hepatocellular carcinoma (HCC) in cirrhotic patients with spontaneous bacterial peritonitis (SBP). *Gastroenterology* 1995;4:1132 (A). (Oral).
- **JM Llovet**, R Bartolí, F March, R Planas, B Viñado, E Cabré, J Arnal, P Coll, V Ausina, MA Gassull. DNA fingerprinting demonstrates that spontaneous bacterial peritonitis are mainly due to translocated bacteria of gut origin. *Hepatology* 1995;22:237 (A). *Congress of AASL. Chicago, 1995*. (Poster)
- R Bartolí, R Planas, **JM Llovet**, B Viñado, J Perez, E Cabré, J Arnal, I Ojanguren, V Ausina, MA Gassull. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. *JPEN* 1995; (A). *XVII ESPEN Congress. Rome, 1995*. (Poster)
- **JM Llovet**, R Bartolí, F March, R Planas, B Viñado, E Cabré, J Arnal, P Coll, V Ausina, MA Gassull. DNA fingerprinting demonstrates that spontaneous bacterial peritonitis are mainly due to translocated bacteria of gut origin. *Hepatology* 1996;23:1-56, (A). *Biennial Scientific Meeting of the IASL. Cape Town, 1996*.
- **JM Llovet**, J Bruix, J Fuster, A França, JC García-Valdecasas, M Navasa, A Rimola, L Grande, C Brú, J Visa, J Rodés. Liver transplantation for small hepatocellular carcinoma. Results of a restrictive policy. *J Hepatol* 1996; (Poster)
- Boix L, Bruix J, Castells T, França A, **Llovet JM**, Rivera F, Rodés J. Circulating mRNA for alpha-fetoprotein in patients with hepatocellular carcinoma. Evidence of tumor dissemination after transarterial embolization. *Hepatology* 1996;24:349A. *47th Congress of AASLD. Chicago, 1996*. (Poster)
- **JM Llovet**, J Bruix, J Fuster, and the Liver Transplantation Unit. Liver transplantation (OLT) for small hepatocellular carcinoma (HCC). Results of a restrictive policy. *Hepatology* 1996;24:350A. *47th Congress of AASLD. Chicago, 1996*. (Poster)
- **JM Llovet**, J Bruix, A Castells, J Bustamante, C Brú, J Rodés. Prospective follow-up of untreated hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. *Hepatology* 1997;26:246A. *48th Congress of AASLD. Chicago, 1997*. (Poster)
- M Solé, A Palacin, **JM Llovet**, R Miquel, A Ribé, J Bruix, A Cardesa. Value of sinusoidal CD34 expression for the diagnosis of border-line hepatocellular nodules in cirrhosis. *Pathol Res Pract* 1997;193:446A. *16th European Congress of Pathology. Maastricht, 1997* (Oral).
- J Bruix, **JM Llovet**, A Castells, C Brú, X Montañá, R Vilana, C Ayuso, J Rodés. Treatment of hepatocellular carcinoma by transarterial embolization: a prospective placebo controlled trial. *Hepatology* 1997;26:249A. *48th Congress of AASLD. Chicago, 1997*. (Oral)
- Martinez J, Vilana R, Bianchi LI, Solé M, **Llovet JM**, Bruix J, Brú C. Accuracy of ultrasound (US) in the detection and staging of hepatocellular carcinoma in cirrhotic patients undergoing orthotopic liver transplantation (OLT). A prospective study. *Eur J Ul* 1998;7 (Suppl1):24. *European Congress of Radiology. France, 1998*. (Poster)
- Vilana R, Martinez X, Gilabert R, Bianchi LI, Nicolau C, Solé M, Vianney A, **Llovet JM**, Bruix J, Brú C. Detection and staging of hepatocellular carcinoma (HCC) with ultrasound: Analysis of 320 consecutive explanted livers. *J Ultrasound Med* 1998;16:S119. *American Institute of Ultrasound in Medicine. Boston, 1998*. (Poster)
- **JM Llovet**, Jordi Bruix, Josep Fuster, Concepció Brú, Ramon Vilana, Sebastian Capurro and the Liver Cancer Study Group. Long-term outcome after radical treatment for hepatocellular carcinoma: a single center experience. *Hepatology* 1998;28:340A. *49th Congress of AASLD*.

Chicago, 1998. (Poster).

- **JM Llovet**, J Bruix, J Fuster, for the Barcelona Clínic Liver Cancer Group. Intention to treat analysis for radical treatment of hepatocellular carcinoma: resection vs transplantation. *J Hepatol* 1999; 96A. *European Congress of EASL. Nàpols 1999.* (Poster)
- **JM Llovet**, J Bruix, S Capurro R Vilana for the Barcelona Clínic Liver Cancer Group. Long-term survival after ethanol injection for small hepatocellular carcinoma in 100 cirrhotic patients. Relevance of maintained success. *J Hepatol* 1999; 100A. *European Congress of EASL. Naples 1999.* (poster)
- **JM Llovet**, M Sala, L Castells, J Suarez, V Vargas, J Bruix, and the Barcelona Clinic Liver Cancer Group. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. *J Hepatol* 1999; 100A. *European Congress of EASL. Naples, 1999.* (Poster)
- **JM Llovet**, X Mas, J. Aponte, J Fuster, M Navasa and J Bruix. BCLC Group Radical treatment of hepatocellular carcinoma during the waiting list for orthotopic liver transplantation: a cost-effectiveness analysis on an intention-to-treat basis. *Hepatology* 1999;30:223A. *50th Congress of AASLD. Dallas, 1999.* (Plenary Session)
- M Gimenez, X Forns, JM Sánchez-Tapias, Y Suarez, A Sanchez-Fueyo, S Ampurdanés, JM Barrera, **JM Llovet**, J Bruix, J Rodés, JC Sainz. Amino acid substitutions are highly common within the HCV-1B NS5A region for patients with hepatocellular carcinoma. *Hepatology* 1999;30:460A. *50th Congress of AASLD. Dallas, 1999.* (Poster)
- **JM Llovet**, M Sala, Y Suarez, M Real, R Vilana, L Bianchi, C Ayuso, J Bruix. Two-step treatment of large solitary hepatocellular carcinoma (HCC) by arterial embolization followed by ethanol injection. *J Hepatol* 2000;32:88A. *35th European Congress of EASL. Rotterdam, 2000.* (Poster)
- M Gimenez, X Forns, Y Suarez, A Sanchez-Fueyo, S Ampurdanés, JM Barrera, **JM Llovet**, J Bruix, J Rodés, JM Sánchez-Tapias, JC Sainz. Unusual amino acid heterogeneity within the HCV-1b NS5a region for patients with hepatocellular carcinoma. *J Hepatol* 2000;32:85A. *35th European Congress of EASL. Rotterdam, 2000.* (Poster)
- **Llovet JM**, Vilana R, Brú C, Bianchi LI, Salmeron JM, Sala M, Ayuso C, Pagès M, Bruix J, Rodés J. Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma. *Hepatology* 2000; 32:206A. *51th Congress of AASLD. Dallas, 2000.* (Plenary session).
- **JM Llovet**, M Real, R Vilana, R Planas, S Coll, JJ Aponte, C Ayuso, M Sala, J Muchart, R Solà, J Rodés, J Bruix. Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma. *J Hepatol* 2001;34 (Suppl 1):11A. *36th European Congress of EASL. Prague, 2001.* (Plenary session)
- **Llovet JM**, Sarasin F, Majno P, Mentha J, Hadengue A, Bruix J. Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. *J Hepatol* 2001;34 (Suppl 1): 8A. *36th European Congress of EASL. Prague, 2001.* (Oral, Working party)
- L Boix, C Armengol, M Solé, W Jiménez, **JM Llovet**, J Rodés, J Bruix. VEGF and iNOS expression in human hepatocellular carcinoma. *J Hepatol* 2001;34 (Suppl 1):106A. *36th European Congress of EASL. Prague, 2001.* (Poster).
- C Armengol, L Boix, O Bachs, M Solé, **JM Llovet**, J Rodés, J Bruix. p27 is an independent predictor of recurrence after surgical resection of hepatocellular carcinoma. *J Hepatol* 2001; 34 (Suppl 1):106A. *36th European Congress of EASL. Prague, 2001.* (Poster).
- Majno P, Sarasin F, **Llovet JM**, Bruix J, Mentha J, Hadengue A, Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. *Liver Transplantation* 2001;7:C-71A. *ILTS-ELTA-LIGACE Berlin, 2001.* (Oral)
- **JM Llovet**, J Bruix. Chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of pooled data. *Hepatology* 2001;34:180A. *52th Congress of AASLD. Dallas, 2001.* (Oral).
- **JM Llovet**, M Real, R Vilana, R Planas, S Coll, JJ Aponte, C Ayuso, M Sala, J Muchart, R Solà, J Rodés, J Bruix. Chemoembolization versus conservative management in patients with unresectable hepatocellular carcinoma. *J Clin Oncol* 2002;21 (Part 1):132A. *38th*

Annual Meeting of the American Society of Clinical Oncology. Orlando, 2002. (Oral).

- **JM Llovet**, J Bruix. Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma. *Hepatology* 2002;36:387A. 53th Congress of AASLD. Boston,, 2002. (Oral)
- **JM Llovet**, M Burrel, M Sala, C. Ayuso, M Solé, JR Ayuso, TM Caralt, C. Brú, J Bruix. Angiography is superior to helical CT for detection of early hepatocellular carcinoma prior to liver transplantation. A blinded comparison with histological correlation. *Hepatology* 2002;36:303A. 53th Congress of AASLD. Boston,, 2002. (Oral)
- M Sala, **JM Llovet**, R Vilana, LI Bianchi, C Ayuso, C Brú, J Bruix. Percutaneous treatment for unresectable hepatocellular carcinoma. predictors of long-term survival of 274 patients in a single institution. *J Hepatol* 2003 ;38 (Suppl 1):A .38th European Congress of EASL.Geneva, 2003. (Poster)
- M Sala, J Fuster, **JM Llovet**, JC Garcia-Valdecasas, M Navasa, M Varela, M Solé, A Rimola, J Rodés. J Bruix. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma. An indication of liver transplantation. *Liver Transplantation* 2003; 9: C-32(A). 9th Meeting of ILTS, Barcelona. European Congress of Hepatocarcinogenesis. (Oral) .
- **JM Llovet**, JC García-Valdecasas, J Fuster, M Navasa, R Charco, C Ayuso, M Sala, R García, A Rimola, J Rodés, J Bruix. Living donor liver transplantation for hepatocellular carcinoma with explanted criteria: evaluation of applicability in Europe. *Liver Transplantation* 2003; 9: C-64(A). 9th Meeting of ILTS, Barcelona. (Poster).
- **JM Llovet**, M Sala, J Fuster, M Navasa, F Pons, M Solé, C Ayuso, A Rimola, JC Garcia-Valdecasas, J Bruix. Predictors of drop-out and survival of patients with hepatocellular carcinoma candidates for liver transplantation. *Hepatology* 2003;38:763A. 54th Congress of AASLD. Boston,, 2003 (Poster).
- M García-Retortillo, X Forns, **JM Llovet**, M Navasa, J Turnes, JC Garcia-Pagan, J Bosch, J Fuster, JC García-Valdecasas, A Rimola. Early lobular necrosis and living donor liver transplantation are strong predictors of severe HCV recurrence after liver transplantation. *Hepatology* 2003;38:530A. 54th Congress of AASLD. Boston,, 2003 (Poster)
- Garcia-Retortillo M, Forns X, **Llovet JM**, et al. Hepatitis HCV virus disease recurrence is more severe after LDLT compared with CLT. *J Hepatol* 2004 ;40 (Suppl 1):3A .39th European Congress of EASL.Berlin,2004. . American Transplantation Society, Boston, 2004. *Am J Transplant* 2004;4 (Suppl8):294A (Oral).
- Ferrer J, Fuster J, Charco R, Bombuy E, Fondevila G, Alvarez G, Rodriguez G, Amador A, Sala M, **Llovet JM**, Navasa M, Rimola A, Bruix J, Garcia-Valdecasasa JC. Complications in the donor after righ-lobe adult living donor liver transplantation (LDLT). *J Hepatol* 2004 ;40 (Suppl 1):45A .39th European Congress of EASL.Berlin,2004. American Transplantation Society, Boston, 2004. *Am J Transplant* 2004;4 (Suppl8):183A. ILTS, Kyoto, Japan 2004. *Liver Transplantation*, 2004;10:C-25. (Poster)
- Pons F, Squarcia M, Vilana R, Sala M, Bianchi L, MC Ayuso, Varela M, **Llovet JM**, Brú C, Bruix J. Exclusion of subcapsular tumors prevents peritoneal seeding in HCC patients treated with radiofrequency. *J Hepatol* 2004 ;40 (Suppl 1):A .39th European Congress of EASL.Berlin,2004. (Poster).
- Varela M, Vilana R, Bianchi L, García M, Nicolau N, Sánchez, Ayuso C, Sala M, **Llovet JM** , Bru C, Bruix J. Usefulness of Sonovue microbubble-enhanced ultrasonography in the assessment of the efficacy of percutaneous ablation patients with HCC. *J Hepatol* 2004 ;40 (Suppl 1):A .39th European Congress of EASL.Berlin,2004. (Poster)
- Beaugrand M, Sala M, Degos F, Sherman M, Bolondi L, Evans T, Trinchet JC, N'Kontchou G, **Llovet JM**, Hedegaard K, Hvidberg H, Bruix J. Treatment of advanced hepatocellular carcinoma (HCC) by seocalcitol (a Vit D analogue): An international randomized double-blind placebo-controlled study in 747 patients. *J Hepatol* 2005;42 (Suppl 2):A17. 40th European Congress of EASL.Paris,2005. (Oral)
- **Llovet JM**, Chen Y, Wurmbach E, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Mazzaferro V, Bruix J, Bottinger E, Waxman S, Friedman S. Comparison of gene transcriptional profiles in dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis: identification of molecular markers. *J Hepatol* 2005;42 (Suppl 2):A20 .40th European Congress of EASL.Paris,2005. (Oral)

- **Llovet JM**, Chen Y, Wurmbach E, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Mazzaferro V, Bruix J, Bottinger E, Waxman S, Friedman S. Molecular pathogenesis of hepatocellular carcinoma in HCV-cirrhotic patients: genes and signaling pathways involved. *J Hepatol* 2005;42 (Suppl 2):A98 .40th European Congress of EASL.Paris,2005. (Poster)
- Wurmbach E, Chen Y, Khitrov G, Roayaie S, Fiel I, Schwartz M, Thung S, Battiston C, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, **Llovet JM**. Gene expression profiles in pre-neoplastic lesions and hepatocellular carcinoma in hepatitis C virus -cirrhotic patients . *Proceedings of the AACR 2005*, 46: A836. 96th Annual Meeting AACR , California,USA, 2005 (Poster)
- Chen YB, Wurmbach E, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Mazzaferro V, Bruix J, Bottinger E, Waxman S, Friedman S, **Llovet JM**. Genes and pathways involved in the molecular pathogenesis of hepatocellular carcinoma in HCV-cirrhotic patients. *Proceedings of the AACR 2005*, 46: A290. 96th Annual Meeting AACR , California,USA, 2005 (Poster)
- **Llovet JM**, Chen Y, Wurmbach W, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman S. A molecular signature to discriminate dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis. 57th Congress of AASLD. St Francisco, 2005 (Oral)
- Lemmer ER, Villanueva A, Chen Y, Yea S, Wurmbach E, Schwartz M, Khitrov G, Narla G, Waxman S, Friedman SL, **Llovet JM**. Dysregulation of hedgehog pathway signaling in hepatocellular carcinoma. *Proceedings of the AACR 2006*, 97th Annual Meeting AACR, California,USA, 2005 (Oral).
- Villanueva A, Peix J, Di Feo A, Chen Y, Lemmer E , Van Laarhoven S, Fiel MI, Thung S, Yea S, Roayaie S, Schwartz M, Friedman SL, **Llovet JM**. Molecular targeted therapy of hepatocellular carcinoma with a dual tyrosine kinase receptor inhibitor (AEE788) and an mTPR inhibitor (RAD, everolimus). 58th Congress of AASLD, 2006. Boston. (Oral)
- **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J, for the SHARP Investigators. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial. *J Clin Oncol* 2007: LBA1 ASCO, Plenary Session. Chicago 2007
- Lemmer E, Chen Y, Yea S, Wurmbach E, Schwartz M, Khitrov G, Villanueva A, Narla G, Waxman S, Friedman SL, **Llovet JM**. Hedgehog pathway signaling is upregulated in a subgroup of human hepatitis C virus-associated hepatocellular carcinomas. 41th Meeting of the *European Asociation for the Study of the Liver (EASL)*. Viena, April 26-30, 2006.
- Villanueva A, Peix J, Newell P, Di Feo A, Van Laarhoven S¹ Lemmer E , Fiel MI, Thung S, Yea S, Roayaie , Schwartz M, Martignetti JA, Friedman SL, **Llovet JM**. Molecular combined therapy in hepatocellular carcinoma with a EGFR/Her2/VEGFR RTK inhibitor (AEE788) and an mTOR inhibitor (RAD001, everolimus). Results in vitro and in vivo with tumor xenografts. *American Association for Cancer Research annual meeting. Los Angeles, April 2007*
- Villanueva A, Peix J, Van Laarhoven S, Di Feo A, Chen Y, Lemmer E , Fiel MI, Thung S, Yea S, Roayaie S, Schwartz M, Friedman SL, **Llovet JM**. Targeted molecular combined therapy of hepatocellular carcinoma with a dual tyrosine kinase receptor inhibitor (AEE788) and an mTOR inhibitor (RAD001, everolimus). *AASLD*, Boston, October 2006
- Lemmer ER, Villanueva A, Yea S, Van Laarhoven S, Di Feo A, Peix J, Schwartz M, Narla G, Martignetti J, Waxman S, Friedman SL, **Llovet JM**. Blockade of Hedgehog Pathway signaling inhibits growth of human hepatocellular carcinoma cell lines. *CNIO Meeting on molecular markers*, Madrid, November 2006.
- Villanueva A, Peix J, Di Feo A, Lemmer E , Van Laarhoven S, Fiel MI, Thung S, Yea S, Roayaie S, Chen Y, Schwartz M, Martignetti J, Friedman SL, **Llovet JM**. Activation of PI3k/Akt pathway in hepatocellular carcinoma and its abrogation with a novel tyrosine kinase inhibitor (AEE788) and an mTOR inhibitor (RAD001, everolimus). *CNIO Meeting on molecular markers*, Madrid, November 2006.
- Victoria Tovar, Clara Alsinet, Manel Solé, Augusto Villanueva, Derek Chiang, Laia Cabellos, Adriana Lázaro, Myron Schwartz, Vincenzo Mazzaferro, Jordi Bruix, **Jospe M. Llovet**. Relevance of IGF signaling pathway in human hepatocellular carcinoma, and pre-clinical assessment of novel targeted therapies. 58th Annual Meeting of the *AASLD 2007*. Boston (USA). 2-6 November 2007.

- Villanueva A, Newell P, Peix J, Di Feo A, Van Laarhoven S, Thung S, Fiel MI, Yea S, Roayaie S, Schwartz M, Martignetti JA, Friedman SL, **Llovet JM**. Molecular combined therapy in hepatocellular carcinoma (HCC) with AEE788 (EGFR/Her2/VEGFR inhibitor) and RAD001, everolimus (mTOR inhibitor): Antineoplastic activity in a xenograft model of HCC. 58th Annual Meeting of the AASLD 2007. Boston (USA). 2-6 November 2007
- Villanueva A, Chiang DY, Newell P, Peix J, Hoshida Y, Van Laarhoven S, Thung S, Roayaie S, Alsinet C, Tovar V, Fiel MI, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Golub TR, Friedman SL, Meyerson M, **Llovet JM**. Activation status of PI3K/Akt/mTOR pathway in hepatocellular carcinoma (HCC): Oncogenic role and clinical implications Rictor (mTOR Complex 2). 58th Annual Meeting of the AASLD 2007. Boston (USA). 2-6 November 2007.
- Derek Y. Chiang, Augusto Villanueva, Judit Peix, Philippa Newell, Elisa Wurmbach, Diana Donovan, Rameen Berouhkim, Gad Getz, Myron Schwartz, Sasan Roayaie, Vincenzo Mazzaferro, Jordi Bruix, Samuel Waxman, Scott Friedman, Massimo Loda, Azra H. Ligon, Matthew Meyerson, **Josep M. Llovet**. Integrative genomic classification of hepatitis C virus positive hepatocellular carcinomas. 58th Annual Meeting of the AASLD 2007. Boston (USA). 2-6 November 2007.
- Newell P, Villanueva A, Peix J, Chen Y, Di Feo A, Van Laarhoven S, Lemmer ER, Fiel MI, Thung S, Yea S, Roayaie S, Schwartz M, Martignetti J, Friedman SL, **Llovet JM**. Exploiting the Multiple Mechanisms of Sorafenib: Tumor Growth Inhibition with a Novel Combination of Sorafenib and Rapamycin targeting both Ras and mTOR Pathways. 58th Annual Meeting of the AASLD 2007. Boston (USA). 2-6 November 2007.
- Newell P, Villanueva A, Chiang D, Peix J, Van Laarhoven S, Thung S, Fiel MI, Yea S, Roayaie S, Schwartz M, Kahn M, Friedman SL, **Llovet JM**. Activation of the Wnt/ β -catenin pathway in hepatocellular carcinoma, and *in vitro* growth inhibition with novel small molecule ICG-001. 58th Annual Meeting of the AASLD 2007. Boston (USA). 2-6 November 2007.
- Villanueva A, Newell P, Peix J, Di Feo A, Van Laarhoven S, Thung S, Fiel MI, Yea S, Roayaie S, Schwartz M, Martignetti JA, Friedman SL, **Llovet JM**. Molecular combined therapy in hepatocellular carcinoma with AEE788 (EGFR/Her2/VEGFR inhibitor) and RAD001, everolimus (mTOR inhibitor). 1st Annual Meeting of the International Liver Cancer Association (ILCA). Barcelona (Spain). 5-7 October 2007.
- Villanueva A, Chiang DY, Newell P, Peix J, Hoshida Y, Van Laarhoven S, Thung S, Roayaie S, Fiel MI, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Golub TR, Friedman SL, Meyerson M, **Llovet JM**. Integrative genomic analysis of PI3K/Akt/mTOR pathway in hepatocellular carcinoma: clinical outcome implications. 1st Annual Meeting of the International Liver Cancer Association (ILCA). Barcelona (Spain). 5-7 October 2007.
- Victoria Tovar, Clara Alsinet, Manel Solé, Laia Cabellos, Adriana Lázaro, Augusto Villanueva, Myron Schwartz, Vincenzo Mazzaferro, Jordi Bruix, **Josep M. Llovet**. Role of Insulin-like growth factor signaling pathway in hepatocellular carcinoma. Molecular targeted therapies blocking IGF pathway. 1st Annual Meeting of the International Liver Cancer Association (ILCA). Barcelona (Spain). 5-7 October 2007.
- Newell P, Villanueva A, Chiang DY, Peix J, Van Laarhoven S, Thung S, Fiel MI, Yea S, Roayaie S, Schwartz M, Friedman SL, **Llovet JM**. Activation of the Wnt/ β -catenin pathway in hepatocellular carcinoma, and *in vitro* growth inhibition with novel small molecule ICG-001. 1st Annual Meeting of the International Liver Cancer Association (ILCA). Barcelona (Spain). 5-7 October 2007
- Yujin Hoshida, Augusto Villanueva, Masahiro Kobayashi, Derek Chiang, Amy Camargo, Supriya Gupta, Jamie Moore, Matthew J. Wrobel, Jim Lerner, Michael Reich, Kenji Ikeda, Masashi Hashimoto, Goro Watanabe, Sasan Roayaie, Myron Schwartz, Swan Thung, Stacey Gabriel, Vincenzo Mazzaferro, Jordi Bruix, Scott Friedman, Hiromitsu Kumada, **Josep M Llovet**. Survival gene signature for hepatocellular carcinoma (HCC) from high-throughput profiling of informative transcriptome in archived paraffin-embedded tissue. 1st Annual Meeting of the International Liver Cancer Association (ILCA). Barcelona (Spain). 5-7 October 2007.
- **Llovet JM**, Peña C, Shan M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Presidential Plenary, AASLD 59th Annual Meeting, San Francisco. 2008.
- Chiang D, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, Thung S, Sole M, Tovar

V, Alsinet C, Roayaie S, Schwartz M, Bruix J, Battiston C, Mazzaferro V, Friedman S, Meyerson M, **Llovet JM**. A novel molecular classification of HCV-related hepatocellular carcinoma (HCC) based on integrative genomic analysis. *43rd Meeting of the European Association for the Study of the Liver (EASL). Milan (Italy), April 23-27, 2008. Journal of Hepatology 2008;48 (Suppl 2): S12. (Oral)*

- Newell P, Villanueva A, Chiang D, Lim KH, Cabellos L, Toffanin S, Fiel MI, Thung S, Hoshida Y, Minguez B, Peix J, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman S, **Llovet JM**. Hepatocellular carcinoma with progenitor cell features: clinical and biological characterization. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.9, O-007 (General session).*
- Hoshida Y, Nijman S, Kobayashi M, Chan JA, Brunet J, Chiang D, Villanueva A, Newell P, Hashimoto M, Ikeda K, Watanabe G, Friedman S, Kumada H, **Llovet JM**, Golub T. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.9, O-008 (General session).*
- Toffanin S, Hoshida Y, Lu J, Villanueva A, Chiang D, Minguez B, Newell P, Peix J, Cabellos L, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, Golub T, **Llovet JM**. Mirna-based molecular classification of hepatocellular carcinoma. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.9-10, O-010 (General session).*
- Raoul J, Bolondi L, Craxi A, Moscovici M, Shan M, Voliotis D, Bruix J, **Llovet JM**. Determining the impact of Macroscopic Vascular Invasion (MVI), Extrahepatic Spread (EHS), and ECOG Performance Status (PS) on sorafenib safety and efficacy in patients with advanced hepatocellular carcinoma (HCC): sharp trial subset analyses. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.11, O-014 (General session).*
- Minguez B, Hoshida Y, Villanueva A, Toffanin S, Newell P, Cabellos L, Roayaie S, Schwartz M, Thung S, Mazzaferro V, Bruix J, Friedman S, Golub T, **Llovet JM**. A gene signature enables to discriminate vascular invasion in patients with hepatocellular carcinoma. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.13, O-020 (General session).*
- Newell P, Toffanin S, Villanueva A, Lim KH, Melgar P, Chiang D, Peix J, Deniz K, Alsinet C, Cabellos L, Minguez B, Tovar V, Fiel MI, Thung S, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Meyerson M, Friedman S, **Llovet JM**. Ras pathway activation in hepatocellular carcinoma and enhanced tumor necrosis in a xenograft HCC model with sorafenib and rapamycin. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.21, P-011 (Poster).*
- Chiang D, Cozza A, Minguez B, Villanueva A, Newell P, Peix J, Hoshida J, Thung S, Sole M, Tovar V, Alsinet C, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman S, Meyerson M, **Llovet JM**. Vegfa amplification is a common occurrence in hepatocellular carcinoma. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.23, P-018 (Poster).*
- Tovar V, Alsinet C, Villanueva A, Peix J, Chiang D, Sole M, Thung S, Moyano S, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. Role of IGF axis in early hepatocellular carcinoma: IGF-1R as therapeutic target. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.31, P-040 (Poster).*
- Forner A, Boix L, Sole M, Reig ME, Rodriguez-Lope C, Vilana R, Bianchi L, **Llovet JM**, Bruix J. Role of alpha-fetoprotein, glypican-3 and VEGF-alpha in the diagnosis of hepatocellular carcinoma in nodules smaller than 20 mm. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008; p.46, P-046 (Poster).*
- Reig ME, Forner A, Rimola J, Ayuso C, Boix L, Rodriguez-Lope C, Godoy A, **Llovet JM**, Bruix J. Applicability of sorafenib for the treatment of advanced hepatocellular carcinoma in the conventional clinical practice. *2nd Annual Meeting of the International Liver Cancer*

Association (ILCA). Chicago (USA). 5-7 September 2008. *Book of Abstracts ILCA 2008*; p.56, P-137 (Poster).

- Roayaie S, Bassi D, Labow D, **Llovet JM**, Schwartz M. Repeat hepatectomy for recurrent hepatocellular carcinoma. *2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008*; p.59, P-148 (Poster).
- Ferrer J, Fuster J, Garcia-Valdecasas JC, Sala M, **Llovet JM**, Fondevila C, Calatayud D, Taura P, Sole M, Bruix J. *Measurement of portal hypertension as a selection criteria guarantees good results in liver resection for hepatocellular carcinoma in cirrhosis. 2nd Annual Meeting of the International Liver Cancer Association (ILCA). Chicago (USA). 5-7 September 2008. Book of Abstracts ILCA 2008*; p.62, P-161 (Poster)
- **Llovet JM**, Peña C, Shan M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. *Presidential Plenary. 59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):1-219A. (Presidential Plenary)*
- Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Newell P, Roayaie S, Schwartz M, Thung S, Mazzaferro V, Bruix J, Friedman S, Golub T, **Llovet JM**. Molecular gene signature to identify vascular invasion in hepatocellular carcinoma. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):386A. (Poster)*
- Newell P, Toffanin S, Villanueva A, Chiang D, Cabellos L, Lim K, Melgar Lesmes P, Yea S, Peix J, Deniz K, Thung S, Alsinet C, Minguez B, Tovar V, Hoshida Y, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman S, **Llovet JM**. Mechanisms of RAS pathway in HCC patients, and combination therapies blocking RAS (sorafenib) and mTOR pathways (rapamycin) in vivo. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):983A. (Poster)*
- Tarocchi M, Narla G, Villanueva A, **Llovet JM**, Friedman S. Reduced KLF6 expression correlates with poor prognosis in human hepatocellular carcinoma (HCC), and enhanced chemical carcinogenesis in KLF6 +/- MICE. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):386A. (Poster)*
- Loughlin E, Villanueva A, Chiang D, Newell P, Fiel MI, Allina J, Unkeless J, **Llovet JM**, Odin JA. Expression of the PTEN-associated kinase, MAST2, is significantly increased in human hepatocellular carcinomas. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):947A. (Poster)*
- Hoshida Y, Nijman S, Kobayashi M, Chan J, Brunet JP, Chiang D, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Friedman S, Kumada H, **Llovet JM**, Golub T. Common molecular subclasses of hepatocellular carcinoma identified by meta-analysis of transcriptome data. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):1110A. (Poster)*
- Villanueva A, Newell P, Chiang D, Lim K, Cabellos L, Toffanin S, Fiel MI, Thung S, Hoshida Y, Minguez B, Peix J, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman S, **Llovet JM**. Molecular and clinical characterization of hepatocellular carcinoma with progenitor cell markers. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):85A. (Oral)*
- Toffanin S, Hoshida Y, Lu J, Villanueva A, Chiang D, Minguez B, Newell P, Cabellos L, Roayaie S, Bruix J, Schwartz M, Mazzaferro V, Friedman S, Golub T, **Llovet JM**. miRNA expression profiles reveals a novel subclass of hepatocellular carcinoma. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):97A. (Oral)*
- Reig ME, Forner A, Rimola J, Ayuso C, Rodríguez de Lope C, **Llovet JM**, Bruix J. Applicability and safety of sorafenib for the treatment of advanced hepatocellular carcinoma in the conventional clinical practice. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):963A. (Poster)*
- Craxi A, Porta C, Sangiovanni A, Shan M, Nadel A, Voliotis D, Bruix J, **Llovet JM**, Sorafenib for the treatment of alcohol-related hepatocellular carcinoma (HCC): subanalysis of the phase III SHARP trial. *59th Annual Meeting of the AASLD 2008. San Francisco (USA). Oct 31-Nov 4 2008. Hepatology 2008:48 (Suppl):971A. (Poster)*

- Bruix J, Raoul JL, Sherman M, Shan M, Lentini G, Nadel A, Voliotis D, **Llovet JM**. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage. *44th Meeting of the European Association for the Study of the Liver (EASL). Copenhagen (Denmark), April 22-26, 2009. Journal of Hepatology 2009;50 (Suppl 1): S28-29. (Oral)*
- Villanueva A, Cornella H, Tovar V, Alsinet C, Chiang D, Peix J, Minguez B, Toffanin S, Savic R, Hoshida Y, Lachenmayer A, Thung S, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, **Llovet JM**. Molecular and clinical characterization of RICTOR (mTORC2) as a candidate oncogene in hepatocellular carcinoma. *44th Meeting of the European Association for the Study of the Liver (EASL). Copenhagen (Denmark), April 22-26, 2009. Journal of Hepatology 2009;50 (Suppl 1): S45. (Parallel session)*
- Reig M, Rimola J, Forner A, Rodriguez de Lope C, **Llovet JM**, Ayuso C, Bruix J. Evaluation of tumor perfusion at computed tomography as a tool to detect the effect of sorafenib treatment in patients with hepatocellular carcinoma (HCC). *44th Meeting of the European Association for the Study of the Liver (EASL). Copenhagen (Denmark), April 22-26, 2009. Journal of Hepatology 2009;50 (Suppl 1): S297-298. (Poster)*
- Reig M, Forner A, Rimola J, Rodriguez de Lope C, Ayuso C, **Llovet JM**, Bruix J. Sorafenib for the treatment of advanced hepatocellular carcinoma. Feasibility and safety outside research trials. *44th Meeting of the European Association for the Study of the Liver (EASL). Copenhagen (Denmark), April 22-26, 2009. Journal of Hepatology 2009;50 (Suppl 1): S298. (Poster)*
- Toffanin S, Lachenmayer A, Hoshida Y, Cabellos L, Lu J, Villanueva A, Chiang D, Minguez B, Savic R, Roayaie S, Bruix J, Schwartz M, Mazzaferro V, Waxman S, Friedman S, Golub T, **Llovet JM**. MicroRNA (miRNA) expression profiles define a new molecular subclass of hepatocellular carcinoma. *3rd Annual Meeting of the International Liver Cancer Association (ILCA). Milan (Italy). 4-6 September 2009. Book of Abstracts ILCA 2009; p.7, O-003 (General session).*
- Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Gould J, Gupta S, Gabriel S, Peix J, Colombo M, **Llovet JM**, Golub T. Gene-expression signature predicts development of hepatocellular carcinoma and survival in cirrhotic patients. *3rd Annual Meeting of the International Liver Cancer Association (ILCA). Milan (Italy). 4-6 September 2009. Book of Abstracts ILCA 2009; p.13, O-020 (General session).*
- Villanueva A, Cornella H, Tovar V, Hoshida Y, Alsinet C, Chiang D, Peix J, Sia D, Toffanin S, Minguez B, Savic R, Lachenmayer A, Thung S, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, **Llovet JM**. Identification of mTOR complex 2 (RICTOR) as a potential new molecular target in hepatocellular carcinoma. *3rd Annual Meeting of the International Liver Cancer Association (ILCA). Milan (Italy). 4-6 September 2009. Book of Abstracts ILCA 2009; p.21, P-011 (Poster).*
- Tovar V, Alsinet C, Peix J, Villanueva A, Sia D, Cornella H, Moyano S, Solè M, **Llovet JM**. Novel molecular therapy for hepatocellular carcinoma with a potent multi-tyrosine kinase inhibitor against IGF-1R and Aurora A-B: experimental data. *3rd Annual Meeting of the International Liver Cancer Association (ILCA). Milan (Italy). 4-6 September 2009. Book of Abstracts ILCA 2009; p.30, P-049 (Poster).*
- Reig M, Forner A, Rimola J, Rodriguez de Lope C, Ayuso C, **Llovet JM**, Bruix J. Sorafenib for advanced hepatocellular carcinoma (HCC): Analysis and timing of dose adjustments/treatment interruptions. *3rd Annual Meeting of the International Liver Cancer Association (ILCA). Milan (Italy). 4-6 September 2009. Book of Abstracts ILCA 2009; p.59, P-169 (Poster).*
- Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Gould J, Gupta S, Gabriel S, Peix J, Colombo M, **Llovet JM**, Golub T. Gene-expression signature predicts outcome of liver cirrhosis. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):67A. (Parallel session)*
- Toffanin S, Lachenmayer A, Hoshida Y, Cabellos L, Lu J, Villanueva A, Chiang D, Minguez B, Savic R, Roayaie S, Bruix J, Schwartz M, Mazzaferro V, Waxman S, Friedman S, Golub T, **Llovet JM**. Identification of potential oncogenic micrornas in a molecular subclass of hepatocellular carcinoma. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):78A. (Plenary session)*

- Toracchi M, Lee U, Hannivoort R, Loke J, Narla G, Villanueva A, **Llovet JM**, Friedman S. KLF6 deficiency promotes hepatocellular carcinoma in mice and humans by increasing MDM2 expression and accelerating P53 degradation. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):87A.* (Parallel session).
- Minguez B, Toffanin S, Lachenmayer A, Cabellos L, Difeo A, Melgar-Lesmes P, Savic R, Thung S, Friedman S, **Llovet JM**. Sustained activation of WNT/beta-catenin pathway as a mechanism behind spontaneous hepatocellular carcinoma in FXR knockout mice. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):219A.* (Oral).
- Savic R, Newell P, Villanueva A, Toffanin S, Hoshida Y, Chiang D, Cabellos L, Minguez B, Lachenmayer A, Cornella H, Tovar V, Alsinet C, Peix J, Thung S, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, **Llovet JM**. WNT pathway activation in hepatocellular carcinoma- identification of the WNT co-activator PYGO2 as a candidate oncogene. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):234A.* (Oral).
- Mudbhary R, Villanueva A, Krahn K, **Llovet JM**, Sadler K. UHRF1 is upregulated in hepatocellular carcinoma and regulates the expression of interferon genes. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):916A.* (Poster).
- Reig ME, Forner A, Rodríguez de Lope C, Rimola J, Ayuso C, Mestres C, **Llovet JM**, Bruix J. Emergence of adverse cardiovascular events after long term sorafenib treatment for advanced hepatocellular carcinoma (HCC). *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):1080A.* (Poster).
- Lachenmayer A, Hoshida J, Toffanin S, Lu J, Minguez B, Cabellos L, Chiang D, Bruix J, Schwartz M, Roayaie S, Villanueva A, Savic R, Mazzaferro V, Friedman S, **Llovet JM**. Genome-wide DNA methylation profiling in hepatitis C-related hepatocellular carcinoma. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):1087A.* (Poster).
- Reig ME, Rimola J, Forner A, Rodríguez de Lope C, Ayuso C, **Llovet JM**, Bruix J. Assessment of tumor perfusion by perfusion CT is able to register treatment efficacy and predict tumor progression in patients with advanced hepatocellular carcinoma treated with sorafenib. Differences between responding and non responding patients undergoing sorafenib therapy. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3 2009. Hepatology 2009;50 (Suppl):1091A.* (Poster).
- Villanueva A, Cornella H, Tovar V, Hoshida Y, Alsinet C, Chiang D, Peix J, Minguez B, Sia D, Toffanin S, Savic R, Lachenmayer A, Thung S, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, **Llovet JM**. Activation of mTOR complex 2 in hepatocellular carcinoma: in vitro evaluation as a novel therapeutic target. *60th Annual Meeting of the AASLD 2009. Boston (USA). Oct 30-Nov 3, 2009. Hepatology 2009;50 (Suppl):1138A.* (Poster).
- Villanueva A, Hoshida Y, Tovar V, Sia D, Cornella H, Alsinet C, Peix J, Roayaie S, Thung S, Bruix J, Schwartz M, Mazzaferro V, **Llovet JM**. Genome-based modeling prognosis in hepatocellular carcinoma: proliferation-G3 and adjacent poor signatures independently predict recurrence. *45th Meeting of the European Association for the Study of the Liver (EASL). Vienna (Austria), April 14-18, 2010. Journal of Hepatology 2010;52 (Suppl 1): S54.* (Oral).
- Reig M, Forner A, Rodríguez de Lope C, Rimola J, Tremosini S, Mestres C, Ayuso C, **Llovet JM**, Bruix J. Efficacy and safety of sorafenib at long term in patients with hepatocellular carcinoma (HCC): need to screen for cardiovascular events after long term administration. *45th Meeting of the European Association for the Study of the Liver (EASL). Vienna (Austria), April 14-18, 2010. Journal of Hepatology 2010;52 (Suppl 1): S95.* (Poster).
- Reig M, Rimola J, Forner A, Rodríguez de Lope C, Tremosini S, Ayuso C, **Llovet JM**, Bruix J. Changes in tumor blood volume and perfusion assessed perfusion computed tomography predict the timing of tumor progression in patients with hepatocellular carcinoma treated with sorafenib. *45th Meeting of the European Association for the Study of the Liver (EASL). Vienna (Austria), April 14-18, 2010. Journal of Hepatology 2010;52 (Suppl 1): S96.* (Poster).

- Mínguez B, Toffanin S, Lachenmayer A, Cabellos L, Villanueva A, Difeo A, Melgar-Lesmes P, Thung S, Friedman S, **Llovet JM**. Combination therapy with EGFR1/VEGFR inhibitor (XL647) and sorafenib improves outcomes in a pre-clinical model of HCC. *45th Meeting of the European Association for the Study of the Liver (EASL). Vienna (Austria), April 14-18, 2010. Journal of Hepatology 2010;52 (Suppl 1): S343 (Poster).*
- Savic R, Toffanin S, Lachenmayer A, Minguez B, Cabellos L, Thung S, Ward S., Alsinet C, Villanueva A, Hoshida Y, Roayaie S, Schwartz M, Friedman S, **Llovet JM**. Sorafenib modulates WNT signaling in liver cancer. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.7, O-004 (General session).*
- Reig M, Rodriguez de Lope C, Forner A, Rimola J, Lopez JM, Tremosini S, Ayuso C, **Llovet JM**, Boix L, Bruix J. Biomarker profiling in patients with hepatocellular carcinoma (HCC) treated with sorafenib. outcome prediction and impact of early treatment interruption. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.8, O-007 (General session).*
- Lachenmayer A, Toffanin S, Cabellos L, Minguez B, Savic R, Alsinet C, Hoshida Y, Villanueva A, Friedman S, **Llovet JM**. Combination therapy of the histone deacetylase inhibitor panobinostat with sorafenib shows synergistic pre-clinical efficacy in HCC. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.9, O-010 (General session).*
- Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung S, Bruix J, Roayaie S, Schwartz M, Mazzaferro V, Golub T, **Llovet JM**. Modeling prognosis in early hepatocellular carcinoma using genomic profiling. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.12, O-016 (General session).*
- Raoul J-L, Sherman M, Nadel A, Lentini G, Moscovici M, Voliotis D, Meinhardt G, Bruix J, **Llovet JM**. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): subgroup analyses of the sharp trial by baseline transaminase (ALT/AST)/alpha-fetoprotein (AFP) and bilirubin levels. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.19, P-001 (Top scored posters).*
- Tovar V, Cornellà H, Hoshida Y, Toffanin S, Villanueva A, Sia D, Peix J, Lachenmayer A, Alsinet C, Solé M, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. Role of fibroblast growth factor signaling in human hepatocellular carcinoma. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.25, P-022 (Poster).*
- Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward S, Thung S, Chiang D, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman S, Golub T, Mazzaferro V, **Llovet JM**. Oncogenic role of novel microRNAs in hepatocellular carcinoma. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.27, P-029 (Poster).*
- Mínguez B, Toffanin S, Lachenmayer A, Cabellos L, DiFeo A, Thung S, Friedman S, **Llovet JM**. Combination therapy with xl647 (EGFR/HER2NU/VEGFR inhibitor) improves sorafenib outcomes in a pre-clinical model of HCC. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada (USA). 10-12 September 2010. Book of Abstracts ILCA 2010; p.36, P-060 (Poster).*
- Reig M, Rimola J, Forner A, Rodriguez de Lope C, Tremosini S, Ayuso C, **Llovet JM**, Bruix J. Perfusion-CT for the assessment of treatment efficacy in patients with hepatocellular carcinoma treated with sorafenib. *4th Annual Meeting of the International Liver Cancer Association (ILCA). Canada. 10-12 September 2010. Book of Abstracts ILCA 2010; p.52, P-118 (Poster).*
- Lachenmayer A, Hoshida Y, Toffanin S, Minguez B, Savic R, Cabellos L, Chiang D, Bruix J, Schwartz M, Roayaie S, Villanueva A, Mazzaferro V, Friedman S, **Llovet JM**. DNA hypermethylation subclass of hepatocellular carcinoma associated with aggressive phenotype. *61th Annual Meeting of the AASLD 2010. Boston (USA). Oct 29-Nov 2, 2010. Hepatology 2010;52 (Suppl):68A. (Parallel session).*

- Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Peix J, Solé M, Tovar V, Cornella H, Alsinet C, Pellegrinelli A, Cotsoglou C, Molino E, Citterio D, Lachenmayer A, Thung S, Fuster J, García-Valdecasas JC, Bruix J, Schwartz M, Mazzaferro V, **Llovet JM**. Molecular classification of human intrahepatic cholangiocarcinoma defines two classes with distinct biology and outcome. *61th Annual Meeting of the AASLD 2010. Boston (USA). Oct 29-Nov 2, 2010. Hepatology 2010:52 (Suppl):88A. (Plenary session).*
- Villanueva A, Zong Y, Hoshida Y, Yanger K, Cabellos L, Thung S, Stanger B, **Llovet JM**. Genomic and functional characterization of NOTCH as an oncogenic driver in liver. *61th Annual Meeting of the AASLD 2010. Boston (USA). Oct 29-Nov 2, 2010. Hepatology 2010:52 (Suppl):91A. (Plenary session).*
- Roayaie S, **Llovet JM**, Obeidat K, Labow D, Sposito C, Pellegrini A, Schwartz M, Mazzaferro V, Hepatic resection for HCC<=2cm. *61th Annual Meeting of the AASLD 2010. Boston (USA). Oct 29-Nov 2, 2010. Hepatology 2010:52 (Suppl):91A. (Poster).*
- Ferrer J, Sposito C, Fuster J, Forner A, Bruix J, **Llovet JM**, Navasa M, Rimola J, Taurà P, Fondevila C, Martí M, García-Valdecasas JC, Should indications for liver transplantation be expanded in patients with hepatocellular carcinoma? Lessons learned from a retrospective analysis of tumor characteristics beyond milan criteria. *61th Annual Meeting of the AASLD 2010. Boston (USA). Oct 29-Nov 2, 2010. Hepatology 2010:52 (Suppl):1141A. (Poster).*
- Reig ME, Rimola J, Forner A, Rodríguez de Lope, Tremosini S, Ayuso C, **Llovet JM**, Bruix J. Perfusion-CT changes as tool for assessing treatment efficacy in patients with hepatocellular carcinoma treated with sorafenib. *61th Annual Meeting of the AASLD 2010. Boston (USA). Oct 29-Nov 2, 2010. Hepatology 2010:52 (Suppl):1159A. (Poster).*
- Tovar V, Cornellà H, Hoshida Y, Toffanin S, Villanueva A, Sia D, Peix J, Lachenmayer A, Alsinet C, Solé M, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. Dysregulation of fibroblast growth factor network in early hepatocellular carcinoma. *46th Annual Meeting of the European Association for the Study of the Liver (EASL). Berlin (Germany). March 30-April 3 2011. Journal of Hepatology 2011:54 (Suppl 1):S58-59 (Oral)*
- Reig ME, Boix L, Forner A, Rimola J, Rodríguez de Lope C, Lopez-Oliva JM, Tremosini S, Llach N, **Llovet JM**, Ayuso C, Bruix J. Serum carbonic anhydrase 9 (CA) is a valuable biomarker (BM) to profile patients with hepatocellular carcinoma (HCC) treated with sorafenib and predict their outcome. *46th Annual Meeting of the European Association for the Study of the Liver (EASL). Berlin (Germany). March 30-April 3 2011. Journal of Hepatology 2011:54 (Suppl 1):S260-61 (Poster)*
- Roayaie S, Jibara G, **Llovet JM**, Labow D, Schwartz M. Resection of hepatocellular cancer (HCC) with macroscopic vascular invasion (MVI). *46th Annual Meeting of the European Association for the Study of the Liver (EASL). Berlin (Germany). March 30-April 3 2011. Journal of Hepatology 2011:54 (Suppl 1):S261 (Poster)*
- Forner A, Rimola J, Tremosini S, Reig M, Rodríguez de Lope C, Vilana R, **Llovet JM**, Ayuso C, Bruix J. Atypical patterns of HCC on MRI. Analysis of fat, capsule and signal intensity. *46th Annual Meeting of the European Association for the Study of the Liver (EASL). Berlin (Germany). March 30-April 3 2011. Journal of Hepatology 2011:54 (Suppl 1):S386 (Poster)*
- Tremosini S, Forner A, Boix L, Rimola J, Rodríguez de Lope C, Reig M, Bianchi L, **Llovet JM**, Vilana R, Ayuso C, Solé M, Bruix J. Diagnosis of hepatocellular carcinoma (HCC) ≤2 cm: prospective validation of glypican 3, heat-shock protein 70 and glutamine synthetase staining in biopsy samples. *46th Annual Meeting of the European Association for the Study of the Liver (EASL). Berlin (Germany). March 30-April 3 2011. Journal of Hepatology 2011:54 (Suppl 1):S404 (Poster)*
- Reig M, Boix L, Forner A, Rimola J, Rodríguez de Lope C, Lopez-Oliva JM, Tremosini S, Llach N, **Llovet JM**, Ayuso C, Bruix J. Los niveles séricos de anhidrasa carbónica 9 (AC9) predicen el pronóstico de los pacientes con carcinoma hepatocelular tratados con sorafenib. *XVI Congreso Argentino de Hepatología. Buenos Aires (Argentina). 9-11 June 2011.(Oral)*
- Reig M, Burrel M, Forner A, Barrufet M, Rodríguez de Lope C, Varela M, Tremosini S, **Llovet JM**, Real MI, Bruix J. Resultados actuales de la quimioembolización en pacientes con carcinoma hepatocelular. Impacto en práctica clínica e investigación. *XVI Congreso Argentino de Hepatología. Buenos Aires (Argentina). 9-11 June 2011.(Oral).*

- Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Peix J, Sole M, Tovar V, Cornella H, Alsinet C, Pellegrinelli A, Cotsoglou C, Molino E, Citterio D, Lachenmayer A, Thung S, Fuster J, Garcia-Valdecasas JC, Bruix J, Schwartz M, Mazzaferro V, **Llovet JM**. Molecular characterization of human intrahepatic cholangiocarcinoma in two distinct subclasses. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Tovar V, Cornella H, Villanueva A, Sia D, Peix J, Secanell S, Sole M, **Llovet JM**. FGF signalling is involved in acquired resistance to sorafenib in an in-vivo model of hepatocellular carcinoma. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Tremosini S, Forner A, Boix L, Rimola J, Rodriguez de Lope C, Reig M, Bianchi L, **Llovet JM**, Vilana R, Ayuso C, Sole M, Bruix J. Biopsy diagnosis of hepatocellular carcinoma (HCC) <2 cm: prospective validation of glypican 3, heat-shock protein 70 and glutamine synthetase staining in fine needle biopsy samples. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Roayaie S, Jibara G, Labow D, **Llovet JM**, Schwartz M. Resection of hepatocellular cancer (HCC) with macroscopic vascular invasion (MVI). *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Villanueva A, Zong Y, Alsinet C, Hoshida Y, Sole M, Rodriguez-Carunchio L, Toffanin S, Peix J, Yanger K, Cabellos L, Thung S, Stanger B, **Llovet JM**. Notch signalling as an oncogenic driver in liver cancer. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Reig M, Boix L, Forner A, Rimola J, Rodríguez-Lope C, Lopez-Oliva JM, Llarch N, **Llovet JM**, Ayuso C, Bruix J. Serum carbonic anhydrase 9 (CA9) is a valuable biomarker (BM) to predict the outcome patients with hepatocellular carcinoma (HCC) treated with sorafenib. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Burrel M, Reig M, Barrufet M, Rodríguez de Lope C, Forner A, Llovet JM, Real MI, Bruix J. Survival after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) in 2010. Need to update assumptions for clinical practice and research. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Lachenmayer A, Alsinet C, Toffanin S, Cabellos L, Minguez B, Tsai HW, Hoshida Y, Villanueva A, Friedman S, **Llovet JM**. Overexpression of histone deacetylases in hepatocellular carcinoma, and effect of the HDAC inhibitor panobinostat. *5th Annual Meeting of the International Liver Cancer Association (ILCA). Hong Kong (China). 2-4 September 2011.*
- Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Barretina J, Newell P, Tsai H, Thung SN, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman S, Llovet JM. Wnt-pathway in HCC: characterization of 2 distinct human HCC classes and experimental evidence of signaling blockage by sorafenib. *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.* (Parallel Session).
- Sia D, Hoshida Y, Villanueva A, Ferrer J, Roayaie S, Tabak B, Peix J, Sole M, Tovar V, Cornella H, Alsinet C, Pellegrinelli A, Cotsoglou C, Lachenmayer A, Thung SN, Fuster J, Garcia-Valdecasas J, Bruix J, Schwartz ME, Beroukhi R, Mazzaferro V, Llovet JM. Genomic portrait of two human intrahepatic cholangiocarcinoma classes with distinct outcome. *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.* (Parallel Session)
- Llovet JM, Zucman-Rossi J. Molecular Classification and Novel Targets of HCC. Early Morning Workshops. *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.* (Oral).
- Tovar V, Cornella H, Villanueva A, Hoshida Y, Toffanin S, Sole M, Sia D, Peix J, Alsinet C, Lachenmayer A, Secanella S, Schwartz ME, Mazzaferro V, Bruix J, Llovet JM. FGF signaling dysregulation in HCC and role in the development of acquired resistance to anti-angiogenic therapies. *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.* (Poster)
- Lachenmayer A, Toffanin S, Alsinet C, Cabellos L, Minguez B, Tsai H, Hoshida Y,

- Villanueva A, Friedman SL, Llovet JM, Rationale for testing HDAC inhibitors in HCC: genomic data and pre-clinical studies with panobinostat. *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.*(Poster)
- Reig M, Boix L, Forner A, Rimola J, Rodriguez de Lope C, Lopez-Oliva JM, Tremosini S, LLarch N, Llovet JM, Ayuso C, Bruix J, Serum Carbonic Anhydrase 9 (CA9) in patients with hepatocellular carcinoma (HCC). A valuable biomarker to predict the outcome of HCC patients treated with sorafenib. *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.*(Poster)
 - Roayaie S, Jibara G, Labow D, Llovet JM, Schwartz ME, Resection of Hepatocellular Cancer (HCC) with Macroscopic Vascular Invasion (MVI). *62th Annual Meeting of the AASLD 2011. San Francisco. USA. 4-8 November 2011.*(Poster).
 - Lachenmayer A, Alsinet, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman S, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. *47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona (Spain). 18-22 April 2012. Journal of Hepatology 2012;56 (Suppl 2):S106* (Poster).
 - Wang PR, Xu M, Toffanin S, Li Y, Cornella H, Llovet JM, Russell DW. Induction of hepatocellular carcinoma by in vivo gene targeting. *47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona (Spain). 18-22 April 2012. Journal of Hepatology 2012;56 (Suppl 2):S128* (Poster).
 - Hoshida Y, Villanueva A, Sangiovanni A, Solé M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, minguez B, Iavarone M, Friedman S, Colombo M, Llovet JM, Golub T. Prognostic gene-expression signature for hepatitis C-related early-stage liver cirrhosis. *47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona (Spain). 18-22 April 2012. Journal of Hepatology 2012;56 (Suppl 2):S283* (Poster).
 - Keng V, Alsinet C, Sia D, Sarver AL, Tschida BR, Fan D, Sole M, Lee WL, Kuka TP, Moriarity B, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, **Llovet JM**, Largaespada DA. Gender bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. *6th Annual Meeting of the International Liver Cancer Association (ILCA). Berlin (Germany). 14-16 September 2012.*
 - Kojima K, Yamada S, Wei L, Fujii T, Lauwers GY, Lanuti M, Villanueva A, **Llovet JM**, Tanabe K, Fuchs BC, Hoshida Y. Pre-clinical assessment of HCC chemoprevention in cirrhotic tissue microenvironment: implication of EGF pathway. *6th Annual Meeting of the International Liver Cancer Association (ILCA). Berlin (Germany). 14-16 September 2012.*
 - Toffanin S, Cabellos L, Alsinet C, Harrington A, Cornella H, Reddy MR, Reddy EP, **Llovet JM**. Discovery of novel kinase inhibitors targeting ARK5 for the treatment of hepatocellular carcinoma. *6th Annual Meeting of the International Liver Cancer Association (ILCA). Berlin (Germany). 14-16 September 2012.*
 - Villanueva A, Hoshida Y, Du J, Kojima K, Moeini A, Zender L, Bruix J, Esteller M, Zucman-Rossi J, Mazzaferro V, Golub T, **Llovet JM** on behalf of HEPTROMIC Consortium. Kinome profiling identifies novel candidates for therapies in hepatocellular carcinoma. *6th Annual Meeting of the International Liver Cancer Association (ILCA). Berlin (Germany). 14-16 September 2012.*
 - Toffanin S, Hoshida Y, Kojima K, Villanueva A, Alsinet C, Cabellos L, Mazzaferro V, **Llovet JM**. Overexpression of snornas on the DLK-DIO3 locus defines an aggressive subclass of HCC with oncogenic activity. *6th Annual Meeting of the International Liver Cancer Association (ILCA). Berlin (Germany). 14-16 September 2012.*
 - Toffanin S, Hoshida Y, Kojima K, Villanueva A, Alsinet C, Cabellos L, Cornella H, Mazzaferro V, **Llovet JM**. Aberrant expression of DLK-DIO3 snoRNAs with oncogenic activity in a subclass of hepatocellular carcinoma with aggressive phenotype. *63rd Annual Meeting of the AASLD 2012. Boston. USA. 9-13 December 2012.*(Poster)
 - Villanueva A, Hoshida Y, Du J, Kojima K, Moeini A, Zender I, Bruix J, Esteller M, Zucman-Rossi J, Mazzaferro V, Golub T, **Llovet JM**. Identification of candidate new targets for therapies in hepatocellular carcinoma using kinome profiling. *63rd Annual Meeting of the AASLD*

2012.Boston. USA. 9-13 December 2012.(Poster)

- Toffanin S, Cabellos L, Alsinet C, Harrington AN, Cornella H, Ramana Reddy MV, Premkumar Reddy E, **Llovet JM**. Screening of novel kinase inhibitors identifies ARK5 as a novel therapeutic target for the treatment of hepatocellular carcinoma. *63rd Annual Meeting of the AASLD 2012.Boston. USA. 9-13 December 2012.(Poster)*
- S. Toffanin, L. Cabellos, H. Dong, C. Alsinet, A. Harrington, H. Cornella, R.V. Reddy, P.M. Reddy, **J.M. Llovet**. Discovery of novel kinase inhibitors for the treatment of hepatocellular carcinoma. *EASL The International Liver Congress, Amsterdam 24-28 April 2013 (Poster)*.
- M.-L. Berres, S. Toffanin, C. Aloman, **J.M. Llovet**, M. Merad. Functional role of B cells during development and progression of hepatocellular carcinoma. *EASL The International Liver Congress, Amsterdam 24-28 April 2013 (Poster)*.
- A. N. Harrington, S.Toffanin,X. Chen I.Fiel, D. Sia, H. Cornella, L. Cabellos, O. Miltiadous, S. Roayaie , Hoshida, S. Florman, M. Schwartz,**J. M. Llovet**. Evidence of Molecular Genomic Heterogeneity of Multinodular Hepatocellular Carcinoma Undergong Transplantation. *7th Annual Conference ILCA. USA. 13-15 September 2013 (Poster)*
- H. Cornella, C. Alsinet, K. Hao A. Quaglia, A. Villanueva, Y. Hoshida, N. Giam, D. M. Nagorney, W. Stephen, S. Thung, L. Rodriguez-Carunchio, A. Lachenmayer, B. Mínguez, L. R. Roberts, V.Mazzaferro, M. Schwartz, N. Heaton, **J. M. Llovet**). Molecular Classification of Human Fibrolamellar Hepatocellular Carcinoma. *7th Annual Conference ILCA. USA. 13-15 September 2013 (Oral)*
- A. Villanueva, A. Portela , S. Sayols , V. Hernandez-Gea, C. Battiston , Y. Hoshida , J. Méndez- González , L. Boix , S. Imbeaud , E. Letouzé , J. Fuster , J. Bruix , J. Zucman-Rossi , V. Mazzaferro , M. Steller , **J. M. Llovet**). A Methylation-Based Signature Predicts Survival In Hepatocellular Carcinoma Patients. *7th Annual Conference ILCA. USA. 13-15 September 2013 (Oral)*
- Chen, K.Kojima, C. Canasto- Chibuque , M. Deshmukh , A. Villanueva , A. Sangiovanni , K. Andersson, L. King, M. Kobayashi, H. Kumada, C.Hur, R.Chung, M. Colombo, **J. M. Llovet**, Hoshida Y). Clinical Development of a Liver Stromal Gene Signature for Prognostic Prediction in Liver Cirrhosis and HCC. *7th Annual Conference ILCA. USA. 13-15 September 2013 (Oral)*
- D. Sia , B. Losic, K. Revill, K. Hao, L. Cabellos, Z. Zhang Y. Hoshida, S. Roayaie, S. Thung , M. Schwartz, S. Waxman , V. Mazzaferro 3, E. Schadt , **J. M. Llovet** .Discovery of a tyrosine kinase fusion gene in intrahepatic cholangiocarcinoma. *7th Annual Conference ILCA. USA. 13-15 September 2013 (Oral)*
- K. Revill, T. Wang , A. Lachenmayer1, K. Kojima, A. Harrington , J. Li , Y. Hoshida, **J. M. Llovet**, S. Powers Genome wide methylation analysis and epigenetic unmasking reveals silenced tumor suppressor genes in hepatocellular carcinoma. *7th Annual Conference ILCA. USA. 13-15 September 2013 (Oral)*
- H. Cornella, C. Alsinet, K. Hao A. Quaglia, A. Villanueva, Y. Hoshida, N. Giam, D. M. Nagorney, W. Stephen, S. Thung, L. Rodriguez-Carunchio, A. Lachenmayer, B. Mínguez, L. R. Roberts, V.Mazzaferro, M. Schwartz, N. Heaton, **J. M. Llovet**). Molecular Classification of Human Fibrolamellar Hepatocellular Carcinoma. *AASLD , Washington Nov 1-3, 2013 (Oral)*
- Daniela Sia, Bojan Losic, Kate Revill, Ke Hao,Laia Cabellos, Zhongyang Zhang, Yujin Hoshida, Sasan Roayaie, Swan N. Thung, Myron Schwartz, Samuel Waxman, Vincenzo Mazzaferro, Eric Schadt, **Josep M.Llovet**. Discovery of a tyrosine kinase fusion gene in intrahepatic cholangiocarcinoma. *AASLD , Washington Nov 1-3, 2013 (Oral)*
- Kira Bettermann, Anita Kuldeep Mehta, Eva Lederer, Christina Ernst, Sonja M. Kessler, Xintong Chen, Yujin Hoshida, Nabeel Bardeesy, Bryan C. Fuchs, Kenneth K. Tanabe, Heimo Müller, Vendula Svendova, Michael G. Schimek, Monika Mach, Michael R. Speicher, Vineet Mahajan, Cornelia Stumptner, Andrea Thueringer, Tatjana Stojakovic, Thomas Longerich, Peter Schirmacher, Thomas M. Magin, Pavel Strnad, Claudia D. Fuchs, Michael Trauner, Rita Spika, Alexandra K. Kiemer, Andreas Teufel, Thorsten Maas, Richard Moriggl, Jean S. Campbell, Snorri S. Thorgeirsson, Jim Stauffer, Michael Karin, **Josep M Llovet**, Kurt Zatloukal, Carolin Lackner, Johannes Haybäck. Steatohepatitis-associated Hepatocellular Carcinoma: Evidence of a Keratinopathy. *64th Annual Congress AASLD 1-5 November 2013 (Poster)*

- Augusto Villanueva, Anna Portela, Sergi Sayols, Virginia Hernandez-Gea, Carlo Battiston, Yujin Hoshida, Jesus Mendez-Gonzalez, Loreto Boix, Sandrine Imbeaud, Eric Letouzé, Josep Fuster, Jordi Bruix, Jessica Zucman-Rossi, Vincenzo Mazzaferro, Manel Esteller, **Josep M Llovet**. Genome-wide methylation profiling identifies a 36-signature that predicts survival in surgically resected hepatocellular carcinoma. *64th Annual Congress AASLD 1-5 November 2013* (Poster)
- Helena Cornella, Clara Alsinet, Ke Hao, Laia Cabellos, Alberto Quaglia, Zhongyang Zhang, Xintong Chen, Augusto Villanueva, Yujin Hoshida, Nasra H. Gama, David M. Nagorney, Swan N. Thung, Stephen C. Ward, Leonardo Rodríguez-Carunchio, Anja Lachenmayer, Beatriz Minguez, Lewis R. Roberts, Vincenzo Mazzaferro, Myron Schwartz, Nigel Heaton, **Josep M. Llovet**. Integrative genomic analyses of human fibrolamellar hepatocellular carcinoma. *64th Annual Congress AASLD 1-5 November 2013* (Oral).
- H. Cornella, C. Alsinet, S. Sayols, Z. Zhang, K. Hao, L. Cabellos, A. Quaglia, A. Villanueva, Y. Hoshida, D.M. Nagorney, S. Thung, S. Ward, L. Rodriguez-Carunchio, A. Lachenmayer, B. Minguez, L.R. Roberts, V. Mazzaferro, N. Heaton, M. Esteller, **J.M. Llovet**. Gene expression-based prognostic signature and genomic characterisation of fibrolamellar hepatocellular carcinoma. *EASL International Liver Congress™ 11th April 2014, London, UK*.
- D. Sia, B. Losic, L. Cabellos, A. Moeini, K. Revill, D. Bonal, K. Hao, O. Miltiadous, Z. Zhang, Y. Hoshida, M. Castillo, S. Roayaie, S. Thung, M. Schwartz, S. Waxman, C. Cordon-Cardo, V. Mazzaferro, E. Schadt, **J.M. Llovet**. Discovery of novel mutations and fusion proteins in intrahepatic cholangiocarcinoma. *EASL International Liver Congress™ 11th April 2014, London, UK*.
- Bruix J, Takayama M, Mazzaferro, G. Chau, J. Yang, M. Kokudo, J. Cai, R. T. Poon, K. Han, W. Tak, H. Lee, T. Song, S. Roayaie, L. Bolondi, K. S. Lee, M. Makuuchi, F. Souza, M. Le Berre, G. Meinhardt, **JM Llovet**, STORM investigators. STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of HCC. Abstract 4006. *50th Annual Meeting ASCO. 30th May – 3rd June 2014* (Poster)
- Quetglas, I, Pinyol, R, Dauch, D, Portela A, Villanueva A, Zucman-Rossi J, Esteller M, Mazzaferro V, Zender L, **Llovet JM**. Igf2 is an Oncogenic Driver and Druggable Target in HCC. *ILCA 2014 Annual Conference, Kyoto Japan 5th -7th September 2014* (Oral)
- Sia, D, Harrington A N, Toffanin S, Zhang Z, Chen X, Fiel I, Hao K, Cabellos L, Hoshida Y, Florman S, Schwartz M, **Llovet JM**. Molecular Heterogeneity of Multinodular Hepatocellular Carcinoma. *ILCA 2014 Annual Conference, Kyoto, Japan 5th -7th September 2014* (Oral)
- D. Sia, A. Moeini, B. Losic, L. Cabellos, K. Revill, D. Bonal, K. Hao, O. Miltiadous, Z. Zhang, Y. Hoshida, M. Castillo, S. Roayaie, S. Thung, M. Schwartz, S. Waxman, C. Cordon-Cardo, E. Schadt, V. Mazzaferro, **J. M. Llovet**. Exome Sequencing Identifies Novel Oncogenic Mutations of Araf in Intrahepatic Cholangiocarcinoma and Provides a Genomic Portrait of The Disease. *ILCA 2014 Annual Conference, Kyoto, Japan 5th -7th September 2014* (Poster)
- Moeini A, Tovar V, Torrecilla S, Higuera M, Peix J, Quetglas IM, Rodríguez Carunchi L, Cornella H, Sole M, **Llovet JM**. Chemopreventive Efficacy of the Triple Kinase Inhibitor Nintedanib in a Mouse Model of Hepatocellular Carcinoma. *ILCA 2014 Annual Conference, Kyoto, Japan 5th -7th September 2014* (Poster)
- I.M. Quetglas, R. Pinyol, D. Dauch, A. Portela, A. Villanueva, J. Peix, M. Higuera, A. Moeini, J. Zucman-Rossi, M. Esteller, V. Mazzaferro, L. Zender, **J.M. Llovet** IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies. *26TH EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 18-21 November 2014 Barcelona* (Poster)
- V. Tovar, A. Moeini, S. Torrecilla, M. Higuera, J. Peix, I.M. Quetglas, L. Rodriguez-Carunchio, H. Cornella, M. Sole, **J.M. Llovet**. Preclinical assessment of nintedanib for chemoprevention in hepatocellular carcinoma. *26TH EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 18-21 November 2014 Barcelona* (Poster)
- Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy, Clément Meiller G, Shinde J, Datta S, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, **Llovet JM**, Zucman-Rossi J. Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. *AACR Annual Meeting 2015 Pennsylvania, Philadelphia. 18th to 22th April 2015* (Poster).

- Sia D, Losic B, Moeini A, Cabellos L, Hao K, Reville K, Bonal D, Miltiadous O, Zhongyang Z, Hoshida Y, Cornella H, Castillo M, Pinyol R, Kasai Y, Roayaie S, Thung S, Fuster J, Schwartz M, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, **Llovet JM**. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Samuel Waxman Cancer Research Foundation (SWCRF) Scientific Review Symposium, May 3-4th 2015. New York. USA (Poster)*
- **JM. Llovet**, JW Park, F Torres, T Decaens, E Boucher, JL Raoul, M Kudo, C Chang, V Boige, E Assenat, Y-K Kang, H-Y Lim, I Walters, R Lencioni. Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study. *ASCO Annual Meeting. 29th May to 2nd June 2015, Chicago USA (Poster)*
- Cheng AL, **Llovet JM**, Meinhardt G, Nakajima K, DeSanctis Y, Bruix J. Retrospective Pooled Analysis of Advanced HCC Patients in SHARP and AP Randomized Clinical Trials. *The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015). Osaka, Japan, July 3-5, 2015 (Poster)*.
- Iris Martínez-Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Judit Peix, Monica Higuera, Laia Cabellos, Victoria Tovar, Clara Alsinet, Vincenzo Mazzaferro, Jessica Zucman-Rossi, Manel Esteller, Lars Zender, **Josep M. Llovet**. Igf2 is an Oncogenic Driver in Hcc and Emerges as a Potential Target for Therapies. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Oral)*
- Victoria Tovar, Helena Cornellà, Agrin Moeini, Samuel Vidal, Yujin Hoshida, Daniela Sia, Judit Peix, Clara Alsinet, Iris M. Quetglas, Manel Solé, Josep Domingo-Domenech, Augusto Villanueva, **Josep M. Llovet**. Tumour Initiating Cells Are Mediators of Acquired Resistance to Sorafenib in Hepatocellular Carcinoma. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Oral)*
- Agrin Moeini, Daniela Sia, Hui Dong, Zhongyang Zhang, Genis Camprecios, M Isabel Fiel, Oriana Miltiadous, Xiaochen Sun, Ke Hao, Yujin Hoshida, Swan N Thung, Augusto Villanueva, Myron E Schwartz, **Josep M Llovet**. Mixed Hepatocellular-Cholangiocarcinoma Tumours: Cholangiolocarcinomas and Stem-Cell Subtype Have Unique Molecular Traits. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Oral)*
- Eric Letouzé, Jayendra Shinde, Ludmil B. Alexandrov, Sandrine Imbeaud, Kornelius Schulze, Julien Calderaro, Sandra Rebouissou, Gabrielle Couchy, Clément Meiller, Roser Pinyol, Laura Pelletier, Charles Balabaud, Alexis Laurent, Jean-Frederic Blanc, Vincenzo Mazzaferro, Fabien Calvo, Augusto Villanueva, Jean-Charles Nault, Paulette Bioulac-Sage, Michael R. Stratton, **Josep M. Llovet**, Jessica Zucman-Rossi. Signatures of Known and New Mutational Processes Operative in Liver Cancers. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Oral)*
- Riccardo Lencioni, Joong-Won Park, Ferran Torres, Thomas Decaens, Eveline Boucher, Jean-Luc Raoul, Masatoshi Kudo, Charissa Chang, Valerie Boige, Eric Assenat, Yoon-Koo Kang, Ho-Yeong Lim, Ian Walters, **Josep M. Llovet**. Objective Response by Mrecist Predicts Survival in Hepatocellular Carcinoma: a Multivariate, Time-Dependent Analysis from the Phase 3 Brisk-Ps Study*. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Poster)*
- **Josep M Llovet**, Mihai Pavel, Jordi Rimola, Maria Alba Diaz, Jordi Colmenero, Constantino Fondevila, Josep Fuster, Pere Ginès, Jordi Bruix, Juan Carlos Garcia-Valdecasas. Prospective Pilot Study of Living Donor Liver Transplantation for Patients with HCC Exceeding Milan Criteria *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Oral)*
- Klaus Hoefflich, Agrin Moeini, Margit Hagel, Chandra Miduturu, Daniela Sia, Roser Pinyol, Judit Peix, Qiongfang Fong, Nicolas Stransky, Oleg Schmidt-Kittler, **Josep M Llovet**, Christoph Lengauer, Ben Wolf. Fgf19 Aberrations and Selective Targeting With Fgfr4 Inhibitors for Hepatocellular Carcinoma. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Oral)*
- Jordi Bruix, Ann-Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko DeSanctis, **Josep M Llovet**. Retrospective pooled Analysis Of Advanced Hcc Patients In Sharp And Ap Randomized Clinical Trials. *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015 (Poster)*
- Andrew X. Zhu, Peter R. Galle, Masatoshi Kudo, Richard S. Finn, Ling Yang, Paolo Abada, Shao-Chun Chang, **Josep M. Llovet**. A Randomized, Double-Blind, Placebo-Controlled Phase Study Of Ramucirumab Versus Placebo As Second-Line Treatment In Patients With Hepatocellular

Carcinoma And Elevated Baseline Alpha-Fetoprotein Following First-Line Sorafenib (Reach-2). *ILCA Annual Conference 2015. Paris, France. 4-6 September 2015* (Poster)

- **Llovet JM**, Pavel MC, Rimola J, Diaz MA, Colmenero J, Fondevila C, Fuster J, Gines P, Bruix J, García-Valdecasas JC. Living donor liver transplantation for patients with HCC exceeding Milan criteria: results of pilot study. *AASLD Liver Meeting. San Francisco, USA 13th to 17th November 2015* (Poster).
- Moeini A, Sia D, Zhang Z, Camprecios G, Fiel MI, Miltiadous O, Sun X, Hao K, Hoshida Y, Thung SN, Villanueva A, Schwartz M, **Llovet JM**. Mixed hepatocellular-cholangiocarcinoma tumors: stem-cell subtype and cholangiolocellular carcinoma are unique molecular entities. *AASLD Liver Meeting. San Francisco, USA 13th to 17th November 2015* (Oral).
- Sia D, Harrington A, Zhang Z, Camprecios G, Toffanin S, Moeini A, Fiel MI, Hao K, Higuera M, Miltiadous O, Cabellos L, Cornella H, Hoshida Y, Florman SS, Schwartz ME, **Llovet JM**. Molecular heterogeneity in multinodular Hepatocellular Carcinoma. *AASLD Liver Meeting. San Francisco, USA 13th to 17th November 2015* (Oral).
- Martínez-Quetglas I, Pinyol R, Dauch R, Torrecilla S, Tovar V, Moeini A, Alsinet C, Bonilla S, Portela A, Rodriguez- Carunchio L, Solé M, Villanueva A, Esteller M, Zender L, **Llovet JM**. Re-expression of fetal IGF2 as epdriver and target for therapy in HCC. *The International Liver Congress 2016 - EASL, Barcelona. 13th to 17th April 2016* (Oral)
- Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Fiel MI, Miltiadous O, Martínez-Quetglas I, Hao K, Villanueva A, Thung SN, Schwartz ME, **Llovet JM**. Molecular classification of mixed hepatocellular cholangiocarcinoma tumors. *The International Liver Congress 2016 - EASL, Barcelona. 13th to 17th April 2016* (Poster)
- Sia D, Harrington AN, Torrecilla S, Zhang Z, Camprecios G, Moeini A, Toffanin S, Fiel MI, Hao K, Higuera M, Cabellos L, Cornella H, Mahajan M, Hoshida Y, Villanueva A, Florman S, Schwartz ME, **Llovet JM**. Molecular heterogeneity and trunk driver mutations in hepatocellular carcinoma. *The International Liver Congress 2016 - EASL, Barcelona. 13th to 17th April 2016* (Poster)
- Zhu A, Galle P, Masatoshi K, Finn R, Yang L, Abada P, **Llovet JM**. A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2). *ESMO 18th World Congress on Gastrointestinal Cancer, 29 June-2 July 2016, Barcelona, Spain* (Poster)
- Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta Martin C, Camprecios G, Thung S, Mazzaferro V, Villanueva A, **Llovet JM**. Characterization of the Immune Class of Hepatocellular Carcinoma. *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Oral).
- Craig A, Ahsen M, Villacorta-Martin C, Chen X, Labgaa I, Stueck A, D'Avola D, Ward S, Fiel M, Gunasekaran G, **Llovet JM**, Thung S, Schwartz M, Losic B, Stolovitzky G, Villanueva A. Distinct Spatial Distribution of Gene Expression and Mutations within Single-Nodule Hepatocellular Carcinoma Captures Intra-Tumoural Heterogeneity. *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Oral).
- Sia D, Harrington AN, Torrecilla S, Zhang Z, Camprecios G, Moeini A, Toffanin S, Fiel I, Hao Ke, Higuera M, Cabellos L, Cornella H, Mahajan M, Hoshida Y, Villanueva A, Florman S, Schwartz M, **Llovet JM**. Trunk vs branch drivers: dissecting molecular heterogeneity in HCC. *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Poster).
- Labgaa I, Villacorta-Martin C, D'Avola D, Craig A, Stueck A, Ward S, Fiel MI, Thung S, Friedman S, **Llovet JM**, Ang C, Schwartz M, Villanueva A. Ultra-deep sequencing of circulating tumor dna identifies actionable mutations: exploring applications of a liquid biopsy in HCC. *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Poster).
- Simon-Coma M, Akers N, Sia D, Kuchuk O, Gambato M, Nonell L, Mallo M, Carrillo J, Cairo S, Buendia MA, Vazquez M, Royo L, Pedersen K, Sala M, Sarrias MR, Losic B, **Llovet JM**, Armengol C. Integrative genomic analysis of hepatoblastoma reveal novel molecular drivers. *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Poster).
- Moeini A, Hoefflich K, Pinyol R, Sia D, Miduturu C, Montal R, Peix J, Camprecios G, Cao Q, Stransky N, Schmidt-Kittler O, Miller S, Thung SN, Lengauer C, **Llovet JM**. FGF19 as biomarker for FGFR4 inhibitor trial enrichment in Hepatocellular Carcinoma. *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Poster).

- Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada PB, **Llovet JM**. A randomized, double-blind, placebo-controlled phase III study of Ramucirumab versus placebo as second-line treatment in patients with Hepatocellular Carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2). *ILCA 2016 Annual Conference, Vancouver, CAD, 8th - 9th September 2016* (Poster).
- Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta Martin C, Camprecios G, Thung S, Castro M, Esteller M, Mazzaferro V, Villanueva A, **Llovet JM**. Molecular characterization of the immune class of hepatocellular carcinoma. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November 2016* (Poster).
- Torrecilla S, Salaverria I, Enric Ramis-Zaldivar J, Cabellos L, Beà S, Pinyol R, **Llovet JM**. Molecular characterization of Hepatocellular Carcinomas with Chromothripsis events. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November 2016* (Poster).
- Jiao Y, Zhang Z, Sia D, Hao K, Camprecios G, Bollard J, Lujambio A, **Llovet JM**. Identification of actionable tumor-maintenance genes in HCC by genome-wide copy number variation analysis and shRNA screening. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November 2016* (Poster).
- Kuchuk O, Akers N, Sia D, Simon-Coma M, Martinez-Quetglas I, Gambato M, Nonell L, Mallo M, Carrillo J, Cairo S, Annick Buendia M, Vázquez M, Royo L, Pedersen K, Sala M, Rosa Sarrias M, Mazzaferro V, Losic B, Armengol C, **Llovet JM**. IGF signaling is a promising target for molecular therapies of hepatoblastoma. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November 2016* (Poster).
- G. Meinhardt , J. Bruix , **J. Llovet** , A.-L. Cheng , C. Kappeler . 704P - Analysis of tumor growth rate for advanced hepatocellular cancer patients receiving placebo or sorafenib in the phase 3 SHARP and Asia Pacific trials. *ESMO 2016, Copenhagen, Denmark. 7th -11th October 2016*. (Poster)
- A. Zhu , P. Galle , M. Kudo , R. Finn , L. Yang , P. Abada , **J. Llovet**. 710TiP - A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2). *ESMO 2016, Copenhagen, Denmark. 7th -11th October 2016*. (Poster)
- Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Camprecios G, Thung SN, Castro M, Esteller M, Mazzaferro V, Villanueva A, **Llovet JM**. Molecular characterization of the immune class of hepatocellular carcinoma. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November* (Poster).
- Jiao Y, Zhang Z, Sia D, Hao K, Camprecios G, Bollard J, Lujambio A, **Llovet JM**. Identification of actionable tumor-maintenance genes in HCC by genome-wide copy number variation analysis and shRNA screening. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November* (Poster).
- Torrecilla S, Salaverria I, Ramis-Zaldivar JE, Cabellos L, Beà S, Pinyol R, **Llovet JM**. Molecular characterization of Hepatocellular Carcinomas with Chromothripsis events. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November* (Poster).
- Kuchuk O, Akers N, Sia D, Simon-Coma M, Martinez-Quetglas I, Gambato M, Nonell L, Mallo M, Carrillo J, Cairo S, Guettier C, Branchereau S, Buendia MA, Vázquez M, Royo L, Pedersen K, Sala M, Sarrias MR, Mazzaferro V, Losic B, Armengol C, **Llovet JM**. IGF signaling is a promising target for molecular therapies of hepatoblastoma. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November* (Poster).
- Craig AJ, Ahsen ME, Villacorta-Martin C, Chen X, Labgaa I, Stueck A, D'Avola D, Ward S, Fiel MI, Gunasekaran G, **Llovet JM**, Thung SN, Schwartz ME, Losic B, Stolovitzky G, Villanueva A. Multi-regional integrative genomic analysis reveals intra-tumor heterogeneity in a subset of hepatocellular. *The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November* (Poster).
- **Llovet JM**, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamletthorn W, Thongsawat S, Teufel M, Krissel H, Lim HY. Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS

Hepatocellular Carcinoma (HCC). The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November (Poster).

- Moeini A, Hoefflich K, Pinyol R, Sia D, Miduturu C, Montal R, Peix J, Camprecios G, Cao Q, Stransky N, Schmidt-Kittler O, Miller S, Thung SN, Lengauer C, **Llovet JM**. FGF19 immunostaining as biomarker for trial enrichment testing FGFR4 inhibitors in HCC.). The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November (Poster).
- Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, Stueck A, Ward S, Fiel MI, Mahajan M, Thung SN, Friedman SL, **Llovet JM**, Ang C, Schwartz ME, Villanueva A. Ultra-deep sequencing of circulating tumor DNA identifies druggable mutations: exploring applications of a liquid biopsy in HCC. The AASLD Liver Meeting 2016, Boston USA, 11th to 15th November (Poster).
- Moeini A, Sia D, Harrington AN, Torrecilla S, Zhang Z, Camprecios G, Toffanin S, Fiel M.I, Hao K, Higuera M, Cabellos L, Cornella H, Mahajan M, Hoshida Y, Villanueva A, Florman S, Schwartz ME, **Llovet JM**. Trunk and branch drivers in hepatocellular carcinoma: impact of molecular heterogeneity. EASL. The International Liver Congress 2017, Amsterdam, 19th to 23rd April (Poster).
- Martinez-Quetglas I, Sia D, Jiao Y, Kuchuck O, Martin CV, De Moura MC, Putra J, Camprecios G, Thung S, Mazzaferro V, Esteller M, Villanueva A, **Llovet JM**. Molecular characterization of the immune class of hepatocellular carcinoma. EASL. The International Liver Congress 2017, Amsterdam, 19th to 23rd April (Poster)
- Simon-Coma M, Akers N, Sia D, Royo L, Carrillo J, Pedersen K, Mallo M, Arnal M, Kuchuk O, Gambato M, Cairo S, Buendia MA, Vazquez M, Nonell L, Sala M, Sarrias MR, Losic B, **Llovet JM**. New molecular classification of hepatoblastoma through an integrative genomic and transcriptomic study. EASL. The International Liver Congress 2017, Amsterdam, 19th to 23rd April (Poster)
- Martinez-Quetglas I, Sia D, Jiao Y, Maeda M, Castro M, Esteller M, **Llovet JM**. TGF- β oncogenic pathway in HCC: PMEPA1 as biomarker of treatment response. EASL. The International Liver Congress 2017, Amsterdam, 19th to 23rd April (Poster).
- Pinyol R, Montal R, Takayama T, Chau G-Y, Mazzaferro V, Roayaie S, Lee HC, Poon RT-P, Kokudo N, Zhang Z, Bassaganyas L, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, De la Mata M, Lupo K, Strasser S, Park JW, Camps J, Sole M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, **Llovet JM**. Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial. EASL. The International Liver Congress 2017, Amsterdam, 19th to 23rd April (Oral).
- Martinez-Quetglas I, Sia D, Jiao Y, Kuchuck O, Villacorta Martin C, Castro de Moura M, Putra J, Camprecios G, Thung S, Mazzaferro V, Esteller M, Villanueva A, **Llovet JM**. Molecular Characterization of the immune class of hepatocellular carcinoma. EASL. The International Liver Congress 2017, Amsterdam, 19th to 23rd April (Oral).
- Martinez-Quetglas I, Andreu-Oller C, Moeini A, Pinyol R, Sia D, Esteller M, **Llovet JM**. Oncogenic switch of TGF- β in Hepatocellular carcinoma as potential biomarker for treatment response. 11th ILCA Annual Conference, Seoul, South Korea 15th-17th September 2017 (Poster).
- Pinyol R, Montal R, Martinez-Quetglas I,...and Bruix J, **Llovet JM**. Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in HCC: Biomarker study of the storm phase 3 Trial. 11th ILCA Annual Conference, Seoul, South Korea 15th-17th September 2017 (Oral).
- Torrecilla S, Bassaganyas L, Sia D, Salaverria I, Cabellos L, Pinyol R, Mazzaferro V, **Llovet JM**. Polyploidy and somatic copy number alterations in hepatocellular carcinoma. The AASLD Liver Meeting. Washington, 23rd October 2017 (Poster)
- Montal R, Leow WQ, Montironi C, Bassaganyas L, Moeini A, Sia D, Pinyol R, Cabellos L, Peix J, Maeda M, Tabrizian P, Minguez B, Pawlik T, Labgaa I, L Roberts, Sole M, Fiel MI, Thung S, Roayaie S, Villanueva A, Schwartz M, **Llovet, JM**. Integrative molecular classification of extrahepatic cholangiocarcinoma. EASL 2018, 12th April 2018 (Oral).
- Zhu AX, Kang Y, Yen C, Finn RS, Galle P, **Llovet JM**, Assenat E, Brandi G, Lim H, Pracht M, Rau K, Merle P, Motomura K, Ohno I, Baniele B, Shin D, Gerken G, Abada P, Hsu Y, Kudo M. REACH-2: A randomized, double-blind, placebo-controlled phase 2 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and

elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. ASCO 2018, 4th June 2018 (Oral)

- Sara Torrecilla, Roser Pinyol, Daniela Sia, Leow Wei-Qiang, Huan Wang, Agrin Moeini, Carla Montironi, Laia Bassaganyas, Claudia P. Oliveira, Venancio A. Alves, Anja Lachenmayer, Stephanie Roessler, Beatriz Minguez, Peter Schirmacher, Paolo Boffetta, Jean-François Dufour, Swan N. Thung, Andrew Uzilov, Flair J. Carrilho, Charissa Chang, **Josep M. Llovet**. Molecular characterization of non-alcoholic steatohepatitis-related hepatocellular carcinoma. ILCA Annual Conference, London, United Kingdom 14th-16th September 2018 (Oral)
- Agrin Moeini, Sara Torrecilla, Carla Montironi, Victoria Tovar, Judit Peix, Monica Higuera, Roser Pinyol, Manel Solé, Daniela Sia, **Josep M Llovet**. The immune-mediated cancer-field as target for hepatocellular carcinoma chemoprevention. ILCA Annual Conference, London, United Kingdom 14th-16th September 2018 (Oral).
- **Josep M. Llovet**, Masatoshi Kudo, Richard S. Finn, Peter R. Galle, Jean-Frederic Blanc, Takuji Okusaka, Ian Chau, Paolo B. Abada, Yanzhi Hsu, Andrew X. Zhu. Ramucirumab as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib: Pooled results from two global Phase 3 studies (REACH-2 and REACH), AASLD The Liver Meeting® 2018, San Francisco (Oral)
- Sara Torrecilla, Roser Pinyol, Leow Wei-Qiang, Huan Wang, Agrin Moeini, Carla Montironi, Laia Bassaganyas, Carmen Andreu-Oller, Claudia P. Oliveira, Venancio A. F. Alves, Anja Lachenmayer, Stephanie Roessler, Beatriz Minguez, Peter Schirmacher, Paolo Boffetta, Jean-Francois Dufour, Swan N Thung, Andrew Uzilov, Flair José Carrilho, Charissa Y. Chang, Daniela Sia, **Josep M Llovet**. Integrative Molecular Profiling of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. AASLD The Liver Meeting® 2018, San Francisco (Oral)
- Torrecilla S, Pinyol R, Sia D, Wei-Qiang L, Wang H, Moeini A, Montironi C, Bassaganyas L, Oliveira C, Alves VA, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Boffetta P, Dufour JP, Thung SN, Uzilov A, Carrilho FJ, Chang C, **Llovet JM**. Molecular characterization of non-alcoholic steatohepatitis-related hepatocellular carcinoma. 12th Annual Conference of the International Liver Cancer Association, London, United Kingdom (Oral)
- Agrin Moeini, Sara Torrecilla, Carla Montironi, Victoria Tovar, Judit Peix, Monica Higuera, Roser Pinyol, Manel Solé, Daniela Sia, **Josep M Llovet**. The immune-mediated cancer-field as target for hepatocellular carcinoma chemoprevention. 12th Annual Conference of the International Liver Cancer Association, London, United Kingdom (Oral)
- Robert Montal, Wei Qiang Leow, Carla Montironi, Laia Bassaganyas, Agrin Moeini, Daniela Sia, Roser Pinyol, Laia Cabellos, Judit Peix, Miho Maeda, Carlos Villacorta, Parissa Tabrizian, Christine Sempoux, Beatriz Minguez, Tim Pawlik, Ismail Labgaa, Lewis Robert, Manel Solé, Maria Isabel Fiel, Swan Thung, Sasan Roayaie, Augusto Villanueva, Myron Schwartz, **Josep M Llovet**. Integrative molecular classification of extrahepatic cholangiocarcinoma. 12th Annual Conference of the International Liver Cancer Association, London, United Kingdom. (Oral)
- Andrew Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard Finn, Peter Gale, **Josep M Llovet**, Eric Assenat, Giovanni Brandi, H Yeong Lim, Marc Pracht, Kun-Ming Rau, Philippe Merle, Kenta Motomura, Izumi Ohno, Bruno Daniele, Dong Bok Shin, Guido Gerken, Paolo Abada, Uanzhi Hsu, Masatoshi Kudo. 12th Annual Conference of the International Liver Cancer Association, London, United Kingdom. (Oral)
- Robert Montal, WeiQiang Leow, Carla Montironi, Laia Bassaganyas, Agrin Moeini, Daniela Sia, Roser Pinyol, Judit Peix, Laia Cabellos, Miho Maeda, Carlos Villacorta, Parissa Tabrizian, Christine Sempoux, Beatriz Minguez, Tim Pawlik, Ismail Labgaa, Lewis R Roberts, Manel Solé, Maria Isabel Fiel, Swan N Thung, Sasan Roayaie, Augusto Villanueva, Myron E Schwartz and **Josep M Llovet**. Molecular Classification and Potential Therapeutic Targets in Extrahepatic Cholangiocarcinoma. The Liver Meeting 2018, San Francisco, US (Oral)
- Bassaganyas L, Esteban-Fabré R, Torrecilla S, Moeini A, Franch-Expósito S, Vila-Casadesús M, Nadeu F, Sia D, Salaverria I, Cabellos L, Pinyol R, Camps J, Mazzaferro V, **Llovet JM**. Impact of different aneuploidy profiles on tumor progression and immunity in hepatocellular carcinoma. The Liver Meeting 2018, San Francisco, US (Oral)
- Sara Torrecilla, Roser Pinyol, Leow Wei-Qiang, Huan Wang, Agrin Moeini, Carla Montironi, Laia Bassaganyas, Carmen Andreu-Oller, Claudia P. Oliveira, Venancio A. F. Alves, Anja Lachenmayer, Stephanie Roessler, Beatriz Minguez, Peter Schirmacher, Paolo Boffetta, Jean-Francois Dufour, Swan N, Thung, Andrew Uzilov, Flair José Carrilho, Charissa Y. Chang, Daniela

Sia, **Josep M Llovet**. Integrative Molecular Profiling of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. The Liver Meeting 2018, San Francisco, US (Oral)

- **Josep M Llovet**, Chia-Jui Yen, Richard S. Finn, Yoon-Koo Kang, Masatoshi Kudo, Peter R. Galle, Eric Assenat, Marc Pracht, Ho Yeong Lim, Kun-Ming Rau, Christophe Borg, Jean-Baptiste Hiriart, Bruno Daniele, Thomas Berg, Hyun Cheol Chung, Nathalie Godinot, Chunxiao Wang, Yanzhi Hsu, William R. Schelman, Andrew X. Zhu. Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2). 2019 ASCO Annual Meeting, Chicago (Poster),
- **Josep M Llovet**, Masatoshi Kudo, Ann-Lii Cheng, Richard S. Finn, Peter R. Galle, Shuichi Kaneko, Tim Meyer, Shukui Qin, Corina E. Dutcus, Erluo Chen, Leonid Dubrovsky, Andrew X. Zhu. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. 2019 ASCO Annual Meeting, Chicago (Poster)
- **Josep Llovet**, Masatoshi Kudo, Yoon-Koo Kang, Chai-Jui Yen, Richard S. Finn, Peter R. Galle, Eric Assenat, Kenta Motomura, Takuji Okusaka, Thomas Berg, Chih-Hung Hsu, Masafumi Ikeda, Yanzhi Hsu, Kun Liang, Ryan Widau, William Schelman, L O'Brien, Ling Gao, Andrew X. Zhu. Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis). ESMO Congress 2019. Barcelona (Poster)
- **Josep M. Llovet**, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Konstantin Mamontov, Tim Meyer, Kalgi Mody, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Andrew X. Zhu. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (UHCC): updated results. ESMO Congress 2019. Barcelona (Poster). *Annals of Oncology* (2019) 30 (suppl_5): v253-v324.
- First-Line Combination Therapy With Lenvatinib Plus Pembrolizumab for Patients With Advanced Hepatocellular Carcinoma: Phase 3 LEAP-002 Study. *ILCA 2019*. Chicago.
- Stemmer S, Manojlowic, M, Marinca, Petrov P, Cherciu N, Groza DL, Puscas LA, Ciuleanu TE, Beg MS, Ourcell W, Croitoru AE, Ilieva R, Natosevic S, Nita AL, Harpaz Z, Farbstein M, Silverman M, Fishman P, **Llovet JM**. The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2 , Randomized, Double-Blind, Placebo-Controlled. *ILCA 2019*. Chicago (Poster)
- Torrecilla S., Pinyol P, Wang H, Montironi C, Andreu-Oller C, Torres-Martin M, Peix J Wei-Qiang L, Moeini A, Oliveira CO, Alves VA, Lachenmayer A, Roessler S, Heikenwälder M, Sanyal AJ, Minguez B, Schirmacher P, Boffetta P, Dufour JF, Thung SN, Reeves HL, Uzilov AV, Carrilho FJ, Chang C, Friedman SL, Sia D, **Llovet JM**. Molecular Pathogenesis, Molecular Pathology, Cell Biology and Translational Research Unique molecular traits for NASH-related Hepatocellular Carcinoma *ILCA 2019*. Chicago (Oral)
- Esteban-Fabrá R, Bassaganyas L, Torrecilla S, Moeini 1, Franch-Expósito 3, Vila-Casadesús M, Nadeu F, Torrens L, Cabellos L, Sia D, Salaverria I, Pinyol R, Camps J, Mazzaferro V, **Llovet JM**. Molecular Pathogenesis, Molecular Pathology, Cell Biology and Translational Research Chromosomal stability correlates with the immune class of hepatocellular carcinoma *ILCA 2019*. Chicago (Poster)
- Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, **Llovet JM**, Assenat E, Merle P., Hiriart JB, Chan S, Palmer D, Wang C, Widau R, Hsu Y, Schelman W, Zhu AX. Effect of ramucirumab on albumin-bilirubin grade during treatment of patients with hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes from two randomized phase 3 studies (REACH, REACH-2) *ILCA 2019*. Chicago (Poster)
- Von Felden J, Craig A, Labgaa I, Garcia-Lezana T, D'Avola D, Asgharour A, Bonaccorso A, Tabrizian P, Schwartz ME, **Llovet JM**, Villanueva A. Mutations in circulating tumor DNA predict primary resistance to sorafenib in patients with advanced hepatocellular carcinoma. The Liver Meeting 2019 AASLD. Boston, US (Poster)
- Hernandez-Meza G, Von Felden J, Gonzalez Kozlova E, Craig A, Sayols S, Portela A, Esteller M, Schwartz ME, Mazzaferro V, Losic B, **Llovet JM**, Villanueva A. Genome-Wide DNA Methylation profiling identifies novel epigenetic gatekeepers in hepatocarcinogenesis and

reveals prognostic capacities of cirrhotic tissue. . The Liver Meeting 2019 AASLD. Boston, US (Poster)

- Sia D, Martinez-Torres Miguel, Wang H, Haber P, Puigvehi M, Montirni C, Maeda M, Qiang WL, Harrod E, Taik P, Donovan M, Thung S, Neely J, Mazzaferro V, Schwartz, Villanueva A, Uzilov A, Friedman S, Anderson J, **Llovet JM**. Decoding the immune tumor microenvironment of hepatocellular carcinoma. The Liver Meeting 2019 AASLD. Boston, US (Poster)
- Puigvehi M, Torres-Martin M, Maeda M, Orlando V, Wang H, Leone T, García-López M, Wei-Qiang L, Montironi C, Camprecios G, Torrecilla S, Chibold E, Taivanbaatar E, Yerbolat A, Villanueva A, Uzilov A, Pérez-del-Pulgar S, Chinburen J, Fornis X, Roayaie S, Sia D, **Llovet JM**. Molecular characterization of HBV/HDV-Related HCC in Mongolia. The Liver Meeting 2019 AASLD. Boston, US (Poster)
- Torrens L, Montironi C, Haber P, Kuchuk O, Akers N, Simon-Coma M, Nonell L, Carrillo J, Cairo S, Buendia A, Royo L, Mazzaferro V, Losic B, Sia D, Armengol C, **Llovet JM**. Identification of IGF2 as genomic driver and therapeutic target in hepatoblastoma. The Liver Meeting 2019 AASLD. Boston, US (Poster)
- Esteban-Fabré R, Willoughby CE, Piqué M, Peix J, Abril J, Martin L, Pinyol R, **Llovet JM**. Cabozantinib enhances the efficacy and immune modulatory activity of anti-pd1 treatment in a syngeneic mouse model of HCC. The Liver Meeting 2019 AASLD. Boston, US (Poster)
- Tabrizian P, Holzner M, Halazun K, Agopian VG, Busuttil RW, Yao F, Roberts J, Forman S, Schwartz ME, Emond JC, Samstein B, Brown RS, Najjar M, Capman WC, Doyle M, **Llovet JM**, Mehta N. A US multicenter analysis of 2529 HCC patients undergoing liver transplantation: 10-years outcome assessing the role of down-staging to within milan criteria. The Liver Meeting 2019 AASLD. Boston, US (Plenary session)
- Piqué-Gili M, Pinyol R, Torrecilla S. et al. Molecular and mutational landscape of hepatocellular carcinoma (HCC) Related to non-alcoholic steatohepatitis (NASH).The Liver Meeting 2020 AASLD. Virtual (Poster)
- Montironi, Pinyol R, Castet F et al. La esteatohepatitis no alcohólica (EHNA) limita la acción antitumoral de los inhibidores de punto de control inmunitario en pacientes con carcinoma hepatocelular (CHC). AEEH 2021. Virtual (Oral presentation)
- Abril-Fornaguera J. Torrens L, Carrillo-Reixach J. et al. Identificación de IGF2 como diana terapéutica en Hepatoblastoma. AEEH 2021. Virtual (Poster)
- **Llovet JM**, Singal A, Villanueva A, Finn RS, Kudo M, Galle PR, Wang C, Widau R, Gonzalez Gugel E, Zhu AX, Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): results from two Phase III trials. ASCO 2021. Virtual (Poster)
- Haber PK, Torres M, Dufour JF, Verslype C, Marquardt J, Galle PR, Vogel A, Meyer T, Labgaa I, Roberts LR, Minguez B, Mazzaferro V, Finkelmeier F, Müller T, Schmelzle M, Finn RS, Thung s, Villanueva A, **Llovet JM**, Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. ASCO 2021. Virtual (Poster)
- Montironi C. Immune classification of hepatocellular carcinoma based on new molecular features: the inflamend class. EASL-ILC 2021. Virtual (Oral presentation)
- Abril J. Identification of IGF2 as genomic drive rand actionable therapeutic target in hepatoblastoma. EASL-ILC 2021- Virtual (Oral presentation)
- Torrens L. Molecular characterization of HCC in Mongolia delineates unique genomic features. EASL-ILC 2021- Virtual (Poster)
- Haber P. Molecular Markers of response to anti-PD1 theray in Advanced hepatocellular carcinoma. EASL-ILC 2021- Virtual (Poster)
- Li D, Cheng AL, Lim HY, **Llovet JM**, Zhu Y, Hatogai K, Siegel AB, Kudo M. Pembrolizumab/Quavonlimab cofomulation in combination with Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2 trial in progress. ESMO-GI 2021 (Poster).
- Castet F., Montironi C, Haber PK...**Llovet JM**. Inflamed class HCC: an expansion of the immune class based upon new molecular features. ILCA 2021. Virtual (Top-rated Poster Basic-Translational)

- Esteban R, Willoughby CE, Piqué-Gili M...**Llovet JM** Cabozantinib enhances anti-PD1 efficacy and elicits a neutrophil-based immune response in murine models: implications for human HCC. ILCA 2021. Virtual (Oral Presentation).
- Haber P., Puigvehí M, Castet F... **Llovet JM**. Systematic review and meta-analysis of RCT (2002-2020): is etiology relevant for immunotherapies? ILCA 2021. Virtual (Oral Communication)
- **Llovet JM**, Torrens L, Abril-Fornaguera J et al. Identification of IFG2 as genomic driver and actionable therapeutic target in hepatoblastoma. ILCA 2021. Virtual (ePoster)
- **Llovet JM**, Torrens L. Puigvehí M, et al. Molecular characterization of HCC in Mongolia delineates unique genomic features. ILCA 2021. Virtual (ePoster)
- Haber P, Torres M, Andreu C...**Llovet JM**. Molecular markers of response to anti-PD1 therapy in Advanced hepatocellular carcinoma. ILCA 2021. Virtual (Oral Presentation)
- Montironi C, Castet F, Haber PK.... **Llovet JM**. Inflamed and non-inflamed classes of HCC: a revised immunogenomic. AASLD. Virtual 2021. (Poster)
- Andreu C, Piqué M, Esteban R... **Llovet JM**. PMEPA1 is an aggressive oncogene linked to TGF- β Signalling in Hepatocellular Carcinoma. AASLD. Virtual 2021 (Poster)
- Haber PK, Castet F, Torres-Martín M ... **Llovet JM**. Molecular Markers of response to anti-PD1 therapy in Advanced hepatocellular carcinoma. AASLD 2021. Virtual (Oral)
- Kudo M, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, Kobayash M, Kumada HA, Kaneko S, Pracht M, Meyer T, NAgao S, Saito K, Mody K, Dubrovsky L, **Llovet JM**. Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Study 116 Follow-up Analysis. Canadian Liver Meeting 2022. Virtual (Poster)
- **Llovet JM**, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo B-Y, Ren Z, Cheng A-L, Galle PR, Kaneko S, Kumada H, Kamble S, Norquist JM, Mody K, Dubrovsky L, Siegel AB, Finn RS. Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study. ASCO-GI 2023. San Francisco, US (Poster).
- Cappuyns S, Piqué-Gili M, Esteban-Fabré R, Philips G, Pinyo R, Vandecaveye V, Abril-Fornaguera J, Haber P, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, **Llovet JM**. OS-059-YI Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNAsequencing-derived gene signatures. EASL 2023. Viena. (Oral Presentation)
- Sarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabré, Gino Philips, Roser Pinyol, Albert Gris-Oliver, Vincent Vandecaveye, Jordi Abril-Fornaguera, Carla Montironi, Laia Bassaganyas, Judit Peix, Marcus Zeithoefer, Agavni Mesropian, Júlia Huguet-Pradell, Philipp K. Haber, Raphael Mohr, Tim Meyer, Helen L. Reeves, Julien Edeline, Fabian Finkelmeier, Jörg Trojan, Peter R. Galle, Friedrich Foerster, Beatriz Mínguez, Robert Montal, Mathias Heikenwalder, Chris Verslype, Eric Van Cutsem, Diether Lambrechts, Augusto Villanueva, Jeroen Dekervel, **Josep M. Llovet**. Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. EASL 2024. Milan, Italy (Poster).
- Ugne Balaseviciute, Jordi Abril-Fornaguera, Júlia Huguet-Pradell, Elisa Fernández-Martínez, Albert Gris-Oliver, Alex Rialdi, Agavni Mesropian, Gulay Ulukaya, Dan Hasson, Ieva Keraite, Roser Pinyol, Swan N Thung, Ernesto Guccione, **Josep Llovet**. Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma 36th EORTC-NCI-AACR Symposium. October 2024. Barcelona (Poster)
- E7386 enhances both lenvatinib and anti-PD1 antitumor activity in HCC . A. Mesropian Badalian, A. Gris-Oliver, J. Abril-Fornaguera, M. Piqué-Gili, M. Torres-Marcén, D. Camell-Raventós, J. Peix, E. Fernández-Martínez, U. Balaseviciute, J. Huguet-Pradell, I. Keraite, R. Esteban-Fabré, R. Pinyol, M. Bárcena-Varela, K.E. Lindblad, A. Lujambio, E. Guccione, S.N. Thung, D. Sia, **J.M. Llovet**. 36th EORTC-NCI-AACR Symposium. October 2024. Barcelona (Poster)

- Kudo M, Finn R.S, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dubrovsky L, **Llovet JM**. TACE with or without Lenvatinib Plus Pembrolizumab for intermediate-stage Hepatocellular Carcinoma: Phase 3 LEAP-012 Study. Plenary Session. JAST-HCC 2025. January 2025. Okayama, Japan (Oral Presentation).
- A Mesropian, TP Seraphin, L Žigutyte, [...], Roser Pinyol, [...], **Josep M Llovet**. Artificial intelligence predicts prognostic features of patient survival related to microvascular invasion and molecular classes of hepatocellular carcinoma. (Poster) EACR Congress Lisbon 2025
- U Balaseviciute, M Rahbari, F Springer, [...], Roser Pinyol, [...], **Josep M. Llovet**, M Heikenwälder. Impact of the intratumoral bacteria on immunotherapy outcomes in hepatocellular carcinoma. (Poster) EACR Congress Lisbon 202
- Kudo M, Finn R.S, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dubrovsky L, **Llovet JM**. TACE with or without Lenvatinib Plus Pembrolizumab for intermediate-stage Hepatocellular Carcinoma: Phase 3 LEAP-012 Study. Plenary Session. JAST-HCC 2025. January 2025. Okayama, Japan (Oral Presentation).
- U. Balaseviciute, J. Abril-Fornaguera, J. Huguet-Pradell, [...], Roser Pinyol, [...], **Josep M Llovet**. Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma. (Poster) EASL congress 2025
- U Balaseviciute, M Rahbari, F Springer, [...], Roser Pinyol, [...], **Josep M. Llovet**, M Heikenwälder. The intratumoral microbiome in HCC and its impact on treatment response. (Poster) EASL congress 2025
- A Mesropian, TP Seraphin, L Žigutyte, [...], Roser Pinyol, [...], **Josep M Llovet**. Artificial intelligence-driven prediction of biology-related poor outcome and presence of vascular invasion in hepatocellular carcinoma. (Poster) EASL congress 2025
- E Mauro, T Castro, M Zeitlhofer, [...], Roser Pinyol, [...], **Josep M Llovet**. Phase III trials in HCC: IMbrave 050 and strategies to address non-proportional hazards. (Oral) EASL congress 2025
- Artificial intelligence-driven prediction of biology-related poor outcome and presence of vascular invasion in hepatocellular carcinoma. T. Mesropian, T.P. Seraphin, L. Žigutyte, J. Brooks, E. Mauro, A. Gris-Oliver, R. Pinyol, C. Montironi, M.V. Treeck, J.N. Kather, T. Luedde, **J.M. Llovet**. EACR 2025. June 2025. Lisbon (Poster)
- Impact of the intratumoral bacteria on immunotherapy outcomes in hepatocellular carcinoma. U. Balaseviciute, M. Rahbari, F. Springer, R. Pinyol, A. Gris-Oliver, M. Piqué-Gili, J. Zucman-Rossi, G. Zeller, **J.M. Llovet**, M. Heikenwälder. EACR 2025. June 2025. Lisbon (Poster)
- M Piqué-Gili, A Vila-Escoda, [...] R Pinyol, [...], **Josep M Llovet**. Unique patterns of responders to atezolizumab + bevacizumab in advanced HCC as per spatial transcriptomics analysis (Oral). ILCA Annual Conference 2025.

Cano-Segarra, G, Hernández A, Gris-Oliver A,...**Llovet JM**. Cancer-associated fibroblast in hepatocellular carcinoma tumor microenvironment and prediction of resistance to atezolizumab + bevacizumab treatment. EASL Summit 2026. Edinburgh (Oral – Plenary).

Local presentations in Scientific Meetings

1. J Boix, R Morillas, **JM Llovet**, C Gomes-Vieira, P Humbert, R de León, E Cabré, M Esteve, MA Gassull. Técnica combinada de esfinterotomía endoscópica con hilo-guía anterógrada. *XI Jornada nacional de endoscopia digestiva (JNED) Granada, 1989.*
2. Abad-Lacruz A, González-Huix F, Cabré E, Boix J, Gomes-Vieira C, **Llovet JM**, Esteve M, Fernández-Bañares F, Humbert P, Gassull MA. Factores pronósticos y probabilidad de desarrollar encefalopatía en 91 pacientes con cirrosis hepática avanzada. Análisis multivariante. *Gastroenterol y Hepatol* 1990;13:158. *XV Congreso de la AEEH. Madrid, 1990.*
3. Abad -Lacruz A, González-Huix F, Cabré E, Boix J, Gomes-Vieira MC, **Llovet JM**, Esteve M, Fernández-Bañares F, Humbert P, Gassull MA. Aparición del primer episodio de encefalopatía en la historia natural de la cirrosis hepática avanzada. Factores predictivos. Análisis univariante. *Rev. Esp. Enferm. Dig* 1990, 77 (supl I):143.
4. Esteve-Comas M, Núñez MC, Boix J, Fernández-Bañares F, González-Huix F, Abad-Lacruz A, Cabré E, Gil A, Quer JC, **Llovet JM**, Gassull MA. Influencia de la actividad inflamatoria sobre el perfil de ácidos grasos poliinsaturados (AGPI) en la Enfermedad Inflamatoria Intestinal. *Nutrición Hospitalaria* 1990; V (supl 1:18).
5. Fernández-Bañares F, Planas R, Cabré E, Morillas R, De León R, Guílera M, Quer JC, **Llovet JM**, Abad-Lacruz A, Humbert P, Gassull MA. Repercusión sobre el estado nutricional energético-proteico de las paracentesis totales en el tratamiento de la ascitis a tensión en la cirrosis hepática. *Nutrición Hospitalaria* 1990;5(Supl1):15.
6. González-Huix F, Esteve-C M, Acero D, De Leon R, Quer JC, Cabré E, Abad Lacruz A, **Llovet JM**, Fernández-Bañares F, Gassull MA. "Tratamiento nutricional en los brotes agudos de la enfermedad inflamatoria intestinal: nutrición enteral total versus nutrición parenteral total". *I Reunión Española de Trabajo sobre la Enfermedad Inflamatoria Intestinal. Zaragoza, 1990.*
7. Bertrán X, Fernández-Bañares F., Planas R., Cabré E, Morillas R, De León R, Guílera M, Quer JC, **Llovet JM**, Domènech E y Gassull MA. Repercusión sobre el estado nutricional energético-proteico de la paracentesis total asociada a la infusión de albúmina o dextrano-70 en el tratamiento de la ascitis a tensión en la cirrosis hepática. *VII Congreso de la SENPE. Palma de Mallorca, 1990.*
8. Esteve-Comas M, Núñez MC, Boix J, Fdez-Bañares F, González-Huix F, Abad-Lacruz A, Cabré E, Gil A, Quer JC, **Llovet JM**, Gassull MA. Influencia de la actividad inflamatoria sobre el perfil de ácidos grasos poliinsaturados en la enfermedad inflamatoria intestinal. *VII Congreso de la SENPE. Palma de Mallorca, 1990.*
9. Morillas R, Boix J, **Llovet JM**, Cebrecos I, Guílera M, Ojanguren I, Oller B, Gassull MA. Forma infrecuente de presentación de un tumor pancreático. *XII JNED. Reus, 1990.*
10. **JM Llovet**, R. Planas, R. Morillas, JC. Quer, E. Cabré, J. Boix, P. Humbert, M. Guílera, E. Domènech, X. Bertran y MA Gassull. Factores pronósticos de la mortalidad hospitalaria en pacientes cirróticos con peritonitis bacteriana espontánea (PBE). Análisis multivariante. *Gastroenterol y Hepatol* 1991; 14:72. *VIII Jornades SCD. St Feliu, 1991.*
11. F González-Huix, R de León, D Acero, M Esteve, M Figa, A Abad-L, F Fdez-Bañares, M Guílera, **JM Llovet**, E Cabré, MA Gassull. Nutrición enteral polimérica (NETP) como tratamiento primario de la enfermedad de Crohn (EC). Resultados preliminares de un estudio controlado. *Gastroenterol y Hepatol* 1991; 14:279. *VIII Jornades de la SCD. St Feliu, 1991.*
12. De León R, Cabré E, Esteve M, Fernández-Bañares F, **Llovet JM**, Esteve Comas M, Planas R, Boix J, Humbert P, Gassull MA. Análisis de bioimpedancia corporal (BIA) en el diagnóstico de malnutrición energicoproteica (MEP) en la cirrosis hepática. *Gastroenterol Hepatol* 1991;14:409. *XVI Congreso de la AEEH. Mallorca 1991.*
13. González-Huix F, De Leon R, Acero D, Esteve M, Figa M, Abad-L A, Fernández-Bañares F, Guílera M, **Llovet JM**, Cabré E, Gassull MA. Nutrición enteral total polimérica (NETP) como tratamiento primario de la enfermedad de Crohn (EC). Resultados preliminares de un estudio controlado. *Nutrición Hospitalaria* 1991; VI:(supl1):39. *XVIII Congreso nacional de la SEPD. Valladolid. 1991.*

14. **JM Llovet**, R Planas, R Morillas, JC Quer E Cabré, J Boix, P Humbert, M Guilera, E Domènech, X Bertrán, MA Gassull. Factores pronósticos de la mortalidad hospitalaria en pacientes cirróticos con peritonitis bacteriana espontánea (PBE). Análisis multivariante. *Rev. Esp. Enf. Digest.* 1991;80 (Supl I):47-48. *XVIII Congreso nacional de la Sociedad Española de Patología Digestiva (SEPD). Valladolid. 1991.*
15. De León R, Abad A, Cabré E, Esteve M, Fernández-Bañares F, Planas R, Humbert P, Quer JC, **Llovet JM**, Morillas R, Gassull MA. Monitorización mediante análisis de bioimpedancia (BIA) de los cambios en la composición corporal inducidos por la nutrición enteral total (NET) en pacientes con enfermedad inflamatoria intestinal (EII). *Nutrición Hospitalaria* 1991;6(Supl1):67.). *VII Congreso de la SENPE. Santander, 1991.*
16. **JM Llovet**, J Boix, JC Quer, I Ojanguren, E Cabré, M Esteve, M Guilera, R Morillas, MA Gassull. Hemorragia digestiva alta por mucosa gástrica "agrietada". *XIII JNED. Zaragoza, 1991.*
17. M Guilera, J Boix, **JM Llovet**, JC Quer, R Planas, P Humbert, A Abad, A Raventós, MA Gassull. Ileocolitis infecciosa simulando ileocolitis granulomatosa. *XIII JNED. Zaragoza, 1991.*
18. JC Quer, J Boix, **JM Llovet**, R Morillas, S Martí, P Humbert, R Planas, F Fernandez-Bañares, MA Gassull. Yeyunocolitis de causa inusual. *XIII JNED. Zaragoza, 1991.*
19. Grupo Colaborativo para el Estudio de la Peritonitis bacteriana Espontánea. Comparación de dos dosis distintas de cefotaxima en el tratamiento de la peritonitis bacteriana espontánea. Resultados preliminares de un estudio multicéntrico, prospectivo y aleatorio. *Gastroenterol y Hepatol* 1992;15:270-1. *XVII Congreso de la AEEH. Madrid, 1992.*
20. Morillas R, Quer JC, Planas R, Galán A, Cabré E, Ruzafa A, **Llovet JM**, Guilera M, Gassull MA. Efecto del tratamiento de la hipertensión portal con propanolol (P) y 5- Mononitrato de isosorbida (MN) sobre la función renal en la cirrosis hepática. *Gastroenterol y Hepatol* 1992; 15:283. *XVII Congreso de la AEEH. Madrid, 1992.*
21. Humbert P, López de Soria P, Fdez-Bañares F, Planas R, Boix J, Quer JC, Morillas R, **Llovet JM**, Doménech E, Bertrán X, Gassull MA. Test del aliento de hidrógeno tras la administración oral de magnesio (Mg BHT). Método simple para valorar la secreción ácida gástrica. *Gastroenterol y Hepatol* 1992; 15:207.
22. Morillas R, Quer JC, Planas R, Galan A, Cabré E, Ruzafa A, **Llovet JM**, Guilera M, Gassull MA. Efecte del tractament de la hipertensió portal amb propanolol (P) i 5-mononitrat d'isosorbida (MNI) sobre la funció renal en la cirrosi hepàtica. *I Congrés de la SCD. Tarragona, 1992.*
23. P Humbert, P López de Soria, F Fernández-Bañares, R Planas, J Boix, JC Quer, R Morillas, **JM Llovet**, E Doménech, X Bertrán, MA Gassull. Test de l'alé d'hidrògen després de l'administració oral de magnesi (MgBHT): mètode simple per valorar la secreció àcida gàstrica. *I Congrés de la SCD. Tarragona, 1992.*
24. Quer JC, Boix J, Guilera M, **Llovet JM**, Esteve M, Villagrasa M, Gassull MA. Afectación duodenal pseudotumoral de etiología vírica. *XIV JNED. Burgos, 1992.*
25. Bertrán X, Boix J, Doménech E, **Llovet JM**, Garcia F. Leishmaniosis colónica y colitis pseudomembranosa. *XIV JNED. Burgos, 1992*
26. **JM Llovet**, R Bartolí, R Planas, J Arnal, E Cabré, A Urban, I Ojanguren, A Ibañez, X Bertran, MA Gassull. Relación de la translocación bacteriana (TB) con la peritonitis bacteriana espontánea (PBE) en ratas cirróticas. *Gastroenterol y Hepatol* 1993;16:269. *II Congrés de la SCD. Sitges, 1993. Gastroenterol y Hepatol* 1993;16:201-202. *XVIII Congreso de la AEEH. Madrid, 1993.*
27. A Follo, **JM Llovet**, M Navasa, R Planas, X Forns, A Francitorra, A Rimola, MA Gassull, V Arroyo, J Rodés. Incidencia, factores predictivos y pronóstico del deterioro de la función renal en la peritonitis bacteriana espontánea (PBE). *Gastroenterol y Hepatol* 1993; 16:246. *XVIII Congreso de la AEEH. Madrid, 1993*
28. **JM Llovet**, Bartolí R, Planas R, Arnal J, Cabré E, Urban A, Ojanguren I, Ibañez A, Gassull MA. Relación de la translocación bacteriana (TB) con la peritonitis bacteriana espontánea en ratas cirróticas. *Rev. Esp. Enf. Digest.* 1993;83: Supl.I (43-45). *XX Congreso Nacional de la SEPD. Barcelona, 1993.*
29. Humbert P, López de Soria P, Fdez-Bañares F, J Juncà, Boix J, Quer JC, **Llovet JM**, Gassull

- MA. Valoració del test de l'alé d'hidrògen amb el magnesi en comparació amb el pepsinògen i sèric com a primer pas en el diagnòstic de l'anèmia perniciosa. *II Congrés de la SCD. Sitges, 1993.*
30. Forns X, Follo A, **Llovet JM**, Francitorra A, Navasa M, Planas R, Rimola A, Arroyo V, Rodés J. Incidencia, mortalidad y factores asociados al desarrollo de insuficiencia renal en la peritonitis bacteriana espontánea (PBE) nosocomial. *Gastroenterol Hepatol* 1993;17:206-207.
 31. JC Quer, R Morillas, R Planas, J Boix, P Humbert, E Cabré, **JM Llovet**, E Domènech, MA Gassull. Somatostatina vs esclerosis de varices en el tratamiento de la hemorragia digestiva por varices esofágicas: resultados finales de un estudio prospectivo y aleatorio. *Gastroenterol y Hepatol* 1994;17:162. *XIX Congreso de la AEEH. Madrid, 1994.*
 32. **JM Llovet**, MP Rdguez-Iglesias, M Menacho, R Planas, E Cabré, MA Gassull. Peritonitis bacteriana espontánea: Comparación entre cirróticos con y sin descontaminación intestinal selectiva previa. *Gastroenterol y Hepatol* 1994;17:172. *XIX Congreso de la AEEH. Madrid, 1994.*
 33. **JM Llovet**, R Bartolí, R Planas, M Jimenez, E Cabré, J Arnal, R Galimany, X Bertran, V Ausina, MA Gassull. Relación entre la translocación bacteriana y la peritonitis bacteriana espontánea en ratas cirróticas con ascitis. *Gastroenterol y Hepatol* 1994;17:171. *III Congrés de la SCD, 1994.*
 34. JC Quer, R Morillas, R Planas, J Boix, P Humbert, E Cabré, **JM Llovet**, E Domènech, MA Gassull. Somatostatina frente a escleroterapia en el tratamiento de la hemorragia aguda por varices esofágicas: resultados finales de un estudio prospectivo y aleatorio. *Gastroenterol y Hepatol* 1994;17:210. *III Congrés de la SCD, 1994.*
 35. Grupo Catalán para el Estudio de la Hepatitis Vírica. Interferón en la hepatitis crónica C. Estudio multicéntrico comparativo de dos pautas terapéuticas. *Gastroenterol Hepatol* 1994;17:176-177. *III Congrés de la SCD, 1994.*
 36. **JM Llovet**, R Bartolí, R Planas, M Gimenez, E Cabré, J Arnal, R Galimany, X Bertran, MA Gassull. Relación entre la translocación bacteriana y la peritonitis bacteriana espontánea en ratas cirróticas con ascitis. *Gastroenterol y Hepatol* 1994;17:217. *XIX Congreso de la AEEH. Madrid, 1994.*
 37. Quer JC, Morillas R, **Planas R**, Boix J, Humbert P, Cabré E, Llovet JM, Domènech E, Gassull MA. Somatostatina vs escleroterapia en la hemorragia aguda por varices esofágicas: resultados finales de un estudio prospectivo y aleatorio. *Gastroenterol Hepatol* 1994;17:162.
 38. **JM Llovet**, MP Rdguez-Iglesias, M Menacho, R Planas, E Cabré, MA Gassull. Peritonitis bacteriana espontánea en cirróticos con y sin descontaminación intestinal selectiva previa. *Gastroenterol y Hepatol* 1994;17:240. *III Congrés de la SCD, 1994.*
 39. Grupo colaborativo para el estudio de la peritonitis bacteriana espontánea. Eficacia de ofloxacino por vía oral frente a cefotaxima endovenosa en la peritonitis bacteriana espontánea (PBE) no complicada. Resultados preliminares de un estudio multicéntrico, prospectivo y aleatorizado. *Gastroenterol y Hepatol* 1994;17:215-16. *XIX Congreso de la AEEH. Madrid, 1994.*
 40. Grupo Catalán para el Estudio de la Hepatitis Vírica. Interferón en la hepatitis crónica C. Estudio multicéntrico comparativo de dos pautas terapéuticas. *Gastroenterol y Hepatol* 1994;17:277.
 41. R Bartolí, **JM Llovet**, R Planas, B Viñado, J Perez, E Cabré, J Arnal, I Ojanguren, V Ausina, MA Gassull. La descontaminació intestinal selectiva amb norfloxacin reduïx la translocació bacteriana (TB) en rates cirròtiques amb ascites sotmeses a shock hipovolèmic. *Gastroenterol y Hepatol* 1995;4:191. *IV Congrés de la SCD, 1995.*
 42. MP R-Iglesias, **JM Llovet**, E Moitinho, M Menacho, R Bataller, R Planas, M Navasa, A Castells, E Cabré, V Arroyo, MA Gassull, J Rodés. ¿Té millor pronòstic la peritonitis bacteriana espontània (PBE) en cirròtics amb descontaminació intestinal selectiva (DIS) prèvia?. *Gastroenterol y Hepatol* 1995;4:211. *IV Congrés de la SCD, 1995.*
 43. E Moitinho, M Navasa, **JM Llovet**, R Bataller, A Castells, R Planas, J Bruix, MA Gassull, J Rodés. Carcinoma Hepatocelular (CHC) en pacientes cirròtics con peritonitis bacteriana espontánea (PBE). Prevalencia e importancia pronóstica. *Gastroenterol y Hepatol* 1995;4:212. *IV Congrés de la SCD, 1995.*

44. R Bartolí, **JM Llovet**, R Planas, B Viñado, J Perez, E Cabré, J Arnal, I Ojanguren, V Ausina, MA Gassull. La descontaminación intestinal selectiva con norfloxacin reduce la translocación bacteriana (TB) en ratas cirróticas sometidas a shock hipovolémico. *Gastroenterol y Hepatol* 1995;5:232. *XX Congreso de la AEEH. Madrid, 1995.*
45. **JM Llovet**, MP Rodríguez-Iglesias, E Moitinho, M Menacho, R Bataller, R Planas, M Navasa, A Castells, E Cabré, V Arroyo, MA Gassull, J Rodés. ¿Tiene mejor pronóstico la peritonitis bacteriana espontánea (PBE) en cirróticos con descontaminación intestinal selectiva (DIS) previa?. *Gastroenterol y Hepatol* 1995;5:246. *XX Congreso de la AEEH. Madrid, 1995.*
46. E Moitinho, M Navasa, **JM Llovet**, R Bataller, A Castells, R Planas, J Bruix, MA Gassull, J Rodés. Prevalencia e importancia pronóstica del carcinoma hepatocelular (CHC) en pacientes cirróticos con peritonitis bacteriana espontánea. *Gastroenterol y Hepatol* 1995;5:259. *XX Congreso de la AEEH. Madrid, 1995*
47. R Bartolí, **JM Llovet**, F March, R Planas, B Viñado, E Cabré, J Arnal, P Coll, V Ausina, MA Gassull. La translocación bacteriana de gérmenes intestinales es causa de peritonitis bacteriana espontánea en la rata cirrótica. Estudio de identidad genética bacteriana. *Gastroenterol y Hepatol* 1996;2:97. *V Congr s de la Societat Catalana de Digestologia. Girona, 1996.*
48. P Sort, A Castells, **JM Llovet**, C Br , J Bruix, J Rod s. Repercusi n de los programas de screening en la historia natural y el pron stico del carcinoma hepatocelular. *Gastroenterol y Hepatol* 1996;2:121. *V Congr s de la Societat Catalana de Digestologia. Girona, 1996.*
49. R Bartolí, **JM Llovet**, F March, R Planas, B Viñado, E Cabré, J Arnal, P Coll, V Ausina, MA Gassull. La translocaci n bacteriana de g rmenes intestinales es causa de peritonitis bacteriana espont nea en la rata cirr tica. Estudio de identidad gen tica bacteriana. *Gastroenterol y Hepatol* 1996;19:3. *XXI Congreso de la AEEH. Madrid, 1996.*
50. R Bartolí, **JM Llovet**, F March, R Planas, B Viñado, E Cabré, J Arnal, P Coll, V Ausina, MA Gassull. La translocaci n bacteriana de g rmenes intestinales es causa de peritonitis bacteriana espont nea en la rata cirr tica. Estudio de identidad gen tica bacteriana. *Rev. Esp. Enf. Digest.*, 1996. *XXIII Congreso Nacional de la SEPD. Sevilla, 1996.*
51. **JM Llovet**, J Bruix, A Castells, J Fuster, M Sol , M Navasa, A Rimola, C Ayuso, X Monta  a, C Br , L Grande, JC Valdecasas., J Visa, J Rod s. Trasplante hep tico (TOH) en el tratamiento del carcinoma hepatocelular (CHC) de peque o tama o. *Gastroenterol y Hepatol* 1997;20:104 . *XXII Congreso de la AEEH. Madrid, 1997.*
52. **JM Llovet**, J Bruix, A Castells, J Fuster, M Sol , M Navasa, A Rimola, C Ayuso, X Monta  a, C Br , L Grande, JC Valdecasas., J Visa, J Rod s. Trasplante hep tico (TOH) en el tratamiento del carcinoma hepatocelular (CHC) de peque o tama o. *Gastroenterol y Hepatol* 1997;20 (S1):2 *VI Congr s de la Societat Catalana de Digestologia. Andorra, 1997.*
53. **JM Llovet**, J Bruix, A Castells, J Bustamante, C Br , J Rod s. Historia natural del hepatocarcinoma:Implicaciones en el dise o y evaluaci n de estudios terap uticos. *Gastroenterol y Hepatol* 1998; 21:32A. *VII Congr s de la Societat Catalana de Digestologia. Baix Camp, 1998.*
54. P.Joya, **JM Llovet**, M Real, J Bustamante, R Vilana, X Monta  a, MC Ayuso, C Br , J Bruix, J Rod s. Tratamiento del hepatocarcinoma no quir rgico: embolizaci n con polivinil alcohol vs espongositan. *Gastroenterol y Hepatol* 1998; 21:52A. *VII Congr s de la Societat Catalana de Digestologia. Baix Camp, 1998.*
55. **JM Llovet**, J Bustamante, J Bruix, A Castells, C Br , J Rod s. Prospective follow-up of untreated hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. *Gastroenterol y Hepatol* 1998; 21(2):9A *XXIII Congreso de la AEEH. Madrid, 1998*
56. **JM. Llovet**, J. Bruix, J. Fuster y el Grupo de Estudio del Carcinoma Hepatocelular.. Resecc n vs trasplante en el tratamiento del carcinoma hepatocelular: analisis segun intencion de tratamiento.*Gastroenterol y Hepatol* 1999;22:38A.*VII Congr s de la Societat Catalana de Digestologia. Palma de Mallorca, 1999.*
57. J Bruix, S Capurro, **JM Llovet**, R Vilana i Grup de l'Estudi del Carcinoma Hepatocel.lular. Tractament del carcinoma hepatocel.lular de petit tamany mitjan ant injecci  intratumoral d'etanol. An lisi de 100 pacients. *Gastroenterol y Hepatol* 1999;22:47A. *VII Congr s de la Societat Catalana de Digestologia. Palma de Mallorca, 1999.*
58. **JM. Llovet** ,J. Bruix, J. Fuster y el Grupo de Estudio del Carcinoma Hepatocelular. Resecc n

- vs trasplante en el tratamiento del carcinoma hepatocelular: analisis según intencion de tratamiento. *Gastroenterol y Hepatol* 1999;22:45 A. XXIV Congreso AEEH. Madrid, 1999
59. **JM Llovet**, J Bruix , S Capurro, R Vilana i Grup de l'Estudi del Carcinoma Hepatocel.lular. Tratamiento del carcinoma hepatocelular de pequeño tamaño mediante inyección intratumoral de etanol. Análisis de 100 pacientes. *Gastroenterol y Hepatol* 1999;22: 54 A. XXIV Congreso de la AEEH. Madrid, 1999.
 60. M Sala, **JM Llovet**, Y Suarez, R Vilana, M Real, J Bruix. Tractament del CHC únic no resecable amb embolització arterial seguida d'injecció intratumoral d'etanol. *Gastroenterol y Hepatol* 2000. VIII Congrés de la SC de Digestologia. Tortosa 2000.
 61. M Giménez-Barcons, X Forns, S Ampurdanés, Y Suarez, A Sanchez-Fueyo, JM Barrera, **JM Llovet**, J Bruix, J Rodés, JC Sáinz, JM Sánchez-Tapias. Heterogeneidad genética del VHC en la region NS5A: un posible marcador del desarrollo de carcinoma hepatocelular en la cirrosis hepática. *Gastroenterol y Hepatol* 2000;23:106 A. XXV Congreso de la AEEH. Madrid, 2000.
 62. M Sala, **JM Llovet**, R Vilana, C Brú, LI Bianchi, JM Salmerón, C Ayuso, M Pagès, J Bruix, J Rodés. Elevado riesgo de diseminación tumoral tras radiofrecuencia en pacientes con carcinoma hepatocelular único. *Gastroenterol y Hepatol* 2001;24:91A. Xe Congrés de la SC de Digestologia . Lloret 2001. AEEH. XXVI Congreso de la AEEH. Madrid, 2001.
 63. **JM Llovet**, MI Real, M Sala, R Planas, S Coll, R Vilana, MC Ayuso, J Muchart, C Acosta, JJ Aponte, X Montañá, R Solá, C Bru, J Rodés, J Bruix. Quimioembolización vs control en el tratamiento del carcinoma hepatocelular. estudio multicéntrico, prospectivo, controlado y aleatorizado. *Gastroenterol y Hepatol* 2001;24:85A. Xe Congrés de la SC de Digestologia , Lloret 2001. XXVI Congreso de la AEEH. Madrid, 2001.
 64. **JM Llovet**, FP Sarasin, P Majno, G Mentha, A Hadengue, J Bruix. Trasplante hepático de donante vivo para el carcinoma hepatocelular. Análisis de coste-efectividad. *Gastroenterol y Hepatol* 2001;24:87A. XXVI Congreso de la AEEH. Madrid, 2001.
 65. R Vilana, L Bianchi, **JM Llovet**, M Sánchez, M Pagés, M Sala, C Ayuso, J Bruix, C Brú. Utilidad de las técnicas de Doppler color y potenciador de señal en la valoración de la vascularización del carcinoma hepatocelular de pequeño tamaño. Estudio com parativo con la TC helicoidal pre y postratamiento percutáneo. *II Jornades Tècniques de la Corporació Sanitària de Barcelona. "Present y futur del càncer a Barcelona". Barcelona, 2001.*
 66. L Bianchi, R Vilana, **JM Llovet**, M Pagés, M Sanchez, M Sala, C Ayuso, J Bruix, C Brú. Tratamiento percutáneo del carcinoma hepatocelular: inyección intratumoral de etanol vs radiofrecuencia. Eficacia, ventajas e inconvenientes de ambas técnicas. *II Jornades Tècniques de la Corporació Sanitària de Barcelona. "Present y futur del càncer a Barcelona". Barcelona, 2001.*
 67. M Burrel, MC Ayuso, M Sanchez, M Pagès, JR Ayuso, TM Caralt, C.de Juan, E Cores, R Miquel, C. Iglesias, **JM Llovet**, J Bruix. Detecció, caracterització, i estadificació intrahepàtica del carcinoma hepatocel.lular mitjançant la tècnica d'angiogram 3D amb contrast. *II Jornades Tècniques de la CSB. Barcelona, 2001.*
 68. Ayuso C, De Juan C, Ayuso JR, **Llovet JM**, García-Valdecasas JC. Trasplante hepático de adulto de donante vivo: evaluación mediante RM de la distribución vascular y del cálculo de volumen. XXVI Congreso Nacional de la SERAM. Canarias. *Radiologia* 2002, 44: 167A.
 69. **JM Llovet**, J Bruix. Revisión sistemática de ensayos clínicos controlados para el carcinoma hepatocelular irresecable. Evidencia de mejoría en la supervivencia mediante quimioembolización. *Gastroenterol y Hepatol* 2003;26:88. XXVIII Congreso de la AEEH.Barcelona, 2003.
 70. M Sala, **JM Llovet**, R Vilana, LI Bianchi, C Ayuso, C Brú, J Bruix.Tratamiento percutáneo del carcinoma hepatocelular no resecable. Predictores de supervivencia a largo plazo en una cohorte de 274 pacientes. *Gastroenterol y Hepatol* 2003;26:62.. XXVIII Congreso de la AEEH.Barcelona, 2003.
 71. Villanueva A, Newell P, Tovar V, Alsinet C, Cornella H, Minguez B, Chiang D, Peix J, Cabellos L, Toffanin S, Fiel M, Thung S, Hoshida Y, Mazzaferro V, Bruix J, Raoyaie S, Schwartz M, Friedman S, **Llovet JM**. Caracterización molecular e impacto pronóstico del carcinoma hepatocelular de probable origen en células progenitoras. *Gastroenterol y Hepatol* 2009;129:173. XXXIV Congreso de la AEEH.Madrid, 2009.(Poster).

72. Alsinet C, Toffanin S, Hoshida Y, Lu J, Villanueva A, Chiang D, Minguez B, Newell P, Cabellos L, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, Golub t, **Llovet JM**. Clasificación molecular del carcinoma hepatocelular mediante el perfil de expresión de microRNA. *Gastroenterol y Hepatol* 2009;129:173. XXXIV Congreso de la AEEH.Madrid, 2009.(Poster).
73. Reig M, Boix L, Forner A, Rimola J, Rodríguez de Lope C, Lopez-Oliva JM, Tremosini S, Llarch N, **Llovet JM**, Ayuso C, Bruix J. Los niveles séricos de anhidrasa carbónica 9 (AC9) predicen el pronóstico de los pacientes con carcinoma hepatocelular tratados con sorafenib. *Gastroenterol y Hepatol* 2011;115:118 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
74. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Peix J, Sole M, Tovar V, Cornella H, Alsinet C, Pellegrinelli A, Cotsoglou C, Molino E, Citterio D, Lachenmayer A, Thung S, Fuster J, García-Valdecasas JC, Bruix J, Schwartz M, Mazzaferro V, **Llovet JM**. La clasificación molecular del colangiocarcinoma humano intrahepático define 2 clases con distinta biología y pronóstico. *Gastroenterol y Hepatol* 2011;119:122 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
75. Villanueva A, Alsinet C, Zong Y, Hoshida Y, Yanger K, Toffanin S, Cabellos L, Thung S, Stanger B, **Llovet JM**. Caracterización genómica y funcional de Notch1 como nuevo oncogén en el carcinoma hepatocelular. *Gastroenterol y Hepatol* 2011;123:126 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
76. Tremosini S, Forner A, Boix L, Rimola J, Rodríguez de Lope C, Reig M, Bianchi L, **Llovet JM**, Vilana R, Ayuso C, Solé M, Bruix J. Validación prospectiva del rendimiento diagnóstico del glypican-3, heat-shock protein-70 y glutamine synthetase para el diagnóstico de carcinoma hepatocelular en nódulos < 2cm. *Gastroenterol y Hepatol* 2011;127:130 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
77. Tovar V, Cornellà H, Hoshida Y, Toffanin S, Villanueva A, Sia D, Peix J, Lachenmayer A, Alsinet C, Solé M, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. Deregulación del sistema fibroblast growth factor en el carcinoma hepatocelular. *Gastroenterol y Hepatol* 2011;139:209 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Poster)
78. Tremosini S, Forner A, Rimola J, Reig M, Rodríguez de Lope C, Vilana R, **Llovet JM**, Boix L, Solé M, Ayuso C, Bruix J. Diagnóstico no invasivo del carcinoma hepatocelular en cirróticos: análisis de la grasa intratumoral, cápsula o de la intensidad de la señal no mejora el rendimiento diagnóstico de la RM dinámica. *Gastroenterol y Hepatol* 2011;139:209 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Poster)
79. Reig M, Burrell M, Forner A, Barrufet M, Rodríguez de Lope C, Varela M, Tremosisni S, Montanya J, **Llovet JM**, Real MI, Bruix J. Resultados actuales de la quimioembolización en pacientes con carcinoma hepatocelular. Impacto en práctica clínica e investigación. *Gastroenterol y Hepatol* 2011;139:209 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Poster)
80. Villanueva A, Newell P, Tovar V, Alsinet C, Cornella H, Minguez B, Chiang D, Peix J, Cabellos L, Toffanin S, Fiel M, Thung S, Hoshida Y, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman S, **Llovet JM**. Caracterización molecular e impacto pronóstico del carcinoma hepatocelular de probable origen en células progenitoras. *Gastroenterol y Hepatol* 2009;129:173. XXXIV Congreso de la AEEH.Madrid, 2009.(Poster).
81. Alsinet C, Toffanin S, Hoshida Y, Lu J, Villanueva A, Chiang D, Minguez B, Newell P, Cabellos L, Roayaie S, Schwartz M, Bruix J, Mazzaferro V, Friedman S, Golub t, **Llovet JM**. Clasificación molecular del carcinoma hepatocelular mediante el perfil de expresión de microRNA. *Gastroenterol y Hepatol* 2009;129:173. XXXIV Congreso de la AEEH.Madrid, 2009.(Poster).
82. Reig M, Boix L, Forner A, Rimola J, Rodríguez de Lope C, Lopez-Oliva JM, Tremosini S, Llarch N, **Llovet JM**, Ayuso C, Bruix J. Los niveles séricos de anhidrasa carbónica 9 (AC9) predicen el pronóstico de los pacientes con carcinoma hepatocelular tratados con sorafenib. *Gastroenterol y Hepatol* 2011;115:118 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
83. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Peix J, Sole M, Tovar V, Cornella H, Alsinet C, Pellegrinelli A, Cotsoglou C, Molino E, Citterio D, Lachenmayer A, Thung S, Fuster J, García-Valdecasas JC, Bruix J, Schwartz M, Mazzaferro V, **Llovet JM**. La clasificación molecular del colangiocarcinoma humano intrahepático define 2 clases con distinta biología y pronóstico. *Gastroenterol y Hepatol* 2011;119:122 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)

84. Villanueva A, Alsinet C, Zong Y, Hoshida Y, Yanger K, Toffanin S, Cabellos L, Thung S, Stanger B, **Llovet JM**. Caracterización genómica y funcional de Notch1 como nuevo oncogén en el carcinoma hepatocelular. *Gastroenterol y Hepatol* 2011;123:126 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
85. Tremosini S, Forner A, Boix L, Rimola J, Rodríguez de Lope C, Reig M, Bianchi L, **Llovet JM**, Vilana R, Ayuso C, Solé M, Bruix J. Validación prospectiva del rendimiento diagnóstico del glypican-3, heat-shock protein-70 y glutamine synthetase para el diagnóstico de carcinoma hepatocelular en nódulos < 2cm. *Gastroenterol y Hepatol* 2011;127:130 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Oral)
86. Tovar V, Cornellà H, Hoshida Y, Toffanin S, Villanueva A, Sia D, Peix J, Lachenmayer A, Alsinet C, Solé M, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. Deregulación del sistema fibroblast growth factor en el carcinoma hepatocelular. *Gastroenterol y Hepatol* 2011;139:209 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Poster)
87. Tremosini S, Forner A, Rimola J, Reig M, Rodríguez de Lope C, Vilana R, **Llovet JM**, Boix L, Solé M, Ayuso C, Bruix J. Diagnóstico no invasivo del carcinoma hepatocelular en cirróticos: análisis de la grasa intratumoral, cápsula o de la intensidad de la señal no mejora el rendimiento diagnóstico de la RM dinámica. *Gastroenterol y Hepatol* 2011;139:209 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Poster)
88. Reig M, Burrell M, Forner A, Barrufet M, Rodríguez de Lope C, Varela M, Tremosini S, Montanya J, **Llovet JM**, Real MI, Bruix J. Resultados actuales de la quimioembolización en pacientes con carcinoma hepatocelular. Impacto en práctica clínica e investigación. *Gastroenterol y Hepatol* 2011;139:209 XXXVI Congreso Anual de la AEEH Madrid, 2011.(Poster)
89. Forner A, Rimola J, Tremosini S, Reig M, Rodríguez de Lope C, Vilana R, **Llovet JM**, Ayuso C, Bruix J. Diagnóstico no invasivo del carcinoma hepatocelular en cirróticos: análisis de la grasa intratumoral, cápsula o de la intensidad de la señal no mejora el rendimiento diagnóstico de la RM dinámica. XXI Congrès de la Societat Catalana de Digestologia, Girona 2012
90. Reig M, Burrell M, Forner A, Barrufet M, Rodríguez de Lope C, Tremosini S, Montanya X, **Llovet JM**, Real MI, Bruix J. Resultats de la quimioembolització en pacients amb carcinoma hepatocel•lular. Impacte en pràctica clínica i investigació. XXI Congrès de la Societat Catalana de Digestologia, Girona 2012
91. Forner A, Tremosini S, Boix L, Rimola J, Rodríguez de Lope C, Reig M, Bianchi L, **Llovet JM**, Vilana R, Ayuso C, Solé M, Bruix J. Validació prospectiva del rendiment diagnòstic del glypican-3, heat-shock proteïna-70 i glutamine synthetase per al diagnòstic del carcinoma hepatocel•lular en nòduls <2cm. XXI Congrès de la Societat Catalana de Digestologia, Girona 2012
92. Tovar V, Cornella H, Hoshida Y, Villanueva A, Solé M, Toffanin S, Sia D, Peix J, Alsinet C, Lachenmayer A, Secanella S, Schwartz M, Mazzaferro V, Bruix J, **Llovet JM**. Papel de la vía de señalización fgf en el carcinoma hepatocelular e implicación en la resistencia adquirida a sorafenib in vivo. XXXVII Congreso Anual de la AEEH Madrid, 2012.(Oral)
93. Alsinet C, Lachenmayer A, Toffanin S, Cabellos L, Minguez B, Tsai H, Hoshida Y, Villanueva A, Friedman S, **Llovet JM**. Papel de HDAC en el carcinoma hepatocelular y análisis de la actividad anti-tumoral en combinación con sorafenib. XXXVII Congreso Anual de la AEEH Madrid, 2012.(Oral, award)
94. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Solé M, Tovar V, Alsinet C, Cornella H, Fan J, Cotsoglou C, Thung S, Fuster J, García-Valdecasas JC, Bruix J, Schwartz M, Beroukhi R, Mazzaferro V, **Llovet JM**. Anàlisi genòmic del colangiocarcinoma humano intrahepàtic. XXXVII Congreso Anual de la AEEH Madrid, 2012.(Poster)
95. Agrin Moeini, Daniela Sia, Bojan Losic, Kate Revill, Ke Hao, Laia Cabellos, Myron E. Schwartz, Samuel Waxman, Vincenzo Mazzaferro, Eric Schadt, **Josep M Llovet**. Proteínas de fusión como dianas terapéuticas en colangiocarcinoma intrahepático. XXXIX Congreso Annual AEEH 19-21 Febrero 2014, Madrid (Oral).
96. Helena Cornellà, Clara Alsinet, Sergi Sayols, Zhang Zhongyang, Heo Ke, Laia Cabellos, Alberto Quaglia, Augusto Villanueva, Yujin Hoshida, Nasra Glama, David M Nagorney, Swan Thung, Stephen Ward, Leo Rodríguez-Carunchio, Anja Lachenmayer, Beatriz Minguez,

- Lewis Roberts, Vincenzo Mazzaferro, Myron Schwartz, Nigel Heaton, Manel Esteller, **Josep M Llovet**. Clasificación molecular y análisis genómico del hepatocarcinoma fibrolamellar. XXXIX Congreso Annual AEEH 19-21 Febrero 2014, Madrid (Oral).
97. Agrin Moeini, Daniela Sia, Bojan Losic, Laia Cabellos, Kate Revill, Dennis Bonal, Ke Hao⁴, Oriana Miltiadous, Zhongyang Zhang, Yujin Hoshida, Mireia Castillo, Sasan Roayaie, Swan N. Thung, Josep Fuster, Myron E. Schwartz, Samuel Waxman, Carlos Cordon-Cardo, Vincenzo Mazzaferro, Eric Schadt, and **Josep M. Llovet**. Discovery of Novel Araf Mutations by Exome Sequencing in Intrahepatic Cholangiocarcinoma. III Jornadas Científicas CIBEREHD, Barcelona 22th 23th October 2014 (Poster)
 98. Iris M. Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Judit Peix, Monica Higuera, Jessica Zucman-Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, **Josep M. Llovet**. IGF2 is an oncogenic driver and druggable target in HCC . III Jornadas Científicas CIBEREHD, Barcelona 22th 23th October 2014 (Oral)
 99. Victoria Tovar, Helena Cornellà, Agrin Moeini, Samuel Vidal, Yujin Hoshida, Daniela Sia, Judit Peix, Clara Alsinet, Iris M. Quetglas, Manel Solé, Josep Domingo-Domenech, Augusto Villanueva, **Josep M Llovet**. La Resistencia del Carcinoma Hepatocelular a Sorafenib está mediada por células iniciadoras de tumor (stem-cell-like cells). 40 Congreso Anual de la AEEH, 24th to 27th February 2015, Madrid (Oral).
 100. Victoria Tovar, Agrin Moeini, Sara Torrecilla, Mónica Higera, Judit Peix, Iris M. Quetglas, Leonardo Rodríguez-Carunchio, Manel Solé, **Josep M Llovet**. Nintedanib es eficaz en la prevención del carcinoma hepatocelular en modelos experimentales de fibrosis. 40 Congreso Anual de la AEEH, 24th to 27th February 2015, Madrid (Oral).
 101. Iris M-Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Judit Peix, Monica Higuera, Jessica Zucman-Rossi, Manel Esteller, Vincenzo Mazzaferro, **Josep M. Llovet**. IGF es una molecula clave en la hepatocarcinogénesis y como Diana terapéutica en el CHC. 40 Congreso Anual de la AEEH, 24th to 27th February 2015, Madrid (Poster).
 102. Moeini A, Sia D, Zhang Z, Camprecios G, Miltiadous O, M. Quetglas I, Fiel MI, Hao K, N. Thung S, Villanueva A, Schwartz M E, **Llovet JM**. Caracterización molecular del hepatocolangiocarcinoma mixto. *41º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH. 17th to 19th February 2016* (Poster).
 103. Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Bonilla S, Portela A, Rodriguez-Carunchio L, Solé M, Villanueva A, Esteller M, Zender L, **Llovet JM**. La re-expresión del IGF2 fetal, primer oncogen epigenético como diana terapéutica en el carcinoma hepatocelular. *41º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 17th to 19th February 2016* (Oral).
 104. Torrecilla S, Pinyol R, Sia D, Wei-Qiang L, Wang H, Moeini A, Montironi C, Bassaganyas L, Oliveira CP, Alves VAF, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Boffetta P, Dufour JF, Thung SN, Uzilov AV, Carrilho FJ, Chang C, **Llovet JM**. Caracterización molecular del carcinoma hepatocelular asociado a esteatohepatitis no alcohólica. *43º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 21-23 February 2018* (Oral).
 105. Torrecilla S, Kuchuk O, Akers N, Sia D, Simon-Coma M, Carrillo J, Martinez-Quetglas I, Gambato M, Royo L, Yoo S, Buendia MA, Sala M, Zhu J, Losic B, Mazzaferro V, Armengol C, **Llovet JM**. La vía de señalización de IGF como diana terapéutica en hepatoblastoma - *43º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 21-23 February 2018* (Oral).
 106. Sia D, Montironi C, Torres-Martin M, Wang H, Haber P, Puigvehi M, Maeda M, Wei-Qiang L, Harrods E, Taik P, Chinburen J, TAivanbaatar E, Chinbold E, Donovan M, Thung SN, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz ME, Villanueva A, Friedman SL, Uzilov A, **Llovet JM**. Caracterización del sistema inmune en el microambiente de los carcinomas hepatocelulares– *45º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 12-14 February 2020* (Oral)
 107. Torrens L, Montironi C, Haber P, Maeda M, Puigvehi M, Kamphorst A, Saberi B, Sia D, **Llovet JM**. Efecto de la combinación de lenvatinib y anti-PD1 sobre el sistema inmune en un modelo experimental de carcinoma hepatocelular – *45º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 12-14 February 2020* (Poster).

108. Esteban-Fabré R, Willoughby CE, Piqué-Gili M, Peix J, Montironi C, Abril-Fornaguera J, Torrens L, Pinyol R, Llovet JM. Cabozantinib aumenta la eficacia y actividad inmunomoduladora de la terapia con anti-PD1 en un modelo murino singénico de carcinoma hepatocelular – 45º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 12-14 February 2020 (Poster).
 109. Puigvehí M, Torres-Martín M, Maeda M et al. Caracterización molecular del carcinoma hepatocelular en Mongolia – 45º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, 12-14 February 2020 (Poster).
 110. Mesropian A, Abril-Fornaguera J, Torrens L....**Llovet JM**. Identificación de IGF2 como diana terapéutica en hepatoblastoma. 47º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, May 2022 (Poster)
 111. Pinyol R, Andreu-Oller C, Piqué-Gili M... **Llovet JM**. MEPA1 es un oncogen de la vía de TGF- β en el carcinoma hepatocelular: datos de RNA de células aisladas (Single Cell RNAseq) y modelos transgénicos. 47º Congreso Anual de la Asociación Española para el Estudio del Hígado AEEH, May 2022 (Oral).
 112. Piqué-Gili M, Cappuyns S, Esteban-Fabré R, Phillips G, Pinyol R, Vandecaveye V, Abril-Fornaguera J, Haver PK, Verslype C, Cutsem EV, Lambrechts D, Villanueva A, Dekervel J, **Llovet JM**. Identificació de dos mecanismes de resposta a atezolizumab + bevacizumab en carcinoma hepatocel·lular avançat mitjançant single-cell RNA sequencing SCD Congress. January 2024 (Oral)
 113. Abril-Fornaguera J, Rialdi A, Duffy M.... **Llovet JM**. WNTinib, un nou inhibidor multi-quinasa amb alta especificitat per el carcinoma hepatocelular amb mutacions a la via de la β -catenina. SCD Congress. January 2024 (Oral)
 114. Piqué-Gili M, Cappuyns S, Esteban-Fabré R, Philips G, Pinyol R, Vancaveye V, Abril-Fornaguera J, Haber PK, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, **Llovet JM**. Identificación de dos mecanismos de respuesta a atezolizumab + bevacizumab en carcinoma hepatocelular avanzado mediante single-cell RNA sequencing. February 2024 (Oral)
 115. U Balaseviciute, M Rahbari, F Springer, [...], Roser Pinyol, [...], **Josep M. Llovet**, Mathias Heikenwälder. The intratumoral microbiome in HCC and its impact on treatment response. (Oral) 50 Congreso Asociación Española para el Estudio del Hígado 2025
 116. E Mauro, T Castro, M Zeitlhofer, Roser Pinyol, [...], **Josep M Llovet**. Ensayos fase III en carcinoma hepatocelular: IMbrave 050 y las estrategias para abordar la no proporcionalidad de los hazards. (Oral) 50 Congreso Asociación Española para el Estudio del Hígado 2025
- A Mesropian, T Paul Seraphin, L Žigutytė, [...], Roser Pinyol, [...], **Josep M Llovet**. Aplicabilidad de la inteligencia artificial en la predicción de la biología molecular de mal pronóstico y la presencia de invasión vascular en el carcinoma hepatocelular. (Oral) 50 Congreso Asociación Española para el Estudio del Hígado 2025

12. ADDENDUM

MEDIA IMPACT

- **TV:** TV news for the research on gene signatures and HCC (Hoshida et NEJM; 2008). TV3 summary of HEPROMIC-European grant. Video interview during ECIO 2013(<http://youtu.be/plfOAEQ0RI>).TV3 interview (<http://www.tv3.cat/3alacarta/html5/#/videos/4880911/>) on the 30th January 2014. TV3 and EFE TV interviews for the publication at Nature Communications 2015 (<http://www.ccma.cat/tv3/alacarta/Telenoticies-vespre/Telenoticies-vespre->

23012015/video/5440804/)
 (<http://www.agenciasinc.es/Multimedia/Videos/Cientificos-del-Hospital-Clinic-descubren-dosmutaciones-en-cancer-de-higado-que-abren-la-puerta-a-un-nuevo-tratamiento>) on the 23th January 2015.

Radio: Several contributions on communications about the NEJM paper La Xarxa Interview December 18th 2014. Cadena Ser and RAC1 Radio interviews for the publication at Nature Communications 2015. Catalunya Radio – July 3, 2014 – “Mutació com a diana terapèutica en colangiocarcinoma” Minute 20’

- Newspapers: Around 950 references in newspapers worldwide for the study published on sorafenib (Llovet et al, NEJM 2008), including *New York Times*, *Wall Street Journal*, etc. Information of new cancer specialists recruited by the Tisch Cancer Institute (Mount Sinai Medical Center) in *The New York Times*. Information on the EU network HEPtromic and most cited papers in Nature Medicine in *La Vanguardia*, *AVUI*, *El País*. Interview in *La Vanguardia* as President of ILCA. ABC supplement. Interview in TVE. Interview for the *Mètode* magazine (Camins de la Ciència 79th edition) from the University of Valencia, pages 5 to 8. Interview in *La Vanguardia* entitled ‘Identifican una proteïna relacionada con el 80% de los tumores malignos de hígado’ on the 30th January 2014. Interview in *La Razón* entitled ‘Identifi cada una proteïna que da lugar a uno de los tumores de hígado de peor pronóstico’ on the 31th January 2014. Interview in *Diario Médico* entitled ‘Identifican un Nuevo oncogene que provoca hepatocarcinoma’ on the 31th January 2014. Interview in *Diario Médico* entitled ‘Mutaciones en la IDH causan un tipo de cancer de hígado’ on the 4th July 2014. Interview in “*La Vanguardia*” 24th November 2014 “El Podio de la Ciència. El Médico que cambió el tratamiento del Cáncer de Hígado”. Publications related to *Nature Communications* 2015: *La Vanguardia* ‘Descubren dos mutaciones en cáncer de hígado que permitirán nuevo tratamiento’, *La Razón* ‘Los cánceres de hígado más agresivos podrían tener tratamiento’, *Diario Médico* ‘Descritas dos mutaciones en colangiocarcinoma intrahepático’, ‘Describen otras dos mutaciones de colangiocarcinoma’, ABC ‘Descubren mutaciones en el cáncer de hígado que permitirán nuevas terapias’, *El Punt Avui* ‘Avenç en el tractament d’un tumor hepàtic’, *La Vanguardia*, *eldia.es*, *elconfidencial.com*, *agenciasinc.es*, *naciódigital.cat* ‘Identifican una nueva diana terapéutica contra el cáncer de hígado’, *sietediasmedicos.com* ‘Investigadores del IDIBAPS identifican una nueva diana terapéutica en cáncer de hígado’, *efefuturo.com* ‘Nueva diana terapéutica contra el cáncer de hígado’, *vilaweb.cat* i *directe.cat* ‘Investigadors de l’IDIBAPS identifiquen una nova diana terapèutica en càncer de fetge’. *La Vanguardia*, *Nació Digital*, *El Nacional*, *Aldia.cat*, *Vilaweb.cat*, *Directe.cat* ‘Sis investigadors del Clínic, en el rànquing dels millors del món’. ‘Catalunya és una potencia Europea en investigació’ *El Punt Avui*, 2017. ‘Pursuing combination strategies with checkpoint and tyrosine kinase inhibitors in hepatocellular carcinoma’ Perspective - *Ascopost.com*, August 2017. Un tratamiento antiplaquetario evita que el hígado graso derive en cáncer. *La Vanguardia*, 2019
- Website:** Video HEPtromic; interview for *epatoncologia.it* website Interview CCCB “Debats sobre els grans reptes de la Biomedicina del Càncer: de la Biomedicina al Pacient” ” (<http://vimeo.com/68287082>.) Publication of a new profile at the HEPtromic webpage <http://www.horizonhealth.eu/project/heptromic/231>). Publications related to *Nature Communications* 2015 publication: *Lainformacion.com*, *www.efefuturo.com*, *ecodiario.economista.es*, www.elconfidencial.com, *elnacional.com.do*, www.immedicohospitalario.es, www.20minutos.es, www.noticias.terra.es, www.europapress.es, www.efe.com/efe/noticias/, video EASL HCC Summit 2-5th February 2017, Geneva Switzerland <https://vimeo.com/203019997> (password: Rock). “Panel – Novel Therapeutics in the Post Genomic Age” - ICAHN School of Medicine at Mount Sinai <https://www.youtube.com/watch?v=ptA4VEepe70>

"The 8 Clinic-Idibaps researchers on the list of the most influential in the world" - <https://www.youtube.com/watch?v=-N5QpAadK4o>

"Translational Medicine – EIT – Crish" <https://www.youtube.com/watch?v=SPWPXPuloLE>.

Gut video abstract - "Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification":

https://www.youtube.com/watch?v=ySi_swq1UgQ&list=PL80fezoRY4BDroZjQVFikD4M2dtRDS6b&index=2&t=2s

<https://easlcampus.eu/videos/easl-policy-dialogues-s2-e7-inequality-liver-care-identifying-and-addressing-disparities> - EASL Policy Dialogues "Inequality in liver care – Identifying and addressing disparities".

Video Answersincme: www.answersincme.com/TAJ

- <https://www.docwirenews.com/post/leap-002-lenvatinib-plus-pembrolizumab-for-first-line-advanced-hcc>
- <https://www.docwirenews.com/post/leap-002-io-vegf-versus-io-io-versus-io-tki>
- <https://www.youtube.com/watch?v=ayqnGkthmBQ>
- <https://www.youtube.com/watch?v=5BIUnQ4u4SM>
- <https://youtu.be/cANjggJwoJ0> <https://www.youtube.com/watch?v=aC8XWuAxXPQ&t=35s>
- <https://www.youtube.com/watch?v=eWDqBlghXRA>
- <https://www.youtube.com/watch?v=VycGyKvkf9M>
- <https://www.youtube.com/watch?v=yuLvLf-3rS8>
- https://easlcampus.eu/search/resources/congress/easl-congress-2024-480/resource_type/easl-studio-311?keys=studio
- <https://www.clinicbarcelona.org/ca/noticies/lidibaps-lidera-un-projecte-dimmunoterapia-de-8-milions-deuros-concedit-per-lassociacio-espanyola-contra-el-cancer-per-millorar-la-supervivencia-en-carcinoma-hepatocel-lular>
- <https://www.oncologyeducation.com/videos/esmo-2024-highlights-presenter-vignette-josep-llovet/>
- <https://www.clinicbarcelona.org/ca/noticies/arrenca-el-projecte-europeu-thrive-per-millorar-el-pronostic-de-nens-i-adults-amb-cancer-de-fetge?from=recerca-translacional-en-oncologia-hepatica>
- <https://www.clinicbarcelona.org/ca/noticies/investigadors-del-clinic-idibaps-revisen-el-tractament-adjuvant-amb-immunoterapia-i-vacunes-del-cancer-de-fetge?from=recerca-translacional-en-oncologia-hepatica>
- <https://www.clinicbarcelona.org/ca/noticies/lidibaps-lidera-un-projecte-dimmunoterapia-de-8-milions-deuros-concedit-per-lassociacio-espanyola-contra-el-cancer-per-millorar-la-supervivencia-en-carcinoma-hepatocel-lular?from=recerca-translacional-en-oncologia-hepatica>
- <https://youtu.be/Z-vzm9Aqn5c>
- <https://youtu.be/0HdIIUrimp4>
- <https://youtu.be/cANjggJwoJ0>
- <https://www.clinicbarcelona.org/ca/noticies/investigadors-del-clinic-idibaps-presenten-prop-de-40-estudis-a-lesmo-2024>
- <https://touchoncology.com/gastrointestinal-cancers/conference-hub/transarterial-chemoembolization-with-lenvatinib-and-pembrolizumab-showed-improvement-in-progression-free-survival-for-hepatocellular-carcinoma/>
- <https://docwirenews.com/post/leap-012-pfs-benefit-with-pembrolizumab-levaratinib-and-tace-vs-tace-alone>
- <https://medicaldigest.org/scientific-contents/interview:leap-012-study-transarterial-chemoembolization-or-without-lenvatinib-pembrolizumab-intermediate-stage-hepatocellular-carcinoma-answersincme.com/SWS>.
- [Onclive: TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC \(Sept. 14, 2024\)](https://www.onclive.com/press-releases/2024/09/14/tace-plus-lenvatinib-and-pembrolizumab-improves-pfs-in-intermediate-stage-hcc)
- [Targeted Oncology: Lenvatinib, Pembrolizumab, and TACE Demonstrate](https://www.targetedoncology.com/news/leap-012-pfs-benefit-with-pembrolizumab-levaratinib-and-tace-vs-tace-alone)

- ## Significant Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma (Sept. 15, 2024)

- [OnLive: Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC \(Oct. 7, 2024\)](#)
- [Targeted Oncology: Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC \(Oct. 28, 2024\)](#)
- [https://farmacosalud.com/presentada-una-triple-combinacion-terapeutica-para-el-cancer-de-higado-que-va-asociada-a-eventos-adversos-tolerables/\(Jan 13, 2025\)](https://farmacosalud.com/presentada-una-triple-combinacion-terapeutica-para-el-cancer-de-higado-que-va-asociada-a-eventos-adversos-tolerables/(Jan 13, 2025))
- La Voz de Galicia: Dos estudios ofrecen el mayor avance en 20 años frente al cáncer de hígado.
<https://www.lavozdegalicia.es/noticia/sociedad/2025/01/09/dos-ensayos-espanoles-muestran-mayor-avance-veinte-anos-tratamiento-cancer-higado/00031736438235571840935.htm> (Jan 9, 2025).
- <https://www.mountsinai.org/about/newsroom/2025/breakthrough-treatment-for-liver-cancer-shows-big-promise-in-global-study> (Jan 9, 2025)
- Bloomberg: Astra, Merck Drugs Set to Shake Up Liver Cancer Treatment
- https://www.bloomberg.com/news/articles/2025-01-08/astra-merck-drugs-set-to-shake-up-liver-cancer-treatment?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJZb3VyY2UiOiJ0eWJzY3JpYmVvR2lmdGVkQXJ0aWNsZSIsImh0dCI6MTczNjQzMjc5MSwiZXBhcnR5b25uZWN0SWQoIlZlM0l0MEFBODBFbFRkM0OEIyOUEJJCUM4MEQyNzFENENDMiJ9.YbOolgKnd5JKx47fmuLNcCj_y3tx1MPZSfjPEKId_f8&leadSource=uverify%20wall (Jan 9, 2025)
- Indian Express: Lancet study has hope for liver cancer: Immunotherapy drug can delay progression in patients who can't be treated with surgery
- <https://indianexpress.com/article/health-wellness/lancet-study-liver-cancer-immunotherapy-drug-can-delay-progression-in-patients-who-cant-be-treated-with-surgery-9768142/> (Jan 9, 2025)
- La Vanguardia: An international study led by Hospital Clínic of Barcelona improves the treatment of liver cancer
<https://www.lavanguardia.com/mediterranean/20250109/10268476/international-study-led-clinic-hospital-improves-treatment-immunotherapy-liver-cancer-barcelona-health-llovet-drug-lancet.html> (Jan 9, 2025)
- TV3: <https://www.3cat.cat/3cat/cancer-de-fetge-en-estadi-intermedi-primera-millora-en-el-tractament-en-20-anys/video/6318903/> (Jan 9, 2025)
- <https://x.com/ContraCancerEs/status/1877282258052079709> (Jan 9, 2025)
- https://www.linkedin.com/posts/contraelcancerinvestigacion_investigandoe ncaerncer-activity-7283136452773732353-tBMt?utm_source=share&utm_medium=member_desktop (Jan 9, 2025)
- <https://x.com/contracancerINV/status/1877368584998899763> (Jan 9, 2025)
- La Vanguardia: trobada una combinació de fàrmacs que millora el tractament del càncer de fetge.
https://mynmedia.mynews.es/document/3441132D/00000370-20250109-004544/?idSeguiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnB6rcF18KdDA9M8b67Awg%2BSsULj%2FGgNGPOJ4qNyUml%3D (Jan 9, 2025)
- La Vanguardia: Hallada una combinación de fármacos que mejora el tratamiento del cáncer de hígado.(Jan 9, 2025)
https://mynmedia.mynews.es/document/3441132D/00000371-20250109-004544/?idSeguiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnB6rcCsCaUG6pYKQ%2FKluLesDq52K%2B9W1u2zeaVLIJM%3D

- Europa Press: Un estudio demuestra la eficacia de dos fármacos para tratar un subtipo de cáncer de hígado. (Jan 9, 2025)
https://mynmedia.mynews.es/document/3441132D/00000012-20250109-000109/?idSeguiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnB5%2Fg3mqcrff5ju7voD3mmkouS97qWbOXA7S5qTWOE%3D
- Ara: Primera millora en vint anys d'un càncer de fetge.
https://mynmedia.mynews.es/document/3441132D/00001271-20250109-000034/?idSeguiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnHD154%2FhJJS6mjQy0PzYRZyVHtstVRKJhoRm7JYNg%3D (Jan 9, 2025)
- La Vanguardia: Un estudio demuestra la eficacia de dos fármacos para tratar un subtipo de cáncer de hígado.
<https://www.lavanguardia.com/sociedad/20250109/10267024/estudio-demuestra-eficacia-dos-farmacos-tratar-subtipo-cancer-higado-ep-agenciaslv20250109.html> (Jan 9, 2025)
- La Vanguardia: Trobada una combinació de fàrmacs que millora el tractament de càncer de fetge.
<https://www.lavanguardia.com/encatala/20250109/10266757/trobada-combinacio-farmacs-millora-tractament-cancer-fetge.html> (Jan 9, 2025)
- El Nacional: Descobert un nou tractament que redueix un 34% la progressió d'un càncer de fetge molt mortífer.
https://www.elnacional.cat/ca/salut/descobert-nou-tractament-redueix-34-progressio-cancer-fetge-molt-mortifer_1342810_102.html (Jan 9, 2025)
- El Nacional: Descubierto un nuevo tratamiento que reduce un 34% la progresión de un cáncer de hígado muy mortífero.
https://www.elnacional.cat/es/salut/descubierto-nuevo-tratamiento-reduce-34-progresion-cancer-higado-muy-mortifero_1342810_102.html (Jan 9, 2025)
- RTVE. <https://x.com/rtvenoticias/status/1877370752803995675> (Jan 9, 2025)
- La Vanguardia: Descubren un nou tractament que redueix un 34% la progressió d'un càncer de fetge altament mortífer.
<https://www.lavanguardia.com/vida/20250109/10266887/descubreixen-nou-tractament-redueix-34-progressio-d-cancer-fetge-altament-mortifer-agenciaslv20250109.html> (Jan 8, 2025)
- La Vanguardia: Dos estudios liderados por españoles avanzan en el tratamiento de un cáncer de hígado.
<https://www.lavanguardia.com/vida/20250109/10266882/dos-estudios-liderados-espanoles-avanzan-tratamiento-cancer-higado-agenciaslv20250109.html> (Jan 8, 2025)
- La Vanguardia: Demuestran la primera mejora terapéutica en 20 años de un subtipo de cáncer de hígado.
<https://www.lavanguardia.com/sociedad/20250109/10266880/demuestran-primera-mejora-terapeutica-20-anos-subtipo-cancer-higado-agenciaslv20250109.html> (Jan 8, 2025)
- La Vanguardia: Un estudio internacional liderado por el Clínic mejora el tratamiento del cáncer de hígado.
<https://www.lavanguardia.com/ciencia/20250109/10266239/hallada-combinacion-farmacos-mejora-tratamiento-cancer-higado.html> (Jan 8, 2025).
- El País: El tratamiento a tres bandas mejora el pronóstico de un tipo de cancer de hígado no operable. <https://elpais.com/salud-y-bienestar/2025-01-08/el-tratamiento-a-tres-bandas-mejora-el-pronostico-de-un-tipo-de-cancer-de-higado-no-operable.html> (Jan 8, 2025)
- La Razón: Hallan dos ármacos eficaces para el cáncer de hígado.
https://mynmedia.mynews.es/document/3441132D/00001714-20250110-000034/?idSeguiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnB5%2Fg3mqcrff5ju7voD3mmkouS97qWbOXA7S5qTWOE%3D

[008067/?idSequiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnHGjoTN3P6JEr7K3QU8Cz%2BvSSbTcmxqplzngdGn1jc%3D](https://www.youtube.com/watch?v=008067/?idSequiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnHGjoTN3P6JEr7K3QU8Cz%2BvSSbTcmxqplzngdGn1jc%3D) (Jan 10, 2025)

- El punt avui: Una nova teràpia redueix un terç la progressió d'un càncer de fetge. https://mynmedia.mynews.es/document/3441132D/00001759-20250110-001018/?idSequiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnHGiu%2FQ0sOwryt9lZMPwHR5mm2Sx%2FoZihZlx%2FaPgRE%3D (Jan 10, 2025).
- Europa press: Un studio demuestra la eficacia de dos fármacos para tratar un subtipo de cáncer de hígado. https://mynmedia.mynews.es/document/3441132D/00000012-20250109-000380/?idSequiment=23215&fromEmail=True&expiration_key=ibmFLewaWhlf7EphZnB5%2Fq3mqcrff5ju7voD3mmkoHnS5va0tBL086lb2Qo%3D (Jan 10, 2025).
- Rac1: Una nova teràpia de l 'Hospital Clínic aconseguix reduir un 35% la progressió d'un càncer de fetge altament mortífer. https://www.antena3.com/noticias/sociedad/investigadores-espanoles-logran-avances-tratamiento-cancer-higado_20250109677fd4e04f1fb700018328a4.html (Jan 9, 2025).
- <https://www.youtube.com/channel/UCIW-omGSEeWwcW2-i0xST9Q> Bioregion Report Presentation 2025

Languages

Catalan: Native. Fluent speaking and writing. Official Proficiency Degree on Catalan (C), Junta Permanent de Català, Generalitat de Catalunya. 1992.

Spanish: Fluent speaking and writing.

English: Fluent speaking and writing.

- First Certificate in English. University of Cambridge. UK. 1986
- Advanced level. Frances King School of English. London. 1997, Escola d'idiomes d'ESADE. 1998. Escola d'idiomes de la Universitat de Barcelona. 1998.
- Faculty at Mount Sinai School of Medicine, New York. 2003-2022

Research Training

Degrees for Human Subject research

- Degree for Human Research as Principal Investigator in the USA: HIPAA Training related to Human Subject Research. National Institutes of Health (NIH). New York, USA, 2007.
- Meta-analysis of Randomized Controlled Trials (20h), 1999. IES. Agència Avaluació Tecnologia. Prof J. Lau, Boston.
- Clinical Trials for the Clinical Oncologist: Principles, Phase I-III trials (6h), 2002. 38th ASCO Meeting . Orlando, USA.
- "Clinical Trials" (50h). 2002. London School of Hygiene and Tropical Medicine. Dir: Prof D. Elbourne., London, UK.
- Molecular Biology in Clinical Oncology (1 week). 2005. AACR, Aspen, Colorado, US

Design of clinical trials, meta-analysis and cost-effectiveness analysis.

- Skills in the management of statistical packages (SPSS 13.0), design and conduction of meta-analysis (Meta-analyst 1990-1997), assessment of sequential design in randomized studies (sequential triangular test PEST Version 3.0), and cost-effectiveness studies (Decision Maker 7.1).

Degrees for Animal research

- Degree on Experimental Research with Animals. "Investigador" for the use of

animals for experimental and other scientific purposes. Comité Ètica i Experimentació Animal, Universitat Barcelona, 1999. Accreditation certified by Departament d'Agricultura, Ramaderia i Pesca, 2001.

Short-term research stays.

- Cedars Sinai Medical Center of the University of California- Los Angeles (UCLA). Liver Transplant Center. (Director: Prof. P. Martin). Sept, 2001